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RNA interference (RNAi), a hallmark of all biological sciences of twenty-first century, 
is an evolutionarily conserved and double-stranded RNA-dependent eukaryotic cell 
defense process. Opportunity to utilize an organisms own gene and to systematically 
induce and trigger RNAi for any desired sequence made RNAi an efficient approach for 
functional genomics, providing a solution for conventional longstanding obstacles in 
life sciences. RNAi research and application have significantly advanced during past 
two decades. This book RNA interference provides an updated knowledge and progress 
on RNAi in various organisms, explaining basic principles, types, and property of 
inducers, structural modifications, delivery systems/methodologies, and various 
successful bench-to-field or clinic applications and disease therapies with some aspects 
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RNA interference (RNAi), being a revolutionary discovery of all biological sciences of twenty-first cen‐
tury and historically known as co-suppression, quelling, and/or post-transcriptional gene silencing (PTGS), is
an evolutionarily conserved, double-stranded RNA-dependent, universal eukaryotic process to clean
“foreign-like” mRNA transcripts in a sequence-specific manner before they generate harmful proteins
or invade the genome. Opportunity to induce and trigger RNAi for any desired sequence signature and
its systematic spreading property from cell-to cell, tissue to tissue, or in whole body system made it an
efficient approach to study the function of any genes and/or sequence signatures of an organism.
Increasing body of our knowledge on a sequence/gene of interest, improved design of RNAi inducers
with its various modifications, development of efficient and specific delivery systems, and optimized
targeting strategies as well as the use of organism’s own gene or gene fragment further made RNAi
advantageous over existing gene manipulation “transgenic” technologies. Hence, RNAi holds a great
potential for agricultural biotechnology and crop improvement, food security, industrial biotechnology
and biofuel production, molecular pharmacology, and treatment of various inflammatory, infectious,
and hereditary diseases such as complex immune and cancer therapy. Addressing all of these, RNAi
research and application significantly advanced in past decade period.
The book RNA interference, a collection of 19 chapters from distinguished laboratories and eminent sci‐
entists of the world conducting state-of-the-art RNAi research, aims to provide readers “up-to-date”
knowledge and progress on basics; types of inducers, triggers, and delivery systems; design and optimi‐
zation requirements; and performance of RNAi in various cell models and organisms. Further, chapters
of this book discuss a wide variety of potential “bench-to-clinic” applications of RNAi and lessons
learned in crop improvement and protection, veterinary and animal protection, molecular pharmacolo‐
gy, and medicine, including its current and future therapeutic potential on inflammatory, blood, central
nervous system, eye, liver, immune and cancer disease therapies with some aspects of limitations, alter‐
native tools, safety, and risk assessment.
Although we missed the latest developments on RNAi repositories, screens, and databases as well as in-
depth coverage of crop RNAi applications and commercialization efforts, I trust that various topics on
advancements of RNAi research and its application, compiled in this single book, should add informa‐
tion to currently available literature sources and be useful for university students as well as private and
public life science researchers, enhancing the reader’s knowledge.
I would like to express my sincere appreciation to all eminent authors of the book chapters for their
contributions, hard work, and full cooperation with my editorial requests. I thank the InTech book de‐
partment, for giving me an editorship opportunity of this book, and Ms. Sandra Bakic and Ms. Iva Sim‐
cic, InTech’s Publishing Process Managers, for their initiation of this book project, coordination of entire
book processing, correspondence with authors, and support and help with this book publication.
Ibrokhim Y. Abdurakhmonov
Center of Genomics and Bioinformatics,
Academy of Sciences of Uzbekistan,








RNA Interference – A Hallmark of Cellular Function and
Gene Manipulation
Ibrokhim Y.  Abdurakhmonov
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/62038
Abstract
The discovery of RNA interference (RNAi) and its utilization in downregulation of spe‐
cific target transcripts have revolutionized gene function analysis and elucidation of
many key biochemical/genetic pathways. The insights into gene function, combined with
a technology that made silencing of gene function possible using the potent, highly spe‐
cific and selective RNAi approaches, provided the solution to longstanding complex ob‐
stacles in targeted crop improvementsfor agriculture, and disease therapies for medicine.
In this introductory chapter, I aim briefly to cover the basics and peculiarities of RNAi
and the advances made in understanding the mechanisms, components, function, evolu‐
tion, application, safety and risk assessment of RNAi, while at the same time highlighting
the related chapters of this book.
Keywords: Gene silencing, RNA interference, RNAi inducers and delivery, RNAi-based
disease therapy, biosafety
1. Introduction
The “central dogma” of genetics as first presented by Francis Crick is that genes, packed inside
the cell as the deoxyribonucleic acid (DNA) molecule, are transcribed into messenger ribonu‐
cleic acids (mRNA), which are subsequently translated into proteins (or enzymes). These final
protein products provide all life functions, and together with DNA and RNA, constitute the
molecules of life. Therefore, if there is a disruption (interference) of a gene function, messenger
RNA synthesis, or protein translation, normal life processes get altered or even stopped. “No
gene-no messenger”, or “no messenger-no protein”, has been the basis of understanding
biological processes. One of the easy-to-access points in cellular processes is messenger RNA
due to its cytoplasmic location, “naked” structure, comparatively short half-life, and temporal
existence between transcription and translation. Further, mRNA is in between the chain of
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
events from DNA to protein; it has the universal chemical structure, consisting of only four
nucleotides, regardless of the encoded message. In contrast, proteins are chemically much
more variable, consisting of combinations of 21 different amino acids, with side chains that
vary from very hydrophilic to highly hydrophobic. If mRNA is altered or eliminated before
translation, there is no functional gene product, which results in changing the cellular process
from the native state. This is the entire rationale of RNA interference (RNAi).
RNA interference is a process in eukaryotic cells in which double stranded endogenous or
exogenous RNA molecules trigger a cytoplasmic response, which involves sequence specific
target identification and destruction. This may include native messenger RNAs (mRNAs) that
code vitally important proteins [1]. Any type of double-stranded RNA (dsRNA) molecules can
activate RNAi where long dsRNAs, microRNAs (miRNAs) and small interfering RNAs
(siRNAs) and their various forms and modifications are considered the main players/inducers
[1]. Let us take a look at RNAi discovery history.
Plant scientists in the 1990s first used targeted gene silencing by introducing an antisense gene
into plants. The first example was silencing of a nopaline synthase (NOS) gene, for which the
silencing was only visible by loss of a band on a Norther blot and loss of NOS activity [2]. The
second antisense gene used in plants targeted the petunia chalcone synthase (CHS) gene,
encoding the first step in floral pigment production, and the result was visible in the loss of
petal pigmentation [3]. Curiously, attempts to create dark pigmented petunia flowers by
overexpression of the same CHS gene resulted in similar colorless petunia petals [4, 5]. It was
thought that such a phenotype was “due to post-transcriptional inhibition of gene expression via an
increased rate of mRNA degradation” [6]. The observed phenomenon was named as “co-suppres‐
sion” of gene expression and the molecular mechanism behind “co-suppression” remained
unknown for many years [7]. Later, a transient gene inactivation of the carotenogenic albino-3
(AL-3) and albino-1 (AL-1) genes was reported after transformation with homologous sequen‐
ces in Neurospora crassa [8]. This phenomenon, named as gene “quelling”, was observed to be
severely destructive but spontaneously and progressively reversible and monodirectional,
resulting in mutant, intermediate, and wild-type phenotypes [8]. In the years to follow, the co-
suppression phenomenon were attributed to inverted repeat T-DNA insertions, which result
in RNA transcripts with internal complementary sequences that can fold back on themselves,
generating double-stranded RNA and can seed the now well-known Argonaute/dicer
silencing system.
Following these seminal discoveries, similar phenomena were discovered in other organisms
including the nematode (Caenorhabditis elegans) and insects (Drosophila melanogaster) from
studying the function of a PAR-1 gene (required for establishing embryo polarity) in the former
and alcohol dehydrogenase in the latter (ADH) [9, 10]. These studies not only demonstrated a
wide range of functionality of “co-suppression” phenomenon but also prompted an intense
effort to understand the exact mechanism causing this process. In one experiment, injection of
dsRNAs associated with muscle protein production into nematodes successfully silenced the
targeted gene. The effect on muscle production was not observed using either mRNA or
antisense RNA [11]. With this work, for the first time, the agent directly responsible for “co-
suppression” was identified and formally named as “RNA interference” or RNAi. This work was
later recognized with the 2006 Nobel Prize.
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In plants, the suppression of targeted genes during viral infections was discovered [12] and
subsequently developed into a system by which plant gene function may be studied through
inhibition by infection with viruses bearing a short sequence targeted against plant mRNAs
[13]. This phenomenon was termed as "virus-induced gene silencing" (VIGS) and is often used
to study gene function in plant species that are recalcitrant to transformation or just take a very
long time to regenerate.
Over the past decade, RNAi has been demonstrated in many eukaryotes including humans as
well as some prokaryotic life forms [14] and has been recognized to form an integral part of
many gene regulatory networks during development. This revolutionary breakthrough in
biological science has become a valuable in vitro, in vivo, and ex vivo manipulation of gene
expression, allowing for large-scale studies of gene function. It is now a routine laboratory
practice to introduce the desired gene-specific dsRNA inducers into cells and selectively,
robustly, and systematically silence the targeted sequence signature revealing its cellular
function. In addition, RNAi has become an efficient tool for agricultural biotechnology to
improve production [15] and combat disease pests as well as for medicine and molecular
pharmacology to cure complex infectious, inflammatory, and hereditary diseases [16].
Figure 1. Dynamics of scientific publications devoted to the RNA interference for the past three decades. Source:
PubMed [18] data sorted by the year of publications, which were retrieved by the search with the unquoted keyword
“RNA interference”]
RNAi research has rapidly advanced and expanded over the past decade, evidenced by
increasing numbers of publications, research projects, and practical applications in both
agriculture and medicine. For example, searching Google Scholar [17] with the unquoted
keyword “RNA interference” retrieved over 1 million (1,110,000) documents. Repeating the
same search with “organism-specified RNA interference” in PubMed database [18] on the same
date returned a total of 50,824 indexed scientific documents with a major pick after 2002
reaching to over 1,000 scientific publications per year (Figure 1). The distribution of specified
search results revealed a number of PubMed-indexed, RNAi-related publications for human
(32,007), plant (3,701), animal (27,751), insect (4,145), fungal (690), and prokaryotic (119)
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organisms. Moreover, the therapeutic application of RNAi is also expanding rapidly with 9,953
articles related to this topic and found in PubMed searching with “RNA interference therapy”
keyword. In this brief introductory chapter, I aim to cover the basic understanding behind
RNAi and an update knowledge on its applications, limitations, safety, and risks, highlighting
and discussing some of the key points presented in this book.
2. Components, mechanism, and function
The principle mechanism of RNAi is complex, but very straightforward and easy to under‐
stand. RNAi is induced by the introduction of specific exogenous dsRNA either by virus
genome RNAs, injection of synthetic dsRNAs or, in plants, is mediated by Agrobacterium.
RNAi is also part of the normal development and dsRNAs are produced by endogenous genes
encoding miRNA precursors or other long dsRNA molecules. In either case, the dsRNAs are
recognized by the enzyme dicer and cleaved into short, double-stranded fragments of ~19-25
base pair long siRNAs [1]. These siRNAs are separated into two single-stranded RNAs
(ssRNAs), which are referred to as the “passenger” and the “guide” strands. The passenger
strand is degraded, while the guide strand is picked up by the RNA-induced silencing complex
(RISC) that has enzymatic digestion activity and contains the key components of Argonaute
(AGO) and P-element induced wimpy testis (PIWI) proteins [1]. The RISC proteins perform
the unwinding of the guide and passenger strands in ATP-independent manner [19, 20];
however, ATP is required to unwind and remove the cleaved mRNA strand from the RISC
complex after catalysis [21]. There are effector proteins such as RDE-4 (nematodes) and R2D2
(insects) that recognize exogenous dsRNAs and stimulate dicer activity. R2D2 also has a
differentiating function for siRNA strands by stably binding to 5' end of the passenger strand,
thus directing the guide strand to the RISC [22]. Here, it should be noted that the 5′ end of the
guide strand is involved in matching and binding the target mRNA while the 3′ end physically
arranges target mRNAs into the cleavage-favorable site of the RISC complex [21]. AGO/PIWI
proteins localize within the specific P-body regions in the cytoplasm, considered to be a critical
site for RNAi [23–25].
It is not clear as yet how the guide strand-bound active RISC complex finds mRNA targets
within the cell, but it is known that this process is sequence-specific. Once the target mRNA is
identified and captured though RNAi machinery, RISC cleaves the target mRNA rendering it
untranslatable [1]. In most cases, the entire process is triggered by amplification of the cleavage
process through synthesis of additional dsRNAs from primarily digested fragments of mRNA.
Upon annealing to the mRNA target, the guide RNA may also be extended by RNA-dependent
RNA polymerase (RdRP), resulting in extended “secondary” dsRNAs which in turn may lead
to the formation of new siRNAs that enhance and further systematically spread the degrada‐
tion of the target mRNA in cytoplasm [26, 27].
Although the pathways toward RNAi from exogenous and endogenous dsRNA converge at
the RISC and use the same downstream RNAi machinery, there are also some clear differences
in their processing and handling [1]. Endogenous dsRNAs cleaved by dicer (1) produce 20–25
bp fragments with a two-nucleotide overhang at the 3′end of siRNA duplex [1], while the
length of exogenous dsRNAs-derived siRNAs, required for specificity, is unknown. Exoge‐
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nous dsRNAs are distinctly (2) handled by the above-mentioned effector proteins, RDE-4 or
R2D2 [26, 27], whereas siRNA derived from endogenous dsRNAs (i.e., miRNA precursors) are
handled by double-stranded miRNA precursor-binding DGCR8 and Drosha proteins with
RNAse III enzyme activity. Plants do not have Drosha homologs, instead, processing of
miRNA to siRNAs is carried out by one of four dicer-like proteins. Endogenous miRNAs (3),
except some plant miRNAs, typically have several mismatches to the target sequence, while
siRNAs derived from exogenous dsRNAs usually are designed to have a perfect match to the
target. Most importantly, (4) endogenous dsRNA-derived miRNAs are capable of mildly
inhibiting the translation of hundreds of mRNAs [28–30], while exogenous dsRNA-derived
ones usually silence only single specific target [31]. Depending on organisms, for instance in
C. elegans and D. melanogaster, (5) distinct Argonaute proteins and dicer enzymes [32, 33]
process miRNAs and exogenous siRNAs. Furthermore, endogenously processed miRNAs
prevalently (6) interact with miRNA response elements (MREs) located within the 3'-UTRs
region of target mRNAs. Upon binding to MREs, miRNAs can decrease the gene expression
of various mRNAs by either inhibiting translation (in animals) or directly causing degradation
of the transcript (in plants). In contrast, exogenous dsRNA-derived siRNAs may interact with
any complementary sequence region of the target mRNA, causing direct cleavage of the
transcript [1]. miRNAs may actually regulate translation of target mRNAs in dual ways, as
translation regulation by miRNAs oscillates between repression and activation during the cell
cycle through a yet unknown mechanism [34].
The main biological function of RNAi is regulation of gene activity of cells at the post-
transcriptional level (PTGS) either by the inhibition of translation of mRNA or by direct
degradation of the mRNA. In addition to PTGS, RNAi pathway components may contribute
to maintenance of genome organization and structure, mediated by RNA-induced histone
modification. Histone modification in turn affects heterochromatin formation and may silence
gene activity at the pre-transcriptional level [35]. This process is referred to as “RNA-induced
gene silencing (RITS) and requires dicer, siRNA and RISC component proteins such as AGO
and R2D2 [36]. In addition, RNAi components and inducers (siRNA/dicer/AGO) may also
possibly upregulate expression of genes in binding into a promoter region and through histone
demethylation, a process dubbed RNA activation [37, 38].
Because of sequence-specific recognition, regulatory properties, and the possibility of systemic
spreading of dsRNAs, RNAi is the key “sterilizing agent” of cells and tissues, and it functions
as potent immune response against foreign nucleic acids from viruses, transposons, or
transformation events which can invade and harm the genome and its stability [39]. The
chapters presented in Section 2 of this book have a more detailed coverage of the history of
the RNAi discovery, mechanism, and functional components and on the biological role of
RNAi including natural small RNAs/microRNAs as well as long noncoding RNAs in gene
regulations.
3. Differences among organisms
Although the RNAi pathway is a universal process in eukaryotic cells, and it consists of similar
component(s), mechanisms, and functions as described above, there are some variations
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among organisms in both up-take of exogenous dsRNAs and induction of RNAi. First, RNAi
is systemic and heritable in plants and C. elegans. The systemic spreading of RNAi in plants
occurs because of transfer of siRNAs between cells through plasmodesmata and the phloem
[40]. Second, in plants, RNAi induces epigenetic silencing of genes through methylation of
promoters of targeted genes which may be passed to the next generation [41], while in
Drosophila and mammals this is not the case. Third, plant miRNAs have perfect or nearly
perfect complementary to their target genes and directly cleave and degrade targeted mRNA.
In contrast, animal miRNAs have one or more mismatches to target sequence and halt the
translation process [42].
RNAi is not found in some eukaryotic protozoa (e.g., Leishmania major and Trypanosoma cruzi)
[43, 44]. Some fungi (e.g., Saccharomyces cerevisiae) lack specific RNAi component(s) and the
reintroduction of these missing components can recover RNAi [45, 46]. Further, prokaryotic
organisms have distinctive RNA-dependent gene regulation system controlled by RNA
products of translation-inhibiting genes. These regulatory RNAs are not processed by dicer
enzymes, differentiating them from eukaryotic RNAi [47]. However, recently, the clustered
regularly interspaced short palindromic repeats (CRISPR/Cas9) interference system has been
characterized in prokaryotes, which is a gene silencing pathway analogous to eukaryotic RNAi
systems [14]. The CRISPR interference system has its specific components, advantages, and
limitations that are well described in the literature [48, 49], but will not be presented here. The
chapter by Dr. Devi Singh and his colleagues in Section 2 of this book has a detailed coverage
of RNAi in various organisms. RNAi in various organisms is also discussed in the chapter by
Galay et al. presented in Section 6 of this book, highlighting the specifics of RNAi in ticks while
Dr. Tayota and his colleagues present an interesting methodological paper on RNAi in the
water flea in Section 3.
4. Evolution
Studies on components, mechanisms, and functions of RNAi have demonstrated variations
among organisms, differences in eukaryotes and prokaryotes, and indicate that RNAi is
derived from an ancestral immune defense function against transcripts of transposons and
viruses [50, 51]. Although some eukaryotes might have lost RNAi components or, even, the
entire pathway following the emergence of the Eukaryota, parsimony-based phylogenetic
analyses suggest that an ancestral lineage of all eukaryotes possibly had a primitive RNAi
capability including relevant components for some key functions such as histone modification
[50]. Phylogenetic studies also indicate that miRNAs of plants and animals may have evolved
independently, but the conservation of some key proteins involved in RNAi also indicate that
the last common ancestor of modern eukaryotes already possessed an siRNA-based gene
silencing system. The RNAi-like defense system of prokaryotes is functionally similar, but
structurally distinct from the eukaryotic RNAi system [52]. It seems likely that a proto-RNAi
system possessed at least some form of dicer-like, AGO, PIWI, and RdRP proteins. These basic
components were shared by major eukaryotic lineages and functioned within an RNA
degradation exosome complex [53].
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Being an important component of an antiviral innate immune defense system in eukaryotes,
RNAi components and various interaction/regulatory mechanisms, including the miRNA
pathway, evolved later but at faster rates under strong directional selection [54]. This could
have been a means of generating an improved response to the evolutionary arms race with
viral genes. Correspondingly, some plant viruses have evolved the means to suppress the
RNAi response in their host cells [55]. Extensive studies reported that an ancient duplication
of RNAi components followed by species-specific gene duplications and losses provided
evolutionary diversification, specificity and adaptation of the RNAi system in many organisms
[56]. Chapter(s) presented in Section 2 has covered some evolutionary aspects of RNAi.
5. Applications
Since its first discovery as anti-sense gene suppression, co-suppression or quelling phenomenon,
the sequence specificity, efficiency, and systemic spreading (in some organisms) characteristics
of RNAi to suppress target gene expression have caught researchers’ attention and soon
became an attractive and powerful tool for gene function discovery in life sciences [1]. By full
or partial suppression of target gene expression using RNAi, the change in cell physiology
and/or developmental phenotype helps to reveal the function of the target gene. Therefore, a
utilization of RNAi has revolutionized the annotation of cellular functions of many unknown
and unique genes, adding to our understanding the complex genetic/biochemical pathways
and their interactions. Thanks to its partial silencing effect, RNAi also helped to discover the
function of genes when complete knockout would cause lethality [57]. Moreover, by targeting
homologous sequences within a gene family, a single RNAi construct can suppress the
expression of multiple members of a gene family, and thus reveal phenotypes that would have
been missed in a single mutant due to redundancy in gene function.
The results of the functional genomics studies, advances in the understanding of the RNAi
mechanism, improved design of trait-specific RNAi inducers (such as miRNAs), selection of
target gene sequences combined with the development of proper delivery systems, as well as
screens for “off-target” and cross reactivity have brought the practical applications of RNAi
far beyond its initial experimental reach.
Agricultural application of RNAi through tissue culture-derived genetic modifications and
transgenic research in a wide range of technical, food, and horticulture crops have been
particularly successful and have solved many problems. Examples include, but are not limited
to, crop yield and quality improvements [15, 58], food/nutrient quality improvements and
fortification [59–62], decreasing the harmful precursors and carcinogens [63, 64], and im‐
provement of plant pest and disease resistance [65–66]. Many of these applications are now
evaluated for commercialization or are already in commercial production [67]. In this context,
targeting far red (FR) photoreceptor gene (PHYA1) using RNAi approach [15], our team
succeed to develop the world’s first RNAi cotton cultivars with improved fiber quality and
other key agronomic traits without adversely affecting the yield, which successfully passed
multi-environmental large field trials and have been approved for cotton farming in Uzbeki‐
stan.
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Therapeutic application of RNAi has also been successful in medicine and molecular phar‐
macology with examples in inflammatory and infectious disease [68-71], cancer [72-75], as well
as hereditary and neurodegenerative diseases [76]. Indeed, for many other disorders RNAi
may have great potential. To highlight advances made on this field, in Section 4 of this book,
we present several relevant chapters on advances of RNAi application in key human diseases
of blood, ocular, nervous, kidney, and oncogenic origin. In addition, Section 5 chapters discuss
RNAi utilization in various immune and infectious diseases. Section 6 chapters present the
latest advances of RNAi application in studies of insects and parasitic pests such as ticks. All
of these chapters highlight various aspects of RNAi and add interesting insights to the present
RNAi discussions.
6. Safety and risk assessment
Manipulation of the organisms’ own genetic sequence signature(s) (cis-genesis) is usually
considered safer compared to “trans-genesis” that utilizes “foreign” genetic material to create
genetically modified (GM) crops and its products [77]. However, for RNAi, when broken down
to ~21 nucleotides this quickly may lose its meaning, as a trans-RNAi will only work if it has
sufficient homology to an endogenous target transcript. Chemically, RNA is “generally
recognized as safe (GRAS)” or it is “rarely formally considered in risk assessment” [67]. Despite this
and many other examples of successful application of RNAi technology in agriculture and
medicine, there may be risks associated with high or repeated dosages of dsRNA, which
inadvertently may interfere with unintended target sequences. A growing body of evidences
suggests that testing for the safety and assessing possible risks associated with the use of RNAi-
derived products sound practical, in particular, evidence of the remarkable stability of dsRNAs
in the environment, their survival and resistance in the acidic conditions of the digestive tracts
of higher organisms, and consequent transmissibility of dsRNA from foods to humans/
animals. Further, production of possibly harmful “secondary” dsRNAs [67] by primary RNAi
inducers raised an early warning signal regarding the GRAS signature of any RNA molecule
and the possibility of risks for human health and environment.
Safety concerns about RNAi-based drugs are exemplified by the lethality of 23 out of 49 distinct
RNAi therapy experiments in mice because of potential "off-target" effects that could shut
down non-targeted gene(s) with sequence similarity to therapeutic RNAi inducer [78]. This
observed lethality, however, could be due to “oversaturation" of the dsRNA pathway and
delivery issues of short hairpin RNAs [79] that needs to be optimized for harmless therapeutic
applications. There are several suggested approaches to minimize or eliminate such “off-
target”, “oversaturation” or delivery issues, in particular through the use of (1) comprehensive
in silico target and off-target analyses [80], (2) modified designing of RNAi inducers with
improved target selectivity, and (3) efficient delivery systems.
There may also be concerns about the uptake of intact plant miRNA by consumers through
plant diet. Plant microRNAs and some long dsRNA molecules, with sequence complimentary
and perfect matches to endogenous human genes, were demonstrated to survive the digestive
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tract of humans and can freely and routinely enter the blood system [67, 81]. In vitro human
cell culture experiments further showed that such plant siRNA entered into human blood
system could silence endogenous human genes due to sequence complementarity. While this
may require attention of regulatory systems on one hand, on the other hand, human con‐
sumption of food crops with natural occurring siRNAs is considered safe and so far has not
caused any dramatic biohazards or risk [81]. The chapters in Section 3 of this book also present
updated information on RNAi delivery methods (e.g. Tayota et al.); synthesis, chemical and
structural modifications, and designing for high specificity and selectivity of RNAi inducers
(see Gvozdeva and Chernolovskaya), and limitations of RNAi and possible alternative
technology such as ER-targeted intrabodies for gene silencing (see chapter by Backhaus and
Böldicke).
Risk assessment and available protocols/guidelines are in the early stages of development.
Some suggest that dsRNA-derived products must be subject to risk assessment studies [67].
Other findings indirectly support the safety of RNAi [81, 82], provided its use is within specific
dosage ranges, the correct delivery system is in place and RNAi inducers without possible off-
target effects, unintended gene silencing and secondary dsRNA production can be designed.
However, it is always advisable to admit to possible risks of any novel genomic technology,
including RNAi, and consider potential biohazards and evaluate risks for environmental
health, before release of a new product [58, 81–85]. To accomplish this, Heinemann et al. [67]
proposed the following five-step guidance: (1) to perform detailed in silico comparative
bioinformatics analyses for targets of designed dsRNA and identify possible “off-targets” in
key consumers; (2) to experimentally quantify designed dsRNAs, and the processing of any
other unknown sequence signatures or secondary dsRNA as a result of introducing intended
RNAi inducer into recipient or its product; (3) to test possible biohazards and risks due to
exposure of RNAi product in animal and human cell/tissue culture; (4) to conduct animal
feeding experiments for the long-term physiological and toxicological patterns and possible
chronic effects; and (5) to perform clinical trials of RNAi-derived products in humans.
7. Conclusions and future perspectives
Thus, being a revolutionizing discovery in genome biology to characterize functions of any
desired unknown genetic sequences, the discovery of RNAi has significantly widened our
knowledge on core cellular processes. This knowledge has created opportunities and solutions
to longstanding obstacles in conventional agriculture and medicine, offering a bright future
to curing complex human and animal diseases, improve crop production and protection, and
a sustained global food security through proper manipulation of key genes with agricultural
or medicinal importance. Although key issues on specificity, selectivity, and delivery of RNAi
inducing structures still exist, and some safety risks associated with the use of RNAi products
have been recognized, the general believe is that RNAi is a safer technology than trans-
genomics utilizing “foreign” genetic information. Safe applications, however, require proper
designing, dosage and delivery of RNAi inducers, and before its delivery for wide consumer
market, the safety risks should be assessed. Addressing the advances made over the past three
decades in RNAi research and commercialization, in this book, we have compiled and
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presented a diverse collection of chapters contributed by the science research communities.
We all believe that RNAi, in combination with the rapidly expanding genomic information in
key organisms and novel genome editing tools, will become even more powerful and efficient,
and that we will all enjoy its benefits far into the future.
Acknowledgements
I thank the Academy of Sciences of Uzbekistan and Committee for Coordination Science and
Technology Development of Uzbekistan for basic science FA-F5-T030; and several applied
(FA-A6-T081 and FA-A6-T085) and innovation (I-2015-6-15/2 and I5-FQ-0-89-870) research
grants. I am particularly grateful and thank the Office of International Research Programs
(OIRP) of the United States Department of Agriculture (USDA) – Agricultural Research Service
(ARS) and U.S. Civilian Research & Development Foundation (CRDF) for international
cooperative grants P121, P121B, and UZB-TA-2292, which are devoted to study, development,
application, risk assessment, and commercialization of RNAi cotton cultivars and their
products. I sincerely thank Dr. Alexander R. van der Krol, Waginengen University, Nether‐
lands, and Dr. Eric J. Devor, Iowa State University, the USA, for their critical reading and
suggestions to this chapter manuscript.
Author details
Ibrokhim Y.  Abdurakhmonov*
Address all correspondence to: genomics@uzsci.net
Center of Genomics and Bioinformatics, Academy of Science, Ministry of Agriculture and
Water Resources, and “UzCottonIndustry” Association of the Republic of Uzbekistan,
Tashkent, Uzbekistan
References
[1] Hannon GJ. RNA interference. Nature. 2002;418:244–51. DOI: 10.1038/418244a
[2] Rothstein SJ, Dimaio J, Strand M, Rice D. Stable and heritable inhibition of the ex‐
pression of nopaline synthase in tobacco expressing antisense RNA. Proc Natl Acad
Sci U S A. 1987;84:8439–8443. DOI:10.1073/pnas.84.23.8439
[3] van der Krol AR, Lenting PE, Veenstra J, van der Meer IM, Koes RE, Gerats AGM,
Joseph N. M. Mol JNM, Stuitje AR. An anti-sense chalcone synthase gene in trans‐
genic plants inhibits flower pigmentation. Nature 1988;333:866–869.DOI:
10.1038/333866a0
RNA Interference12
presented a diverse collection of chapters contributed by the science research communities.
We all believe that RNAi, in combination with the rapidly expanding genomic information in
key organisms and novel genome editing tools, will become even more powerful and efficient,
and that we will all enjoy its benefits far into the future.
Acknowledgements
I thank the Academy of Sciences of Uzbekistan and Committee for Coordination Science and
Technology Development of Uzbekistan for basic science FA-F5-T030; and several applied
(FA-A6-T081 and FA-A6-T085) and innovation (I-2015-6-15/2 and I5-FQ-0-89-870) research
grants. I am particularly grateful and thank the Office of International Research Programs
(OIRP) of the United States Department of Agriculture (USDA) – Agricultural Research Service
(ARS) and U.S. Civilian Research & Development Foundation (CRDF) for international
cooperative grants P121, P121B, and UZB-TA-2292, which are devoted to study, development,
application, risk assessment, and commercialization of RNAi cotton cultivars and their
products. I sincerely thank Dr. Alexander R. van der Krol, Waginengen University, Nether‐
lands, and Dr. Eric J. Devor, Iowa State University, the USA, for their critical reading and
suggestions to this chapter manuscript.
Author details
Ibrokhim Y.  Abdurakhmonov*
Address all correspondence to: genomics@uzsci.net
Center of Genomics and Bioinformatics, Academy of Science, Ministry of Agriculture and
Water Resources, and “UzCottonIndustry” Association of the Republic of Uzbekistan,
Tashkent, Uzbekistan
References
[1] Hannon GJ. RNA interference. Nature. 2002;418:244–51. DOI: 10.1038/418244a
[2] Rothstein SJ, Dimaio J, Strand M, Rice D. Stable and heritable inhibition of the ex‐
pression of nopaline synthase in tobacco expressing antisense RNA. Proc Natl Acad
Sci U S A. 1987;84:8439–8443. DOI:10.1073/pnas.84.23.8439
[3] van der Krol AR, Lenting PE, Veenstra J, van der Meer IM, Koes RE, Gerats AGM,
Joseph N. M. Mol JNM, Stuitje AR. An anti-sense chalcone synthase gene in trans‐
genic plants inhibits flower pigmentation. Nature 1988;333:866–869.DOI:
10.1038/333866a0
RNA Interference12
[4] van der Krol AR, Mur LA, Beld M, Mol JN, Stuitje AR. Flavonoid genes in petunia:
addition of a limited number of gene copies may lead to a suppression of gene ex‐
pression. Plant Cell. 1990;2:291-–99. DOI:10.1105/tpc.2.4.291
[5] Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase
gene into petunia results in reversible co-suppression of homologous genes in trans".
Plant Cell. 1990; 2:279–289. DOI:10.1105/tpc.2.4.279
[6] van Blokland R, van der Geest N, Mol JNM, Kooter JM. Transgene-mediated sup‐
pression of chalcone synthase expression in Petunia hybrida results from an increase
in RNA turnover. Plant J. 1994;6:861–877. DOI:10.1046/j.1365-313X.1994.6060861.x.
[7] Mol JNM, van der Krol AR. Antisense nucleic acids and proteins: fundamentals and
applications. New York: Marcel Dekker; 1991. 231 p. ISBN 0-8247-8516-9.
[8] Romano N, Macino G (1992). Quelling: transient inactivation of gene expression in
Neurospora crassa by transformation with homologous sequences. Mol Microbiol.
1992;6:3343–3353. DOI:10.1111/j.1365-2958.1992.tb02202.x
[9] Guo S, Kemphues K. par-1, a gene required for establishing polarity in C. elegans em‐
bryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell.
1995;81:611–620. DOI:10.1016/0092-8674(95)90082-9
[10] Pal-Bhadra M, Bhadra U, Birchler J. Cosuppression in Drosophila: gene silencing of
alcohol dehydrogenase by white-Adh transgenes is polycomb dependent. Cell.
1997;90: 479–490. DOI:10.1016/S0092-8674(00)80508-5
[11] Fire A, Xu S, Montgomery M, Kostas S, Driver S, Mello C. Potent and specific genetic
interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:
806–811. DOI:10.1038/35888. PMID 9486653
[12] Ratcliff F, Harrison B, Baulcombe D. A similarity between viral defense and gene si‐
lencing in plants. Science. 1997;276:1558. DOI:10.1126/science.276.5318.1558.
[13] Godge MR, Purkayastha A, Dasgupta I, Kumar PP.Virus-induced gene silencing for
functional analysis of selected genes. Plant Cell Rep. 2008;27: 209-219. DOI:
[14] Hale C, Kleppe K, Terns RM, Terns MP. Prokaryotic silencing (psi)RNAs in Pyrococ‐
cus furiosus. RNA. 2008;14:2572–2579. DOI: 10.1261/rna.1246808
[15] Abdurakhmonov IY, Buriev ZT, Saha S, Jenkins JN, Abdukarimov A, Pepper AE.
Cotton PHYA1 RNAi enhances major fiber quality and agronomic traits of cotton
(Gossypium hirsutum L). Nature Communications.2014;4:3062; DOI:10. 1038/
ncomms4062
[16] Kupferschmidt K. A Lethal Dose of RNA. Science. 2013;341:732–733. DOI:10.1126/
science.341.6147.732
[17] Google Scholar. 2015. Available from: http://scholar.google.com [Accessed
2015-09-06]
RNA Interference – A Hallmark of Cellular Function and Gene Manipulation
http://dx.doi.org/10.5772/62038
13
[18] PubMed database. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed [Ac‐
cessed from 2015-09-06]
[19] Matranga C, Tomari Y, Shin C, Bartel D, Zamore P. Passenger-strand cleavage facili‐
tates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell.
2005;123: 607–620. DOI:10.1016/j.cell.2005.08.044
[20] Leuschner P, Ameres S, Kueng S, Martinez J. Cleavage of the siRNA passenger
strand during RISC assembly in human cells. EMBO Rep. 2006;7:314–320. DOI:
10.1038/sj.embor.7400637
[21] Haley B, Zamore B. Kinetic analysis of the RNAi enzyme complex. Nature Structural
& Molecular Biology. 2004;11:599–606. DOI:10.1038/nsmb780
[22] Tomari Y, Matranga C, Haley B, Martinez N, Zamore P; Matranga; Haley; Martinez;
Zamore. A protein sensor for siRNA asymmetry. Science. 2004;306:1377–1380. DOI:
10.1126/science.1102755
[23] Sen G, Blau H. Argonaute 2/RISC resides in sites of mammalian mRNA decay known
as cytoplasmic bodies. Nat Cell Biol. 2005;7: 633–636. DOI:10.1038/ncb1265. PMID
15908945
[24] Lian S, Jakymiw A, Eystathioy T, Hamel J, Fritzler M, Chan E. GW bodies, micro‐
RNAs and the cell cycle. Cell Cycle. 2006;5:242–245. DOI:10.4161/cc.5.3.2410
[25] Jakymiw A, Lian S, Eystathioy T, Li S, Satoh M, Hamel J, Fritzler M, Chan E. Disrup‐
tion of P bodies impairs mammalian RNA interference. Nat Cell Biol.2005;7:1267–
1274. DOI:10.1038/ncb1334
[26] Parker G, Eckert D, Bass B. RDE-4 preferentially binds long dsRNA and its dimeriza‐
tion is necessary for cleavage of dsRNA to siRNA. RNA. 2006;12:807–818. DOI:
10.1261/rna.2338706
[27] Liu Q, Rand T, Kalidas S, Du F, Kim H, Smith D, Wang X. R2D2, a bridge between
the initiation and effector steps of the Drosophila RNAi pathway. Science. 2003;301:
1921–1925. DOI:10.1126/science.1088710
[28] Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Lins‐
ley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate
large numbers of target mRNAs. Nature. 2005;433:769–773. DOI:10.1038/nature03315.
PMID 15685193
[29] Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Wide‐
spread changes in protein synthesis induced by microRNAs. Nature. 2008:455: 58–63.
DOI:10.1038/nature07228
[30] Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP.The impact of microRNAs
on protein output. Nature.2008;455: 64–71. DOI:10.1038/nature07242
RNA Interference14
[18] PubMed database. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed [Ac‐
cessed from 2015-09-06]
[19] Matranga C, Tomari Y, Shin C, Bartel D, Zamore P. Passenger-strand cleavage facili‐
tates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell.
2005;123: 607–620. DOI:10.1016/j.cell.2005.08.044
[20] Leuschner P, Ameres S, Kueng S, Martinez J. Cleavage of the siRNA passenger
strand during RISC assembly in human cells. EMBO Rep. 2006;7:314–320. DOI:
10.1038/sj.embor.7400637
[21] Haley B, Zamore B. Kinetic analysis of the RNAi enzyme complex. Nature Structural
& Molecular Biology. 2004;11:599–606. DOI:10.1038/nsmb780
[22] Tomari Y, Matranga C, Haley B, Martinez N, Zamore P; Matranga; Haley; Martinez;
Zamore. A protein sensor for siRNA asymmetry. Science. 2004;306:1377–1380. DOI:
10.1126/science.1102755
[23] Sen G, Blau H. Argonaute 2/RISC resides in sites of mammalian mRNA decay known
as cytoplasmic bodies. Nat Cell Biol. 2005;7: 633–636. DOI:10.1038/ncb1265. PMID
15908945
[24] Lian S, Jakymiw A, Eystathioy T, Hamel J, Fritzler M, Chan E. GW bodies, micro‐
RNAs and the cell cycle. Cell Cycle. 2006;5:242–245. DOI:10.4161/cc.5.3.2410
[25] Jakymiw A, Lian S, Eystathioy T, Li S, Satoh M, Hamel J, Fritzler M, Chan E. Disrup‐
tion of P bodies impairs mammalian RNA interference. Nat Cell Biol.2005;7:1267–
1274. DOI:10.1038/ncb1334
[26] Parker G, Eckert D, Bass B. RDE-4 preferentially binds long dsRNA and its dimeriza‐
tion is necessary for cleavage of dsRNA to siRNA. RNA. 2006;12:807–818. DOI:
10.1261/rna.2338706
[27] Liu Q, Rand T, Kalidas S, Du F, Kim H, Smith D, Wang X. R2D2, a bridge between
the initiation and effector steps of the Drosophila RNAi pathway. Science. 2003;301:
1921–1925. DOI:10.1126/science.1088710
[28] Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Lins‐
ley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate
large numbers of target mRNAs. Nature. 2005;433:769–773. DOI:10.1038/nature03315.
PMID 15685193
[29] Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Wide‐
spread changes in protein synthesis induced by microRNAs. Nature. 2008:455: 58–63.
DOI:10.1038/nature07228
[30] Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP.The impact of microRNAs
on protein output. Nature.2008;455: 64–71. DOI:10.1038/nature07242
RNA Interference14
[31] Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miR‐
NAs: how many mechanisms? Trends Cell Biol 2007;17:118–126. DOI:10.1016/j.tcb.
2006.12.007
[32] Okamura K, Ishizuka A, Siomi H, Siomi M (2004). "Distinct roles for Argonaute pro‐
teins in small RNA-directed RNA cleavage pathways". Genes Dev. 2004;18:1655–
1666. DOI:10.1101/gad.1210204
[33] Lee Y, Nakahara K, Pham J, Kim K, He Z, Sontheimer E, Carthew R. Distinct roles for
Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell.
2004;117:69–81. DOI:10.1016/S0092-8674(04)00261-2
[34] Vasudevan S, Tong Y, Steitz JA. Switching from Repression to Activation: Micro‐
RNAs Can Up-Regulate Translation. Science. 2007;318:1931–1934. DOI:10.1126/
science
[35] Holmquist G, Ashley T. Chromosome organization and chromatin modification: in‐
fluence on genome function and evolution. Cytogenet Genome Res.2006;114:96–125.
DOI:10.1159/000093326
[36] Verdel A, Jia S, Gerber S, Sugiyama T, Gygi S, Grewal S, Moazed D. RNAi-mediated
targeting of heterochromatin by the RITS complex. Science. 2004;303:672–676. DOI:
10.1126/science.1093686
[37] Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R.
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci
USA.2006;103:17337–17342. DOI:10.1073/pnas.0607015103
[38] Check E. RNA interference: hitting the on switch. Nature. 2007;448: 855–858.DOI:
10.1038/448855a
[39] Stram Y, Kuzntzova L. Inhibition of viruses by RNA interference. Virus Genes.
2006;32:299–306. DOI:10.1007/s11262-005-6914-0
[40] Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipurksy SL, Dar‐
nell J. Molecular Cell Biology. 5th ed. New York; W.H; 2004.963 p. ISBN
978-0-7167-4366-8.
[41] Jones L, Ratcliff F, Baulcombe DC. RNA-directed transcriptional gene silencing in
plants can be inherited independently of the RNA trigger and requires Met1 for
maintenance. Curr Biol. 2001;11:747–757. DOI:10.1016/S0960-9822(01)00226-3
[42] Saumet A, Lecellier CH. Anti-viral RNA silencing: do we look like plants ?. Retrovir‐
ology. 2006;3:3. DOI:10.1186/1742-4690-3-3
[43] DaRocha W, Otsu K, Teixeira S, Donelson J. Tests of cytoplasmic RNA interference
(RNAi) and construction of a tetracycline-inducible T7 promoter system in Trypano‐
soma cruzi. Mol Biochem Parasitol. 2004;133:175–86. DOI:10.1016/j.molbiopara.
2003.10.005
RNA Interference – A Hallmark of Cellular Function and Gene Manipulation
http://dx.doi.org/10.5772/62038
15
[44] Robinson K, Beverley S. Improvements in transfection efficiency and tests of RNA in‐
terference (RNAi) approaches in the protozoan parasite Leishmania. Mol Biochem
Parasitol. 2003;28:217–228. DOI:10.1016/S0166-6851(03)00079-3
[45] Aravind L, Watanabe H, Lipman DJ, Koonin EJ. Lineage-specific loss and divergence
of functionally linked genes in eukaryotes. Proc Natl Acad Sci USA. 2000;97:11319–
11324. DOI:10.1073/pnas.200346997
[46] Drinnenberg IA, Weinberg DE, Xie KT, Nower JP, Wolfe KH, Fink GR, Bartel DP.
RNAi in budding yeast. Science 2009;326:544–550. DOI:10.1126/science.
[47] Morita T, Mochizuki Y, Aiba H. Translational repression is sufficient for gene silenc‐
ing by bacterial small noncoding RNAs in the absence of mRNA destruction". Proc
Natl Acad Sci USA. 2006;103:4858–486. DOI:10.1073/pnas.0509638103
[48] Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. CRISPR interference
(CRISPRi) for sequence-specific control of gene expression. Nature Protocols
2013;8:2180–2196. DOI:10.1038/nprot.2013.132
[49] Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N,
Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPR-
mediated modular RNA-guided regulation of transcription in eukaryotes. Cell.
2013;154:442–451. DOI:10.1016/j.cell.2013.06.044
[50] Cerutti H, Casas-Mollano J. On the origin and functions of RNA-mediated silencing:
from protists to man". Curr Genet. 2006;50:81–99. DOI:10.1007/s00294-006-0078-x
[51] Buchon N, Vaury C. RNAi: a defensive RNA-silencing against viruses and transposa‐
ble elements. Heredity. 2006;96:195–202. DOI:10.1038/sj.hdy.6800789.
[52] Shabalina S, Koonin EV. Origins and evolution of eukaryotic RNA interference Ecol
Evol. 2008;23:578–587. DOI: 10.1016/j.tree.2008.06.005
[53] Anantharaman V, Koonin E, Aravind L. Comparative genomics and evolution of
proteins involved in RNA metabolism. Nucleic Acids Res. 2002;30:1427–64. DOI:
10.1093/nar/30.7.1427
[54] Obbard DJ; Jiggins FM; Halligan DL; Little TJ. Natural selection drives extremely
rapid evolution in antiviral RNAi genes. Curr Biol. 2006;16:580–585. DOI:10.1016/
j.cub.2006.01.065
[55] Lucy A, Guo H, Li W, Ding S. Suppression of post-transcriptional gene silencing by a
plant viral protein localized in the nucleus. EMBO J. 2000;19:1672–1680. DOI:10.1093/
emboj/19.7.1672
[56] Hu Y, Stenlid J, Elfstrand M, Olson A. Evolution of RNA interference proteins dicer
and argonaute in Basidiomycota. Mycologia. 2013;105:1489–1498.DOI: 10.3852/13-171
[57] Voorhoeve PM, Agami R. Knockdown stands up. Trends Biotechnol. 2003;21:2–4.
DOI:10.1016/S0167-7799(02)00002-1
RNA Interference16
[44] Robinson K, Beverley S. Improvements in transfection efficiency and tests of RNA in‐
terference (RNAi) approaches in the protozoan parasite Leishmania. Mol Biochem
Parasitol. 2003;28:217–228. DOI:10.1016/S0166-6851(03)00079-3
[45] Aravind L, Watanabe H, Lipman DJ, Koonin EJ. Lineage-specific loss and divergence
of functionally linked genes in eukaryotes. Proc Natl Acad Sci USA. 2000;97:11319–
11324. DOI:10.1073/pnas.200346997
[46] Drinnenberg IA, Weinberg DE, Xie KT, Nower JP, Wolfe KH, Fink GR, Bartel DP.
RNAi in budding yeast. Science 2009;326:544–550. DOI:10.1126/science.
[47] Morita T, Mochizuki Y, Aiba H. Translational repression is sufficient for gene silenc‐
ing by bacterial small noncoding RNAs in the absence of mRNA destruction". Proc
Natl Acad Sci USA. 2006;103:4858–486. DOI:10.1073/pnas.0509638103
[48] Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. CRISPR interference
(CRISPRi) for sequence-specific control of gene expression. Nature Protocols
2013;8:2180–2196. DOI:10.1038/nprot.2013.132
[49] Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N,
Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPR-
mediated modular RNA-guided regulation of transcription in eukaryotes. Cell.
2013;154:442–451. DOI:10.1016/j.cell.2013.06.044
[50] Cerutti H, Casas-Mollano J. On the origin and functions of RNA-mediated silencing:
from protists to man". Curr Genet. 2006;50:81–99. DOI:10.1007/s00294-006-0078-x
[51] Buchon N, Vaury C. RNAi: a defensive RNA-silencing against viruses and transposa‐
ble elements. Heredity. 2006;96:195–202. DOI:10.1038/sj.hdy.6800789.
[52] Shabalina S, Koonin EV. Origins and evolution of eukaryotic RNA interference Ecol
Evol. 2008;23:578–587. DOI: 10.1016/j.tree.2008.06.005
[53] Anantharaman V, Koonin E, Aravind L. Comparative genomics and evolution of
proteins involved in RNA metabolism. Nucleic Acids Res. 2002;30:1427–64. DOI:
10.1093/nar/30.7.1427
[54] Obbard DJ; Jiggins FM; Halligan DL; Little TJ. Natural selection drives extremely
rapid evolution in antiviral RNAi genes. Curr Biol. 2006;16:580–585. DOI:10.1016/
j.cub.2006.01.065
[55] Lucy A, Guo H, Li W, Ding S. Suppression of post-transcriptional gene silencing by a
plant viral protein localized in the nucleus. EMBO J. 2000;19:1672–1680. DOI:10.1093/
emboj/19.7.1672
[56] Hu Y, Stenlid J, Elfstrand M, Olson A. Evolution of RNA interference proteins dicer
and argonaute in Basidiomycota. Mycologia. 2013;105:1489–1498.DOI: 10.3852/13-171
[57] Voorhoeve PM, Agami R. Knockdown stands up. Trends Biotechnol. 2003;21:2–4.
DOI:10.1016/S0167-7799(02)00002-1
RNA Interference16
[58] Saurabh Satyajit, Vidyarthi AS, Prasad D. RNA interference: concept to reality in
crop improvement. Planta. 2014;239:543–564. DOI:10.1007/s00425-013-2019-5
[59] Sunilkumar G, Campbell L, Puckhaber L; Stipanovic R, Rathore K. Engineering cot‐
tonseed for use in human nutrition by tissue-specific reduction of toxic gossypol.
Proc Natl Acad Sci USA.2006:103:18054–18059. DOI:10.1073/pnas.0605389103
[60] Siritunga D, Sayre R. Generation of cyanogen-free transgenic cassava. Planta.
2003;217:367–373. DOI:10.1007/s00425-003-1005-8
[61] Le L, Lorenz Y, Scheurer, S, Fötisch K, Enrique E, Bartra J, Biemelt S, Vieths S, Sonne‐
wald U. Design of tomato fruits with reduced allergenicity by dsRNAi-mediated in‐
hibition of ns-LTP (Lyc e 3) expression. Plant Biotechnol J. 2006;4:231–242. DOI:
10.1111/j.1467-7652.2005.00175.x
[62] Niggeweg R, Michael A, Martin C.Engineering plants with increased levels of the an‐
tioxidant chlorogenic acid. Nat Biotechnol.2004;22:746–54. DOI:10.1038/nbt966
[63] Gavilano L, Coleman N, Burnley L, Bowman M, Kalengamaliro, Hayes A, Bush L,
Siminszky B. Genetic engineering of Nicotiana tabacum for reduced nornicotine con‐
tent". J Agric Food Chem. 2006;54:9071–9078. DOI:10.1021/jf0610458
[64] Allen R, Millgate A, Chitty J, Thisleton J, Miller J, Fist A, Gerlach W, Larkin P. RNAi-
mediated replacement of morphine with the nonnarcotic alkaloid reticuline in opium
poppy". Nat Biotechnol.2004;22:1559–1566. DOI:10.1038/nbt1033
[65] Zadeh A, Foster G. Transgenic resistance to tobacco ringspot virus. Acta Virol.
2004;48:145–152
[66] Mao YB, Cai WJ, Wang JW, Hong GJ, Tao XY, Wang LJ, Huang YP, Chen XY. Silenc‐
ing a cotton bollworm P450 monooxygenase gene by plant-mediated RNAi impairs
larval tolerance of gossypol. Nat Biotechnol. 2007;25:1307–1313. DOI: 10.1038/nbt1352
[67] Heinemann JA, Agapito-Tenfen SZ, Carman JA. A comparative evaluation of the reg‐
ulation of GM crops or products containing dsRNA and suggested improvements to
risk assessments. Environ Int. 2013;55:43–55. DOI: 10.1016/j.envint.2013.02.010
[68] Crowe S. Suppression of chemokine receptor expression by RNA interference allows
for inhibition of HIV-1 replication. AIDS. 2003;17 Suppl 4:S103–S105. DOI:
10.1097/00002030-200317004-00014
[69] Kusov Y, Kanda T, Palmenberg A, Sgro J, Gauss-Müller V. Silencing of Hepatitis A
Virus Infection by Small Interfering RNAs. J Virol. 2006;80:5599–610. DOI:10.1128/
JVI.01773-05
[70] Jia F, Zhang Y, Liu C.A retrovirus-based system to stably silence hepatitis B virus
genes by RNA interference. Biotechnol Lett. 2006;8:1679–1685. DOI:10.1007/
s10529-006-9138-z
RNA Interference – A Hallmark of Cellular Function and Gene Manipulation
http://dx.doi.org/10.5772/62038
17
[71] Hu L, Wang Z, Hu C, Liu X, Yao L, Li W, Qi Y. Inhibition of Measles virus multiplica‐
tion in cell culture by RNA interference. Acta Virol. 2005;49:227–234. DOI: Not availble
[72] Putral L, Gu W, McMillan N. RNA interference for the treatment of cancer". Drug News
Perspect. 2006;19:317–324. DOI:10.1358/dnp.2006.19.6.985937
[73] Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy". Cancer Gene
Ther. 2005;12:217–227. DOI:10.1038/sj.cgt.7700791
[74] Li C, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf J. Delivery of RNA
interference. Cell Cycle. 2006;5:2103–2109. DOI:10.4161/cc.5.18.3192
[75] Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer
Sci. 2006;97:689–696. DOI:10.1111/j.1349-7006.2006.00234.x
[76] Raoul C, Barker S, Aebischer P. Viral-based modelling and correction of neurodegener‐
ative  diseases  by  RNA interference.  Gene  Ther.  2006;3:487–495.  DOI:10.1038/sj.gt.
3302690
[77] Hou H, Atlihan N, Lu ZX. New biotechnology enhances the application of cisgenesis in
plant breeding. Front Plant Sci. 2014;5:389. DOI: 10.3389/fpls.2014.00389.
[78] Check E. RNA treatment kills mice. Nature. 2006; DOI:10.1038/news060522-10
[79] Grimm D, Streetz K, Jopling C, Storm T; Pandey K, Davis C, Marion P, Salazar Kay F,
Kay M. Fatality in mice due to oversaturation of cellular microRNA/short hairpin
RNA pathways. Nature. 2006;441:537–541. DOI:10.1038/nature04791
[80] Qiu S, Adema C, Lane T. A computational study of off-target effects of RNA interfer‐
ence. Nucleic Acids Res. 2005;33:1834–1847. DOI:10.1093/nar/gki324
[81] Petrick JS, Brower-Toland B, Jackson AL, Kier LD. Safety assessment of food and feed
from  biotechnology-derived  crops  employing  RNA-mediated  gene  regulation  to
achieve desired traits: a scientific review. Regul Toxicol Pharmacol. 2013;66:167–176.
DOI: 10.1016/j.yrtph.2013.03.008
[82] Kamthan A, Chaudhuri A, Kamthan M, Datta A. Small RNAs in plants: recent devel‐
opment and application for crop improvement. Front Plant Sci. 2015;6:208. DOI:
10.3389/fpls.2015.00208
[83] Lemgo GN, Sabbadini S, Pandolfini T, Mezzetti B. Biosafety considerations of RNAi-
mediated virus resistance in fruit-tree cultivars and in rootstock. Transgenic Res.
2013;22:1073–1088. DOI: 10.1007/s11248-013-9728-1.
[84] Ramesh SV. Non-coding RNAs in crop genetic modification: considerations and pre‐
dictable environmental risk assessments (ERA). Mol Biotechnol. 2013;55:87–100. DOI:
10.1007/s12033-013-9648-6
[85] Auer C, Frederick R. Crop improvement using small RNAs: applications and predic‐
tive ecological risk assessments. Trends Biotechnol. 2009;27:644–651. DOI: 10.1016/
j.tibtech.2009.08.005
RNA Interference18
[71] Hu L, Wang Z, Hu C, Liu X, Yao L, Li W, Qi Y. Inhibition of Measles virus multiplica‐
tion in cell culture by RNA interference. Acta Virol. 2005;49:227–234. DOI: Not availble
[72] Putral L, Gu W, McMillan N. RNA interference for the treatment of cancer". Drug News
Perspect. 2006;19:317–324. DOI:10.1358/dnp.2006.19.6.985937
[73] Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy". Cancer Gene
Ther. 2005;12:217–227. DOI:10.1038/sj.cgt.7700791
[74] Li C, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf J. Delivery of RNA
interference. Cell Cycle. 2006;5:2103–2109. DOI:10.4161/cc.5.18.3192
[75] Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer
Sci. 2006;97:689–696. DOI:10.1111/j.1349-7006.2006.00234.x
[76] Raoul C, Barker S, Aebischer P. Viral-based modelling and correction of neurodegener‐
ative  diseases  by  RNA interference.  Gene  Ther.  2006;3:487–495.  DOI:10.1038/sj.gt.
3302690
[77] Hou H, Atlihan N, Lu ZX. New biotechnology enhances the application of cisgenesis in
plant breeding. Front Plant Sci. 2014;5:389. DOI: 10.3389/fpls.2014.00389.
[78] Check E. RNA treatment kills mice. Nature. 2006; DOI:10.1038/news060522-10
[79] Grimm D, Streetz K, Jopling C, Storm T; Pandey K, Davis C, Marion P, Salazar Kay F,
Kay M. Fatality in mice due to oversaturation of cellular microRNA/short hairpin
RNA pathways. Nature. 2006;441:537–541. DOI:10.1038/nature04791
[80] Qiu S, Adema C, Lane T. A computational study of off-target effects of RNA interfer‐
ence. Nucleic Acids Res. 2005;33:1834–1847. DOI:10.1093/nar/gki324
[81] Petrick JS, Brower-Toland B, Jackson AL, Kier LD. Safety assessment of food and feed
from  biotechnology-derived  crops  employing  RNA-mediated  gene  regulation  to
achieve desired traits: a scientific review. Regul Toxicol Pharmacol. 2013;66:167–176.
DOI: 10.1016/j.yrtph.2013.03.008
[82] Kamthan A, Chaudhuri A, Kamthan M, Datta A. Small RNAs in plants: recent devel‐
opment and application for crop improvement. Front Plant Sci. 2015;6:208. DOI:
10.3389/fpls.2015.00208
[83] Lemgo GN, Sabbadini S, Pandolfini T, Mezzetti B. Biosafety considerations of RNAi-
mediated virus resistance in fruit-tree cultivars and in rootstock. Transgenic Res.
2013;22:1073–1088. DOI: 10.1007/s11248-013-9728-1.
[84] Ramesh SV. Non-coding RNAs in crop genetic modification: considerations and pre‐
dictable environmental risk assessments (ERA). Mol Biotechnol. 2013;55:87–100. DOI:
10.1007/s12033-013-9648-6
[85] Auer C, Frederick R. Crop improvement using small RNAs: applications and predic‐




Gene Regulation by Small RNA Molecules

Chapter 2
RNA Interference Technology — Applications and
Limitations
Devi Singh, Sarika Chaudhary, Rajendra Kumar, Preeti Sirohi,
Kamiya Mehla, Anil Sirohi, Shashi Kumar, Pooran Chand and
Pankaj Kumar Singh
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/61760
Abstract
RNA interference (RNAi), an evolutionarily conserved mechanism triggered by double-
stranded RNA (dsRNA), causes gene silencing in a sequence-specific manner. RNAi
evolved naturally to mediate protection from both endogenous and exogenous pathogen‐
ic nucleic acids and to modulate gene expression. Multiple technological advancements
and precision in gene targeting have allowed a plethora of potential applications, ranging
from targeting infections in crop plants to improving health in human patients, which
have been reviewed in this chapter.
Keywords: RNA interference, miRNA, RNAi mediated gene silencing, RNA-induced si‐
lencing complex
1. Introduction
Ascribing the structure and function relationship to a gene and modulating its expression to
manifest the desired phenotype have been major challenges for scientists. [1] In order to
elucidate the phenotype(s) associated with a given gene, various gene-targeting techniques
have been tried with mixed success. Gene silencing can be executed at transcriptional gene
silencing (TGS) and posttranscriptional gene silencing (PTGS) levels. [2] The TGS involves
targeting genes at DNA level by altering promoter and enhancer efficiencies, methylation
status of genes, and deleting parts of genes by homologous recombination, transcription
activator-like effector nucleases (TALENs), and clustered regularly interspaced short palin‐
dromic repeats (CRISPR)/Cas9 systems. [3] The PTGS techniques rely upon the breakdown of
mRNA by various technologies, including antisense RNA, ribozymes, DNAzymes, micro‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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RNAs, and RNA interference (RNAi). [4] Among all these techniques, RNAi is the most
efficient tool for targeted gene silencing. RNAi is now routinely utilized across multiple
biological disciplines to determine gene function. RNAi is also being utilized for therapeutic
interventions to downregulate the expression of genes involved in disease pathogenesis. The
current review is focused on recent advancements in the biology and applications of RNAi.
2. RNAi-mediated gene silencing: A historical perspective across multiple
species
2.1. Discovery of RNAi in plants and fungi
R. Jorgensen and his colleagues identified a novel mechanism of post-transcriptional gene
silencing in Petunia. [5] They were attempting to introduce a chalcone synthase gene under a
strong promoter to deepen the purple color of Petunia flowers; however, instead of getting a
stronger purple color flower they observed that most flowers lost their color. Thus, they
observed diminished expression of both the homologous endogenous gene and the exoge‐
nously introduced transgenic copy of the gene and termed the phenomenon as co-suppression.
[5] Although the exact mechanism of this phenomenon remained undeciphered at that time,
the posttranscriptional nature of gene silencing was still appreciated. [5-7]The suppression of
endogenous gene expression by transformation of exogenous homologous sequences was later
termed as quelling in Neurospora crassa. [8, 9]
2.2. RNAi in Ceanorhabdites elegans
In 1995, Guo and Kempheus attempted to knock down the expression of PAR-1 gene by
antisense RNA in C. elegans; they observed a similar loss of gene expression with sense RNA
controls as well [10]. At that time, they could not explain the mechanistic basis of such an
observation. In 1998, Andrew Fire, Craig C. Mello, and their colleagues demonstrated efficient
and specific interference of gene expression by introducing double-stranded RNA in the
nematode C. elegans [11]. The genetic interference was genetically heritable and was stronger
than the antisense strategy. This novel phenomenon was termed as RNA interference or RNAi
by Fire and colleagues [11].
Subsequently, Lisa Timmons and Andrew Fire demonstrated that C. elegans, when fed on
bacteria genetically engineered to express dsRNA for unc-22 and fem-1 genes, showed specific
and reversible silencing of unc-22 and fem-1 genes in the worm [12, 13]. High-throughput
genetic screens have been developed by either feeding the worms on genetically engineered
bacteria expressing dsRNA or soaking or injecting the nematode with dsRNA. Functional
genomic analysis of chromosomes I and III in C. elegans have been performed by Fraser and
Gonczy, respectively, utilizing the RNA interference strategy [14, 15].
2.3. RNAi technology in Drosophila
Specific gene silencing has been achieved in the embryo extracts and cultured cells of Drosophila
flies by utilizing the RNAi tool [16]. Zamore and colleagues utilized Drosophila melanogaster
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observation. In 1998, Andrew Fire, Craig C. Mello, and their colleagues demonstrated efficient
and specific interference of gene expression by introducing double-stranded RNA in the
nematode C. elegans [11]. The genetic interference was genetically heritable and was stronger
than the antisense strategy. This novel phenomenon was termed as RNA interference or RNAi
by Fire and colleagues [11].
Subsequently, Lisa Timmons and Andrew Fire demonstrated that C. elegans, when fed on
bacteria genetically engineered to express dsRNA for unc-22 and fem-1 genes, showed specific
and reversible silencing of unc-22 and fem-1 genes in the worm [12, 13]. High-throughput
genetic screens have been developed by either feeding the worms on genetically engineered
bacteria expressing dsRNA or soaking or injecting the nematode with dsRNA. Functional
genomic analysis of chromosomes I and III in C. elegans have been performed by Fraser and
Gonczy, respectively, utilizing the RNA interference strategy [14, 15].
2.3. RNAi technology in Drosophila
Specific gene silencing has been achieved in the embryo extracts and cultured cells of Drosophila
flies by utilizing the RNAi tool [16]. Zamore and colleagues utilized Drosophila melanogaster
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embryo lysates to demonstrate the cleavage of long dsRNA strands into short interfering
dsRNA fragments (siRNA) of ~22 nucleotides (nt) [16]. Later Elbashir and colleagues demon‐
strated that chemically synthesized 21- or 22-nt-long dsRNA carrying 3′ overhangs could
induce efficient RNA cleavage in embryo extracts from Drosophila [17].
2.4. RNAi in mammalian systems
A global nonspecific inhibition of protein synthesis was observed in mammalian cells by
exposing them to dsRNAs that were greater than 30 base pairs (bp) in length [18]. RNA-
dependent  protein  kinase  (PKR),  and 2′,  5′  oligoadenylate  synthetase  (2′,  5′-OAS)  were
responsible for the nonspecific silencing. PKR phosphorylates eIF-2α, a translation initiation
factor, to shut down global protein synthesis. A synthesis product of enzyme 2′, 5′-OAS activates
RNase L, which induces nonspecific degradation of all mRNAs in a mammalian cell [18]. Long
dsRNAs induce interferon response that activates both of these enzymes in mammalian cells
[19]. The nonspecific interference pathways represent the mammalian cell response to viral
infection or other stress [20]. Tuschl and colleagues demonstrated that RNA interference could
be directly mediated by small interference RNA (siRNA) in cultured mammalian cells [21].
However, because siRNA does not integrate into the genome, the RNAi response from siRNA
is only transient. In order to induce stable gene suppression in mammalian cells, Hannon and
his colleagues utilized RNA Pol III promoter-driven (e.g., U6 or H1) expression of short hairpin
RNAs (shRNAs) [22]. Various approaches have since been developed for mammalian cells to
obtain successful gene silencing. Some of the successful gene silencing approaches are listed in
Table 1.
Kingdom Species Silencing process Induction stimulus
Fungi Neurospora Quelling Transgene(s)
Saccharomyces pombe RNAi dsRNA
























Vertebrates Human, Mouse, Zebrafish, RNAi dsRNA
Table 1. Gene silencing approaches
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3. The mechanism of silencing
RNAi-mediated gene silencing is executed by siRNAs. The process of silencing begins with
the cleavage of long dsRNAs into 21–25 -nt fragments of siRNAs in cytoplasm [16, 17]. The
process is catalyzed by Dicer enzyme [23]. These siRNAs are inserted into multiprotein
silencing complex, which is known as RNA-induced silencing complex (RISC). Subsequent
unwinding of siRNA duplex, in turn, leads to active confirmation of RISC complex (RISC*).
Next, target mRNA (mRNA to be degraded) is recognized by antisense RNA, which signals
RISC complex for the endonucleolytic degradation of the homologous mRNA. Tuschl and his
colleagues have defined the directionality of dsRNA processing and the target RNA cleavage
sites [17]. According to their results, target mRNA is cleaved in the centre of the region that is
recognized by complimentary guide siRNA, which is 10–12 -nt away from the 5′ terminus of
siRNA [17]. The RNAi process is completed by the last step of siRNA molecule amplification.
It is well established that the next generation of siRNAs is derived from the priming on the
target mRNA by RNA-dependent RNA polymerase (RdRp) enzyme by existing siRNAs. The
second generation of siRNAs is effective in inducing a secondary RNA interference that is
defined as transitive RNAi. The transitive RNAi causes a systemic genetic interference in plants
and C. elegans. Interestingly, transitive and systemic RNAi is absent in Drosophila and mammals
owing to the lack of RdRp in both organisms [24]. An illustration of the function of RNAi is
demonstrated in Figure 1.
A multitude of studies suggests a possible link between RNAi and chromatin remodeling [24].
The dsRNA works at TGS and PTGS in plants, where both pathways related and assist in gene
silencing. Only TGS is heritable and drives methylation of endogenous sequences. Multiple
proteins, including Polycomb in Drosophila and C. elegans [22], and Piwi in Drosophila [25],
execute silencing at both TGS and PTGS levels. Volpe and his colleagues documented that
RNAi complex proteins, including Dicer, Agronaute, and RdRp, assist in centromeric silencing
in Schizosaccharomyces pombe [26]. This suggests that RNAi contributes to the maintenance of
genomic stability [26].
4. Enzymes involved in RNAi
4.1. Dicer
Dicer was first characterized and defined in Drosophila by Bernstein et al. [27]. Dicer belongs
to the RNase III-class and assists in ATP-dependent siRNA generation from long dsRNAs.
Importantly, human Dicer does not require ATP for the cleavage of long dsRNAs [28].
Structurally, Dicer is a large (~220-kDa) multi-modular protein that acts as an antiparallel
dimer. Dicer has multiple domains, including an N-terminal putative DExH/DEAH box RNA
helicase/ATPase domain, an evolutionarily conserved PAZ domain, two neighboring domains
that resemble RNase III, and a dsRNA-binding domain. PAZ domain in dicer helps in
recognizing the end of dsRNA, whereas RNase III domain helps in the cleavage of dsRNA.
Function of other domains is not fully known. Dicer orthologs has been defined in many
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organisms, including S. pombe, Arabidopsis thaliana (CARPEL FACTORY [CAF]), Drosophila
(DCR-1 and DCR-2), C. elegans (DCR-1), mouse, and humans. In addition to RNAi, Dicer also
assists in the generation of microRNAs in multiple organisms [29].
4.2. RNA-Induced Silencing Complex (RISC)
RISC is a ribonucleoprotein complex that fragments mRNAs through the production of a
sequence-specific nuclease. At first, while working on Drosophila embryo extracts, Zamore and
his colleagues identified ~250 kDa precursor complex, which turns into an activated complex
of 100 kDa upon addition of ATP. However, Hannon and his colleagues found a 500-kDa
complex from Drosophila S2 cells [30, 31]. The siRNA is an important part of RISC and was the
first to be identified. It acts as a template and guides RISC to the target mRNA molecule. To
date, a number of RISC protein components are known in Drosophila and mammalian species.
Interestingly, these components are not completely overlapping, which suggests the develop‐
mental stage-specific or evolutionarily non-conserved nature of the components of RISC
complex [24].
Figure 1. Mechanism of RNAi-mediated silencing. The model demonstrates double-stranded RNA (dsRNA) can gener‐
ate either from exogenous natural sources, such as a viral infection, exogenous artificial sources such as transfection, or
natural synthesis. The dsRNA is then processed by a multimeric Dicer enzyme to generate siRNA that can be further
amplified by RNA-dependent RNA polymerase (RdRp). The siRNA subsequently interacts with an array of proteins to
form RNA-induced silencing complex (RISC) that is activated in an ATP-dependent manner. The activated RISC
(RISC*) can then induce chromatin remodeling or TGS, or induce target RNA cleavage, or cause miRNA-mediated
translational inhibition.
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The first RISC protein component identified was Agronaute-2, a C. elegans RDE-1 homologue
[32]. Argonaute (AGO) proteins are part of an evolutionarily conserved protein family and
they play a central role in RNAi, determination of stem cell developmental regulation, and
tumorigenesis. AGOs are ~100 kDa highly basic proteins that contain N-terminal PAZ and
mid- and C-terminal PIWI domains [33]. The PAZ domain is an RNA-binding module, which
is involved in protein–protein interactions, whereas PIWI is essentially required for target
cleavage. Some AGO proteins that are involved in RNAi are listed in the Table 2.
Species Argonaute homolog Essentiality for RNAi Citations
Arabidopsis AGO1 Essential for co-suppression and
PTGS
ZWILE Non-essential
Tetrahymena TWI1 Essential for DNA elimination
Neurospora QDE2 Required component of RISC
C. elegans RDE-1 Forms complex with Dicer
ALG-1 Nonessential
ALG-2 Nonessential
PPW-1 Essential for germline RNAi
Drosophila Aubergine Localizes with dsRBP Staufen and
RNA helicase Vasa. Essential for
maturation-dependent RNAi
generation.
dAgro1 Essential in embryos, acts
downstream of RNAi generation
dAgo2 Required component of RISC
dAgo3 Prediction based on DNA
sequence
PIWI Essential for PTGS and TGS
Mammals (human) EIF2C2/hAgo2 Part of RISC complex and
catalyzes the miRNA –directed
cleavage
Table 2. Argonaute homolog proteins in RNAi
Some RISC components are non-AGO proteins, including dFXR and VIG in Drosophila, the
fragile X mental retardation 1 (FMR1) homolog in Drosophila, and germin3/4 in mammals [34].
4.3. RNA helicase
RNA helicases cause unwinding of dsRNA. However, Dicer contains its own helicase activity
in the N-terminal helicase domain. Hence, the helicase proteins putatively function down‐
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stream of the RISC complex. Two major RNA helicase families are involved in RNAi [35]. SDE3
from A. thaliana and its homologous proteins in mouse, human, and Drosophila constitute the
first such helicase family. The second family contains Upf1p from yeast and an Upf1 homo‐
logue (SMG-2) in C. elegans. The Upf1/SMG-2 is characterized by cysteine-rich motif conserved
across species and multiple C-terminal Ser-Gln (SQ) doublets. MUT-6, a DEAH-box helicase
in C. elegans is also putatively involved in transposon suppression. Another RNA helicase
Germin3 resides in complex with human AGO protein EIF2C2/hAgo2 [36].
4.4. RNA-dependent RNA polymerase (RdRp)
RdRp catalyzes the amplification and triggering of RNAi, which is usually in small amounts.
RdRp catalyzes the siRNA-primed amplification by polymerase chain reaction to convert
mRNA into dsRNAs, a long form that is cleaved to produce new siRNAs [37]. Lipardi and his
colleagues demonstrated RdRp-like activity in Drosophila embryo extracts, but the enzyme
responsible for the RdRp activity in the Drosophila or human is not known. Some of the RdRps
involved in RNAi have been summarized in Table 3.
Species RdRp homolog Essentiality for RNAi Citations
Arabidopsis SDE1 Essential for PTGS by
transgenes but not by viruses
Neurospora QDE1 Essential for co-suppression
C. elegans EGO1 Essential for germline RNAi
RRF1 Essential for RNAi in soma
RDE9 Forms complexes with Dicer
Table 3. RdRps involved in RNAi
5. Various small RNA isoforms related to RNAi
5.1. Small interfering RNAs (siRNAs)
Small interfering RNAs are 21–23-nt-long double-stranded RNA molecules with 2–3-nt
overhangs at the 3′ termini. siRNAs are normally generated, as mentioned in the above
sections, by the cleavage of long double-stranded RNAs by RNase III (Dicer) [16]. siRNAs must
be phosphorylated at the 5′ termini by endogenous kinases to enter into the RISC complex [31].
It is thought that the hydroxylated 3′ termini are essential for the siRNA-primed amplification
step catalyzed by RdRps. However, Zamore et al. showed that non-priming alterations in the
3′ hydroxyl group did not adversely affect RNAi-mediated silencing [38]. They went on to
explain that siRNAs operate as guide RNAs for gene repression but not as primers in the
human and Drosophila RNAi pathways [38]. Conversely, Hamada et al. showed in mammalian
cells that modifying the 3′ end of the antisense strand of siRNA abolished the RNAi effect,
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while modifying the 3′ end of the sense strand did not affect the RNAi silencing [39]. These
findings support the model that each strand of siRNA has different functions in the RNAi
process, and the 3′ hydroxylated end of the antisense strand may prime the amplification.
Ambros et al. discovered endogenous siRNA in more than 500 genes in wild-type C. elegans
[39]. This suggests that siRNA may be a globally conserved and common molecule among
species.
5.2. Micro RNAs (miRNAs)
miRNAs are 19–25-nt small RNA species produced by Dicer-mediated cleavage of endogenous
~70-nt noncoding stem-loop precursors. The miRNAs, while allowing mismatches, can either
repress the target mRNA translation (mostly in mammals) or facilitate mRNA destruction
(mostly in plants) [40]. miRNAs lin-4 and let-7 were the first ones to be identified in C.
elegans [40]. So far, about 2000 different miRNAs have been identified in plants, animals, and
lower species. While some miRNAs are evolutionarily conserved, others are specific for some
developmental stages or are species-specific. Different terminologies are referred to in
literature. According to one terminology, the miRNAs with well-characterized functions (e.g.,
lin-4 and let-7) are referred to as small temporal RNAs (stRNAs), while other similar small
RNAs of unknown functions are called miRNAs [40]. Multiple miRNAs have been character‐
ized for their physiological roles in cancer and other diseases [41, 42]. Comparisons between
siRNA and miRNA have been listed in the Table 4.
Resemblences
siRNA miRNA
1. The siRNAs require processing from long dsRNAs. 1. The miRNAs require processing from stem-loop precursors
that are ~70 nt long.
2. An RNase III enzyme Dicer is required for processing. 2. Dicer is required.
3. The siRNAs are usually ~22 nt long. 3. The miRNAs are also ~22 nt long.
Disparities
siRNA miRNA
1. The siRNAs are double-stranded structures with 2-nt
3′ overhangs that are formed during cleavage by Dicer.
1. The miRNAs are single-stranded structures.
2. The siRNA require high homology with the mRNA to
bind and cleave.
2. The miRNAs can function even with a few mismatched
nucleotides.
3. The siRNAs mediate target mRNA cleavage by RISC. 3. The miRNAs can either block target mRNA translation by
binding to it or mediate target mRNA cleavage by RISC.
4. The siRNAs are usually triggered by transgene
incorporation, viral infection, or active transposons.
4. The miRNAs are constitutively expressed cellular RNA
moieties with potential roles in development, and cell
proliferation and death.
Table 4. Comparative characteristics of siRNA and miRNA
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5.3. Tiny noncoding RNAs (tncRNAs)
Ambros and his colleagues discovered the first tncRNAs in C. elegans. They identified and
characterized 33 new tncRNAs in C. elegans by performing cDNA sequencing and comparative
genetics [40]. The tncRNAs are very similar to miRNAs with regard to their size, single-
stranded structure, and lack of a precise complementarity to a given mRNA. However, they
are distinct with regard to their lack of processing from a “miRNA-like hairpin precursor”,
and phylogenetic nonconservation. Similarly to miRNA, tncRNAs are transcribed from
noncoding sequences. However, their developmental role is not fully understood. According
to Ambros and his colleagues, it is plausible that some of the miRNAs might be processed from
noncoding mRNAs in the course of RNAi [40].
6. Evolutionary relevance of RNAi in the immunological responses
RNAi may provide a systemic way to immunize an organism against the invasive nucleic
acids from viruses and transposons via inducing the RNAi responses. Virus-induced gene
silencing (VIGS) in plants is accomplished by RNAi. Multiple genetic links between RNAi
and virulence are known. Many plant viruses code for viral suppressors of gene silencing
(VSGS). VSGS acts as a virulence determinant, and hence, is required for developing anti-
virulence response in the host. In response to the virulence, the host can also modify its
PTGS/RNAi mechanisms to prevent  future infections.  RNAi can even target  DNA virus
amplification in plants [43]. VIGS mechanisms exist not only in plants and nematodes but
also in other species; for example, flock house virus (FHV), a virus that infects Drosophila,
also codes for a potential silencing suppressor (b2) [24]. Nonetheless, the precise function
of RNAi in mammalian antiviral defense is not clear.
RNAi also plays a crucial role in the development process of multicellular organisms. When
mutated, CARPEL FACTORY, a Dicer homologue in Arabidopsis, can cause developmentally
defective leaves and induce overproliferation of floral meristems. Inactivation of Dicer by
mutations causes developmental problems and sterility in C. elegans. Mutations in AGO
protein influence normal development in Drosophila as well. Hence, components of RNAi
pathway play a significant role in normal development, but such components and the affiliated
gene products play crucial roles in related but distinct gene regulation pathways [23].
A potential role of RNAi and human disease pathogenesis has been proposed due to associa‐
tion of RNA binding proteins with RISC complex, such as Vasa intronic gene (VIG) and the
fragile X mental retardation protein (FMRP) Drosophila homologue [36].
7. RNAi as a functional genomics tool and its applications for therapy
RNAi technology is applicable for gene silencing in many species. RNAi has been used
extensively in C. elegans for functional genomics. High-throughput investigation of most of the
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~19,000 genes has been accomplished. Ahringer and his colleagues produced an RNAi library,
representing ~86% of the genes of C. elegans [15]. This strategy has been successfully attempted
in multiple other model organisms, including human [44].
RNAi has also been utilized successfully in mammalian cells [44]. Various methods have been
employed for siRNA knockdown of specific genes in mammalian cells. DNA-vector-mediated
RNAi silences genes transiently in mammalian cells, while other expression systems are used
for stable silencing. The promoters of RNA polymerase (pol) II and III (U6 and H1, alone or
together) have been used for stable silencing. Furthermore, tRNA promoter-based systems
have been used for this purpose. However, pol III-based short hairpin RNA (shRNA) expres‐
sion systems (e.g., H1 RNA pol-based pSuper vector) are suitable choices. Retroviral-vector-
based delivery of siRNAs has also been utilized for more efficient silencing. Two classes of
retrovirus vectors have been employed: (1) HIV-1-derived lentivirus vectors and (2) Oncore‐
trovirus-based vectors, such as Moloney murine leukemia virus (MoMuLV) and Murine stem
cell virus (MSCV). Transgenic mice have been established with germline transmission of a
shRNA expression cassette for silencing of genes not targeted by homologous recombination-
based approaches [45]. Desirable applications of this technique include inducible and cell type-
specific expression patterns.
The use of RNAi is not limited to the determination of mammalian gene function, and also
could be used for treating viral infections and cancer [46, 47]. Viral and human genes that are
needed for viral replication can be attacked to generate viral-resistant host cells or to treat viral
infections [47]. Oncogenes, which accelerate cancer growth, can be targeted by RNAi [48, 49].
Targeting of molecules important for neovascularization could prevent tumor growth [50].
This book presented several chapters with detailed discussions of therapeutic aspects of the
RNAi in immune, blood, cancer, and brain diseases. We refer readers to those chapters (by Hu
et al.; Gu; and Cho and Kim) rather to continue repeated information here.
8. Conclusions
Fast progress in RNAi technology has shown promise for use in reverse genetics and therapy.
However, mechanistic complexities of this technology still need to be determined. RNAi has
now been established as a revolutionary tool for functional genomics in organisms. Multiple
studies have defined the role of RNAi in mammalian and plant defense systems. A plethora
of studies have utilized RNAi technology to modulate gene expression. RNAi-based full
genomic screens have allowed identification of specific genes, controlling a given trait with
high accuracy. Further studies will continue to unravel the unlimited potential of RNAi to
serve humankind.
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Abstract
Tumors could evade the control of CD8+ T and/or NK cell-mediated surveillance by dis‐
tinct immune escape strategies. These include the aberrant expression of HLA class I anti‐
gens, coinhibitory or costimulatory molecules, and components of the interferon (IFN)
signal transduction pathway. In addition, alterations of the tumor microenvironment
could interfere with a proper antitumoral immune response by downregulating or inhib‐
iting the frequency and/or activity of immune effector cells and professional antigen pre‐
senting cells. Based on the identification as major mediators of the posttranscriptional
silencing of gene expression, microRNAs (miRNAs) have been suggested to play a key
role in many biological processes known to be involved in neoplastic transformation. In‐
deed, miRNA expression is frequently deregulated in many cancer types and could have
tumor-suppressive as well as oncogenic potential. This review focused on the characteri‐
zation of miRNAs, which are involved in the control of the immune surveillance or im‐
mune escape of tumors and their use as potential diagnostic and prognostic biomarkers
as well as therapeutic targets. Moreover, miRNAs can have dual activities by affecting the
neoplastic and immunogenic phenotype of tumors.
Keywords: APM, IFN, immune escape, microRNA, tumor microenvironment
1. Introduction
Tumors have developed different strategies to evade immune recognition by cytotoxic T
lymphocytes (CTLs) as well as natural killer (NK) cells. This is caused by alterations of the
tumor itself, changes of the tumor microenvironment (TME), reduced frequency, and impaired
function of diverse immune subpopulations. The processes leading to immune evasion of
tumors are diverse and could be associated with structural alterations and/or deregulation of
genes/proteins from tumor cells, but also from different immune cells important for recogni‐
tion and killing of tumor cells or in the induction of immune suppression. The identification
of microRNAs (miRNAs), involved in the RNA interference (RNAi)-based control of these
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
immune modulatory molecules, clarified the complexity of the mechanisms conditioning
tumor immune escape. This review is focused on the identification and characterization of
immune modulatory miRNAs (im-miRNAs) in tumors, thereby altering the antitumoral
immune response by miRNAi-mediated RNAi.
2. The MHC class I antigen processing and presentation machinery (APM)
The major histocompatibility complex class I (MHC) molecules present an array of peptide
epitopes for surveillance by CD8+ T cells. These peptides are classically derived from proteins
synthesized in the cytosol. Upon proteasomal degradation of ubiquitinated proteins, the
yielded peptides are then transported into the endoplasmic reticulum (ER) via the heterodi‐
meric peptide transporter associated with antigen processing (TAP). The peptide transport
into the ER is ATP dependent and sequence specific. The TAP heterodimer associates in ER
with a number of other proteins to form the peptide loading complex (PLC). These include the
chaperone tapasin, which recruits MHC class I heavy chain (HC)/β2-microglobulin (β2-m)
dimers and calreticulin. The peptides are either trimmed by ER-resident aminopeptidases or
directly loaded onto MHC class I molecules [1]. Upon peptide loading, the PLC dissociates
from the trimer consisting of the MHC class I HC, β2-m, and peptide is then transported via
the trans Golgi to the cell surface and exposed to CD8+ CTLs [1].
3. Immune stimulatory and immune inhibitory molecules and immune
response
An effective T-cell response requires two signals. The first is mediated by the interaction with
MHC class I antigens on the antigen-presenting cells (APC), and the second is mediated by
the interaction of B7 family members on APC with CD28 or CTLA4 on T cells. The prototypes
of B7 family members are B7-1 (CD80) and B7-2 (CD86). During the last years, the B7 family
was growing consisting of B7-H1 (PDL-1), B7-H2, B7-H3, B7-H4, and B7-H6 molecules [2, 3].
While B7-H1 and B7-H4 represent coinhibitory molecules, B7-H2 was identified as costimu‐
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H2 binds to the receptor ICOS, which results in activation of T cells through
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B7-H6 has been identified as ligand for the NK cell receptor NKp30 and is detectable on surface
or in the cytosol of tumor cells and as soluble factor in the peritoneal fluid [7], while it is not
expressed on healthy cells. The interaction of B7-H6 with NKp30 is involved in NK cell
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immune modulatory molecules, clarified the complexity of the mechanisms conditioning
tumor immune escape. This review is focused on the identification and characterization of
immune modulatory miRNAs (im-miRNAs) in tumors, thereby altering the antitumoral
immune response by miRNAi-mediated RNAi.
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meric peptide transporter associated with antigen processing (TAP). The peptide transport
into the ER is ATP dependent and sequence specific. The TAP heterodimer associates in ER
with a number of other proteins to form the peptide loading complex (PLC). These include the
chaperone tapasin, which recruits MHC class I heavy chain (HC)/β2-microglobulin (β2-m)
dimers and calreticulin. The peptides are either trimmed by ER-resident aminopeptidases or
directly loaded onto MHC class I molecules [1]. Upon peptide loading, the PLC dissociates
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the trans Golgi to the cell surface and exposed to CD8+ CTLs [1].
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responses [8]. It is noteworthy that many other coinhibitory molecules have also been identi‐
fied and their role on immune responses is currently under investigation [2, 3].
4. Features of the interferon-γ-mediated signal transduction
Interferons (IFN) are a group of pleiotropic cytokines that play a key role in the intercellular
communication during innate and adaptive immune responses, in particular in the host
defense against viral and bacterial infections and neoplastic transformation [9]. The IFN family
could be classified into type I and type II IFNs, which differ in their activity regarding immune
modulation [10].
IFN-γ belongs to the type II IFN and is a central regulator of immune responses by controlling
and modulating the expression of targets essential for cell-cell communication and cellular
interactions. It is secreted by activated T cells, NK cells, and macrophages and induced by DC
and monocytes stimulated with bacterial cell wall components [11]. IFN-γ exerts its activity
by binding to its heterodimeric receptor consisting of IFN-γ-R1 and IFN-γ-R2 subunits [12,
13]. This results in the dimerization of the receptor subunits followed by activation (trans‐
phosphorylation) of the receptor-associated tyrosine kinases JAK1 and JAK2 belonging to the
Janus kinase (JAK) family and phosphorylation and dimerization of the JAK-associated STAT1
transcription factor. The activated STAT1 is translocated into the nucleus and recruited to the
IFN-γ-activated sequence (GAS) element of the promoters of the STAT1 target genes leading
to their transcriptional activation.
IFN-γ-regulated genes can be classified into primary and secondary responsive genes. Primary
responsive genes are induced early due to the binding of STAT dimers to the GAS element in
the promoter region of target genes, like IRF1, CXCL9, and CXCL10 [14]. IRF1 binds to IFN-
stimulated response elements (ISRE) and modulates gene induction of the secondary respon‐
sive genes. IFN-γ induced the transcription of MHC class I and class II antigens and of many
APM components and at high concentrations could lead to a caspase-dependent apoptosis. In
addition, IFN-γ is involved in amplifying toll-like receptor (TLR) signaling by increasing or
inhibiting the transcription of TLRs, chemokines, and cytokines [15, 16]. Furthermore, IFN-γ
promotes the induction of SOCs proteins (suppressor of cytokine signaling), which inhibit IFN-
γ signaling by a negative feedback loop, resulting in the inactivation of JAK1 and JAK2 [17].
Moreover, IFN-γ signaling is controlled by inhibiting JAK1, JAK2, and IFN-γ-R1 via dephos‐
phorylation mediated by SH2-domain-containing protein tyrosine phosphatase 2 [18], by
proteasomal degradation of JAK1 and JAK2 [18] and by inhibition of STAT1, which is mediated
by the protein inhibitor of activated STAT1 [19].
5. Distinct levels of tumor immune escape
Tumors have developed different strategies to escape immune surveillance, which could occur
at the level of immune cells, tumor micromilieu, and the tumor itself (Figure 1). The frequency,
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activity, and function of CD8+ and CD4+ T lymphocytes, DC, NK cells, and B cells are often
downregulated in peripheral blood of tumor patients, while the number of immune-suppres‐
sive myeloid-derived suppressor cells (MDSC), NKT cells, and regulatory T cells (Treg) is
upregulated [20-23].
Figure 1. Tumor immune escape mechanisms containing (A) loss of tumor antigen expression; (B) variations in tumor
antigen processing; (C) defects in the peptide transporter TAP, chaperone tapasin, and protease ERAP1; (D) defects in
expression of MHC class I heavy chain and β2-microglobulin; (E) release of anti-inflammatory cytokines; (F) downre‐
gulation of IFN-γ-R1, JAK1, JAK2, STAT1, and STAT2; (G) altered phosphorylation states of STAT1; (H) impaired up‐
regulation of IFN-γ regulated genes (MHC class I, APM); (I) upregulated expression of HLA-G; (J) altered methylation
pattern of IRF; (K) overexpression of SOCS1; and (L) protection from T-cell-mediated apoptosis.
The tumor microenvironment (TME) consists of various cellular and soluble factors and is of
clinical relevance since its composition significantly correlates with the tumor patients’
outcome. These include different cellular components, such as fibroblasts, blood vessels,
immune cells, stroma cells, extracellular matrix, and soluble factors such as immune-suppres‐
sive cytokines, like interleukin (IL)-10, transforming growth factor (TGF)-β, metabolites,
arginase and prostaglandin, hypoxia, and pH, which negatively interfere with the antitumoral
immune responses.
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In tumors, an aggressive and deregulated growth of neoplastic transformed cells, which
overexpress proangiogenic factors, such as the vascular endothelial growth factor (VEGF),
leads to the development of organized blood vessels. These blood vessels are fundamentally
different from the normal vasculature. Tumor-associated fibroblasts (TAF) represent the major
constituents of the tumor stroma and produce growth factors, including the VEGF and
inhibitory cytokines that activate extracellular matrix thereby contributing to the tumor
growth.
Furthermore, cancer is often driven by inflammation mediated by monocytes and tumor-
associated macrophages (TAM), which belong to the innate immune cells. Macrophages could
be classified in type 1 and 2 macrophages. While M1 macrophages express a series of proin‐
flammatory cytokines, chemokines and effector molecules, the M2 macrophages express a
wide array of anti-inflammatory molecules, including IL-10, IL-35, TGF-β, and adenosine.
TAMs are mainly of the M2 phenotype and secrete different cytokines, chemokines and
proteases, which promote tumor angiogenesis, growth, metastasis as well as immune sup‐
pression.
In addition to TAM and TAF, MDSC represent a heterogeneous population derived from
myeloid progenitors [20]. They can promote tumor growth by enhancing angiogenesis or
suppression of innate and adaptive immune responses. Regarding the innate immune cells,
MDSCs  suppress  NK  cell  cytotoxicity,  promote  M2  macrophage  differentiation,  and
modulate  the  priming  activity  of  mature  DC  [24].  Moreover,  MDSCs  suppress  T-cell
responses by induction of apoptosis, secretion of immune modulatory factors, modulation
of amino acid metabolism, restriction of T-cell homing, and induction of Treg [25-28]. Tregs
suppress the activity of immune cells and maintain immune tolerance to self-antigens. They
express CD4, CD25 and FoxP3 [22]. The elevated numbers of Tregs in cancer is due to their
efficient migration into the tumor sites [29], local expansion in the tumor environment[29],
and de novo generation within the tumor [30].
5.1. Alterations of the tumors
Immune escape mechanisms include loss or downregulation of HLA class I antigens and/or
components of the antigen processing machinery (APM), upregulation of nonclassical HLA-
G and HLA-E antigens, and coinhibitory molecules, including PDL-1, as well as alterations of
signaling transduction cascades, including in particular the IFN signaling pathway [31]. The
frequency of these different mechanisms highly varied between tumor (sub)types and is often
correlated with a worse prognosis and reduced survival of tumor patients.
5.1.1. MHC class I abnormalities
The classical MHC class I pathway and the APM components are involved in eradication of
developing tumors [32]. Since CD8+ CTLs recognize and eliminate cells presenting tumor
antigens via HLA class I molecules, loss of HLA class I expression results in evasion of CTL-
mediated cell death [33]. Abnormalities of HLA class I antigens are often due to downregula‐
tion of various components of the MHC class I APM, in particular of TAP, tapasin, β2-m, and
MHC class I HC. Structural alterations of these components are rare, while MHC class I defects
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are mainly due to deregulation of the different components, which could be controlled at the
transcriptional, epigenetic (methylation, acetylation), posttranscriptional (e.g., microRNAs,
protein degradation), or posttranslational (phosphorylation) level.
HLA-G has been demonstrated as a nonclassical HLA class I antigen, which is in general only
expressed on immune privileged organs, but also on many tumors of distinct origin [34]. The
overexpression of HLA-G or secretion of soluble HLA-G are directly associated with tumor
progression and reduced patients’ survival. It suppresses antitumoral immune responses by
binding to receptors of various immune populations, thereby inhibiting the sensitivity to CTL-
and NK cell-mediated lysis in particular [34]. In contrast, tumor cells with deficient expression
of classical HLA class I molecules are eradicated by NK cells.
5.1.2. Check points as important regulators of immune response
During carcinogenesis, members of the B7-family play a key regulatory role of both stimulato‐
ry and inhibitory T-cell responses, which depends on the available B7 ligand and receptor on
the respective target and immune cells [35, 36]. Interestingly, B7-H1 and B7-H4 were often
overexpressed on tumors leading to impaired immune recognition. By interaction with these
coinhibitory molecules, the intensity of the T-cell responses is reduced by raising the thresh‐
old of activation, halting proliferation, enhancing apoptosis, and inhibiting the differentia‐
tion of effector cells [37].
5.1.3. Role of IFN-γ in cancer immunogenicity
Abnormalities of MHC class I expression on tumor cells due to the downregulation or loss of
APM component expression are common mechanisms, by which tumor cells can escape from
anti-tumor-specific immunity [38, 39]. In addition, tumor cells are often not susceptible to
treatment with IFN-γ, which could be due to structural alterations or deregulation of constit‐
uents of the IFN signal pathway. Several studies confirmed that defects in the IFN-γ receptor
signaling cascade could be occur at multiple steps of this pathway, including lack of the
expression of the IFN-γ-R1, abnormal forms of JAK2, lack of expression of JAK1 [40], altered
phosphorylation, repressed STAT1 expression, and overexpression of SOCS1. The latter results
in an increased negative feedback regulation of the IFN-γ signal cascade. The defects in the
IFN-γ receptor signaling cascade caused impaired expression of IFN-γ regulated genes.
Previous studies demonstrated that IFN-γ responsive genes are frequently downregulated in
tumor cells due to impaired IRF1 expression as well as defective transcriptional and posttran‐
scriptional regulation of components involved in the IFN-γ signal transduction pathway. The
loss of the IFN-γ-mediated upregulation of TAP in a renal cell carcinoma is associated with
the lack of IRF1 and STAT1 binding activities as well as JAK1, JAK2, and STAT1 phosphory‐
lation [41]. This impaired IFN-γ-mediated phosphorylation could not be restored by JAK1 and/
or JAK2 gene transfer. Furthermore, an impaired STAT1-phosphorylation associated with the
loss of IFN-γ-mediated MHC class I upregulation was also reported in melanoma and
colorectal carcinoma cells [42].
RNA Interference42
are mainly due to deregulation of the different components, which could be controlled at the
transcriptional, epigenetic (methylation, acetylation), posttranscriptional (e.g., microRNAs,
protein degradation), or posttranslational (phosphorylation) level.
HLA-G has been demonstrated as a nonclassical HLA class I antigen, which is in general only
expressed on immune privileged organs, but also on many tumors of distinct origin [34]. The
overexpression of HLA-G or secretion of soluble HLA-G are directly associated with tumor
progression and reduced patients’ survival. It suppresses antitumoral immune responses by
binding to receptors of various immune populations, thereby inhibiting the sensitivity to CTL-
and NK cell-mediated lysis in particular [34]. In contrast, tumor cells with deficient expression
of classical HLA class I molecules are eradicated by NK cells.
5.1.2. Check points as important regulators of immune response
During carcinogenesis, members of the B7-family play a key regulatory role of both stimulato‐
ry and inhibitory T-cell responses, which depends on the available B7 ligand and receptor on
the respective target and immune cells [35, 36]. Interestingly, B7-H1 and B7-H4 were often
overexpressed on tumors leading to impaired immune recognition. By interaction with these
coinhibitory molecules, the intensity of the T-cell responses is reduced by raising the thresh‐
old of activation, halting proliferation, enhancing apoptosis, and inhibiting the differentia‐
tion of effector cells [37].
5.1.3. Role of IFN-γ in cancer immunogenicity
Abnormalities of MHC class I expression on tumor cells due to the downregulation or loss of
APM component expression are common mechanisms, by which tumor cells can escape from
anti-tumor-specific immunity [38, 39]. In addition, tumor cells are often not susceptible to
treatment with IFN-γ, which could be due to structural alterations or deregulation of constit‐
uents of the IFN signal pathway. Several studies confirmed that defects in the IFN-γ receptor
signaling cascade could be occur at multiple steps of this pathway, including lack of the
expression of the IFN-γ-R1, abnormal forms of JAK2, lack of expression of JAK1 [40], altered
phosphorylation, repressed STAT1 expression, and overexpression of SOCS1. The latter results
in an increased negative feedback regulation of the IFN-γ signal cascade. The defects in the
IFN-γ receptor signaling cascade caused impaired expression of IFN-γ regulated genes.
Previous studies demonstrated that IFN-γ responsive genes are frequently downregulated in
tumor cells due to impaired IRF1 expression as well as defective transcriptional and posttran‐
scriptional regulation of components involved in the IFN-γ signal transduction pathway. The
loss of the IFN-γ-mediated upregulation of TAP in a renal cell carcinoma is associated with
the lack of IRF1 and STAT1 binding activities as well as JAK1, JAK2, and STAT1 phosphory‐
lation [41]. This impaired IFN-γ-mediated phosphorylation could not be restored by JAK1 and/
or JAK2 gene transfer. Furthermore, an impaired STAT1-phosphorylation associated with the
loss of IFN-γ-mediated MHC class I upregulation was also reported in melanoma and
colorectal carcinoma cells [42].
RNA Interference42
IFN-γ treatment is able to restore the expression of many genes belonging to the MHC class I
APM [43, 44]. As a consequence, anti-tumor-specific immune responses can be induced,
suggesting that IFN-γ acts as key regulator of immunogenicity [45]. Its antitumoral activity
includes also the induction of apoptosis and inhibition of cell proliferation by STAT1 activa‐
tion, which induces expression of cell cycle inhibitor, CDKN1A [46]. In addition, the IFN-γ-
mediated upregulation of MHC class I antigens could be due to DNA demethylation of MHC
class I APM genes, suggesting that IFN-γ acts as an epigenetic modifier of APM components
[47]. Therefore, IFN-γ is a major player in the regulatory network combating tumor cell
proliferation and tumor survival.
6. Features of miRNAs
miRNAs are small noncoding ~22 nucleotide long regulatory RNAs encoded in the human
genome,  which  control  the  posttranscriptional  gene  expression  by  binding  to  the  3′-
untranslated region (UTR) of mRNA of target genes, thereby affecting their stability and/or
their translation [48]. An individual miRNA could target numerous cellular mRNAs, while
single miRNA can be regulated by several proteins [49, 50]. miRNAs have emerged as key
players  in  the  posttranscriptional  control  of  gene expression and based on their  predic‐
tion appear to be directly involved in the expression of at least 50% of all protein-coding
genes in mammals [51].
A strong relationship between miRNAs and human cancer has been developed during the past
years. High throughput analysis allows the comparison of miRNA expression pattern in
normal and tumor tissues demonstrating global changes within the miRNA expression in
different malignancies. Interestingly, the miRNA genes were frequently located at fragile sites
and cancer-associated chromosomal regions. The deregulation of the biogenesis and expres‐
sion of miRNAs is involved in the initiation as well as progression of tumors, metastasis
formation, and therapy resistance [52]. Furthermore, miRNAs can participate in reprogram‐
ming components of the tissue tumor microenvironment (TME) in order to promote tumor‐
genicity [53]. In the following sections, miRNAs are described as powerful RNAi inducing
regulators of immune modulatory genes involved in escape from immune surveillance.
Moreover, this review highlights some miRNAs and their roles in immune escape and
discusses these miRNAs as putative targets for (immune) therapy (Figure 2).
6.1. Antigen processing and presentation machinery and miRNAs
Recent studies showed identified miRNAs able to affect the expression of APM components.
Microarray analysis of miRNA-9 overexpressing nasopharyngeal carcinoma cells demonstrat‐
ed that miRNA-9 controls the expression of components of the classical MHC class I pathway.
miRNA-9 targets many IFN-induced genes and MHC class I APM molecules, such as the
proteasome subunits PSMB8 and PSMB10, TAP1, β2-m, HLA-B, HLA-C, and the nonclassical
HLA-F and HLA-H antigens [54]. However, the binding of miRNA-9 to the 3′-UTR of these
molecules has not yet been shown. miRNA-9 is involved in the cellular differentiation [55] and
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aberrantly expressed in many cancer types breast cancer[56], colon cancer [57], nasopharyng‐
eal carcinoma [58], and melanoma [59], suggesting that the decreased miRNA-9 expression is
associated with tumor suppressor activity. In contrast, miRNA-9 expression is increased in
brain cancer [60] and in Hodgkin’s lymphoma [61], implying an oncomir potential. Further‐
more, miRNA-9 has been shown to regulate the proliferation [56, 60-62] epithelial-mesenchy‐
mal transition (EMT), invasion and metastasis [62-64], apoptosis [56], tumor angiogenesis
[63-64], and evasion of immune surveillance in many cancer types [54]. Although the function
of miRNA-9 in the classical MHC class I pathway has still to be characterized in extent,
miRNA-9-mediated regulation of APM deficiencies might be at least partially responsible for
the T cell-mediated immune escape.
Besides miRNA-9, the ER stress-induced miRNA-346 modulates the expression of APM
components and IFN-induced genes as shown by miRNA arrays. Functional studies revealed
that TAP1 is a direct target of miRNA-346 using overexpression and RNAi knockdown
experiments with miRNA mimic and miRNA inhibitors. The ER stress-mediated MHC class
I-associated antigen presentation decrease might be explained by increased miRNA-346
expression [65], although the function of miRNA-346 in cancer has not yet been fully analyzed.
The inflammation and overexpression of miRNA-451 are associated with the carcinogenesis
of lung cancer. A decrease in the proliferation, invasion, and metastatic potential of lung cancer
cells was detected after the overexpression of miRNA-451. In addition, the proteasome subunit
Figure 2. Scale of miRNAs targeting immune pathways in cancer exhibit an imbalance of tumor-suppressive miRNAs,
which occur more frequent than oncogenic miRNAs as per knowledge from today. Oncogenic miRNA are highly ex‐
pressed in cancer, while tumor-suppressive miRNAs possess a reduced expression.
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PSMB8 has been identified as a direct target of miRNA-451 using both bioinformatics and dual
luciferase reporter assays. This was confirmed by miRNA-451-overexpressing lung cancer
cells, demonstrating a reduced PSMB8 protein expression. These data suggest that miRNA-451
inhibits the development and metastasis of lung cancer [66].
There  are  variations  that  exist  in  the  3′-UTR  of  HLA-C,  which  modulate  the  miRNA-
binding  capacity  and  consequently  the  HLA-C  surface  expression.  miR-148a  has  been
shown  to  bind  to  the  HLA-C  3′-UTR.  Next  to  cancer,  the  miRNA-148a  expression  is
associated with the control  of  HIV [67-70].  Furthermore,  miRNA-181a is  upregulated in
Hepatitis B virus infected cells and has a binding site in the 3′-UTR of the HLA-A gene,
which might be a target of miRNA-181a [71].  Moreover, viral DNA or RNA can encode
miRNAs, e.g., miRNA-US4-1 from the human cytomegalovirus, which targets the amino‐
peptidase ERAP1, thereby blocking CTL response [72].
6.2. Control of HLA-G and MHC-related proteins by miRNAs
Recently, a number of HLA-G-specific miRNAs have been identified, which belong to the
miRNA-148 family consisting of three members, miRNA-148a, miRNA-148b, and miRNA-152.
These miRNAs have been shown to act as tumor suppressors in many tumors, including
prostate, ovarian, endometrial, and colorectal cancer [69, 73, 74]. In addition, other miRNAs
such as miRNA-133, miRNA-548, and miRNA-628 have been identified to inhibit HLA-G
expression. The HLA-C-regulating miRNAs are involved in inducing T and/or NK cell
responses and have a tumor-suppressive capacity. Moreover, some of the HLA-G-regulated
miRNAs are inversely expressed when compared to HLA-G in tumor lesions and are associ‐
ated with disease progression [74].
The cytotoxicity of NK cells is determined by activating and inactivating signals. The ligands
of the activating NK cell receptor NKG2D are the major histocompatibility complex class I-
related molecules (MIC) A and B and the human cytomegalovirus UL16-binding proteins
(ULBP) [73]. The expression of MICA and MICB is controlled by several oncogenic miRNAs,
like miRNA-10b, miRNA-17-5p, miRNA-20a, miRNA-25, miRNA-93, and miRNA-106b,
which increase the proliferative, invasive, and angiogenic potential of tumors [73, 75-83] and
affect the NK cell cytotoxicity. The tumor-suppressive miRNA-302c, miRNA-376a, and
miRNA-433-3p showed a reduced expression in cancer and target the 3′-UTR of MIC [73,
84-87]. Furthermore, the expression of ULBP is regulated by many tumor-suppressive
miRNAs, e.g., miRNA-34a/c, miRNA-140-5p, miRNA-302c, miRNA-409-3p, and miRNA-433-
p, and by the oncogenic miRNA-650 [73, 83, 85, 87].
6.3. Control of B7 family members by miRNA
The expression of B7 family members is subject to the regulatory control of miRNAs: B7-H1
could act as a costimulatory molecule, which is expressed on B cells, T cells, macrophages, and
DCs [88], and acts as a ligand for PDL-1. miRNA-513 targets B7-H1 and inhibits its expression
by translational repression [89]. In this context, Tamura and coworkers identified an associa‐
tion between low expression of B7-H2 and the escape from immune surveillance indicating
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that B7-H2 has a potential role in tumorigenesis. B7-H2 [90] is a direct target of miRNA-24,
which inhibits B7-H3 expression and therefore is involved in cancer immune evasion. B7-H3
is an immune regulatory molecule, which is often overexpressed in different cancers and
associated with metastasis and poor prognosis [91, 92]. Its expression could be posttranscrip‐
tionally regulated by miRNA-29c. The miRNA-29c-mediated downregulation of B7-H3
expression was found in breast cancer and acts therefore as tumor-suppressive miRNA [93].
Furthermore, another B7-H3-regulating miRNA, miRNA-187, has been identified in clear renal
cell carcinoma, and its expression is downregulated in this disease [94]. The coinhibitor B7-H4
functions as a negative mediator of immune responses. So far, no information exists about the
role of miRNAs in the regulation of B7-H4 expression. In addition, miRNAs binding to the 3′-
UTR of B7-H6 have not yet been identified.
6.4. Control of the IFN-γ pathway by miRNAs
The regulation of IFN-γ signaling includes negative as well as positive regulators, such as
kinases and phosphatases as well as transcription factors. A main regulatory role of IFN-γ
signaling is attributed to miRNAs, affecting genes involved in proliferation, differentiation,
signal transduction, immune response, and carcinogenesis [50, 95].
IFN-γ can modulate the expression levels of miRNAs and to regulate miRNAs at the level of
miRNA biogenesis [96], whereas miRNAs can inhibit IFN expression directly or indirectly. In
addition, studies have confirmed that miRNAs are able to target components of the IFN-γ
signaling pathway and components of the JAK/STAT-pathway can regulate miRNAs simul‐
taneously. The latter has been described by controlling miRNA expression via transcription
factors, such as c-myc, the hypoxia-induced factor (HIF), and STATs [97]. The contribution and
regulatory role of miRNAs in IFN-γ signaling is still under investigation and an emerging
research area. Here, to highlight the regulatory function of miRNAs in the IFN-γ signaling
pathway, the functional role of miRNA-155 has been described in more detail.
miRNA-155 proceeding from the non-protein-coding transcript of the BIC gene RNA is
required for the normal function of B, T, and DC [98. 99], and its expression is increased during
B cell, T cell, macrophage, and DC activation [100]. miRNA-155 has been shown to regulate
IFN-γ production in NK cells, while its disruption or knockdown suppressed IFN-γ induction
of NK cells [101]. Additional studies reported that miRNA-155 also downregulates IFN-γ-R
expression [102]. Furthermore, STAT1 upregulates miRNA-155, which in turn downregulates
SOCS1, a negative inhibitor of JAK1 [103]. These findings illustrate that a single miRNA can
regulate several target mRNAs of the IFN cascade and miRNAs can be regulated by a number
of targets.
miRNA regulating components of IFN-γ signaling pathway mainly act as tumor-suppressive
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that B7-H2 has a potential role in tumorigenesis. B7-H2 [90] is a direct target of miRNA-24,
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promote apoptosis of pancreatic cancer cells by regulating JAK2/STAT3 signaling pathway
[108, 109], as well as miRNA-101, which promotes apoptosis of breast cancer cells by targeting
JAK2 [110]. Similar results were found for STAT1 and miRNA-145 [111]. miRNA-145 is
reported to be downregulated in several cancers [112, 113] and has STAT1 as direct target [111].
Moreover, STAT1 is able to upregulate miRNA-29 family members in melanoma cells, which
inhibit melanoma cell proliferation by downregulating CDK6 [114].
Further studies confirmed that miRNA-223 and miRNA-150 are equally involved in IFN-γ
signaling, but their role in cancer cells is still controversially discussed. Both miRNA-150 and
miRNA-223 could exert oncogenic or tumor-suppressive activity. In hepatocellular carcinoma,
acute myeloid leukemia (AML) [115] and gastric mucosa-associated lymphoid tissue lympho‐
ma miRNA-223 expression is repressed [116], while an upregulation of miRNA-223 has been
recently described in T-cell acute lymphocytic leukemia (T-ALL) [117]. In this context, Moles
and coworkers [118] demonstrated that both miRNA-223 and miRNA-150 target STAT1 3′-
UTR and reduce STAT1 expression, which in turn results in reduced expression of IFN-γ-
regulated genes. The expression of miRNA-150 is upregulated in CD19+ B cells from chronic
lymphocytic leukemia [119, 120], while in chronic myeloid leukemia [121, 122], ALL [123] and
mantel cell carcinoma miRNA-150 is downregulated. Moreover, miRNA-150 is upregulated
in adult T-cell leukemia/lymphoma cells. This discrepant expression pattern of miRNA-223
and miRNA-150 suggests that both miRNAs could act as oncogenic as well as tumor suppres‐
sor miRNAs, which are dependent on the cellular context.
6.5. Role of miRNAs in immune cell function
Cancer cells upregulate and downregulate different miRNAs in immune cells to limit the
antitumor response. It is well known that tumor cells reprogram the myeloid compartment to
evade the immune system and promote tumorigenesis. This might be partially mediated by
alterations in the miRNA expression pattern. The miRNA-155 modulates the immune response
mediated by T cells, NK cells, B cells, and antigen presenting cells, such as macrophages and
DC [124]. Furthermore, miRNA-155 expression has been found to be downregulated in TAMs
[125], but also in hepatocellular carcinoma. The restoration of miRNA-155 in macrophages
leads to enhanced T-cell function by targeting the suppressor of cytokine signaling. Other
miRNAs, like miRNA-142-3p, miRNA-125b, and miRNA-19a-3p, are often downregulated in
TAMs, thereby limiting the tumor infiltration of macrophages and reducing the therapeutic
effect of adoptive transfer. The restoration of miRNA-125b in macrophages enhances antitu‐
mor response by targeting the IFN-regulatory factor 4, which promotes the M2 macrophage
phenotype [126].
Recently, miRNAs have been identified to play a role in MDSC that regulate immune sup‐
pression within the tumor microenvironment. miRNA array analysis identified a number of
deregulated miRNAs, e.g., miRNA-494, which suppresses the antitumor CD8+ T-cell responses
due to response to TGF-β. miRNA-494 targets PTEN in MDSC, which is responsible for the
enhanced immune suppression of CD8+ T cells [127]. Furthermore, a number of other miRNAs
are downregulated in MDSC [128], which promote the differentiation of myeloid cells and
regulate immune-suppressive signaling pathways.
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In addition, miRNAs have been demonstrated in tumor-infiltrating lymphocytes. The sup‐
pression of T-cell activity is due to different mechanisms, including the dysregulation of
miRNA expression. In CD4+ T cells from tumor bearing mice and tumor patients, the expres‐
sion of miRNA-17-92 family members was reduced, while T cells derived from miRNA-17-9
transgenic mice demonstrated a superior type 1 phenotype [129]. Furthermore, the expression
of miRNA-155 was shown to promote antitumor responses. miRNA-155 in combination with
miRNA-146a could upregulate the IFN-γ production of T cells. Furthermore, cancer cells could
regulate miRNAs in T cells in order to modulate antitumor T-cell responses. In order to escape
immune surveillance, cancer cells alter the expression of transcription factors, surface recep‐
tors, soluble chemokines/cytokines, and miRNAs to support the immune system. The down‐
regulation of miRNA-124 increases Treg infiltration and reduces cytokines production through
an altered expression of STAT3, which represents a target of miRNA-124. In contrast, tumor-
secreted miRNA-214 induces Treg. Regarding NK cells, the TGF-β-inducible miRNA-183
affects NK cell activity [130]. Thus, the regulation of miRNAs within the cancer cell alters the
TME through manipulation.
7. Conclusion and future perspectives
Taken together, during the past years, the posttranscriptional control of gene expression by
miRNAs has gained relevance as key regulator in a wide variety of physiological and pathophy‐
siological processes due to the role of miRNA-mediated RNAi not only in differentiation,
proliferation, apoptosis, immune responses but also in viral and bacterial infections as well as
neoplastic transformation (Table 1). A deregulated expression of miRNAs has been often found
in tumors of distinct origin, which have been classified into oncogenic or tumor-suppressive
miRNAs known to play an essential role in cancer initiation and progression. Therefore, these
miRNAs could act as potential biomarkers and therapeutic targets in cancer. In silico predic‐
tion analysis further proposed that many miRNAs could target different immune modulato‐
ry molecules expressed either on tumor cells or on different immune cell subpopulations.
As summarized, an emerging relevance of miRNAs in mounting the tumor immune escape
by altering the communication between cancer cells, immune cells, and other components of
the TME has been demonstrated. This leads to another level of complexity due to the involve‐
ment of miRNAs in the interaction between cancer cells and immune cells. These miRNAs
might not only provide new insights into tumor growth and progression as well as antitumoral
immune responses but also represent promising therapeutic targets for (immune) therapy. To
date, many cancer-deregulated miRNAs have been identified in particular in cancer cells and
also in components of the TMA. However, their role in modulating the antitumor immune
responses has not yet been characterized in detail. Although the majority of the miRNA
alterations detected are dedicated to cancer cells, there is already evidence that miRNAs of
infiltrating immune cells also particularly influence tumorgenicity. The identification of
further im-miRNAs as well as their functional characterization might lead to a plethora of
novel candidate biomarkers for monitoring of immune responses, which might be also
potentially used for targeted RNAi therapy.
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Table 1. Identified miRNAs involved in the tumor immune escape and their tumor–associated function.
Controversially discussed miRNAs are found as tumor suppressors in some cancer types, while exhibiting oncogenic
properties in other cancer types. n.d., no data.




APC, antigen presenting cell; APM, antigen processing machinery; β2-m, β2-microglobulin;
CDKN, cyclin-dependent kinase inhibitor; CTL, cytotoxic T lymphocyte; CXCL, chemokine
(CXC motif) ligand; DC, dendritic cell; GAS, IFN-γ-activated sequence; HC, heavy chain; HLA,
human leukocyte antigen; IFN, interferon; IL, interleukin; IRF, interferon regulatory factor;
ISRE, IFN-stimulated response element; im-miRNA, immune modulatory miRNA; JAK, janus
kinase; LMP, low molecular mass polypeptide; MAPK, MAP kinase; MDSC, myeloid-derived
suppressor cell; MHC, major histocompatibility complex; MIC, major histocompatibility
complex class I-related molecule; miRNA, microRNA; NK, natural killer cell; PD, programmed
death; PDL, PD ligand; PLC, peptide loading complex; STAT, signal transducer and activator
of transcription; SOCS, suppressor of cytokine signaling; TAF, tumor-associated fibroblast;
TAM, tumor-associated macrophage; TAP, transporter associated with antigen processing;
TGF, transforming growth factor; TLR, toll-like receptor; TME, tumor microenvironment;
Treg, regulatory T cell; ULBP, human cytomegalovirus UL16-binding protein; UTR, untrans‐
lated region; and VEGF, vascular endothelial growth factor.
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Abstract
General complexities in versatile animals are not always proportional to their genome
size. A notable example is that the salamander genome size is 15-fold larger than that of
human, which mostly contains unfolded “junk DNA.” A vast portion of this non-protein-
coding unfolded DNA undergoes transcriptional regulation and produces a large num‐
ber of long noncoding RNAs (lncRNAs). LncRNAs play key roles in gene expression and
therapies of different human diseases. Recently, novel lncRNAs and their function on the
silencing or activation of a particular gene(s) are regularly being discovered. Another im‐
portant component of gene regulation is high packing of chromatin, which is composed
of mainly repetitive sequences with negligible coding potential. In particular, an epige‐
netic marker determines the state of the gene associated with it, whether the gene will be
expressed or silenced. Here, we elaborately discuss the biogenesis pathway of lncRNAs
as well as their mechanism of action and role in gene silencing and regulation, including
RNA interference. Moreover, several lncRNAs are the common precursors of small regu‐
latory RNAs. It is thus becoming increasingly clear that lncRNAs can function via numer‐
ous paradigms as key regulatory molecules in different organisms.
Keywords: Transcriptional silencing, long noncoding RNA, cancer, neurological disor‐
der, Drosophila
1. Introduction
Since the earliest days of molecular biology, RNA-mediated gene regulation was known to the
researchers, and it was first suggested that noncoding RNA (ncRNA) might have a role in gene
regulation by interacting with promoters [1, 2]. After more than four decades of research, the
discovery of RNA interference (RNAi) has revolutionized our perception of the mechanism of
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
gene regulation, organization of chromosomes, and epigenetic regulations. Important clues to
ncRNA regulatory mechanisms came from homology-dependent gene silencing in plants,
which can be initiated by transgenes and recombinant viruses [3]. Studies on the nematode
Caenorhabditis elegans, the fruit fly Drosophila melanogaster [4], fungi mainly yeast, mammalian
cells, and plants revealed transcriptional silencing mechanisms involving RNAi, chromatin,
and its various modifications [3]. RNAi operates mainly posttranscriptionally; however, its
components are associated with transcriptional gene silencing and heterochromatin forma‐
tion, too [5].
Recent findings have made it clear that transcriptional gene silencing (TGS), posttranscrip‐
tional gene silencing (PTGS), and chromatin modifications are utilized by eukaryotic cells to
bring about endogenous gene regulation, chromosome organization, and nuclear clustering.
The RNA interference mechanisms mainly target the transposable elements, which are
abundant and perhaps a defining component of heterochromatin. The role of ncRNA in dosage
compensation, inactivation of X chromosome, genomic imprinting, polycomb silencing, and
blocking of interactions between enhancers and promoters by chromatin insulators is well
proven. Although the studies strongly point towards the involvement of RNAi, its role has not
been demonstrated directly [6].
The non-protein-coding transcripts longer than 200 nucleotides are known as long noncoding
RNAs to differentiate superficially this class of ncRNAs from microRNAs, short interfering
RNAs, piwi-interacting RNAs, small nucleolar RNAs, etc [7]. LncRNAs have emerged as
important regulators of cell physiology and pathology. Different studies have come up with
an increasing number of lncRNAs showing tissue-specific expression; however, the exact
mechanism of action of only a few lncRNAs has been elucidated in vivo [8–14]. The biological
functions and mechanisms of action of the majority of lncRNAs still remain unknown.
LncRNAs can interact with a wide range of molecules and can form RNA-RNA, RNA-DNA,
or RNA-protein complexes through specific RNA functional domains [15], resulting in
extensive functional diversities. Recent research focuses on lncRNAs and divulges the
association of lncRNAs with epigenetic machinery to control chromatin structure, nuclear
clustering, and gene expression. The studies reveal that lncRNAs may act together with many
histone- and DNA-modifying enzymes to modify the histones or DNA. In addition, a recent
discovery of a cardioprotective lncRNA showed a targeting mechanism through ATP-
dependent chromatin remodeling factors [16], indicating an extensive role of lncRNAs in
chromatin structure and regulation. The mechanisms of how lncRNAs control chromatin by
covalent modifications are extensively reviewed in the literature [17–20].
The study of lncRNAs has taken the center stage for the researchers working with epigenetic
regulations, and there is a report of a new lncRNA regulating a disease, or transcriptome
studies come up with a new class of noncoding RNA, or we are introduced to hitherto
unknown mechanisms by which an lncRNA regulates a particular gene almost on a weekly
basis. These are all possible due to the introduction of many advanced, high-throughput
genomic technologies such as microarrays and next-generation sequencing (NGS). There are
a huge number of reported lncRNAs that are not derived from protein-coding genes, and in
spite of this vast number of reports on lncRNA, we have just started getting a clear picture
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about how lncRNAs function, how many different types of lncRNAs exist, and how many of
the reported lncRNAs are biologically important.
2. The C-value enigma and junk DNA
It  has  long  been  known  that  developmental  complexity  or  size  of  an  animal  does  not
correspond with C-value or the amount of DNA in the haploid genome [21–23]. The lower
animal in the evolution ladder, salamander, has a genome size 15 times larger than that of
humans [21], and this discrepancy is known as the “C-value paradox” [23]. Since the introns
were discovered, we started to presume that the C-value paradox was now solved [24]. We
are  almost  sure  that  humans  have  about  25,000–35,000  protein-coding  genes  unlike  the
overestimates of 50,000–100,000 from the initial days of the Human Genome Project [25].
The remaining huge amount of noncoding DNA was termed as “junk DNA” [24, 26] due
to the presence of transposons, pseudogenes, and simple repeats, which occupies about 50–
70% of the human genome [27]. C-value enigma poses a discrepancy in genome size and
number  of  protein-coding genes.  Phylogenetically  close  genera  may vary  in  C-value  by
around four- to five fold [28].
In spite of their “junk” status, scientists were always curious to study them and even realized
that “being junk doesn’t mean it is entirely useless” [26]. It was hypothesized that the junk
DNA might be useful in chromosomal pairing, genome integrity, gene regulation, mRNA
processing, and serving as a reservoir for evolutionary innovation. We are now pleasantly
surprised at their foresight. In the 1970s, it was already thought that noncoding RNA products,
such as rRNAs, tRNAs do not make up the whole transcribed genome.
The scale of “pervasive transcription,” however, was not fully appreciated until the late 1990s
and early 2000s. After the arrival of whole-genome technologies, from microarray hybridiza‐
tion and deep sequencing analysis techniques, it was recently shown that 70–90% of our
genome is transcribed at some point during embryogenesis [29]. Some recently identified
transcripts may be present at as low as 0.0006 copies per cell [30]. Another concern is that tiling
microarrays can come up with false positives, low dynamic range, resolution, and low
concordance between studies [31]. The existence of noncoding transcription in intergenic
regions is evident from correlations with chromatin signatures, such as DNase1 hypersensi‐
tivity, and histone modifications such as H3K9ac, H3K4me3, and H3K36me3 [31]. Although
these studies report novel and conserved lncRNAs, that is not enough to explain the function
of 70–90% of the genome and biological functionality of the ncRNAs. In 1969, Britten and
Davidson presented a model for regulation of gene expression in eukaryotic cells where
ncRNAs have important roles as regulatory intermediaries to convey signals from sensory to
receptor elements [1]. Some of the first examples of gene-specific regulatory roles of lncRNAs
were revealed with the discovery of lncRNAs involved in epigenetic regulation, such as H19
[32] and X-inactive specific transcript (Xist) [33, 34].




These lncRNAs are located as separate units and do not overlap protein-coding genes. Some
of these are known as lincRNAs for large intergenic (or intervening) noncoding RNAs
(lincRNAs) [35]. Many of the lincRNAs were identified through chromatin signatures for
actively transcribed genes (H3K4me3 at the promoter and H3K36me3 along the transcribed
length). Many of the characterized lncRNAs are transcribed by RNA Pol II, polyadenylated,
and spliced and have an average length of 1 kb.
4. Natural antisense transcripts
In this study, transcription occurs in the antisense strand of annotated transcription units;
about 70% of sense transcripts have reported antisense counterparts [36]. The overlap between
these sense/antisense pairs can be a complete sequence, but natural antisense transcripts are
mostly found to be enriched around the 5′ promoter or 3′ terminator ends of the sense
transcript. The most extensively studied example of sense/antisense pairing is Xist/Tsix
(lncRNA antisense to Xist), with two RNAs that control X chromosome inactivation [37]. In
addition, many imprinted regions contain coding/noncoding sense/antisense pairs, such as
Kcnq1 (potassium channel, voltage-gated KQT-like subfamily Q, member 1)/Kcnq1ot1 (Kcnq1
overlapping transcript 1) [38] and Igf2r (insulin-like growth factor 2 receptor)/Air (antisense
Igf2r RNA) [39]. These pairs are generally less spliced or polyadenylated when compared to
mRNAs or stand-alone lncRNAs.
5. Long intronic ncRNAs
Introns have long been known to contain small ncRNAs such as small nucleolar RNAs
(snoRNAs) and microRNAs (miRNAs). However, by large-scale transcriptomic or computa‐
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sequences. It is also very difficult to ascertain whether an lncRNA locus is entirely intergenic
because lncRNA transcripts are often incomplete and they can originate from a protein-coding
gene’s promoter or enhancer on either strand [42]. Tiling microarray technique is often useful
to detect intergenic transcripts [43]. However, controversial results were found here and these
experiments can be ruled out [31]. Early lncRNA collections relied primarily on sequenced
cDNA and EST clones [44]. More recently, RNA-Seq has come up with a number of lncRNAs
derived from whole transcriptome sequencing. RNA-Seq generates millions of 35–100 nt
sequences read in parallel, and it has been confirmed that a large chunk of intergenic sequences
are transcribed into lncRNAs [45]. The high-throughput and impartial nature of this technique
is being utilized for the detailed assessment of the contribution of lncRNAs to a variety of tissue
and/or species under different conditions.
To accurately distinguish noncoding from coding transcripts, sophisticated approaches have
been developed. For example, the Coding Potential Calculator [46] takes into account six features
of a transcript, including the proportion of the transcript enclosed by the candidate peptide-
encoding region, and the sequence similarity to known proteins. An evolutionary approach,
followed in phyloCSF, predicts ncRNAs when their sequence differences among species do not
show preference as to whether they disrupt or not putatively encode peptides [47].
Experimentally determined transcripts always are relied on more than predicted ones. The
availability of large proteomic databases can be utilized to investigate whether a specific RNA
molecule is translated into a protein. In vitro translation assays have been used, too, but they
do not necessarily reflect in vivo biology. A true lncRNA should not bind with translation
machinery, and this approach is also adopted in the identification of candidate lncRNA.
However, a study has reported that 50% of a set of putative lncRNAs are ribosome associated
[48], leaving in doubt whether this test is accurate in separating coding from noncoding
transcripts. To assign an lncRNA, an experimental determination of the function of a transcript
will be necessary. Nevertheless, some transcripts possess both RNA- and coding-sequence-
dependent functions [49] and demarcating them will be difficult. A computational or experi‐
mental method has not yet been developed that discriminates accurately between coding and
noncoding transcripts. For the time being, we can rely on in silico screens for the protein-coding
potential of putative lncRNAs but be aware that these will contain false-positive predictions,
too, especially for genes that encode short polypeptides.
Although many genomes contain a substantial number of lncRNA loci, we still do not know
the proportion and number of these that are biologically functional. Because the functional
mechanisms of most noncoding transcripts or transcript regions are unknown, it is difficult to
design point mutation or deletion experiments and their results are difficult to interpret. Even
RNAi techniques are not being helpful to assign the functionality of the ncRNAs.
7. Mechanisms of action
We do not know yet the mechanistic detail of the enormous number of reported lncRNAs.
However, a few that have been thoroughly studied provide clues regarding how lncRNAs
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might carry out gene regulation (Figure 1). In addition, many lncRNAs blur the line of different
categories and employ several different mechanisms. The discovery of new lncRNAs and more
thorough characterization of those already known will reveal additional modes of action.
It has been found that a major role of lncRNA is to recruit regulatory proteins for the regulation
of chromatin states [50]. This kind of lncRNAs may act in cis, on adjacent or nearby genes, or
they might act in trans, regulating genes located in distant domains or chromosomes. Polycomb
repressive complex 2 (PRC2) interacts with a large number of lncRNAs [51–54]. The Drosophi‐
la polycomb proteins, first discovered as homeotic gene, express during development [55, 56].
These include enhance of zeste homolog 2 (Ezh2, catalytic subunit in PRC2), which is a key
H3K27 methyltransferase, and the Pc/Chromobox (Cbx) family proteins in PRC1, chromodo‐
main-containing proteins that can bind trimethylated H3K27 [55, 56]. Observed interactions
of polycomb proteins with lncRNAs suggest that polycomb recruitment is RNA directed in
mammals. HOX transcript antisense RNA (HOTAIR) in the homeobox (HOX) C cluster is
reported to repress transcription of HOXD in trans through interaction with PRC2 [57]. Xist
RNA-containing repeat A (RepA) has been found to recruit PRC2 [58]. RepA targets PRC2 to
the Xist promoter resulting in Xist up-regulation. The interesting fact is that RepA/Xist
interaction with PRC2 may be blocked by the antisense Tsix transcript, also interacting with
PRC2 and competitively inhibiting the painting of Xist on inactive X chromosome [58].
Other epigenetic complexes interact with lncRNAs as well, such as the H3K9 methyltransferase
G9a interacting with the imprinted lncRNA Air [59]. Kcnq1ot1 has been hypothesized to recruit
both PRC2 and G9a to the promoter of Kcnq1 [60] acting as a scaffold. On the other hand,
antisense ncRNA in the INK4 locus (ANRIL), associated with p15/INK4 (inhibitors of CDK4
family) B-p16/INK4A-p14/ARF tumor suppressor gene cluster, interacts with both the PRC1
component Cbx7 and the PRC2 component Suz1 [61, 62]. HOTAIR also interacts with the
lysine-specific demethylase 1 (LSD1)/corepressor protein of LSD1 (CoREST)/repressor for
element 1-silencing transcription factor (REST) complex in addition to PRC2 to prevent gene
activation [63].
LncRNAs can also act by recruiting factors involved in gene activation. Such factors from the
HOXA (homeotic gene A cluster), two lncRNAs, Mistral (Mira), and HOXA transcript at the
distal tip (HOTTIP) have been involved in recruiting the mixed lineage leukemia (MLL)
complex in cis regulation [64, 65].
An H3K4 trimethylase, myeloid/lymphoid or mixed-lineage leukemia (MLL), is a member of
the Trithorax group of developmentally important gene-activating proteins in flies [66]. Using
3C or chromosome conformation capture technique, it was found that multiple loci, which are
40 kb apart in the HOXA cluster, are in close physical proximity, enabling MLL to regulate
their expression. Other than histone modifications, lncRNAs also impact epigenetic regulation
by modulating DNA methylation at CpG dinucleotides, which has an important role in the
stable repression of genes [67]. During embryogenesis, methylation markers are first to be
found on previously unmethylated DNA by the DNA (cytosine-5-)-methyltransferase 3α
(Dnmt3a) and 3β (Dnmt3b) and later maintained through DNA replication by Dnmt1. Tsix
might be converted to Xist by utilizing Dnmt3a activity to methylate and finally silence the
Xist promoter [68, 69]. In the same way, Kcnq1ot1 may recruit Dnmt1 [70].
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LncRNA-directed methylation has also been implicated in the regulation of rDNA. Ribosomal
DNA exists in the genome as tandem repeat units [71]. Each unit encodes a polycistronic
transcript consisting various rRNAs, and each unit is separated by intergenic spacers (IGSs)
transcribed by RNA Pol I [72]. Recently, it was reported that IGS transcripts undergo proc‐
essing into 150- to 300-nt fragments called promoter (p)RNAs, which act as scaffolds to recruit
poly (ADP ribose)-polymerase-1 (PARP1) [73], the ATP-dependent nucleolar chromatin
remodeling complex (NoRC) [74], and Dnmt3b [75]. A conserved hairpin structure is formed
by pRNA that binds both PARP1 and the TIP5 subunit of NoRC, leading to TIP5 conformation
change resulting in the recruitment of NoRC to the nucleolus, where rDNA is located [74, 76].
The interesting fact is that the recruitment of Dnmt3b by pRNA is dependent on DNA:RNA
triplexing, possibly via Hoogsteen base pairing, between the 5′ end of pRNA and the rDNA
promoter [75]. The DNA:RNA triplex formation might be a general mechanism by which
lncRNAs recruit trans factors to specific DNA loci. LncRNAs are intrinsically bound to
chromatin during transcription and transcribed from a single locus in the genome, so they
have a direct allele- and locus-specific control in cis unlike transcription factors. The length of
lncRNAs is also suitable to reach out and capture epigenetic marks. This cis-acting mechanism
Figure 1. Mechanisms of lncRNA function (modified from Kung et al. [129]).
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resembles transcriptional gene silencing seen in the yeast Schizosaccharomyces pombe in
assembling centromeric heterochromatin [77, 78].
The nucleus is always in the dynamic state and is the center for most of the essential functions
of an organism [79]. Recent studies indicate that lncRNAs are the key regulators of nuclear
compartments. The structure and function of several nuclear bodies seem to be controlled by
RNA. One example is nuclear-enriched abundant transcript 1 (NEAT1) that maintains the
stability of paraspeckles, which participate in the nuclear retention of mRNAs after adenosine-
to-inosine hyperediting [80, 81]. NEAT1 interacts with paraspeckle proteins, such as p54/
NONO and PSP [80–82] and recruits these proteins to form paraspeckles. This is an active
process where continuous transcription of NEAT1 is required [84]. The related molecules,
NEAT2 or metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), are involved
in the localization of serine/arginine (SR) splicing factors to nuclear speckles where they can
be stored and later modified by phosphorylation [85]. MALAT1 directs these splicing factors
to sites of transcription, ultimately controlling the alternative splicing of certain mRNA
precursors [86]. MALAT1 interacts with the PRC1 subunit Cbx4/Pc2 and participates in the
transportation of genes between nuclear compartments for silencing and activation. Extracel‐
lular growth signals help unmethylated Cbx4 to bind MALAT1 and localize its target genes,
along with Lysine (K)-specific demethylase 1A (LSD1) to interchromatin granules that usually
cluster around nuclear speckles. However, Cbx4 gets methylated in the absence of extracellular
signal and instead binds another lncRNA TUG1, then binds with Ezh2, and translocates to
silencing compartments called polycomb bodies [87]. Although these recent observations have
started to open up an avenue to understand lncRNA and their mechanisms of action, we are
still way behind. The function of an overwhelming number of lncRNAs that are being
discovered almost daily is unknown until now.
8. Epigenetic regulation
The two most abundant modes of action of lncRNAs are the modulation of chromatin by
recruiting histone proteins and transcription factors within specific chromatin-modifying
complexes. A very good example of recruitment of specific histones is X chromosome inacti‐
vation (XCI), which is caused by “Xist” as described in the earlier section [58]. A similar event
is genomic imprinting, where genes are expressed from the allele of only one parent. One of
the first and best studied lncRNAs is H19, which is mutually imprinted with insulin-like
growth factor 2 (Igf2). This lncRNA is highly expressed, but its deletion has no phenotypic
outcome, and it is anticipated to function as a microRNA precursor [88]. Other lncRNAs (e.g.,
Air, Kcnq1ot1, and HOTAIR) show modulatory activities both in cis or in trans and regulating
gene expression through partnering with chromatin-modifying complexes [70, 89]. Specifical‐
ly, HOTAIR is a trans-acting lncRNA that serves as a scaffold for two histone modification
complexes: it binds both to PRC2 and to LSD1 [63]. In the Arabidopsis plant, it was found that
different environmental conditions are able to induce the transcription of related NATs (i.e.,
COOLAIR) that eventually silence a flower repressor locus, flowering locus c (FLC) [90].
Recently, it was discovered that lncRNA, namely COLDAIR, bearing minor differences from
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COOLAIR (transcribed in the sense direction relative to FLC mRNA transcription), interacts
on its own with PRC2 and targets it to FLC [41]. Other trans-acting lncRNAs have different
functions, some of which remain incompletely defined. There are several poorly defined
trans-acting lncRNAs, such as the p21-associated ncRNA DNA damage activated (PANDA),
which is induced upon DNA damage in a p53-dependent manner and it controls the expression
of proapoptotic genes [91].
9. Transcriptional regulation
The discovery and characterization of promoter-associated RNAs opened up a new under‐
standing on how genes are regulated during transcription. These RNAs are localized within
the promoter and consist of various sizes of RNA molecules [92]. The long ones are found at
a single-gene level and are associated with the modification of DNA methylation and deme‐
thylation patterns [93] as mentioned earlier. Interestingly, long (antisense) pRNAs generally
form double-stranded molecules that are processed into endo-siRNAs, and since they have
sequence complementarity with the promoter, they induce transcriptional gene silencing [20,
94–96] or activation [97–99].
LncRNAs sometimes affect transcription by acting as coregulators or by regulating the
association and activity of coregulators. One example is embryonic ventral forebrain-2 (Evf-2)
that functions as a coactivator for the homeobox transcription factor distal-less homeobox 2
(Dlx2) [100].
10. Posttranscriptional regulation
lncRNAs not only have a role in transcription but also they function in splicing, mRNA
stability, and translation. Antisense lncRNA sometimes bind to the sense RNA, conceal the
splice sites, and thereby modify the balance between splice variants. Antisense transcript
RevErbAα modifies the splicing of thyroid hormone receptor alpha genes (TRα) TRα1 and
TRα2 mRNAs [101].
The terminal differentiation-induced ncRNA (TINCR) associates with Staufen 1 but not with
the complex between TINCR-NA, which is a differentiation factor [102].
LncRNAs have also been implicated in translational regulation. An example is the antisense
for PU1 mRNA. Its translation is inhibited by an antisense polyadenylated lncRNA with a half-
life longer than the original transcript [103]. Another example is the lncRNA Uchl1, which is
controlled by mammalian target of rapamycin (mTOR) pathway, shuttles from the nucleus to
the cytoplasm, and controls the translation of the ubiquitin carboxy-terminal hydrolase L1
(UCHL1) mRNA by promoting its association with polysomes [104].
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11. Role of lncRNAs in cancer and other human diseases
The genome-wide association studies identify several cancer risk loci outside of protein-
coding regions. Of 301 single-nucleotide polymorphisms currently linked to cancer, only 12
(3.3%) modify the amino acid sequence of the protein, and most of the loci are located in
the introns (40%) or intergenic regions (44%) [105]. These facts and the observations that
miRNA and lncRNAs are involved in differentiation and development point towards the
fact that alterations in their expression profiles could be correlated with cancer develop‐
ment. Reports suggested that lncRNAs have tissue-specific expression and is found to be
deregulated  in  distinct  types  of  cancers.  For  example,  overexpression  of  miR-155  was
reported  in  hematopoietic,  breast,  lung,  and  colon  cancers  [106],  whereas  miR-21  is
overexpressed in glioblastoma [107]. In addition, lymphoproliferative disorders were found
in transgenic mice overexpressing miR-17-92 [108]. Incidences of lung, colon, and gastric
cancers  were found to be correlated with the overexpression of  miR-17-92 cluster  [109].
LncRNAs have been associated with cancer development likewise. The lncRNA MALAT1
is up-regulated in several  cancer types,  resulting in an increase in cell  proliferation and
migration  in  lung and colorectal  cancer  cells  [105].  The  role  of  MALAT1 in  controlling
alternative  splicing of  pre-mRNAs [86]  can be deduced from this.  A more recent  study
indicates  that  MALAT1 may also  participate  in  the  regulation  of  gene  expression  by  a
mechanism other than alternative splicing in lung metastasis [110].
Other studies have shown that miRNA and lncRNAs both can function as tumor suppressor
genes or oncogenes. The tumor suppressor gene p53 regulates the three gene members of the
Figure 2. Posttranscriptional gene silencing by lncRNA and miRNA (adapted from Gomes et al. [130]).
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miR-34 family. Curiously, the microRNA-34 (miR-34) activation resembles p53 activity, such
as the induction of cell cycle arrest and promotion of apoptosis, and p53-mediated apoptosis
becomes defective in the absence of miR-34 [111].
LncRNAs that recruit epigenetic modifiers to specific loci such as ANRIL, XIST, HOTAIR, and
KCNQ1OT1 are found to have altered expression in a variety of cancers [112]. Another lncRNA
called TERRA binds telomerase, inhibiting its activity in vitro [113], and is observed to be down-
regulated in many cancer cells, linking it with the longevity of cancer cells.
Chromatin remodeling by lncRNA is linked to other diseases such as facioscapulohumeral
muscular dystrophy (FSHD) [97], lethal lung developmental disorder [114], and the HELLP
syndrome, a pregnancy-associated disease [114] in addition to cancer. The HELLP stands for
H = hemolysis (breakdown of red blood cells), EL = elevated liver enzymes (liver function),
and LP = low platelet counts (platelets help the blood clot). These examples directly link
lncRNA and miRNAs in cancer biology and other human diseases and indicate the involve‐
ment of a complex interplay among their biogenesis pathways, their regulatory mechanisms,
and their targets.
Figure 3. Relationship among various noncoding RNAs and different disorders caused by them (adapted from Gomes
et al. [130].
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12. Dosage compensation and X inactivation
X chromosome inactivation (XCI) occurs in females during embryogenesis, where either the
maternal or paternal X chromosome is randomly silenced. The molecular mechanisms of XCI
are not yet fully understood. However, it is known that a 500-kb stretch of DNA at Xq13 known
as the X-inactivation centre (XIC) is the site for initiation of X inactivation. There are several
lncRNAs, including X-inactive specific transcript (Xist), its antisense transcript Tsix, X-
inactivation intergenic transcription elements (Xite), Jpx transcript, and Xist activator (Jpx),
and others play pivotal roles in XCI [115]. Xist was one of the first to be identified and best
studied lncRNAs. It is a ~17-kb transcript (~19 kb in humans) expressed from the future inactive
X chromosome (Xi) [116]. Tsix is a ~40-kb antisense transcript to Xist. It negatively regulates
Xist. Recent studies indicate that Xite is a transcriptional enhancer of Tsix [115], and likewise,
Jpx RNA appears to help in Xist expression [117].
When two homologous X chromosomes are brought at close proximity, Tsix and Xite initiate
the inactivation process by counting, and this is associated with the presence of RNA poly‐
merase II (RNAPII) [118, 119]. The chromatin insulator CTCF, which binds to Tsix and Xite
genomic loci [120], play an important role. The transcription factor OCT4 is then hypothesized
to bind with Tsix promoters of one of the X chromosomes, which then converts to active X
chromosome (Xa) due to increased transcription of Tsix [120]. Thereafter, Dnmt3a is recruited
to the Xa and establishes stable silencing of Xist on the Xa [115, 118].
13. LncRNA in genomic imprinting
In mammals, genomic imprinting is an epigenetic marker in a way that their expression
occurs specifically in parental  origin manner.  This occurs during early gametogenesis in
nearly 1% of protein-coding genes. To date, we have identified around 150 imprinted genes
in mice. Imprinted genes are often located in clusters of size from a few kilobases to 2 to
3 Mb. LncRNAs are present in all the identified and elucidated imprinted clusters as their
partners.  The  expression  of  lncRNAs is  reciprocally  linked with  corresponding  protein-
coding genes [121–123].
Genomic imprinting mainly happens by chromatin insulators [124–126] and lncRNAs [38,
127]. LncRNAs repress flanking gene promoters in cis action (Kcnq1ot1 and Airn lncRNAs
[115]). However, several reports indicate that lncRNAs function as a major force in the
regulation of parent-of-origin-specific expression. Today, we know that the human genome
contains more than 58,648 lncRNA expressed genes compared to only 21,313 protein-coding
genes [128]. The majority of the lncRNAs act by interacting with chromatin-modifying
complexes such as PRC2, G9a, hnRNPK, and SWI/SNF, recruiting them sequentially to silence
genes in cis or trans action [57, 60].
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12. Dosage compensation and X inactivation
X chromosome inactivation (XCI) occurs in females during embryogenesis, where either the
maternal or paternal X chromosome is randomly silenced. The molecular mechanisms of XCI
are not yet fully understood. However, it is known that a 500-kb stretch of DNA at Xq13 known
as the X-inactivation centre (XIC) is the site for initiation of X inactivation. There are several
lncRNAs, including X-inactive specific transcript (Xist), its antisense transcript Tsix, X-
inactivation intergenic transcription elements (Xite), Jpx transcript, and Xist activator (Jpx),
and others play pivotal roles in XCI [115]. Xist was one of the first to be identified and best
studied lncRNAs. It is a ~17-kb transcript (~19 kb in humans) expressed from the future inactive
X chromosome (Xi) [116]. Tsix is a ~40-kb antisense transcript to Xist. It negatively regulates
Xist. Recent studies indicate that Xite is a transcriptional enhancer of Tsix [115], and likewise,
Jpx RNA appears to help in Xist expression [117].
When two homologous X chromosomes are brought at close proximity, Tsix and Xite initiate
the inactivation process by counting, and this is associated with the presence of RNA poly‐
merase II (RNAPII) [118, 119]. The chromatin insulator CTCF, which binds to Tsix and Xite
genomic loci [120], play an important role. The transcription factor OCT4 is then hypothesized
to bind with Tsix promoters of one of the X chromosomes, which then converts to active X
chromosome (Xa) due to increased transcription of Tsix [120]. Thereafter, Dnmt3a is recruited
to the Xa and establishes stable silencing of Xist on the Xa [115, 118].
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127]. LncRNAs repress flanking gene promoters in cis action (Kcnq1ot1 and Airn lncRNAs
[115]). However, several reports indicate that lncRNAs function as a major force in the
regulation of parent-of-origin-specific expression. Today, we know that the human genome
contains more than 58,648 lncRNA expressed genes compared to only 21,313 protein-coding
genes [128]. The majority of the lncRNAs act by interacting with chromatin-modifying
complexes such as PRC2, G9a, hnRNPK, and SWI/SNF, recruiting them sequentially to silence
genes in cis or trans action [57, 60].
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14. Perspectives
LncRNA has diversified tentacles for functions. Those include an alteration of transcriptional
profiles, controlling of protein expression, complex structural or organizational roles, RNA
processing or RNA editing and role of being the precursor of small RNAs. Because a very small
fraction of lncRNA have been molecularly characterized to date, many more yet to be discov‐
ered that fit into this diversified functional paradigms. Future work will definitely ask many
more questions about the interplay of lncRNA transcripts and whether it is sufficient to have
fundamental sequence of events or not. Many lncRNAs play intermediate roles in cis regulation
that gets represented in ectopic expression in trans regulation.
Most recent challenges are to identify how the molecular function of each type of lncRNA
results in different diseases of the organism. LncRNA appears to expose numerous develop‐
mental events such as the generation of photoreceptor cells in retina development, control of
cell surveillance, cell cycle progression of mammary gland development, and finally genera‐
tion of knockout animal development. Many lncRNAs are not eliminated as transcriptional
noise in the genome but are useful for normal developmental processes.
LncRNA has a tremendous impact on disease development due to its flawless miscegenation.
In tumor formation, the expression of lncRNAs is very important. They function like specific
markers of tumor formation. However, the exact mechanism by which tumor initiation,
formation, and progression would occur is not fully understood. It is true that the interplay
and significant role of lncRNA in different disease research is really an unexplored area, which
is eventually determining the new therapeutic targets. Recently, it was found that lncRNA
may form β-amyloid plaques in Alzheimer’s disease. This possibility suggested that noncoding
transcript might serve as an attractive drug target for Alzheimer’s disease.
Most conventionally, genetic information may run through protein-coding sequences, but it
is now found that transcription is pervasive through the nucleic acid content of eukaryotic
genome, which generated a numerous number of lncRNA, which are possibly the key
regulators of protein-coding sequences. We anticipate that many more surprises are yet to be
explored in the coming decades. Therefore, future research might provide more pleasant but
unexpected surprises in the lncRNA function.
15. Conclusion
The above description exhibits a brief survey of the current status of knowledge regarding the
identification, localization, functions, and mechanisms of actions of lncRNAs related to
different human diseases. A fraction of genomic nucleic acid is transcribed to protein, but an
overwhelming majority of the genome sectors of the organisms contain lncRNA with unknown
functional efficacy. Some are nuclear or cytoplasmic and are highly overexpressed, and others
are rarely detected. Truly, it is impossible to discern the important criteria such as stability,
conservation, and time of expression related to human diseases. LncRNA in the Xic is only
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found in placental mammals and is not conserved in other mammals. However, this limited
conservation might not be essential in other higher animals. The true test for real function lies
in the mechanism, genetic pathway, and tissue-specific activity for each lncRNA. The genome
of an organism is not always streamlined by the natural selection. Thus, here, we really tried
to avoid the speculative statements about localization, function, and dissecting mechanism
regarding long noncoding RNA. Truly, we have just begun to scratch the skin of LncRNA in
the human body. The lncRNA world is so galactically vast that we have an enormous task to
completely learn about it. We feel that additional discoveries of lncRNA may provide a real
exciting phase in the study of RNA world.
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Abstract
This review focuses on current strategies of development of noncanonical synthetic RNA
interference (RNAi) inducers with structural modifications for promoting better gene si‐
lencing with low risk of side effects. A particular focus is on longer RNA duplexes 25–30
nucleotides (nt) in length that mimic Dicer substrates to improve interaction of RNAi in‐
ducers with RNAi machinery. Various design strategies of efficient Dicer substrate small-
interfering RNA (siRNA) are described. It was found that the length, chemical
modifications, and overhang structure influence the gene silencing activity and RNA-in‐
duced silencing complex (RISC) assembly. Special attention is paid to the long double-
stranded RNA duplexes that induce effective gene silencing in Dicer-dependent or Dicer-
independent mode. Some structural variants of shorter siRNAs, including hairpin and
dumbbell siRNAs and fork-siRNA (fsiRNA) with several nucleotide substitutions at the
3′ end of the sense strand, are also analyzed. These structural modifications provide effi‐
ciently increased gene silencing of targets with unfavorable duplex thermodynamic
asymmetry. Recent data remove the length and structure limits for the design of RNAi
effectors, and add another example in the list of novel RNAi-inducing molecules differ‐
ing from the classical siRNA, which is discussed in this chapter.
Keywords: RNAi, siRNA, fsiRNA, dsiRNA, tsiRNA, structural modifications, mechanism
of action
1. Introduction
RNA interference is a conserved mechanism of a sequence-specific posttranscriptional gene
silencing triggered by double-stranded RNAs homologous to the silenced gene [1, 2]. Long
double-stranded RNA(dsRNAs) are cleaved in the cell by RNase III class endonuclease Dicer
into short fragments 21–22 nucleotides (nt) in length with 2–3-nt 3′ overhangs at both ends [3,
4]. These fragments (small-interfering RNAs, siRNAs) enter RNA-induced silencing complex
(RISC) and associate with core proteins belonging to Argonaute (AGO) family [5]. AGO
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unwinds the duplex and cuts one of the strands in the middle, and then this strand (designated
as “passenger”) dissociates from the complex and is degraded by cellular ribonucleases. The
other strand (designated as “guide”) remains in activated RISC and recognizes the cellular
mRNA complementary to the guide strand. The configuration of the complex determines
which strand remains in the complex and which strand leaves and degrades. Active RISC
complex containing the guide strand binds to the complementary mRNA and induces its
cleavage. When the cleaved mRNA is released, RISC is recycled for a new round of cleavage
[4, 6]. The details of the RNAi mechanism are well reviewed in literature [7–9].
Synthetic small-interfering RNAs have become an advanced and powerful tool for specific
gene silencing and could be considered as promising class of therapeutics for the treatment of
diseases associated with overexpression of specific genes [10–12]. However, therapeutic
applications of canonical non-modified siRNAs are limited by their sensitivity to ribonucleas‐
es, possibility of unfavorable guide strand selection, and activation of innate immune system
by siRNA containing immunostimulatory motives in the sequence, which can lead to poor
gene silencing efficiency [13, 14]. Different structural variations of the RNAi inducers together
with chemical modification were developed to overcome these problems.
This review focuses on current strategies of development of siRNA structural modifications
for promoting better gene silencing with low risk of side effects, with particular focus on longer
siRNA duplexes 25–30 nt in length that mimic Dicer substrates (Dicer substrate siRNA
(dsiRNA)) [15–20]. Special attention has been paid to the long double-stranded RNA duplexes,
which induced effective gene silencing and did not require Dicer-mediated processing of the
substrate into smaller units: trimer RNA (tsiRNA) with 63 nt in length and tripartite-interfering
RNA (tiRNA) with 38 nt in length [21, 22]. Applications of some structure variations of shorter
siRNAs and the potential of different synthetic RNAi inducers in different applications have
also been reviewed and summarized.
2. Dicer substrate interfering RNAs
Long dsRNAs homologous to the targeted mRNA were successfully used for silencing of gene
expression in nonmammalian species [1, 4]. Early attempts to use long dsRNAs in mammalian
cells triggering of RNAi failed due to activation of innate immune system by dsRNA [15].
Although activation of innate immunity may be beneficial for the therapy in some cases,
uncontrolled induction of the interferon response results in global changes in gene expression
profile and, in some cases, in cells death [23–25]. It was found that chemically synthesized 21-
mer RNA duplexes with 2-nt 3′ overhangs at both ends, which directly mimic the products
produced by Dicer, efficiently suppressed gene expression in mammalian cells [4, 26]. These
duplexes, referred to as canonical siRNAs, are widely used in biomedical research [11]. Later,
it was found that RNA duplexes, smaller than 30 nt in length but longer than siRNAs, were
significantly more efficient than canonical siRNAs and did not induce interferon response in
a variety of cell lines [15]. It was established experimentally that 27-mer duplexes possess
maximal silencing activity, longer duplexes demonstrated reduced silencing activity, and 40–
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45-mer duplexes were inactive. At the same time, 27-mer duplexes, named as Dicer substrate
siRNA (dsiRNA), were efficiently cleaved by Dicer producing a variety of 21-nt-long distinct
products. High potency of 27-mer duplexes initially was explained by the formation of siRNA
pool containing functional siRNAs with extremely high silencing activity. Some of 27-mer
duplexes were significantly more potent at nanomolar or picomolar concentrations than the
specific 21-mer siRNA selected according to the current computational algorithms [15].
However, further experiments demonstrated that none of the synthetic 21-nt siRNAs, included
in the corresponding set to all possible products of Dicer processing of 27-mer duplexes,
demonstrated the same level of silencing activity as 27-mers at low concentrations [15].
Based on the earlier observations that Dicer participates both in the cleavage of dsRNAs
and  in  the  incorporation  of  the  products  of  cleavage  into  RISC  complex  in  Drosophila
melanogaster, it has been suggested that Dicer could participate in direct loading of siRNA
into  RISC and in  RISC assembly  [16,  27].  It  has  been experimentally  proved that  dsiR‐
NAs form the RISC loading complex (RLC) in vitro more efficiently than the canonical 21-
mer siRNA duplexes [18]. Because Dicer does not form complexes with 21-base pair (bp)
duplexes, it was assumed that Dicer facilitates RLC formation after dsRNA cleavage without
dissociation from the  cleavage product.  These  findings  become a  basis  for  the  develop‐
ment of a new class of RNAi inducers [16, 17, 28].
The silencing activity of dsiRNA depends on its structure. At the first step of recognition,
PAZ (Piwi Argonaut and Zwille) domain of Dicer predominantly “anchors” two ribonucleo‐
tides  on 3′  overhangs because  those  blunt  27-mer  duplexes  are  not  good substrates  for
Dicer. PAZ domain plays a vital role in the orientation of bound RNA in the active site of
the enzyme and determines the cleavage position on RNA for AGO protein.  Unlike 21-
mer siRNA,  where  two-base  3′-deoxynucleotide  overhangs  are  often  used regardless  of
their complementarity to the target mRNA sequence (mostly dTdT), the overhang sequen‐
ces are important for the properties of dsiRNA. Incorporation of deoxynucleotides at the
3′  ends  of  dsiRNA  strands  has  an  adverse  effect  on  dsiRNA  processing  [19].  The  se‐
quence  of  3′  terminal  overhangs  could control  dicing polarity  and strand selection into
RISC.  Thus,  Dicer  preferentially  binds  with  purine/purine  (GG,  AA)  nucleotides  [19].
Protruding  nucleotides  added  to  the  3′  terminal  of  the  antisense  strand  facilitate  its
preferential  loading into  RISC [19].  Hence,  asymmetric  duplexes  with  one  2-nt  3′  over‐
hang and DNA residues on the blunt end of the duplex provide a single favorable PAZ
binding site and reduce heterogeneity of cleavage products (Figure 1) [16–18, 29, 30].
The stability of dsiRNA in physiological fluids is extremely an important factor for its
applications in vivo [31]. Although dsRNAs are more stable in comparison with single-
stranded RNAs and 21-bp siRNA, they still rapidly degrade in the serum [32]. It was found
that bonds with 3′ pyrimidine nucleotides are cleaved faster than bonds with 3′ purines. Kubo
and his colleagues demonstrated that degradation rate of dsiRNAs correlated with the amount
of pyrimidines at the 3′ end [31]. At the same time, degradation rate of dsiRNAs also correlates
with the presence of AU-rich domains that might be related to low thermal stability, easy
dissociation, and faster cleavage by both endo- and exonucleases. Chemical modifications can
improve nuclease stability and reduce off-target effects [33–36]. Fluorescein modification of 3′
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end of 27-mer RNA duplexes significantly reduces RNAi activity because 3′ ends are important
for interaction with Dicer and should be available for the proper recognition [15]. On the other
hand, dsiRNAs with chemical modifications of the 5′ end possess high nuclease stability and
RNAi activity in the cell-cultured medium. Thus, 5′-end amino-modified dsiRNA demon‐
strated improved RNAi activity and stability in the cell-cultured medium [31].
Incorporation of 2′-O-methyl modifications is an efficient and inexpensive method to improve
nuclease resistance of synthetic RNA duplexes [33, 37–40]. However, dsiRNA duplexes with
modifications of all or the majority of nucleotides in both sense and antisense strands are
practically inactive, because extensive modification blocks the cleavage of duplex by Dicer [17].
Limiting the modifications to incorporation of only 9–11 modified bases into the antisense
strand and avoiding modifications in the site of Dicer cleavage prevents this undesired effect
[17]. Mass spectrometry analysis of in vitro dicing reactions showed that modified duplexes
produce a mixture of 21- and 22-nt species, whereas unmodified duplexes are processed only
into 21-mer species. If modifications were spaced further away from the dicing site, a prefer‐
ential accumulation of 21-mer species was observed [17]. However, it was noted that in some
cases, usually, a good modification pattern may decrease the silencing activity of dsiRNA. This
phenomenon has been related to the newly unidentified sites in the sequence context of some
chemically modified dsiRNAs, contributing to impairment of dsiRNAs silencing effect [17].
These observations could explain differences in the efficiency of various dsiRNAs and made
possible the creation of the modification patterns compatible with dicing.
Accumulation of experimental data revealed that 27–30-bp dsRNAs, including dsiRNA and,
in some cases, even 21-bp siRNA, could stimulate innate immune system and induce interferon
response in certain cell types [23]. Toll-like receptors (TLRs) 7 and 8 appear to be the main
molecules responsible for the immune recognition of siRNA and dsiRNA, whereas toll-like
receptor 3 recognizes longer than 30-bp dsRNA [41, 42]. Activation of innate immune system
through TLRs results in the production of interferon α, tumor necrosis factors α, and inter‐
Figure 1. The scheme of dsiRNA design (according to [17]). N – ribonucleic acids, d - deoxyribonucleic acids, short
arrows – the site of Dicer cleavage.
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leukins IL6 and IL12 [42]. Immunostimulatory properties of siRNA are sequence dependent;
TLR7 and TLR8 receptors recognize GU-rich sequences of siRNA [43]. Moreover, several
immunostimulatory motifs of siRNA enriched in GU nucleotides were identified [44, 45]. It is
recommended to avoid these motives in siRNA and dsiRNA design; unfortunately, not all
immunostimulatory motifs have been discovered that complicate the design procedure.
Earlier, it was demonstrated that chemical modifications involving 2′ position of the ribose
ring in siRNA could block the immune response [46]. Incorporation of 2′-O-methyl U and G
bases into siRNA significantly reduced immunostimulatory activity of siRNA in vitro and in
vivo, containing immune-stimulating motives in the sequence [41]. Moreover, the effective
suppression of immunostimulatory activity could be reached by using only a small percentage
of modified nucleotides (<10%). Collingwood and his colleagues [17] applied this approach to
dsiRNA and demonstrated that limited 2′-O-methyl modifications of uridine and guanosine
into antisense strand of dsiRNA efficiently prevent induction of innate immune response in
different cell lines.
Another option to reduce nonspecific effects of dsiRNA is to use enzymatically produced pools
of Dicer substrate RNA [20]. Dicer from the protozoan parasite Giardia intestinalis was used to
obtain enzymatically produced dsiRNAs. It cuts long dsRNA into fragments from 25 to 27 nt
in length. The sequences-related side effects were decreased in the pool of enzymatically
produced dsiRNAs due to the low concentration of individual dsiRNAs with undesirable
sequence.
In the cases when silencing of more than one gene is required, the transfection of siRNA
mixture is used. Co-transfection of different siRNAs may result in different knockdown
efficiency of individual targets due to competition between siRNAs for RISC loading depend‐
ing on the thermodynamic asymmetry of the duplexes [30]. Therefore, preliminary testing is
required to assess the degree of competition between various siRNAs. Competition between
RNAi inducers aimed at different mRNAs could be avoided by using Dicer substrate RNA.
Entry of dsiRNAs into RNAi pathway is not limited by RISC loading step, and discrimination
of canonical siRNAs based on RISC incorporation is reduced. These beneficial properties of
dsiRNAs can provide an effective tool for targeting multiple mRNAs.
Currently, siRNAs have become a powerful tool for effective suppression of expression of
target genes in vitro and in vivo applications. Moreover, several compounds are already used
in clinical trials. However, the examples of Dicer substrate RNAs usage in vivo are fewer in
number. Several studies use dsiRNA to silence therapeutically relevant genes in vivo (Table
1). Frequently, cancer-related genes and genes of viruses [50, 51, 56–59] are chosen as targets
for dsiRNAs [47–49]. Several researchers used TNFα gene as a target for the treatment of
inflammatory and autoimmune diseases [52–54]. Murine models are the most popular animal
models among various studies that used dsiRNA in vivo [47–54]; however, there are studies
where other animal models, for example, rats, were used [53, 55]. An exciting example of
dsiRNA application was described by Doré-Savard and his colleagues, who demonstrated, for
the first time, the efficient suppression of target genes in central nervous system (CNS) of rats
by dsiRNA [55]. In this study, 27-mer dsiRNAs were used to reduce expression of neurotensin
receptor-2 (NTS2) involved in ascending nociception. dsiRNAs were formulated with cationic
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lipid i-Fect and used in intrathecal spinal cord injection. Extremely low doses of dsiRNA (0.005
mg/kg) efficiently silenced NTS2 mRNA and protein levels for 3–4 days. It is known that
administration of high doses of non-modified siRNA increases the risk of activation of innate
immune system, especially when siRNA is used together with cationic lipids. Low doses of
highly active dsiRNAs could minimize this adverse effect. No apparent toxicity and other off-
target effects were found during the experiment [55]. The dose–response experiments per‐
formed in another study [28] also show that 27-mer Dicer substrate RNA provide improved
gene silencing when used at lower concentrations [28]. The silencing activity of canonical 21-
mer siRNAs was compared with that of dsiRNA at 1 and 5 nM concentrations. The 27-mer
dsiRNA displayed more potent gene silencing at 1 nM concentration, while at 5 nM concen‐
tration, the difference in silencing was less pronounced [28].
Experimental
system





25D/27-mer cdc20 (mouse) Breast
cancer
20 nM >80% cell growth inhibition [47]
Mice 2 μg/mouse Tumor growth inhibition
after second injection
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[57]
PC-3 cells 25D/27-mer HSP27 (human) Prostate
cancer
50 nM >50% reduction of both
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tumor weight
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10 nM 50% mRNA reduction [53]
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Structure Target (gene) Disease Concentra-
tion/dose
Biological effect Reference
Rat 0.005 mg/kg 86% and 62% mRNA level
reduction in lumbar dorsal
root ganglia and in spinal
cord, respectively
Table 1. Application of dsiRNA for silencing of disease-related genes (summarized from PubMed). 25/27-mer –
dsiRNAs with 25 - base sense strand and 27 – base antisense strand; 25D – 2 bases at the 3’-end are substituted with
DNA; 2’OMe – 2’ – O methyl modifications as described in [17].
In another study, potent 2′-O-methyl modified dsiRNAs targeted to β-catenin were designed
[49]. It is known that β-catenin acts as the transcription factor and its overexpression causes
the development of several types of cancer, including liver cancer. At the first step, large-scale
screening of 488 dsiRNAs for in vitro mRNA knockdown activity was performed to choose
the most efficient dsiRNAs for targeting β-catenin. Then, the absence of immunostimulatory
activity attributed to selected dsiRNA was confirmed using the assay based on the ability of
an oligonucleotide to induce the production of antibodies to the PEGylated components of the
lipid nanoparticles containing oligonucleotides. dsiRNA was administered to mice intrave‐
nously twice a week during 3 weeks after implanting Hep 3B tumor cells. dsiRNAs induced
strong β-catenin mRNA knockdown and efficient tumor inhibition. Other examples of
dsiRNAs applications as potential therapeutics for inhibition of the disease-related overex‐
pressed genes in vivo and in vitro have been summarized in Table 1.
Beneficial properties of dsiRNAs make these structures popular inhibitors of target genes. At
first, dsiRNAs induce more potent silencing of the target genes at lower concentrations than
canonical siRNAs. The next advantage of dsiRNAs is longevity of silencing: In some cases, it
lasts up to 10 days. Then, the usage of dsiRNAs enables to minimize off-target effects such as
toxicity and heterogeneity of processed products. An additional benefit is the high potency of
dsiRNAs in silencing of multiple mRNAs where canonical siRNAs due to competition during
RISC loading step appear to be less effective. The main disadvantage of dsiRNA is the higher
cost of synthesis in comparison with canonical siRNA. However, low dosage of dsiRNA used
in experiments eliminates this drawback. On the other hand, dsiRNAs share with siRNAs the
same problems in therapeutic applications. The major challenge lies in the delivery of these
structures into desired cells, tissues, and organs. To overcome this problem, various ap‐
proaches are developed; however, this question has not been completely answered yet.
Nevertheless, dsiRNA as potent inducers of RNAi offers promising strategies for efficient
therapy.
3. Interfering RNA with noncanonical duplex structure
Different variations of siRNA duplex structures were proposed to improve their silencing
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Different variations of siRNA duplex structures were proposed to improve their silencing
activity. Here we will consider three types of the most frequently used siRNAs with structural
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modifications of duplexes: short hairpin RNAs (shRNAs)/microRNA (miRNA) mimics,
dumbbell RNAs, and fork-siRNA (Figure 2).
Figure 2. The different types of interfering RNAs with non-canonical duplex structures.
The identification of a large class of endogenous regulatory RNA molecules – microRNAs
(miRNAs) arouse interest in constructing the similar synthetic structures for efficient silencing
of target genes. miRNA precursors are generated in the cell as long primary transcripts that
are cleaved in nucleus by RNase III class nuclease Drosha [60–62]. Then, they are exported to
the cytoplasm and cleaved by Dicer, which is active at processing of complex hairpin structures
[63]. It is known that Dicer substrates more effectively enter RISC complex than canonical
siRNA and induce more potent RNAi [15–17, 28]. Moreover, shRNAs could interact with
particular chaperones that promote recognition of shRNA by Dicer [64]. miRNAs form
imperfect complementary complexes containing bulges with 3′ untranslated region of the
target mRNA, wherein the position of the loops defines the mechanism of action: target
cleavage or the block of translation. In the first case, synthetic miRNA mimics have no
advantages over shRNA, and in the second case, they do not act in a catalytic mode. Therefore,
synthetic miRNA applications are restricted to exploring the miRNA-regulated pathways
involved in the natural processes, or development of replacement therapy for the diseases
associated with mutation in specific miRNA. The use of shRNA seems to be more promising.
Although long dsRNA hairpins are prepared synthetically, enzymatically, or endogenously
expressed, plasmid or viral vectors could be used in nonmammalian organisms. Long RNA
hairpins cannot be applied in mammals for the specific gene silencing because they also induce
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interferon response in mammals via the same mechanism used by long RNA duplexes [3, 65,
66]. Therefore, length of hairpin RNAs for application in this type of species is limited by 30
bp. shRNAs expressed by different vectors under control of RNA polymerase III and CMV
promoters were proved to efficiently trigger RNAi [67, 68].
Applications of viral vector-based expression of shRNAs are limited because of some obstacles
such as possibility of insertional mutagenesis, malignant transformation, and host immune
response [69]. At the same time, an application of plasmid vectors is safe, but inefficient
delivery into cells limits its use only for experimental purposes, where antibiotic resistance
genes included in the vector is used for the selection. In contrast to expressed shRNA, synthetic
shRNA seems to be more attractive for RNAi-based therapies. It was found that chemically
synthesized short hairpin RNAs (shRNAs) with 19–29-base-pair stem, at least 4-nucleotide
loop and 2-nucleotide 3′ overhangs are more potent inducers of RNAi than the canonical small-
interfering RNAs targeted to the same sequence in mRNA [64, 70–73]. Two main types of
shRNAs with opposite positions of the loops were designed (Figure 3). The right loop
structures (R-shRNAs) have sense strand at the 5′ end of the hairpin, whereas the left loop
shRNAs (L-shRNAs) have antisense strand at the 5′ end of the hairpin (Figure 3) [71–74]. The
majority of studies were carried out using R-hand loop structure.
Figure 3. General structures of L-shRNAs and R-shRNA (according to [71]). Red color: sense strand, blue color: anti‐
sense strand.
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delivery into cells limits its use only for experimental purposes, where antibiotic resistance
genes included in the vector is used for the selection. In contrast to expressed shRNA, synthetic
shRNA seems to be more attractive for RNAi-based therapies. It was found that chemically
synthesized short hairpin RNAs (shRNAs) with 19–29-base-pair stem, at least 4-nucleotide
loop and 2-nucleotide 3′ overhangs are more potent inducers of RNAi than the canonical small-
interfering RNAs targeted to the same sequence in mRNA [64, 70–73]. Two main types of
shRNAs with opposite positions of the loops were designed (Figure 3). The right loop
structures (R-shRNAs) have sense strand at the 5′ end of the hairpin, whereas the left loop
shRNAs (L-shRNAs) have antisense strand at the 5′ end of the hairpin (Figure 3) [71–74]. The
majority of studies were carried out using R-hand loop structure.
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It was clearly demonstrated that the silencing activity of shRNAs depends on stem length, loop
length, sequence, and terminal overhangs [70]. Dicer efficiently cleaves shRNA with certain
minimum stem of 19 nt in length forming 22-nt products starting from the free 3′ end of the
RNA.
Correct 3′ overhangs increase the efficacy and specificity of processing, whereas blunt-end
shRNAs produce a set of products [64]. In the case of endogenously expressing regulatory
RNAs, 3′ UU overhangs of miRNA precursors generated by Drosha cleavage determine
subsequent proper recognition and processing by Dicer [75]. Synthetic shRNA with similar
overhangs and mimicking the products of Drosha preprocessing is used. The presence of a 3′-
UU overhang improves silencing activity of 19-mer shRNAs as 3′-UU overhangs might
provide additional site for PAZ domain of Dicer [70].
The loop length also plays a crucial role in the silencing activity of shRNAs. Thus, it was found
that 29-nt stem and 4-nt loop inhibited the target gene expression more efficiently as compared
with shRNA with 19-nt stem and loop [76, 70]. In contrast, when 9-nt loop was used for 19-nt
stem shRNA, it demonstrated more potent silencing of target genes than longer shRNA with
the 4-nt loop. Brummelkamp and his colleagues also demonstrated that shRNAs with 19-nt
stem and 9-nt loops possessed the maximum silencing activity as compared with shRNAs with
7-nt loops, while shRNA with 5-nt loops were inactive [68]. All observed differences in the
silencing activities of shRNA, divergent in the length of the stem and loop, were more
pronounced under low or intermediate concentrations. The silencing activity of different
shRNAs, used at high concentrations, did not depend substantially on the loop length [70].
These results may be explained by the fact that the loop length influences the efficiency of
processing by Dicer. [64]. Indeed, 4-nt loops of shRNA with 19-nt stem have poorer confor‐
mation flexibility at the junction between the duplex stem and a single strand of the loop. As
short loops are set close or at the Dicer cleavage site, the restriction-associated conformational
changes made shRNAs stems poor substrates for Dicer. Therefore, shRNAs with short loops
and 19-nt stem enter RISC complex in the later stages and remain not processed by Dicer [64].
It was suggested that another single-strand-specific ribonuclease, independent from Dicer,
cleaved this type of shRNA. On the other hand, shRNAs with 19-nt stem and longer loops (9–
10 nt) are efficiently processed by Dicer [76].
The potency of 19-nt stem shRNAs, targeted to the same sequence, depends on the position of
the loop. Right (R)-shRNAs 19 nt in length are significantly less active than left (L)-shRNAs of
the same length [71, 72]. However, the position of the loop (left or right) in longer shRNAs did
not affect their activity. It was suggested that low potency of R-shRNA form is related to the
fact that 5′ end of the antisense strand must be readily available for the efficient binding of
AGO2 in the RISC complex. Otherwise, the 5′ end of sense strand would enter RISC and the
target mRNA would not be cleaved. [77]. L-shRNAs with a short loop of 1–2 nt in length could
be active. Moreover, L-shRNAs without any loop, where sense strand is directly connected
with antisense strand, may be also active. In this case, the sense strand is shorter than antisense
strand and the loop is formed by 3′ end of the antisense strand [71].
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Moreover, the nature of nucleotides in 3′ overhang does not influence the activity of L-shRNA
and 3′ overhangs could be substituted for deoxyribonucleotides [71]. The high efficiency of L-
shRNAs may be explained by the high energy of binding of antisense strand with AGO2 due
to availability of 5′ end of antisense strand in L-shRNA, dominated over the influence of
overhangs and loop length. [71].
shRNAs have similar but not identical sequence preferences with siRNAs. Thus, the functional
shRNAs have mainly AU nucleotides at position 9 and GC nucleotides at position 11, while
these preferences are less significant in functional siRNA. At the same time, the functional
shRNAs have the similar thermodynamic asymmetry as functional siRNAs. The computer
algorithms for selection of potent shRNAs have been developed [76].
Short hairpin RNAs are a little more resistant to nucleases than siRNAs due to the protection
of one end; however, shRNAs still quickly degrade in biological fluids [78]. The elegant method
to stabilize non-modified RNA strands was described by Abe et al. [79]. Abe and his colleagues
constructed dumbbell-shaped RNA structures and demonstrated their potency as RNAi
inducers with stability in the biological fluids [79]. Dumbbell-shaped RNAs were designed by
analogy with DNA dumbbells consisted of double-helical stem and closed by two hairpin
loops. Dumbbell-shaped RNA structures are used as models for the analysis of local structures
in DNA [80]. Local unwinding of duplexes facilitates enzymatic cleavage by nucleases. Two
loops at the both ends of dumbbell RNA stabilize the duplex and limit its enzymatic cleavage
[79, 81]. Dumbbell structures get processed by Dicer much more slowly in comparison with
their linear analogues due to inefficient recognition by Dicer. The rate of processing depends
on the stem length, too. For example, dumbbell RNAs with 27-bp-stem length were processed
more quickly than the same sequence with 15–19-bp stem length. RNA dumbbells with 23-bp
stems and 9-nt loops were found to be the most active. Indeed, 9-nt loops are commonly used
in shRNAs as the most effective hairpin loops [67]. The stem length was optimized to keep
high potency and reduce interferon response. Silencing activity of these dumbbell RNAs was
significantly higher than that induced by linear counterparts and was retained for longer
period even at lower concentrations [81]. The introduction of deoxynucleotides into the loop
of dumbbell RNAs further significantly increases shRNA stability in biological fluids without
loss of silencing activity. Moreover, the loop of dumbbell RNAs can be modified by carriers
such as aptamers and peptides [81]. All benefits of dumbbell RNAs make them new potent
RNAi inducers. The main disadvantage of these structures is the high cost of their synthesis
in comparison with canonical siRNAs. At the same time, the low dosage and prolonged
silencing effect can reduce expenses. The detailed scheme of RNA dumbbell synthesis is
described by Abe and his colleagues [82].
Another type of RNAi inducer, fork-siRNA, was first introduced by Hohjoh [83]. Fork-siRNAs
contain base substitutions in the 3′ end of the sense strand of siRNA, resulting in destabilization
of the duplex [83–85]. The effect of fork-siRNAs is explained by the fact that thermodynamic
asymmetry of the duplexes determines the orientation of siRNA in RISC. Thermodynamic
stability of the terminal regions of the duplex defines which strand is cleaved and dissociated
during RISC activation, and another strand remains in the activated RISC and guides target
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mRNA recognition and cleavage [86]. Antisense strand of siRNA must be included in activated
RISC for efficient gene silencing, if activated RISC contains the sense strand no silencing occur.
The selection of active siRNAs may be complicated if a target mRNA is mutated or is a
chimerical gene. To address this issue, the favorable asymmetry can be achieved by the
introduction of several base substitutions at the 3′ end of the sense strand. Mismatches at the
3′ end of the sense strand, resulting in the formation of unpaired or destabilized regions,
increase the silencing activity of siRNA with low or moderate concentrations [83]. The number
of mismatches in fork-siRNA also plays a crucial role in its silencing activity [85]. Fork-siRNAs
with one to two mismatches at the 3′ end possess silencing activity similar to that of canonical
siRNAs, indicating that this number of mismatches is not enough for the efficient silencing.
Fork-siRNA with four mismatches is the most potent, whereas fork-siRNA with six mismatch‐
es possesses reduced silencing activity [85].
An optimal number of mismatches depend on the overall thermodynamic stability of the
duplex. Computational algorithms for siRNA sequence selection determine the recommended
range of Tm difference between the terminal regions, and four mismatches could work for
sequences within the range. On the other hand, mismatches in the 3′ part of the sense strand
and long unpaired ends increase the sensitivity of fork-siRNA to nucleases. Consequently, the
application of non-modified fork-siRNAs in vivo is limited by the fact that they have reduced
stability in biological fluids due to the increased degradation by nucleases [83, 85]. To solve
this problem, the algorithm for designing nuclease-resistant fork-siRNAs that contain 2′-O-
methyl modifications in nuclease-sensitive sites was developed, which allows obtaining fork-
siRNAs whose stability is comparable to that of canonical siRNAs [85].
Thereby, fork-siRNAs may improve unfavorable asymmetry of siRNA with low or moderate
silencing activity, especially when the selection of functional siRNA is restricted by the
sequence content of the corresponding mRNA. It makes sense to use them for silencing of
uneasy or precisely located targets.
4. Short noncanonical RNA
siRNA shorter than canonical siRNA could also induce efficient silencing of target genes in
mammalian cells acting via RNAi mechanism [87–90]. Short siRNAs have some benefits as
inducers of RNAi such as reduction of immune response and decreased cost of the synthesis
[76]. Various strategies have been used to design the minimal length for inducing RNA
interference. As A-form helix of RNA plays an essential role for inducing RNAi, Chiu and Rana
[91] found minimal length of dsRNA A-form helical structure required to enter active RISC
complex. They demonstrated that siRNA with 16 bp in length and 2-nt 3′ overhangs repre‐
senting ~ 1.5 helical turns efficiently assembles into catalytically active RISC and was sufficient
for silencing of target genes. Indeed, 16-mer siRNAs were more potent in comparison to 19-
mer siRNAs, while 15-mer siRNAs silenced gene expression at lower efficacy than 16-mer
siRNAs, and 14–13-mer siRNAs were practically inactive [87]. It was demonstrated that the
mechanism of target cleavage was different: cleavage sites in 16-mer siRNAs were shifted to
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3 nt in comparison with 19-mer siRNAs (Figure 4). The 16-bp siRNAs induced the silencing
faster than canonical siRNA due to the higher efficacy of RISC formation [87, 91]. Moreover,
asymmetric duplexes with 3′ overhang on the antisense strand only demonstrated reduced
off-target silencing in comparison with symmetric duplexes of the same length due to
preferential incorporation of the guide strand into the RISC complex [91]. Thus, considering
the benefits of 16-mer siRNAs, they possess high potential for using in biomedical studies, but
new examples of their use are not available.
Figure 4. The mechanism of Dicer cleavage for 19 bp siRNA and short siRNA 16 bp in length. Arrows indicate cleav‐
age sites defined by the 5’-end of guide strand (according to [87]).
Antisense siRNA also have been proposed as RNAi triggers. The sense strand of siRNA
duplex is degraded and antisense strand remains in the active RISC to target complemen‐
tary mRNA. Early studies demonstrated that 5′-phosohorylated antisense siRNAs with 22–
40 nt in length were able to induce gene silencing in Caenorhabditis elegans [92, 93]. Several
studies investigated the possibility of using antisense strand of siRNA 19–29 nt in length
for  transient  knockdown  of  target  genes  in  mammalian  cells  [88–90].  Antisense  siRNA
entered  the  RISC  complex  and  provided  mRNA  cleavage  but  with  lower  efficiency  in
comparison with canonical siRNA. Antisense siRNA and canonical siRNA possess similar
mRNA target position effects, cleavage fragment production, and tolerance to mutational
and chemical modifications. However, antisense siRNA modified at 3′ end by fluorescein
group or deoxyribose showed reduced silencing activity compared with canonical siRNA,
where  silencing  activity  remained  at  the  same  level  in  spite  of  3′  modifications  [89].
Moreover, the velocity of mRNA degradation induced by antisense siRNA is higher than
that provided by canonical siRNA, but the duration of silencing effect is shorter. Thus, it
was assumed that  antisense siRNA induces  RNAi through similar  pathways as  double-
stranded siRNA but enters the pathway at the intermediate stage [89].
The differences in the silencing activity between antisense and canonical siRNAs may be
explained by the low intracellular stability of the single-stranded RNA and by low efficacy of
association with RISC [89]. Among the advantages of siRNAs, a lower price of synthesis and
no side effects associated with the induction of interferon response should be considered [88].
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Partial boranophosphate backbone (BP) modifications were designed to increase the stability
and the silencing activity of the antisense siRNA [88]. BP-modified antisense siRNAs possess
silencing activity comparable to unmodified double-stranded siRNAs. Partial 2′-O-methyl
modification was used for the stabilization of antisense RNA, the activity resulting in single-
stranded siRNA was comparable with the activity of double-stranded siRNA when used in
high or intermediate concentrations, where in low concentration, canonical siRNAs were more
active [85].
Overall, in spite of lower silencing activity compared with canonical siRNA, antisense siRNA
may be used in specific situations, for instance, to eliminate off-target silencing of genes in the
case when the sense strand has substantial homology to nontarget genes [88].
5. Long-interfering RNAs
Long dsRNAs >30 nt in length efficiently silence the expression of target gene in nonmamma‐
lian cells [1, 4]. The early attempts to use the similar structures for efficient knockdown of target
genes in mammalian cells failed due to activation of interferon response [4, 94]. Later, various
design strategies have been developed to prevent the induction of interferon response and
construct new potent RNAi inducers [21, 95, 96]. Depending on the architecture of duplexes,
all long dsRNAs may be divided into linear and branched structures.
Partial 2′-O-methyl modification effectively prevents the activation of interferon response by
Dicer-substrate RNAs [17]; therefore, it was proposed to use similar approach for longer linear
duplexes [21]. Longer siRNAs containing the sequence of canonical siRNAs repeated two and
three times are called dimer (42 nt in length) and trimer (63 nt in length) small-interfering RNA.
Selective 2′-O-methyl modifications were introduced into nuclease-sensitive sites of both sense
and antisense strands of dimer and trimer siRNAs, the modifications in the sites of potential
Dicer cleavage were omitted. Selectively modified dimer and trimer siRNAs, unlike the
unmodified ones, did not induce interferon response in cultured cells. The trimers (called
tsiRNA) were significantly more active at lower dose-equivalent (per moles of 21 bp) concen‐
trations than their canonical analogues but the silencing effect develops more slowly [21] and
acts in a Dicer-independent mode, presumably via direct RISC loading. Although the Dicer
cleavage sites were free from modifications, modifications in flanking regions of tsiRNAs could
inhibit the Dicer cleavage. The observed mechanism may be associated with a specific pattern
of modification, used by the authors, which cannot be excluded such that the change in the
pattern will allow the tsiRNA to be processed by Dicer and act through a canonical mechanism.
Targeting single mRNA by RNAi inducer for therapeutic purposes has several limitations: (1)
the presence of mutation in the target site reduces the efficiency of silencing, which is especially
important for viral genes, and (2) signal pathways involved in cancer cell growth contain
duplications of regulatory elements and bypass regulatory pathways [97–99]. Thus, simulta‐
neous inhibition of several genes seems to be an effective strategy. Co-transfection of several
siRNAs may be not effective due to competition between siRNAs [30]. Therefore, long linear
synthetic siRNAs targeted two or more genes hold great promise in these cases.
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Peng and his colleagues designed long linear siRNA at least 30 nt in length (multi-siRNAs) for
dual-gene silencing [95]. To avoid undesired interferon response and improve RNAi potency,
2′-O-methyl modifications and gap in either sense or antisense strands were used. 2′-O-methyl
modifications were introduced into every second nucleotide of both strands. The gap divided
the complementary strand into two equal segments. It was demonstrated that multi-siRNAs
with the gap provided more efficient simultaneous silencing of two target genes in comparison
with corresponding single-target siRNAs (Figure 5). Interestingly, the simultaneous silencing
of two target genes by long siRNA without gap was ineffective. It was supposed that the gap
may provide sites for Dicer or facilitate Dicer processing. Because the Dicer substrates have
preference in RISC loading, multi-siRNAs could possess more efficient silencing activity than
canonical siRNAs [16, 18]. The experiments demonstrated that silencing effects of multi-siRNA
was eliminated when AGO2 was downregulated confirming the action through the same
RNAi pathway as canonical siRNAs [95]. However, further experiments are required to clarify
the exact mechanism of increased activity of these siRNAs.
Figure 5. Design of long linear duplexes with gap in either sense or antisense strands. Red color: sense strand, blue
color: antisense strand.
Long unmodified siRNAs up to 42 nt in length were used for silencing of gene expression in
some specific cell lines without the induction of interferon response [96–101]. For example,
direct fusion of two 17- and 19-bp long non-modified siRNAs resulted in efficient silencing of
two target genes [96]. Two RNAs were merged "head-to-head" in a way that the 5'-ends of both
antisense strands would look outside from the duplex allowing efficient and stereospecific
AGO2 binding and efficient silencing of both targets [96]. Heterologous duplexes merged
“head-to-tail” of antisense strands demonstrated reduced silencing activity [96]. Similar results
were obtained for tandem siRNAs of 40–42 nt in length consisting of 21+21 and 21+23 units
[101] as well as 40-nt long duplexes [100]. These results may be explained by the fact that the
induction of interferon response depends on the cell type [23]. Indeed, some cell lines may
possess reduced immune-sensitivity to the siRNA treatment and the results obtained on the
cell cultures cannot be unacceptable for in vivo experiments.
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Another class of long siRNAs are various branched structures (Figure 6). Initially, branched
oligonucleotides were applied to study mRNA splicing [102–104]. Then diverse branched
structures were used as building blocks for self-assembling nanostructures [105–107]. More‐
over, nanostructures of different shapes and sizes have been proposed as an effective delivery
system for siRNA, ribozymes, etc. [106, 107]. Recently, it has been demonstrated that branched
small RNA structures may also be effective RNAi inducers. Thus, these duplexes can simul‐
taneously inhibit two or more genes and possess improved silencing activity and intracellular
delivery properties [96–109]. Different strategies are developed to form branches. Symmetric
doubler phosphoramidites are used to construct branches with two or four strands [108]. In
another variant, trebler phosphoramidite structure with extended short DNA linker is used as
a core for branched small RNA with three arms [110]. Direct annealing was used to design
RNAs with three and four arms [111, 109]. However, base pairing close to the junction region
may be disturbed and single-stranded nuclease-sensitive region may be formed.
Figure 6. The architecture of various multi-target branched siRNAs. Different colors indicate siRNA units targeted to
various genes.
Chang and his colleagues introduced tripartite RNA structure without any linker containing
three 19-bp-duplex regions obtained by annealing of three 38-nt single-stranded RNAs [111].
The 5′ end of each antisense strand was directed outside, making seed regions of all antisense
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strands accessible for AGO2 loading. Single-stranded regions near the strand junction were
defended by 2′-O-methyl modifications affecting six nucleotides. It was demonstrated that
tripartite small RNA more efficiently silences the expression of three target genes in compar‐
ison with a mixture of corresponding canonical siRNAs due to a more efficient intracellular
delivery by Lipofectamine [111]. Specifically, tripartite small RNA was not processed by Dicer
possibly due to the influence of 2′-O-methyl modifications introduced into the single-stranded
region of tripartite RNA [111]. Similar structures without any modifications, designed by
another group of scientists, were efficiently processed by Dicer into 20-nt products [109]. On
the other hand, tripartite small RNA without any modifications was unstable in biological
fluids and quickly degraded.
Tetramer RNA consisted of four arms 23 bp in length proved to be more stable and also acts
in a Dicer-dependent mode. Both trimer and tetramer siRNAs provided prolonged RNAi effect
and efficiently inhibited the expression of three or four genes simultaneously. The influence
of the structures on the interferon response was not reported [109].
Overall, long linear and branched siRNAs could be efficiently used for simultaneous inhibition
of multiple genes. Selective 2′-O-methyl modifications and specific elements of the structure
(gaps, nonnucleotide insertions) could reduce undesired interferon response. The application
of long RNAi inducers is restricted by the complexity of the design (in the case of branched
molecules) and the higher cost of synthesis in comparison with canonical siRNAs; however,
recent advances in the synthesis of oligoribonucleotide allows overcoming these problems.
Long linear and branched siRNAs could be useful for the development of anticancer and
antiviral therapeutics targeting multiple genes.
6. Conclusion
Small-interfering RNAs provide universal and effective method for the silencing of target
genes because almost all genes could be targeted by siRNAs. A large number of diseases,
associated with hyperexpression of certain genes or expression of their chimeric or mutated
variants, could be treated by inhibition of gene expression; therefore, siRNA has a great
potential as a new therapeutic drug. Different design strategies have been used to improve
properties of siRNAs and reduce off-target effects. Structural modifications can expand the
boundaries of siRNA applications.
At present, synthetic siRNAs structurally mimicking the Dicer substrates (dsiRNAs) are
widely used as potent RNAi inducers. The use of dsiRNA may prevent the development of
undesired toxicity associated with off-target effects of both the inducer and the transfection
reagent or any type of carrier due to the lower effective concentrations and the increase in the
longevity of silencing. Therefore, application of dsiRNAs is considered to be extremely
promising in anticancer and antiviral therapeutics as well as for the treatment of chronic
diseases where multiple administrations are necessary to reach the desired silencing effect.
Chemical modification patterns compatible with Dicer processing were designed and suc‐
cessfully applied for prevention of undesired stimulation of immune system and for acquiring
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6. Conclusion
Small-interfering RNAs provide universal and effective method for the silencing of target
genes because almost all genes could be targeted by siRNAs. A large number of diseases,
associated with hyperexpression of certain genes or expression of their chimeric or mutated
variants, could be treated by inhibition of gene expression; therefore, siRNA has a great
potential as a new therapeutic drug. Different design strategies have been used to improve
properties of siRNAs and reduce off-target effects. Structural modifications can expand the
boundaries of siRNA applications.
At present, synthetic siRNAs structurally mimicking the Dicer substrates (dsiRNAs) are
widely used as potent RNAi inducers. The use of dsiRNA may prevent the development of
undesired toxicity associated with off-target effects of both the inducer and the transfection
reagent or any type of carrier due to the lower effective concentrations and the increase in the
longevity of silencing. Therefore, application of dsiRNAs is considered to be extremely
promising in anticancer and antiviral therapeutics as well as for the treatment of chronic
diseases where multiple administrations are necessary to reach the desired silencing effect.
Chemical modification patterns compatible with Dicer processing were designed and suc‐
cessfully applied for prevention of undesired stimulation of immune system and for acquiring
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nuclease resistance. Single-stranded structured synthetic siRNAs, such as Dicer-processed
short hairpin RNA and dumbbell RNA, possess all benefits as Dicer substrates and exhibit
additional flexibility in fine-tuning of the stability, kinetics, and silencing duration. Long RNAi
inducers, acting in a Dicer-dependent or Dicer-independent mode, effectively silence target
genes at low concentrations. Multi-target siRNAs have a great promise in the treatment of
complex diseases such as cancer and immune-inflammatory disorders or viral infections [108].
Long linear or branched structures with selective chemical or structural modifications could
successfully inhibit the expression of several genes without undesired off-target effects.
Currently, however, the complexity and high cost of the synthesis restrict the biomedical
application of long small RNAs. Some structural modifications in siRNAs have specific
applications. Fork-siRNA are successfully being used for the silencing of genes with restricted
selection of sequence content such as chimeric or point-mutated genes.
siRNAs with various structural modifications find a wide application in biomedical research
and therapeutics. Some of them have already been used in clinical trials. The great success was
achieved in the multi-target therapy that may increase treatment effectiveness. However, the
therapeutics applications are limited by the inefficient delivery of these compounds into
organs, tissues, and cells. Problem of low bioavailability of siRNA in vivo could be overcome
by two ways: the better delivery and the higher activity. Future expansion of the repertoire of
RNAi inducers contributes to resolving of both challenges. Although many approaches are
developed, more efforts are still needed to improve safety and efficiency of siRNA in vivo.
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Abstract
It is well known that most daphnid species have several attractive life history characteris‐
tics such as cyclical parthenogenesis, environmental sex determination, and predator-in‐
duced defense formation. Recent advances in high-throughput omics technologies make
it easy to obtain a huge number of potential candidate factors involved in environmental
stimuli-triggered phenotypic alterations. Furthermore, our group has developed a micro‐
injection system to introduce foreign materials such as nucleotides and chemicals into the
early-stage (one-cell stage) egg of Daphnia pulex and Daphnia magna. Consequently, we es‐
tablished a microinjection-based RNAi system that allows arbitrary gene functions to be
investigated. However, this microinjection system does not seem to have pervaded in the
daphnid research community due to its low throughput and high level of skills required.
In this chapter, we review the microinjection method and its RNAi system in water fleas,
D. pulex and D. magna, providing some technical tips and making challenging proposals
for the development of novel high-throughput RNAi methods. Finally, we provide an
overview of recently developed gene functional analysis methods such as overexpression
and genome-editing systems.
Keywords: Daphnia pulex, Daphnia magna, genome editing, microinjection, RNAi-related
gene
1. Introduction
The cladoceran crustacean water fleas are representative zooplankton ubiquitously found in
freshwater habitats around the world [1]. Among them, species of the family Daphniidae,
particularly genus Daphnia, have been well studied. All age classes of daphnids are principle
consumers of algae and thus play an important role in the food web in freshwater ecosystems.
In addition to this ecological significance, over the last decade, daphnids have drawn consid‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
erable attention as a good indicator organism for aquatic toxicology and have thus been used
in ecotoxicological studies [2]. Moreover, for over 100 years, they have shown various adaptive
phenotypic alterations in response to external environmental stimuli, including environmental
sex determination (ESD) [3, 4], cyclical parthenogenesis, in which the mode of reproduction
changes between parthenogenesis and sexual reproduction [3, 4], and inducible defense, which
is a predator-triggered alteration of body shape [5, 6]. The acquisition of such sophisticated
life history strategies has enabled daphnids to prosper around the world. These environmental
stimuli-triggered phenomena in daphnid species have attracted many scientists involved in
ecological, developmental, and evolutionary biology [4, 7–12]. Although recent progress in
sequencing technology facilitates the deciphering of genome and transcriptome information
using ‘nonmodel organisms’, analytical methods for arbitrary gene functions are still insuffi‐
ciently developed. In studies involving daphnids, the whole-genome sequencing project of D.
pulex has been completed [12]. Furthermore, a microinjection system using early-stage
embryos has been established, allowing gene functional analyses, including RNA interference
(RNAi), to be possible in daphnids [13, 14]. Even though this microinjection-based experi‐
mental method can be used in two representative daphnid species, D. pulex and D. magna,
some experimental aspects are different between them due to the difference in size of their
early-stage embryos.
This chapter introduces Daphnia species as attractive models for eco-evo-devo studies and
summarizes technical methods and tips for microinjection-based RNAi in D. pulex and D.
magna. Finally, we review recent advances in the application of microinjection methods in
daphnids such as genome editing and transgenesis.
1.1. Life cycle
Daphnids produce offspring either by parthenogenesis or by sexual reproduction in response
to external environmental conditions. This mode of reproduction is referred to as cyclical
parthenogenesis. They have a short generation period that lasts approximately 1 week under
constant laboratory conditions, and their lifetime spans over 2 months or as much as 1 year
when reared under colder temperatures [15]. Under optimal growing conditions, daphnids
parthenogenetically produce offspring that expand their population consisting almost
exclusively of females. This results in the exponential growth of genetically identical clone
clusters. Mother daphnids produce several dozen eggs in their own brood chamber as a clutch
just a few minutes after molting. Embryonic development occurs in the brood chamber.
Subsequently, neonates are released to the outside just before the mother molts. Then indi‐
vidual mothers in the parthenogenetic phase repeat molting, spawning, and the release of
neonates throughout their lifetime (Figure 1, parthenogenetic phase).
On the other hand, when environmental conditions deteriorate, for instance, a short day-
length, lower temperature, food shortage, overcrowding, and the presence of predators, males
are induced by parthenogenesis and are, therefore, genetically identical to their sisters and
mother [4, 7–9, 16, 17] (Figure 1, sexual reproductive phase). In other words, an individual
parthenogenetic mother has the potential to produce female and male offspring in response
to changes in external environmental conditions. After copulation, sexual eggs, referred to as
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resting eggs that are enclosed in an ephippium (modified carapace that is darkly pigmented
by melanin), are produced. Resting eggs can tolerate extreme conditions such as drying,
freezing, and digestion by fish and can remain viable for over 100 years [18]. When favorable
conditions are restored, female neonates hatch out from resting eggs and reinitiate the
parthenogenetic phase, thus building up a new population (Figure 1, sexual reproductive
phase).
Figure 1. Schematic drawing of cyclical parthenogenesis in daphnids.
1.2. Daphnia as model species for ecological, evolutionary and developmental biology: eco-
evo-devo
Although several details are still controversial, recent molecular phylogenetic analyses of the
Arthropoda have revealed that the Crustacea clade is not monophyletic and is divided into at
least three clades (Ostracoda, Malacostraca, and Branchiopoda) that include daphnids (Figure
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Hexapoda form a sister group (Figure 2). This suggests that a growing body of findings
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tionary and developmental aspects of Arthropoda, connecting knowledge between well-
studied Hexapoda and more primitive Arthropoda clades.
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Figure 2. Phylogenetic tree of the Arthropoda. The branching pattern is based on Oakley et al. [19] with some modifica‐
tions [20].
D. pulex and D. magna have long been used in ecological, evolutionary, developmental, and
ecotoxicological studies as representative model daphnid species for the following reasons:
D. pulex is ubiquitously widespread around the world, including Japan (Figure 3A), and shows
striking phenotypic alterations in response to predator-released chemicals, forming ‘neckteeth’
[5]; D. magna has a huge body size among cladoceran species (maximum length of approxi‐
mately 10 mm, Figure 3B); they are easy to maintain and rear under laboratory conditions;
they propagate rapidly because of their short generation time and reproductive cycle; embry‐
onic development can be observed in vitro; male offspring can be induced by administration
of juvenile hormone agonists [21, 22]. In addition, individuals within a single strain are most
likely genetically identical due to the diploidy of the parthenogenetic eggs that are maintained
by mitosis-like meiosis, which skips a part of the first meiosis [23], allowing the environmental
effects on their physiological and developmental processes to be investigated under a constant
genetic background. Furthermore, we established a reliable induction system for environ‐
mental sex determination (ESD) studies using the D. pulex WTN6 strain, in which the sex of
the offspring can be controlled by changing the day-length conditions in which long-day (14
h light:10 h dark) and short-day (10 h light:14 h dark) conditions can induce female and male
offspring, respectively [17], and for inducible defense in several D. pulex strains where the
incidence and number of neckteeth vary in response to different concentrations of Chaoborus
kairomone [24].
In addition to the aforementioned advantages, useful experimental tools are available, for
example, embryonic developmental staging [25, 26], whole-mount in situ hybridization and
immunostaining using developing embryos [27], immunofluorescence and fluorescence in
situ hybridization (FISH) [28], an expressed sequence tags (ESTs) database [29], and genetic
linkage maps [30–32]. Furthermore, the whole-genome sequencing of D. pulex is complete [12,
32], although that of D. magna is still ongoing (https://wiki.cgb.indiana.edu/display/magna/
Home). In addition, recent growing omics and bioinformatics technology enables daphnid
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researchers to investigate cells, tissues, and organisms from a multilevel perspective such as
the transcriptome [12, 33–35], proteome [36], or metabolome [37]. Thus, various excellent
experimental tools and an increasingly huge accumulation of omics data make D. pulex and
D. magna attractive model organisms for studying the molecular mechanisms underlying
phenotypic alterations that depend on external environmental conditions. These reliable
induction systems of focal phenotypes are indispensable for analyzing their physiological and
developmental mechanisms.
Figure 3. Daphnia pulex (A) and D. magna (B). Upper and lower parts indicate the adult and embryo just after ovulation,
respectively.
2. Microinjection-based RNA interference (RNAi) in daphnid species
As mentioned above, recent high-throughput sequencing technologies have enabled biologists
to use nonmodel organisms to easily access genomic information. However, the development
of experimental methods for gene functional analysis still hampers their reverse genetics
approach. To date, the RNAi method in D. pulex and D. magna has been established by a
microinjection method using early-stage embryos. Although our previous reports described
detailed methodology for microinjection and the tips, tricks, and traps associated with this
methodology [13, 14], there are slight differences for each daphnid species. Furthermore,
descriptions of genes involved in the RNAi machinery is insufficient. Therefore, we compa‐
ratively summarize the tips to manipulate the microinjection methods in detail prior to
focusing on the current status of daphnid RNAi. We then introduce the gene repertoires
involved in the RNAi mechanism in D. pulex and D. magna genomes.




The daphnid microinjection system uses parthenogenetic eggs just after ovulation into the
mother’s brood chamber. The individual mother begins to lay eggs into the brood chamber a
few minutes after releasing neonates and molting. To obtain many healthy eggs, eggs from 2
to 6-week-old daphnids should be collected.
There are two major technical issues in microinjection of daphnids. One is the rapid hardening
of the egg membrane just after ovulation [38], which is caused by enzymatic activity of
peroxidase. The second problem is a substantial difference between the internal and external
osmotic pressures of the egg. The former issue hampers the penetration of the egg membrane
by a needle while the latter causes the leakage of egg components after injection. To overcome
these problems, Kato et al. [13] and Hiruta et al. [14] established improved protocols for
microinjection in D. magna and D. pulex, respectively. They succeeded in the transient inhibi‐
tion of the egg membrane hardening by ice-cold treatment just after ovulation. They also found
the best culture conditions after injection by increasing external osmotic pressures: M4 medium
[39] with 80-mM sucrose in D. magna [13] and a 2% agar plate covered with 60-mM sucrose
dissolved in M4 media in D. pulex [14].
In addition, since the fineness of the needle is critical for the success of microinjection, we next
describe a detailed preparation method. A glass needle is made from a glass capillary tube
(GD-1; Narishige, Tokyo, Japan) by a micropipette puller (P-97/IVF; Sutter Instrument, Novato,
CA, USA). The programmed P-97 parameters are as follows: heat: 845; pull: 50; velocity: 120;
time: 200; pressure: 500. The value of the ‘heat’ parameter required for the ramp test is based
on the manufacturer’s protocol because this value depends on a combination of the filament
and the glass capillary. In our case, using a combination of a regular P-97 filament and a GD-1
glass capillary, the ‘heat’ parameter value ranges between 845 and 870.
Based on the aforementioned information, we describe next the manipulation procedure of
microinjection using daphnids eggs.
1. The setting of tools for microinjection and surgery are shown in Figure 4A-C. A glass Petri
dish is prepared by placing two cover glasses side by side with M4-sucrose at ambient
temperature.
2. The synthesized double-strand RNA (dsRNA) is mixed with an equal amount of 2-mM
Chromeo 494 fluorescent dye (Active Motif Chromeon GmbH, Tegernheim, Germany),
which is used as a visible marker for injection. When using D. pulex eggs, it is possible to
confirm whether injection has succeeded by visual observation since the eggs are more
transparent than D. magna eggs (Figure 3). A visible marker is thus not essential.
3. The dsRNA solution (1.0–1.5 μL) is loaded into the needle. The tip of the needle is then
manually cut off using forceps under a stereomicroscope.
4. Mother daphnids just before molting (brood chamber is empty) are collected and observed
until spawning begins. They are transferred to ice-cold M4-sucrose medium just before
spawning is complete (4–5 eggs remain in each ovary).
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5. Eggs are surgically obtained from the mother daphnid and placed in ice-cold M4-sucrose
medium.
6. One to three eggs are immobilize by placing them at the edge of the left cover glass and
are injected by using a microinjector (Femtojet, Eppendorf, Hauppauge, NY, USA) and a
micromanipulator (MN-153, Narishige, Tokyo, Japan ; Figure 4D–F). The right cover glass
is used as a holder when the needle is not withdrawn from the egg. Microinjections can
be carried out within 1 h after ovulation.
7. The injected eggs are transferred into a plastic 6-well plate with 80-mM M4-sucrose
medium for D. magna [13] or a 2% agar plate on a 6-well plate with 60-mM M4-sucrose
medium for D. pulex [14] (Figure 4G) and subsequently incubated under constant
temperature (18–20°C).
Figure 4. Microinjection of daphnid egg. (A) Experimental equipment. 1: stereomicroscope; 2: micromanipulator
(MN-153, Narishige, Tokyo, Japan); 3: electronic microinjector (Femtojet, Eppendorf, Hauppauge, NY, USA). (B) Tools
for surgical manipulation. 1: Pasteur pipet (Thomas Scientific, Swedesboro, NJ, USA); 2: glass dish with two cover
glasses; 3: plate for blood test; 4: forceps (Dumoxel #5 Biologie). (C) A glass needle is made from a glass capillary tube
(GD-1; Narishige, Tokyo, Japan). (D) Overview illustration of microinjection field. (E, F) Magnified view and illustra‐
tion of microinjection using D. pulex egg. (G) Schematic illustration of embryo incubation after injection.
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2.2. RNAi machinery in daphnid species
The well-known natural role of RNAi in organisms is the innate immune system against
viruses and transposable elements [40]. Using this phenomenon, RNAi induction has been
developed as an innovative method for gene functional analysis by exogenous application of
dsRNA in Caenorhabditis elegans [41]. The dsRNA is first recognized by Dicer protein and cut
off into short 21–24 nucleotides referred to as short interfering RNAs (siRNA). These are then
invariably incorporated into large Argonaute-containing effector complexes known as RNA-
induced silencing complexes (RISCs), after which one-side strand of the dsRNA is cleaved and
degraded. Finally, the active Argonaute-containing RISC cleaves the target RNA sequence
with the complementary sequence to siRNA [40, 42]. In addition to this core machinery of the
RNAi pathway, many eukaryotes have the potential to amplify an amount of siRNA by a host-
encoded RNA-dependent RNA polymerase (RdRp). However, RdRp orthologs have not been
identified from the Arthropoda genome including D. pulex except for the tick genome [42].
In the D. pulex and D. magna genomes, there are three Dicer and Argonaute paralogs, but the
D. magna genome contains two copies of Dicer. Previous studies have shown that Dicer
paralogs are categorized into two clusters corresponding to the microRNA (miRNA) pathway
(Dicer-1) and the siRNA pathway (Dicer-2) [42, 43]. The miRNA is also a short 21–25 RNA,
which is generated from a hairpin in pre-mRNA, and plays an important role in translational
repression associated with RISC [44]. Phylogenetic analyses found that all Dicer paralogs of
D. pulex and D. magna were classed into the Dicer-1 group [45] (Figure 5A). Moreover, we
successfully recruited three Argonaute paralogs from the genome of each daphnid and
constructed a phylogenetic tree (Figure 5B). Previous studies revealed that Argonaute family
members are key components in different RNA silencing pathways and are categorized into
two subfamilies, Argonaute and PIWI (P-element induced wimpy testis). Argonaute subfamily
members have been found in widespread taxa, including yeast, plants, and animals and have
been identified as Argonaute-1 and Argonaute-2, which are involved in miRNA and siRNA
pathways, respectively. In contrast, the PIWI subfamily has been identified only in animals as
Argonaute-3, which is involved in PIWI-interacting RNA (piRNA) pathways [42, 46, 47]. Four
Argonaute family members were found from D. pulex and D. magna genome sequences in this
study, although only two paralogs have already been previously reported [43]. Phylogenetic
analysis revealed that both paralogs fall into the Arogonaute-1 clade of the Argonaute
subfamily, whereas each one paralog was categorized into Argonaute-3 and PIWI clades of
the PIWI subfamily (Figure 5B). The number of Argonaute family members found in daphnids
seems to be as conserved as in insect species [42, 48], although no Argonaute-2 paralogs have
yet been identified. Taken together, our results suggest that the genomes of daphnids might
lack the Dicer-2 and Argonaute-2 orthologs, which are factors responsible for regulating the
siRNA-inducing transcriptional gene-silencing pathway. In other words, our data imply that
the RNAi machinery of daphnid species might be distinct from the equivalent well-studied
mechanism in insects. To understand the full picture of the RNAi machinery of daphnid
species, further studies that examine domain sequence similarity and gene functional analysis
will be required.
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Figure 5. Phylogenetic trees of Dicer (A) and Argonaute (B). Amino acid sequences were aligned by ClustalW, and the
maximum likelihood trees were constructed from these alignments using the JTT model with bootstrap analyses of
1000 replicates along with complete deletion options (818 and 597 amino acid positions were used, respectively) by
MEGA6 [49]. Branches with bootstrap support >70% are indicated by numbers at nodes. Both D. pulex and D. magna
are indicated in bold. To obtain the predicted sequences encoding the D. magna orthologs of RNAi-related genes, pro‐
tein sequences of D. pulex were used in BLAST searches querying D. magna Genome BLAST (http://arthro‐
pods.eugenes.org/EvidentialGene/daphnia/daphnia_magna/BLAST/). The SID protein sequences of D. pulex were
retrieved from wFleaBase (http://wfleabase.org/). Phylogenetic trees were constructed based on data from McTaggart
et al. [43] with some modifications.
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2.3. Future challenges for development of high-throughput RNAi method in daphnids
Despite the availability of a microinjection-based RNAi method in daphnids, as demonstrated
by knocking down genes responsible for morphogenesis (distal-less and eyeless) [13, 14, 50],
sexual differentiation (doublesex1) [51], endocrine system (ecdysteroid-phosphate phosphatase)
[52], and neurogenesis (single-minded homolog) [53], this method has several experimental
limitations. For example, microinjection can only be performed using an early stage (1-cell
stage) egg, suggesting that this system cannot be used to perform a functional analysis of genes
that act during the adult stage and is unsuitable for large-scale experiments. Moreover,
specialized and skillful technical training is necessary to master the microinjection technique
in daphnids. To overcome those technical hurdles, we introduce two potential ideas to
establish more high-throughput and user-friendly methods for the study of daphnids. One is
electroporation, which is a physical transfection method that uses an electrical pulse to increase
the permeability of cell membranes, allowing nucleic acids and/or chemicals to be introduced
into cells. Recent innovation of the electroporation system has enabled the establishment of
rapid functional analysis in various organisms [54–56]. Indeed, our group has successfully
developed an in vivo electroporation system for the introduction of foreign DNA into neonatal
D. magna within 6 hours after release from the mother’s brood chamber [57]. Therefore, it might
be possible to apply this system for RNAi using various stages of daphnids.
The second method is a feeding (oral delivery) RNAi system, which was first developed in C.
elegans [58]. The feeding RNAi system is the most convenient and inexpensive method for high-
throughput screening since bacteria produce the designed dsRNA that are fed to host animals.
This system has so far been applied in various insects [59] and decapod crustaceans [60–62].
Unlike the time-consuming and troublesome microinjection method that can only be per‐
formed in the early egg stage in daphnids, the alternative feeding RNAi method may poten‐
tially be applied for manipulating a wide range of genes in many individuals at the same time.
3. Extended microinjection-based applications
The microinjection system can be widely applied for the development of not only RNAi but
also other attractive methods for gene functional analysis. Indeed, several microinjection-
based functional methods have been developed in daphnid species. First, a transient overex‐
pression system for arbitrary genes or reporter constructs was established by microinjection
of synthesized mRNA bearing the 5′ cap structure and the 3′ poly(A) tail [51] and a DNA
reporter construct [63]. These methods allow for a gain-of-function analysis, although only one
example has shown that the phenotype induced by transient overexpression was only
observed in the first instar juvenile [51]. However, the aforementioned overexpression and
RNAi system in daphndis suffer from several drawbacks such as incomplete gain- or loss-of-
function, transient effect, and limited analyzable stages.
To overcome these limitations, a transgenic D. magna line was established by using microin‐
jected GFP or DsRED reporter plasmid, although the success rate was quite low (0.67%) [64,
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65]. Furthermore, genome editing with engineered endonucleases is rapidly growing as a
stable experimental method for generating heritable mutations in not only well-known in
model organisms but also in nonmodel organisms. There are three representative methods:
zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and
clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) systems [66]. In
order to perform targeted mutagenesis in the D. pulex and D. magna genomes, TALEN and
CRISPR/Cas9 systems have been established by microinjection of these engineered nucleases
[50, 65, 67]. Taken together, these genome-editing techniques will enable scientists to accu‐
rately define arbitrary gene functions in daphnid species in future studies.
4. Conclusion
Recent growing innovations in high-throughput omics technologies (e.g., genomics, transcrip‐
tomics, proteomics, and metabolomics) enable us to obtain comprehensive profiles of a huge
amount of candidate factors responsible for unique life history features of daphnids [12, 34,
68]. In order to investigate an arbitrary gene function, the establishment of an experimental
method for gene functional analysis has been enthusiastically addressed by researchers using
nonmodel organisms, even in the postgenomic era. In this chapter, we summarized (1) the
experimental procedure with several tips for a microinjection system in D. pulex and D.
magna, (2) information about genes responsible for their RNAi machinery, (3) potential
concepts for novel user-friendly high-throughput RNAi systems in daphnids, and (4) other
microinjection-based applications in daphnids. Further studies involved in the development
of novel experimental methods and investigation of a wide range of gene functions can lead
to a better understanding of the overview of the attractive environmental stimuli-dependent
phenomenon in daphnids.
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Abstract
In  animals  and mammalian cells,  protein  function can be  analyzed by nucleotide se‐
quence-based methods such as gene knockout,  targeted gene disruption, CRISPR/Cas,
TALEN,  zinc  finger  nucleases,  or  the  RNAi  technique.  Alternatively,  protein  knock‐
down approaches are available based on direct interference of the target protein with
the inhibitor.
Among protein knockdown techniques, the endoplasmic reticulum (ER) intrabodies are
potent molecules for protein knockdown in vitro  and in vivo.  These molecules are in‐
creasingly used for  protein  knockdown in  living cells  and transgenic  mice.  ER intra‐
body  knockdown  technique  is  based  on  the  retention  of  membrane  proteins  and
secretory proteins inside the ER, mediated by recombinant antibody fragments. In con‐
trast  to  nucleotide  sequence-based  methods,  the  intrabody-mediated  knockdown acts
only on the posttranslational level.
In this review, the ER intrabody technology has been compared with the RNAi techni‐
que on the molecular level. The generation of intrabodies and RNAi has also been dis‐
cussed.  Specificity  and  off-target  effects  (OTE)  of  these  molecules  as  well  as  the
therapeutic potential of ER intrabodies and RNAi have been compared.
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1. Introduction
For the study of protein function in animals and mammalian cells, DNA-based methods such
as gene knockout, targeted gene disruption, CRISPR/Cas, TALEN, zinc finger nucleases [1],
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as well as the RNAi technique [2] were proven and reliable tools. Besides the RNAi technique,
approaches with miRNA are also very attractive [3]. Silencing of target mRNA can be achieved
using siRNA, miRNA, or shRNA (Box 1).
Box 1
siRNA
Small interfering RNA (siRNA) are small pieces of double-stranded (ds) RNA, usually about 21 nt long,
with 2-nt-long 3′ overhangs at each end. They can be applied for the interference with the protein
translation by binding to the messenger RNA (mRNA), whereby promoting the degradation or destabi‐
lization of the mRNA.
shRNA
shRNAs form hairpin structures, which consist of a stem region of paired antisense and sense strands,
connected by unpaired nucleotides building a loop. They are converted into siRNAs by the same RNAi
machinery that processes miRNAs.
miRNA
MicroRNAs are small RNA molecules, encoded in the genome of plants and animals. These highly
conserved, ~21-mer RNAs regulate the expression of genes by binding to the 3' untranslated regions (3'-
UTR) of specific mRNAs.
Protein knockdown is possible with small molecule inhibitors including peptides, neutralizing
and intracellular antibodies, and allosteric modulators [4–8]. In addition, aptamers and
intramers, in general short single-stranded DNA or RNA oligonucleotides are also potent
molecules for specific inhibition of small molecules, peptides, proteins, or even whole living
cells [9].
Currently, RNAi is the most often used gene-silencing technique in functional genomics [2].
In this article, we described an emerging protein knockdown technology using intracellular
antibodies (intrabodies) targeted to the ER and compared the advantages and disadvantages
of this promising technique with the RNAi technology. We tried to make scientists, who are
interested in protein research or have very specific protein-related questions, familiar with the
ER intrabody technology [10]. The molecular mechanisms of both methods are different.
RNAi-mediated knockdown is based on the interference of siRNA with mRNA (Figure 1),
whereas the protein knockdown by ER intrabodies is exerted upon binding of a recombinant
antibody fragment to its specific antigen inside the ER [10] (Figure 2).
Intrabodies are recombinant antibody fragments targeted to a cell expressing the specific
antigen. Intracellular binding of the intrabody to the antigen results in inhibition of antigen
function. Moreover, intrabodies can specifically be targeted to subcellular compartments such
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Figure 1. Principle of the knockdown of transitory proteins using the RNA interference technique. For knockdown
of the mRNA of transitory proteins, transfection with a specific shRNA-expressing plasmid is sufficient. Although by
using the RNA interference technology all kinds of proteins could be targeted, only knockdown of transitory proteins
is illustrated. (1) Specific shRNA is transcribed and processed by the RNase III Dicer-1 enzyme in mammalian cells in
order to form the mature siRNA. (2) The Argonaute 2 protein (Ago2) is loaded with the siRNA and forms together
with additional proteins the RNA-induced silencing complex (RISC), which is a multiprotein complex consisting of ef‐
fector (Argonaute proteins), accessory proteins, and si/miRNA. During the loading of the Argonaute protein, one
strand of the siRNA duplex is discarded. Next, the RISC complex associates with its target mRNA via complementary
base pairing of the siRNA and the target mRNA. In many cases, the recognition site comprises the 3′ untranslated re‐
gions (UTR) of the mRNA. Finally, target binding leads to mRNA degradation or translational inhibition [11]. mRNA
degradation is mediated through the endonuclease activity of the Argonaute proteins. (3) As a result of mRNA knock‐
down, the target protein is not expressed on the cell surface [11].
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Figure 2. Principle of the specific knockdown of transitory proteins with endoplasmic reticulum (ER)-retained in‐
trabodies. In wild-type cells, transitory proteins are transported through the ER and can be further processed (e.g., gly‐
cosylated) in the Golgi apparatus. These proteins could reside in the secretory cell compartments, secreted through the
plasma membrane (PM), or become integrated in the PM as a membrane protein. For functional inhibition of these pro‐
teins, transfection with an ER intrabody expressing plasmid is sufficient. The intrabody construct consists of an N-ter‐
minal secretion sequence for the translocation in the ER (leader sequence) and the C-terminal retention signal (KDEL).
(1) The intrabody inside of the ER binds to the target protein. This complex of antibody and target protein is further
processed and transported through the secretory pathway. (2) In the cis-cisterna of the Golgi stack, the hERD2 receptor
binds to the KDEL sequence and (3) initiates the retrograde transport back to the ER compartment. This continuous
binding of the intrabody and retrograde transport prevents the target protein to reach its localization where it normal‐
ly acts. (4) The accumulated intrabody–antigen complex in the ER might be transported into the cytoplasm, where it is
marked for degradation by the 26S proteasome [12, 13]. Böldicke and Burgdorf have shown that an anti-toll-like recep‐
tor 2 (TLR2) ER intrabody is degraded by the proteasome (unpublished data).
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as the nucleus, cytoplasm, mitochondria, or ER [10] (Box 2). Currently, the most used and
promising intrabodies are the ER intrabodies, because of the correct folding in the oxidative
environment of the ER [14]. This contrasts with cytosolic intrabodies, in which disulfide
bridges are not formed in the reducing environment of the cytoplasm [15, 16].
Box 2
Intrabodies are intracellularly expressed recombinant antibody fragments, which specifically inhibit the
function of target proteins produced in the same cell [10].
ER Intrabodies retain their corresponding antigen inside the ER by inhibiting the translocation of the
antigen to the cell compartment where it normally acts.
Cytosolic Intrabodies are expressed in the cytoplasm. They inactivate their targets or interfere with the
binding of the target protein to its corresponding binding partner.
The effect of ER intrabodies is based on retention of proteins passing the secretory pathway.
Secretory proteins, membrane proteins, and even Golgi or endosomal-located proteins can be
targeted [17–19], which cannot be reached by classical antibodies, due to the extracellular
presence. Successful functional knockdown was achieved for oncogenic receptors, viral
proteins for preventing virus assembly, cellular virus receptors to block virus entry, and
receptors of the immune system as well as of the nervous system [20–24].
The format of expressed intrabodies is, in general, the single-chain variable fragment (scFv) or
less common the antigen-binding fragment (Fab) [25]. The only prerequisite of ER intrabodies
is the efficient binding to the antigen, and the method to select and generate an ER intrabody
is greatly simplified by phage display. On the contrary, functional cytoplasmic intrabodies
have to inactivate the antigen or have to interfere with the binding of the target protein to its
corresponding binding partner [10].
The starting material for construction of an ER intrabody is an scFv or Fab, which can be
obtained by amplification of the variable domains from a hybridoma clone [26], or scFv
fragments can be selected from phage or yeast display [27, 28].
Early attempts using the intrabody approach failed frequently due to the lack of reliable
techniques for the identification of the correct functional antibody sequence from a hybridoma
clone. The genes of the variable domains for construction of recombinant antibody fragments
can be amplified from hybridoma clones using mixtures of consensus primers [29]. This
approach was used in the beginning. As hybridoma cells could secrete several different
antibodies, it was sometimes difficult to isolate the correct functional sequences of the variable
domains. Presently, with reliable protein sequencing techniques, next generation of DNA
sequencing and optimized consensus primer sequences, the functional antibody DNA can
much better be identified. Furthermore, optimized strategies for amplification of the correct
functional antibody sequence are available [30–32].
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In the case of using in vitro display systems, like phage or yeast cell surface display, the selected
scFv fragment has only to be cloned into the ER-targeting vector. For preliminary characteri‐
zation of the intrabody function, co-transfection of the intrabody expression plasmid with the
corresponding antigen expression plasmid into HEK 293 cells is sufficient and followed by co-
immunoprecipitation and immunofluorescence analysis [33].
In contrast to the ER intrabody technology, the advantage of the RNAi is that it can be applied
for almost every mRNA and also non-coding RNAs. Here, we further compared the RNAi
with the intrabody technology, regarding specificity, off-target effects, and therapeutic
approaches.
2. Intracellular intrabodies versus RNA interference
2.1. Generation of ER intrabodies
The prerequisite for generating intrabodies is the availability of a hybridoma antibody clone
or scFv/Fab fragments selected from in vitro display systems [10]. Starting from a hybrido‐
ma clone, the variable domains of the heavy and light chain are amplified by PCR from the
cDNA. This can be achieved by (1) PCR amplification using consensus primer [29, 34–36],
(2) rapid amplification of cDNA ends (RACE) [30], (3) PCR amplification using adaptor-
ligated cDNA [31],  or (4) inverse PCR with constant region heavy chain and light chain
primer, amplifying the corresponding antibody sequence from circularized double-strand‐
ed cDNA [32] (Figure 3 A).
In most cases, using consensus primers is a fast and efficient approach for amplification of the
correct functional antibody sequence from a hybridoma clone. However, less-common non-
consensus antibody sequences cannot be amplified and primer mismatching could be a
problem. Approaches (no. 2–4 shown in Figure 3) for amplifying the variable antibody
domains are more time-consuming; however, the correct functional antibody gene sequence
can be obtained. The variable domains are compiled by assembly PCR, linking both variable
domains together by a short flexible linker sequence, for example (Gly4Ser)3, resulting in the
scFv fragment. Next, the scFv fragment will be cloned into the ER targeting vector, providing
the ER signal sequence, an myc tag for detection of intrabody, and the KDEL retention sequence
localized at the C-terminus of the intrabody gene [26].
Following the in vitro display pipeline, an scFv fragment or Fab fragment selected by phage
or yeast cell surface display can directly be cloned into the ER targeting vector. Most recombi‐
nant antibody fragments in the scFv or Fab format are selected by phage display or also the
frequently used yeast cell surface display [27, 28, 41]. Other in vitro display systems are
bacterial, mammalian cell surface display, or ribosome display [42–44]. Cytoplasmic intra‐
bodies are generated from hybridoma clones or scFv/Fab fragments from in vitro display
libraries in a similar way and cloned into an appropriate cytosolic targeting vector [10]. The
main difference in comparison to ER intrabodies is that cytosolic intrabodies have to demon‐
strate neutralizing activity, and furthermore stable folding antibody fragments have to be
selected [10].
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Figure 3. Generation of intrabody and RNA interference knockdown constructs. (A) Generation of intrabody knock‐
down vectors. The scFv fragment could be either cloned from hybridoma cell lines or selected from huge human naive
phage display libraries. The antibody variable domain of the light chain (VL) and heavy chain (VH) is amplified from
cDNA using consensus primer mixtures (1), 5′ adapter-ligated PCR or rapid amplification of cDNA ends (RACE) (2) or
with constant domain-specific primer from circularized cDNA (3). The antibody VL and VH genes are assembled as
scFv by fusing both domains with a flexible (Gly4Ser)3-linker sequence and cloned into the ER targeting intrabody vec‐
tor. The scFvs are cloned between an upstream secretion signal and a downstream retention sequence (KDEL). Using
the phage display system, selected scFvs can directly be cloned into the intrabody vector in one cloning step. Shown is
an ER-targeting vector. (B) Generation of siRNA/shRNA/miRNA knockdown vectors. Rational in silico design of siR‐
NA, shRNA, or miRNA mimics using software algorithms like those mentioned in Ref. [37] or in Ref. [38], a recent
publication, deduced from the target cDNA. The algorithms are designed to select appropriated sequences by means
of empiric criteria. Main criteria are an siRNA length of 19–21 nucleotides (nt) in conjunction with 2 nt overhangs at
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their 3′ ends, as well as thermodynamic properties of target mRNA hybridization. Rational design can be expanded by
testing in silico the potential off-target effects of the designed sequences by using genome-wide enrichment of seed se‐
quence matches (GESS) [39] or Haystack [40]. Designed sequences are chemically synthesized and cloned into appro‐
priate mammalian or viral knockdown expression vectors. Alternatively, siRNA can be used for direct cell transfection.
The siRNA/shRNA/miRNA sequences originated from rational design are screened for effective processing, specific
knockdown capabilities, and potential off-target effects. Corresponding clones are selected, and for most applications
3–4 different targeting sequences were chosen and theses libraries are used for the RNA interference knockdown. ER:
endoplasmic reticulum, CDS: coding DNA sequence, p:promoter.
2.2. Generation of siRNA, miRNA, and shRNA
In order to generate siRNAs for a specific target, only the mRNA information about the target
sequence is needed [45] (Figure 3 B). siRNA-mediated mRNA knockdown can be performed
in several ways. In general, cells can directly be transfected with siRNA, using transfection
reagents like lipofectamine. Cells can also be transfected using siRNA/shRNA/miRNA-
expressing plasmids or viral vectors. Long-lasting gene silencing can be achieved with shRNAs
expressed from stably transfected plasmids or from integrated retro- or lentiviral vectors [46].
Several approaches exist for RNA interference-mediated knockdown, the principle workflow
of in silico design, screening, and selection of siRNA/shRNA/miRNA, with best knockdown
properties shown in Figure 3 B. Currently, software algorithms mentioned in Ref. [37] or [38]
can help to find the appropriate knockdown sequences of 19–21 nt length siRNA by analysis
of the optimal thermodynamic properties of mRNA hybridization. Potential off-target effects
can be reduced by in silico optimization with GESS [39] or Haystack [40]. Resulting siRNA/
shRNA/miRNA sequences are tested for effective processing, specific knockdown capability,
and low off-target effects.
2.3. Stability
Intrabodies are stably expressed inside the ER [14], whereas most cytosolic intrabodies are not
correctly folded [15, 16]. On the other hand, siRNA can be cleaved by nucleases, present in the
blood serum and cellular cytoplasm.
2.4. Specificity and Off-Target Effects (OTE)
For the knockdown of distinct target proteins, the specificity of the process is crucial. Other‐
wise, the resulting phenotypes of the induced knockdown experiment might be superimposed
with off-target effects. The specificity of the RNAi and the ER intrabody knockdown technique
is the main difference between them.
Intrabodies, which are also known as intracellular antibodies, are generated from monoclonal
antibodies (mAbs) and phage or yeast antibody repertoires. Intrabodies are very specific to
their targets due to antibody–antigen interactions.
The high specificity of ER intrabodies has been demonstrated for the specific knockdown of
members of the TLRs. The knockdown of toll-like receptor 2 (TLR2) and TLR9, which functions
as a part of the innate immunity and recognizes pathogen-associated molecular patterns
(PAMP), did not influence the expression of other TLRs. The developed anti-TLR2 intrabody
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did not inhibit TLR3-, TLR4-, and TLR9-driven signal transduction [33] and the anti-TLR9
intrabody did not inhibit TLR3-, TLR4-, TLR7-, and TLR8-driven signaling, respectively [18].
Stress response induction in the endoplasmic reticulum (ER), due to the accumulation of
retained and partially unfolded target proteins upon intrabody–antigen complex formation,
was analyzed by measuring the unfolded protein response (UPR) for an overexpressed anti-
p75NTR ER intrabody and could not be proven [24]. No off-target effects of expressed
intrabodies are known yet, particularly any activation of the immune system.
On the other hand, unspecific silencing is a major problem using RNAi-mediated gene
silencing, due to the expression of short-interfering RNA sequences, such as miRNA, siRNA,
shRNA, or dsRNA [47]. The short seed region of these silencing RNAs recognizes and
hybridizes with 2–8 nt to the target mRNA. Even with specific alignment software, it is
practically impossible to exclude any possible transcript, which aligns with the target seed
sequence, because statistically the chance is high to have the same sequence or secondary
structure in other non-target mRNA transcripts too. However, at least software algorithms
such as GESS [39] and Haystack [40] are able to predict potential off-targeted genes. By
computer-aided optimization of the miRNA, siRNA, or shRNA, the OTEs can be reduced to
a minimum.
siRNA can bind to TLR3, TLR7, and TLR8, resulting in secretion of type I interferon and pro-
inflammatory cytokines [48–50]. Aberrant expression of up to more than 1000 genes has also
been described [51].
Fortunately, some progress has been made in the repression of the RNAi-induced immune
response. When siRNA is in vitro transcribed by the T7 polymerase, a 5′-triphosphate group
is added. The 5′ triphosphate is recognized by the innate immunity, and it activates the type
I interferon response. This can be prevented by chemical synthesis of siRNA, which misses the
5′-triphosphate group. Furthermore, the siRNA molecules can be modified by adding 2′-O-
methyl groups, in order to reduce the recognition by toll-like receptors (TLRs) [52]. Interest‐
ingly, this modification additionally hampers degradation of the siRNA by RNases, leading
to an increase in serum half-life [53]. Finally, strong destabilizing unlocked nucleic acids
(UNAs), which were altered to have an acyclic ribose, also reduce the recognition by TLRs [54].
The specific suppression of one allele in heterozygous genes is of concern in dominantly
inherited genetic disorders. Huntington’s disease (HD) is caused by a dominant mutation of
the huntingtin protein (Htt) and an excellent target for the examination of allele-specific
knockdown of the mutated Htt, with high therapeutic potential. Huntington’s disease is based
on a long stretch of CAG triplets on one disease-caused allele [55]. Most of the patients are
heterozygous for the htt gene mutation and 48% of the American and European HD patients
are heterozygous at a single nucleotide polymorphism (SNP) site, making this genetic disease
a bono fide target for specific protein knockdown. Approaches to inhibit the appearance of
Huntington’s disease is silencing of wild type and mutant Htt or silencing of only the disease-
causing allele.
Although it was found in HD mice that co-silencing of wild type and mutant Htt provides
therapeutic benefit, nothing is known of such a long-term suppression of huntingtin [56]. Thus,
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the effect and safety over decades have yet to be proven in clinical trials. Therefore, there is
still a need for high allele-specific inhibition of the mutant Htt protein, which is toxic due to
an expanded polyglutamine (polyQ) motif (CAG motif). Targeting of the CAG motif is not
selective for the mutant allele and affected both alleles. Genotyping of the Huntington’s disease
patients resulted in three single nucleotide polymorphisms (SNP) in huntingtin [57]. Therefore,
an alternative strategy when using RNAi is targeting a single nucleotide mutation localized
in the disease-caused sequence [58]. Furthermore, targeting of the mutant huntingtin SNPs or
the expanded CAG motif by designed artificial miRNAs was recently demonstrated in vitro,
using an allele-specific reporter system and in vivo in a transgenic mouse model [59].
For the RNAi technique, it is possible to discriminate between very similar targets with a
specific reduction on the RNA and protein level [58, 60, 61]. However, there are still some
concerns and limitations. The RNAi-mediated allele-specific knockdown may result in a broad
off-targeting and therefore has to be further evaluated in appropriate preclinical model
systems [62]. Using both target strategies, CAG motif and prevalent mutant SNPs, in the case
of huntingtin, the wild-type allele is also affected by the knockdown, and the knockdown ratio
between the wild type and mutant allele remains unsatisfactory. Furthermore, the shift to in
vivo delivery systems can have a substantial impact on the specificity, as was demonstrated in
the mouse model [59]. Next, a limited expression of the miRNA vectors is important to avoid
saturation of the miRNA processing machinery, as the selectivity seems to be reduced when
miRNAs are highly expressed in vivo [59].
Different alleles can also be targeted and discriminated using specific intracellular antibodies
(intrabodies) and represent a valuable alternative to RNA interference. Intrabodies targeting,
for example, huntingtin have to recognize an epitope common in most disease-associated
huntingtin SNP forms, which also has to be different in the translated amino acid between the
mutant and wild-type allele. Alternatively, they could target the expanded polyglutamine
(polyQ) motif associated with misfolding and aggregation [63]. Furthermore, cytoplasmic
intrabodies have been developed, which efficiently inhibited aggregation of mutant HD [64].
Interestingly, a disulfide bond-free single-domain intracellular antibody with high affinity was
developed after affinity maturation [65] from a specific anti-HD scFv fragment, demonstrating
the power of antibody engineering.
For the allele-specific knockdown, the intrabody technology utilizes the high specificity of
monoclonal antibodies, with no or low concerns about off-target effects and activation of the
immune system. In the case of huntingtin, no RNAi approach was able to discriminate
effectively between the wild-type and mutant expanded polyglutamine stretch [59]. Here,
intracellular antibodies could, in principle, recognize different conformational epitopes
formed by polyglutamine and might be able to discriminate between the length of the polyQ
motifs [63]. However, in the case of the cytoplasmic huntingtin protein, it is more difficult to
generate and select cyto-intrabodies, due to the reducing environment of the cytoplasm. In
general, the allele-specific knockdown strategy should be also applied with ER intrabodies.
The kind of mismatches introduced into siRNAs or artificial miRNAs, in order to increase allele
specificity for preference of the mutant allele, can differ. Purine-to-purine mismatches, for
example, are more effective than purine-to-pyrimidine mismatches. This limitation can be
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the expanded CAG motif by designed artificial miRNAs was recently demonstrated in vitro,
using an allele-specific reporter system and in vivo in a transgenic mouse model [59].
For the RNAi technique, it is possible to discriminate between very similar targets with a
specific reduction on the RNA and protein level [58, 60, 61]. However, there are still some
concerns and limitations. The RNAi-mediated allele-specific knockdown may result in a broad
off-targeting and therefore has to be further evaluated in appropriate preclinical model
systems [62]. Using both target strategies, CAG motif and prevalent mutant SNPs, in the case
of huntingtin, the wild-type allele is also affected by the knockdown, and the knockdown ratio
between the wild type and mutant allele remains unsatisfactory. Furthermore, the shift to in
vivo delivery systems can have a substantial impact on the specificity, as was demonstrated in
the mouse model [59]. Next, a limited expression of the miRNA vectors is important to avoid
saturation of the miRNA processing machinery, as the selectivity seems to be reduced when
miRNAs are highly expressed in vivo [59].
Different alleles can also be targeted and discriminated using specific intracellular antibodies
(intrabodies) and represent a valuable alternative to RNA interference. Intrabodies targeting,
for example, huntingtin have to recognize an epitope common in most disease-associated
huntingtin SNP forms, which also has to be different in the translated amino acid between the
mutant and wild-type allele. Alternatively, they could target the expanded polyglutamine
(polyQ) motif associated with misfolding and aggregation [63]. Furthermore, cytoplasmic
intrabodies have been developed, which efficiently inhibited aggregation of mutant HD [64].
Interestingly, a disulfide bond-free single-domain intracellular antibody with high affinity was
developed after affinity maturation [65] from a specific anti-HD scFv fragment, demonstrating
the power of antibody engineering.
For the allele-specific knockdown, the intrabody technology utilizes the high specificity of
monoclonal antibodies, with no or low concerns about off-target effects and activation of the
immune system. In the case of huntingtin, no RNAi approach was able to discriminate
effectively between the wild-type and mutant expanded polyglutamine stretch [59]. Here,
intracellular antibodies could, in principle, recognize different conformational epitopes
formed by polyglutamine and might be able to discriminate between the length of the polyQ
motifs [63]. However, in the case of the cytoplasmic huntingtin protein, it is more difficult to
generate and select cyto-intrabodies, due to the reducing environment of the cytoplasm. In
general, the allele-specific knockdown strategy should be also applied with ER intrabodies.
The kind of mismatches introduced into siRNAs or artificial miRNAs, in order to increase allele
specificity for preference of the mutant allele, can differ. Purine-to-purine mismatches, for
example, are more effective than purine-to-pyrimidine mismatches. This limitation can be
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overcome by introduction of a second mismatch, preferentially into the seed or cleavage region
of the siRNA/miRNA [59]. Using a set of SNP sites, common in disease-associated alleles, might
enable reaching many patients [57], but it is hard to access the whole population. For those
genotypes that could not be cured by using mutant SNP-targeting siRNA, intrabody-mediated
protein knockdown, recognizing a prevalent mutant epitope could be superior. Whereby, in
the case of SNPs due to the posttranslational targeting, the intrabody technology demonstrates
one of its weaknesses. Discrimination between mutant and wild-type SNP could only be
achieved when the mutant SNP induces a change of the encoded amino acid. In addition,
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Table 1. Intrabodies versus siRNA
2.5. High-throughput screening
Oligonucleotide and cDNA microarrays can be applied for simultaneous quantitative moni‐
toring of gene expression of thousands of genes [66]. A combination of cDNA microarrays and
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RNA interference was used to validate upregulated genes, playing an important role in cancer
development [67]. In this case, a pre-screening with cDNA microarrays is performed followed
by silencing of selected upregulated mRNAs using RNAi. This might also be possible with
intrabodies.
Although high-throughput RNAi screening is very useful in order to validate new genes
involved in cancer pathogenesis or infection processes [68, 69], such high-throughput screen‐
ing is not possible with intrabodies.
2.6. Therapeutic potential of siRNA and ER intrabodies
The therapeutic potential of siRNA and ER intrabodies has been shown in different mouse
models [70–73]. It has been shown that siRNA protected mice from fulminant hepatitis [74],
viral infection [75], sepsis [76], tumor growth [77], and macular degeneration [78]. In these
mouse models, synthetic siRNA was delivered systemically, peritoneally, or subretinally.
Furthermore, in an Alzheimer’s and spinocerebellar ataxia disease-related mouse model,
RNAi suppresses the expression of amyloid-β peptide or ataxia, respectively [79, 80]. In these
mouse models, target-specific RNAi was virally delivered using adeno-associated virus or
Herpes simplex virus. Interestingly, the knockdown of angiopoietin-2 mRNA in a mouse
model with pancreatic carcinoma and xenotransplantation suppresses metastasis and down‐
regulates metalloproteinase-2 [81].
Many ER intrabodies have shown therapeutic potential against relevant targets in cancer,
infection, and brain diseases, for example, ErbB-2, EGFR, VEGFR-2, Tie-2, VEGFR-2 × Tie-2,
metalloproteinases MMP-2, MMP-9, E7 oncoprotein of human papillomavirus, CCR5, TLR2,
TLR9, and amyloid-β protein [18, 33, 82–90]. Nevertheless, only four of these antigens have
been applied in xenograft tumor mouse models so far, using an anti-Tie intrabody [85], a
bispecific VEGFR-2 × Tie-2 intrabody [86], an anti-amyloid-β protein intrabody in an Alz‐
heimer’s disease mouse model [90], and an anti-E7 oncoprotein intrabody in a mouse infection
model with human papillomavirus [89]. Intrabody delivery was performed via adenovirus,
adeno-associated virus, and retrovirus, respectively.
2.6.1. Transgenic mice
Transgenic RNAi mouse against p120-Ras GTPase-activating protein [91] and cytokine-
activated IκB kinase 1 (IKK1) has been established [92]. Furthermore, RNAi transgenic mice
and non-germline genetically engineered RNAi cancer mouse models were established [93].
In contrast to constitutive RNAi transgenic mice, generation of conditional RNAi in mice is
also possible [94].
Recently, two transgenic ER intrabody mice have been generated against VCAM and gelsolin
[71, 72]. In addition, a transgenic mouse expressing an anti-EVH1 intrabody has been pub‐
lished [73]. However, the inhibitory results obtained with these mice have been criticized
because the intrabody was directed to the secretory pathway, but confusingly recognized a
cytosolic protein [95]. Interestingly, the transgenic VCAM intrabody mouse was viable in
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model with human papillomavirus [89]. Intrabody delivery was performed via adenovirus,
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2.6.1. Transgenic mice
Transgenic RNAi mouse against p120-Ras GTPase-activating protein [91] and cytokine-
activated IκB kinase 1 (IKK1) has been established [92]. Furthermore, RNAi transgenic mice
and non-germline genetically engineered RNAi cancer mouse models were established [93].
In contrast to constitutive RNAi transgenic mice, generation of conditional RNAi in mice is
also possible [94].
Recently, two transgenic ER intrabody mice have been generated against VCAM and gelsolin
[71, 72]. In addition, a transgenic mouse expressing an anti-EVH1 intrabody has been pub‐
lished [73]. However, the inhibitory results obtained with these mice have been criticized
because the intrabody was directed to the secretory pathway, but confusingly recognized a
cytosolic protein [95]. Interestingly, the transgenic VCAM intrabody mouse was viable in
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contrast to the lethal knockout mice generated by targeted homologous recombination [96].
The intrabody mice were deficient in VCAM-1 cell surface expression.
2.6.2. Clinical approaches
Different clinical approaches have been performed with siRNA. RNAi-based clinical trials are
ongoing (phase I–III) [62, 97]. For example, a Bevasiranib RNAi targeting VEGF has been
applied to heal macular degeneration [98] and RNAi targeting the RSV nucleocapsid SPC3649
has shown significant anti-viral activity [99].
In comparison to the RNAi, only one example of an ER intrabody targeting erbB-2 has been
applied in a clinical phase I study [82]. As demonstrated, none of the patients treated in this
study exhibited a dramatic clinical benefit.
Both methods share the limitations of viral and non-viral delivery methods. Using integrating
vectors, insertional mutagenesis is still the main problem [100]. Concerning non-viral delivery
methods, lipid-based and peptide polymer-based delivery systems have been applied [101].
However, for some diseases like HD, the non-neurotropic feature of many delivery systems
and the lack of passing the blood–brain barrier (BBB) remain problematic.
Cell- and tissue-specific targeting is also always a concern; however, transductional and
transcriptional targeting is promising [102]. Tissue-specific carrier for siRNA includes
aptamers, antibodies, peptides, proteins, and oligonucleotide agonists [101]. Referring to ER
intrabodies, the use of mRNA in clinical approaches is promising [103].
2.7. Other features
Intrabodies are able to inhibit posttranslational modifications, such as phosphorylation sites
[104, 105]. This is not possible using RNAi. Besides the high specificity of intrabodies, this is
an important advantage of intrabodies over RNAi.
Recently, single-stranded siRNA was used to suppress the spliced variants of proteins [106].
This might also be possible with specific intrabodies (Table 1). In addition, targeting of specific
protein domains and isomers of a protein might also be feasible. For example, miRNA
suppresses specifically an oncogenic isoform [107]. Intriguingly, the suppression of different
protein isoforms with only one intrabody or one siRNA, recognizing a common epitope within
all isoforms, might be possible, for example, the knockdown of all interferon alpha isoforms
(13 different subtypes in human).
2.8. miRNA
It is known that miRNA influences tumorigenesis [3], and therefore miRNA and combined
miRNA/siRNA pharmacological approaches are attractive [108]. miRNA has been applied in
cancer mouse models as for lymphoid malignancies [109]. Furthermore, important studies
using miRNA has been performed for diagnosis, prognosis, and prediction of cancer [108].
One of the most developed microRNA-based candidates is MRX34, a miR-34 mimetic that
restores the function of miR-34 in cancer cells [110], which is applied in an ongoing multicenter
ER-targeted Intrabodies Mediating Specific In Vivo Knockdown of Transitory Proteins in Comparison to RNAi
http://dx.doi.org/10.5772/62103
149
phase I clinical trial. The repression of expression of several potential miR-34 target oncogenes
was demonstrated [111]. Finally, miRNAs can be used to reprogram somatic cells into
pluripotent stem cells [112]. However, siRNA and miRNA share the same silencing machinery
and microRNA causes also off-target effects [113].
3. Conclusions and perspectives
siRNA and ER intrabody technology are both efficient knockdown techniques. siRNA is acting
on the mRNA level, whereas ER intrabodies are acting on the protein level. The strength of
the RNAi technology results from the possibility that nearly all mRNAs of a cell can be targeted.
Currently, the knockdown of proteins mediated by intrabodies is most promising with ER
intrabodies, because they are correctly folded inside the ER and can be generated more easily
than in the past. Because of the availability of many new scFv fragments, generated by research
consortia, one cloning step is sufficient to convert selected scFv fragments into ER intrabodies.
Stable cytosolic intrabodies have to be selected with considerable effort. Two approaches are
successful and reliable: the intracellular antibody capture technology, based on an antigen-
dependent two-hybrid system [114] and single-domain antibodies [115], which are stably
folded in a reducing environment for inhibition of cytoplasmic proteins. Single-domain
antibodies comprise only one V region, the variable domain of the heavy or light chain. Most
successfully applied are camelid single-domain antibodies (VHHs) [115–118]. Alternatively,
human VL and VH domains are also potent molecules and their successful construction is
ongoing [119, 120].
The number of ER intrabodies will increase due to the fact that international research consortia
as the “Affinomics” initiative [121] in the European Union and similar initiatives in the United
States have already generated several thousands of recombinant antibodies, including the V-
region genes, which can be used to build up a new repertoire of intrabodies. Using this pipeline,
the duration for development of intrabodies is similar to that of siRNA/shRNA/miRNAs. In
the future, scFvs against very valuable disease-related targets have to be provided.
The main advantage of intrabodies is their specificity, no off-target effects, and posttransla‐
tional modification inhibition. The specificity of an intrabody can be estimated by immuno‐
assays such as ELISA, flow cytometry, and immunoprecipitation. On the contrary, the
specificity and off-target effects of RNAi are often more difficult to predict.
Conferring to in vivo application, RNAi has been currently applied predominantly in phase 1
and 2 studies [62, 97]. In the future, the success of clinical approaches using RNAi and ER
intrabodies is dependent on the development of safe viral vectors and the development of non-
viral vectors possessing high transfection efficiency [122].
Two attractive applications of RNAi, hardly to perform with ER intrabodies, are genome-wide
screening [68, 69] and reprogramming of somatic cells into pluripotent stem cells [112].
Thus, the ER intrabody approach has demonstrated its huge potential for in vitro and in vivo
analysis of protein function [10]. The ER intrabody technique can complement the RNAi
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phase I clinical trial. The repression of expression of several potential miR-34 target oncogenes
was demonstrated [111]. Finally, miRNAs can be used to reprogram somatic cells into
pluripotent stem cells [112]. However, siRNA and miRNA share the same silencing machinery
and microRNA causes also off-target effects [113].
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Currently, the knockdown of proteins mediated by intrabodies is most promising with ER
intrabodies, because they are correctly folded inside the ER and can be generated more easily
than in the past. Because of the availability of many new scFv fragments, generated by research
consortia, one cloning step is sufficient to convert selected scFv fragments into ER intrabodies.
Stable cytosolic intrabodies have to be selected with considerable effort. Two approaches are
successful and reliable: the intracellular antibody capture technology, based on an antigen-
dependent two-hybrid system [114] and single-domain antibodies [115], which are stably
folded in a reducing environment for inhibition of cytoplasmic proteins. Single-domain
antibodies comprise only one V region, the variable domain of the heavy or light chain. Most
successfully applied are camelid single-domain antibodies (VHHs) [115–118]. Alternatively,
human VL and VH domains are also potent molecules and their successful construction is
ongoing [119, 120].
The number of ER intrabodies will increase due to the fact that international research consortia
as the “Affinomics” initiative [121] in the European Union and similar initiatives in the United
States have already generated several thousands of recombinant antibodies, including the V-
region genes, which can be used to build up a new repertoire of intrabodies. Using this pipeline,
the duration for development of intrabodies is similar to that of siRNA/shRNA/miRNAs. In
the future, scFvs against very valuable disease-related targets have to be provided.
The main advantage of intrabodies is their specificity, no off-target effects, and posttransla‐
tional modification inhibition. The specificity of an intrabody can be estimated by immuno‐
assays such as ELISA, flow cytometry, and immunoprecipitation. On the contrary, the
specificity and off-target effects of RNAi are often more difficult to predict.
Conferring to in vivo application, RNAi has been currently applied predominantly in phase 1
and 2 studies [62, 97]. In the future, the success of clinical approaches using RNAi and ER
intrabodies is dependent on the development of safe viral vectors and the development of non-
viral vectors possessing high transfection efficiency [122].
Two attractive applications of RNAi, hardly to perform with ER intrabodies, are genome-wide
screening [68, 69] and reprogramming of somatic cells into pluripotent stem cells [112].
Thus, the ER intrabody approach has demonstrated its huge potential for in vitro and in vivo
analysis of protein function [10]. The ER intrabody technique can complement the RNAi
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technique in cases where siRNA, shRNA, and miRNA molecules demonstrate unwanted
unspecificity and off-target effects.
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Abstract
Over the past 20 years, RNA interference (RNAi) technology has provided a new regula‐
tory paradigm in biology. This technique can efficiently suppress target genes of interest
in mammalian cells. Small non-coding RNAs play important roles in gene regulation, in‐
cluding both in post-transcriptional and in translational regulation. For in vivo experi‐
ments, continuous development has resulted in successful new ways of designing,
identifying, and delivering small interfering RNAs (siRNAs). Proof-of-principle studies
in vivo have clearly demonstrated that both viral and non-viral delivery methods can pro‐
vide selective and potent target gene suppression without any clear toxic effects. There
are also the persistent problems with off-target effects (OTEs), competition with cellular
RNAi components, and effective delivery in vivo. Although recent researches and trials
from a large number of animal model studies have confirmed that most OTEs are not
dangerous, other important issues need to be addressed before RNAi-based drugs are
ready for clinical use. Currently, RNAi may be harnessed as a new therapeutic modality
for brain diseases. Finally, there are already several RNAi-based human clinical trials in
progress. It is hoped that this technology will have also effective applications in human
central nervous system (CNS)-related disease.
Keywords: RNAi therapy, brain, neurodegenerative disease, allele-specific, neurovascu‐
lar
1. Introduction
During developmental stage and in response to internal and external cellular stresses, small
RNA molecules regulate gene expression [1]. Specialized ribonucleases and RNA-binding
proteins govern the production and action of small regulatory RNAs [2]. In most eukaryotic
cells, RNA interference (RNAi) is a regulatory mechanism using small double-stranded RNA
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
(dsRNA) molecules to direct homology-dependent control of gene activity [3, 4]. Small size
[20–30 nucleotide (nt)] non-coding RNAs and associated proteins regulate the expression of
genetic information [5]. The discovery of RNAi phenomenon widened our understanding of
gene regulation and revealed related pathways in small RNAs [6]. As it processes, RNAi has
been finding widespread in plants [7] and animals [8]. Each small RNA associates with an
Argonaute (AGO) family protein to form a sequence-specific complex. After then, gene-
silencing ribonucleo-protein complex with specificity conferred by base pairing between the
small RNA (guide RNA) and its target mRNA [5]. The pathway is well known as the RNA-
induced silencing complex (RISC), which gives a target mRNA silencing by degradation or
transcriptional regression [2]. Small interfering RNAs (siRNAs) loaded into RISC are double-
stranded, and AGO-2, which having an active catalytic domain in human, cleaves and releases
the “passenger” strand. RISC is activated with a single-stranded “guide RNA” molecule to
impose the specificity recognizing the target by intermolecular base pairing [9].
MicroRNAs (miRNAs) are other endogenous substrates for the RNAi machinery, but the
cellular origins of miRNA and siRNA are distinct. miRNAs are derived from the genome,
whereas siRNAs may be endogenous or arise through viral infection or other exogenous
sources [2]. Typically, miRNAs are initially expressed in the nucleus with a transcript as long
as primary miRNA (pri-miRNA), and the transcripts are at least over 1000 nt. Pri-miRNAs are
processed by the microprocessor complex (histone deacetylase proteins) consisting in Drosha-
DGCR8 [DiGeorge critical region 8 (a double cysteine-ligated Fe (III) heme protein)—DGCR8]
in the nucleus [10, 11]. They are cleaved in the nucleus into 60–70 base pair (bp) hairpins, which
are consisted in single-stranded 5′- and 3′-terminal overhangs and about 10-nt distal loops [12].
In cytoplasm, the loop is further processed by the RNAse III Dicer, and one strand is loaded
onto RISC. The mature miRNAs bind to the 3′ UTR of target mRNAs and then degrade the
target [13]. Despite their differing origins, these RNA processing pathways converge once
either type of RNA assembles into the RISC.
With development of an efficient delivery system in various diseases, RNAi has been an
emerging therapeutic approach for in vivo studies with specific synthetic siRNAs against each
disease. It should be considered as novel and interesting therapeutic challenge with the major
concern how to administer the siRNAs with specific, efficient, and targeted way. Despite some
hurdles for applying to clinical challenges such as anatomical barriers, drug stability and
availability, various delivery routes, and different genetic backgrounds, an application of
siRNAs has become extremely attractive in development of new drugs. Currently, one of the
important challenges in siRNA bioinformatics is target prediction, when there is still no proper
tool with certain drug design grade. Besides specific challenges in siRNA therapeutics, an
efficient delivery method, targeting a specific tissue or cell, is another fundamental challenge.
This chapter introduced two of main themes. The first is the possibilities of therapeutics using
RNAi principles and technique. The second is the challenges with siRNAs or miRNAs
specifically in the area of brain disease. In addition, this chapter provided some prospects of
siRNAs or miRNAs on disease prognosis, progress, and therapeutics in the present and future.
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2. Principles of RNAi therapy
As far as it is true that siRNA has promising benefits, and, concomitantly, siRNA has still some
of technological barriers to be widely used in clinical therapy, which generally due to the lack
of efficient delivery tools. To success with siRNA therapies, an effective and safe carrier system
is required that would overcome the inherent defects of siRNA and achieve maximum gene-
silencing effect. There are many approaches that are being developed to achieve the efficient
delivery of siRNA. In that, non-viral vectors have advantages of reproducibility, low immu‐
nogenicity, and relatively low production cost [14]; therefore, non-viral vectors made siRNA
to be a potential therapeutic and nucleic acid–based drugs, such as plasmid DNAs or antisense
oligonucleotides (ASOs) [15].
2.1. Advantages of RNAi
Theoretically, all disease-associated genes could be amenable to antisense-mediated RNAi
suppression. RNAi can be a strategy for silencing of virtually all annotated protein-encoding
genes in the human genome in large scale. The high specificity of siRNA lets targeting of
disease-specific alleles that differ from the normal allele by only one or few nucleotide
substitutions. This high fidelity and specificity of siRNAs are useful for targeting for some
oncogenes, too.
The first advantage is the powerfulness of RNAi when compared with other antisense
strategies, such as antisense DNA oligonucleotides and ribozymes [16]. It is important fact that
the effector molecules work at much lower concentration than any other antisense oligomers
or ribozymes, suggesting that RNAi has higher potency. This is a critical point to set thera‐
peutics.
The second is efficacy. The efficacy is generally presented by the half level of maximal
inhibition or the value of IC50 against target site. The efficacy level is crucial for determining
thermodynamic stability [17], targeted gene accessibility [18], or structure [18] of designed
siRNA. For designing siRNA, the most important thing is end stability that is different from
each end and is also meaning asymmetry and consistent with selected miRNA [19]. However,
to date, our knowledge of siRNA and the selection of targets are incomplete and being
explored. The identification of “hyperfunctional” siRNAs, functioning at sub-nanomolar
concentration, remains an elusive task.
2.2. Basic strategies for targeting-specific molecules
RNAi can be triggered by two different pathways: (1) a RNA-based approach, where the 21-
nt long duplexed siRNA effectors are delivered to target cells, and (2) a DNA-based strategy,
where the siRNA effectors are produced by intracellular processing of longer RNA hairpin
transcripts [3]. DNA-based strategy is based on short hairpin RNA (shRNA) synthesis in
nucleus and transportation to the cytoplasm through miRNA machinery, which subsequently
is processed by Dicer. Although the direct use of siRNA effectors is simple and effective way
for gene silencing, the effect is transient. Therefore, it is costly for clinical usage due to the need
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of multiple large-scale application. In contrast, DNA-based RNAi drugs have the potential and
stably introduced for application in a gene therapy. In principle, DNA-based RNAi allows a
single treatment of viral vector that delivers shRNA genes to the targeted cells/or tissues.
2.3. Delivery routes for targeting
The effective delivery of siRNAs acts to be significant step in accelerating RNAi-based
treatments. The instability of RNA and the relatively inefficient encapsulation process of
siRNA remain critical issues toward the clinical translation of RNAi as a therapeutic tool. There
are several obstacles for extracellular introduction of siRNA to deliver the target. Under normal
physiological condition, the introduced molecules ought to have a positive charge to diffuse
to cell membrane [20]. It is the simplest way of naked nucleotides or transfecting siRNAs to
deliver into cells [21]. Another technique is microinjection and electroporation for direct
delivery, but it has higher level of cellular toxicity [22]. The delivery routes can be intra-
peritoneal, intra-vascular, intra-muscular, intra-splenic, intra-cranial, and intra-tumoral
injection. In addition, siRNAs can be delivered through subretinal, subcutaneous, mucosal,
topical application, and oral ingestion to improve delivery [22]. However, these transfection
processes should be optimized for siRNA concentration, cell density, and ratio of transfection
reagent to siRNA [23]. Carriers for delivery of siRNA with cationic environment surrounding
of siRNAs can be liposomes and dendrimers. These carriers reduce the nuclease activity and
improve siRNA delivery into cells [24].
Microsponge is one of the mediators for siRNA delivery. Carrier and cargo combine and self-
assemble into nanoscale pleated sheets of hairpin RNA. Subsequently, this complex forms
sponge-like microspheres [25]. The complex of siRNA and microsponges consists in cleavable
RNA strands, and the stable hairpin RNA converts into working siRNA once cells uptake the
complex. Therefore, it can provide a protection for siRNA during delivery and transport it to
the cytoplasm. Single microsponge complex can deliver more than half a million copies of
siRNA when uptaken into a cell [25].
2.4. Stabilizing the siRNA delivery
The stability of the siRNA complexes, penetrating into target cells without stimulating immune
responses, is one of the limiting factors and the major bottleneck for developing siRNA
therapeutic tools. It restricts the delivery of siRNA macromolecular complexes to the desired
cell types, tissues, or organs. Usually, siRNAs do not easily penetrate the cellular membrane
because of their negative charge and macromolecular size. Manipulation of nucleotide bases
is needed to increase stability and protein interactions, which can harness to increase the
structural improvement of siRNAs [26]. The delivery systems for siRNA consist of four main
methods, namely naked, lipid-based, peptide-based, and polymer-based delivery [27].
Basically, polymer-based methods are similar to lipid-based methods in targeting, except some
special triggers, such as temperature, pH, or pulse release [28].
Initial efforts to improve stability addressed above were focused on incorporating chemical
modifications into the sugar backbone or bases of siRNA duplexes [29]. The modified siRNA
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molecules increased stability, which effectively lowered the dose to achieve measurable and
reproducible gene silencing [30]. Several modifications were introduced. The thio (−SH),
hydroxyl (−OH), or iodo (−I) can modify bases in specific sites or utilize the pseudouracil base
in siRNA, which would augment potency of naked siRNA [31]. There are three most popular
chemical modification sites on siRNA structure containing the phosphodiester backbone,
ribose 2′-hydroxyl group (R-2′-OH), and ribose ring. Endogenous cellular endonucleases can
easily digest phosphodiester bond in RNA backbone [32]. Alternative modification is oxygen
bridges of RNA backbone that can be replaced with phosphorothioate, although it would
increase toxicity and reduce silencing activity [33, 34]. Another alternative is boranophosphate
linkages. These are more nuclease resistant and less toxic compared to phosphorothioate [35].
Phosphonoacetate linkages are other candidates [36]. The linkage is completely resistant to
nuclease and is electrochemically neutral when they are esterified [36, 37]. Another modifica‐
tion is 2′-O-methoxyethyl (2′-O-MOE), 2′-O-alkyl, and other bulky groups. These modifica‐
tions can improve anti-nuclease shield of siRNA that simultaneously makes them less tolerable
when they are positioned on 3′ overhangs [38]. Despite disturbing thermodynamic asymmetry
of siRNA by addition of 2′-aminoethyl at 3′ end of passenger strand, this modification
improves efficiency of target silencing [39].
On the other hand, alterations in sugar compartment of nucleotides reduced flexibility and
nuclease sensitivity of siRNA structure [39, 40]. Binding of ribose 2′O into 1′C with methylene
bridges, which finally produces oxetane, forms a locked conformation nucleic acid (locked
nucleic acid—LNA) [41]. In vivo nuclease resistance of this structure is enhanced [42]. In
contrast to LNA, derivatives of RNA without C2′–C3′ sugar bonds (unlocked nucleic acid—
UNA) destabilize a sequence structure [43]. Substitution of pentose with hexose monosac‐
charides, such as cyclohexenyl, anitrol, and arabinose, was applied to develop CeNA, ANA,
and 2′-F-ANA [44], subsequently resulting in enhanced stability of siRNA in vivo [45]. During
systemic delivery, however, internal modifications failed to improve central nervous system
(CNS) entry and uptake. Researchers put new efforts to move toward using liposomes,
nanoparticles, and cell-penetrating peptides (CPPs), among others, to stabilize and navigate
siRNAs into and throughout the brain [46].
2.4.1. Liposomes
Generally, liposomes are classified into three classes: multilmellar vesicle (0.5~20 μm), small
unilamellar vesicles (25~100 nm), and large unilamellar vesicles (100~500 nm) [47]. Liposomes
are developed for passive or active targeting mechanisms in different complexes of liposome
and other interacting molecules, namely lipoplex (cationic liposome-pDNA complex),
liposome polycationic DNA, mannose liposome, and so on [48, 49]. The siRNA with mannose
(Man)-coated liposomes would be useful for treatment of some cancers, especially liver and
brain cancers [50].
2.4.2. Dendrimers
Dendrimers are hyper-branched, tree-shaped, and 3-D structures [51]. Dendrimer can utilize
broad spectrum, and the broad range of functional groups makes it possible to introduce
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dendrimers with extensive applications. There are different classes of cationic and anionic
dendrimers, such as polyamidoamine (PAMAM), polypropylene imine (PPI), and polyethy‐
lene glycol (PEG)-grafted carbosilane [52]. Specific dendritic polymers like PAMAM have been
widely utilized in in vivo drug delivery [53]. Conjugation of Tat peptide (GRKKRRQRRRPQ)
with PAMAM-G5 can efficiently inhibit multi-drug resistance-1 (MDR-1) gene expression in
vitro [51]. Capping poly-l-lysine (PLL) dendrimers with methotrexate enhances stability and
decreases toxicity [54].
2.4.3. Cationic polymers
Cationic polymers include chitosan, gelatin, cationic dextran, cationic cellulose, and cationic
cyclodextrin and some synthetic biocompatible polyethyleneimine (PEI), PLL, poly(amidoa‐
mine)s (PAAs), poly(amino-co-ester), and poly(2-N,N-dimethylaminoethylmethacrylate).
Moreover, they are less immunogenic response because these polymers are natural biode‐
gradable [55].
2.4.4. Cationic peptides
CPPs are cationic peptides. CPPs interact covalently or non-covalently through disulfide or
electrostatic–hydrogen interactions with siRNAs [56]. Viral protein (VP22) [57], MPG (a
peptide vector) [58], amphipathic peptide [59], and poly-arginine [60] were reported the same
abilities. In addition, small cationic polypeptides (poly His, Lys, and Arg) coat and neutralize
siRNA helping to pass through membrane [61].
2.4.5. Nanoparticles
For systemic delivery, a targeted nanocarrier-siRNA complex has been used. There are some
studies that have experimentally condensed DNA or RNA into cancer-targeted nanoparticles
with PEI, PLL, and cyclodextrin-containing polymers [62]. PEI–PEG–arginine–glycine–
aspartic acid (RGD) fusion was used to inhibit vascular endothelial growth factor receptor-2
(VEGFR-2) expression [63]. Angiogenesis can be inhibited by downregulation or silencing of
VEGFR-2 expression [64]. PEGylation of nanoparticles causes “muco-inert” properties, which
enhances diffusion process through mucus and peptidoglycan barriers [65].
2.4.6. Aptamer
siRNAs can be coupled with aptamers or oligodeoxynucleotide through a disulfide bond. This
releases actively into targeted cells siRNAs before cytosolic uptake. Conjugate of aptamer
siRNA has suggested a novel therapeutics with widespread applications in medicine [66].
2.5. Limitations
2.5.1. Competition with endogenous RNAs
In human brain diseases and normal brain development, RNAi potentiates the important role
in normal neuronal function, although it is underestimated. When exogenous shRNA is
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decreases toxicity [54].
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cyclodextrin and some synthetic biocompatible polyethyleneimine (PEI), PLL, poly(amidoa‐
mine)s (PAAs), poly(amino-co-ester), and poly(2-N,N-dimethylaminoethylmethacrylate).
Moreover, they are less immunogenic response because these polymers are natural biode‐
gradable [55].
2.4.4. Cationic peptides
CPPs are cationic peptides. CPPs interact covalently or non-covalently through disulfide or
electrostatic–hydrogen interactions with siRNAs [56]. Viral protein (VP22) [57], MPG (a
peptide vector) [58], amphipathic peptide [59], and poly-arginine [60] were reported the same
abilities. In addition, small cationic polypeptides (poly His, Lys, and Arg) coat and neutralize
siRNA helping to pass through membrane [61].
2.4.5. Nanoparticles
For systemic delivery, a targeted nanocarrier-siRNA complex has been used. There are some
studies that have experimentally condensed DNA or RNA into cancer-targeted nanoparticles
with PEI, PLL, and cyclodextrin-containing polymers [62]. PEI–PEG–arginine–glycine–
aspartic acid (RGD) fusion was used to inhibit vascular endothelial growth factor receptor-2
(VEGFR-2) expression [63]. Angiogenesis can be inhibited by downregulation or silencing of
VEGFR-2 expression [64]. PEGylation of nanoparticles causes “muco-inert” properties, which
enhances diffusion process through mucus and peptidoglycan barriers [65].
2.4.6. Aptamer
siRNAs can be coupled with aptamers or oligodeoxynucleotide through a disulfide bond. This
releases actively into targeted cells siRNAs before cytosolic uptake. Conjugate of aptamer
siRNA has suggested a novel therapeutics with widespread applications in medicine [66].
2.5. Limitations
2.5.1. Competition with endogenous RNAs
In human brain diseases and normal brain development, RNAi potentiates the important role
in normal neuronal function, although it is underestimated. When exogenous shRNA is
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introduced into the neuron, it might be considered whether the RNAi machinery perturbs
normal physiologic condition of the system. Bioactive drugs that rely on cellular processing
to exert their action face the risk of saturating such pathways and hence perturb the natural
system. Sometimes, ectopically introduced RNAi does not trigger the silencing process because
siRNA/shRNA activity may depend on the endogenous miRNA to achieve efficient target
silencing. Mice that received liver-directed associate adeovirus (AAV)-encoded shRNAs were
damaged in liver with dose-dependent manner. Within 2 months, the mice were killed by
introducing high doses of AAV-encoded shRNAs. It was interpreted that the liver-specific
miRNA was unexpectedly down-regulated by introducing shRNA [67]. The enhanced
expression of Exportin 5, the nuclear export component, increased RNAi efficacy, which was
shown by competition assay [68].
2.5.2. Stimulation of innate immune responses
RNAi therapy is importantly considered because of its potential for generating an adverse
immune response, particularly in neurodegenerative diseases with affected brain. It has been
already known as “heightened state of alert” to start chronic pro-inflammatory signaling
cascades [30]. All evolutionary conserved mechanisms aimed at combating against invading
viral pathogens [69]. In general, innate immune responses to non-virally delivered siRNAs are
mediated by members of the toll-like receptor (TLR) family or by the two different dsRNA-
sensing proteins: retinoic acid-inducible gene-1 and dsRNA-binding protein kinase [70].
Certain siRNA sequence motifs invoked TLR7-dependent immune stimulation [71]. The
particular sequence motif (5′-GUCCUUCAA-3′) seems to be recognized by TLR7 in plasma‐
cytoid dendritic cells and activates immune responses. The GU-rich regions, so-called “danger
motifs,” stimulated innate immune responses and lead to secretion of inflammatory cytokines
in a cell type and sequence-specific manner. As siRNA-mediated immune induction seems to
rely on endosome-located TLR receptors (TLR7 and TLR8) [72], the delivery and compart‐
mentalization of the siRNA significantly influence the cellular responses [3]. These interactions
can occur during endosomal or lysosomal compartments’ internalization or intracellular
release of the siRNA molecule. It has a manner of dose and sequence dependence. Importantly,
the chemically modified or nanoparticle-encased siRNA complexes avoid stimulation of
immune response.
2.5.3. Suppression of off targets
Harmfulness of RNAi is “OTE.” Genome-wide sequencing analyses have clearly demonstrat‐
ed that siRNA-treated cells show off-target silencing of a large number of genes [73]. The
research result suggests that siRNAs with a 2′-O-MOE modification at the second base can
significantly reduce off target without compromising the degree of silencing target [74].
Experimentally, it has been verified that off targets have 6~7-nt long matching to the siRNA,
and it is called “seed” region [75]. When the siRNA guide strand contains seed-sequence
matching to mRNA 3′-UTR regions, the siRNA guide strand functions as a miRNA, which
might lead to harmful OTEs by translational repression [76]. To avoid siRNA seed matching
with mRNA 3′ UTRs, the use of online 3′-UTR search algorithms would potentially reduce the
detrimental OTEs [75].
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The OTEs can also derive from non-specific changes in gene expression due to the activation
of the interferon response (IR) [77]. The OTEs can change another gene by binding either strand
of the shRNA to partially complementary sequences rather than binding to the intended target
gene [77]. In case of dsRNA, it can result in a signaling cascade that culminates with the
activation of interferon responsive genes and global translational repression [78]. Neverthe‐
less, IR activation was variable among the siRNAs used for each of these studies, and one recent
report did not detect IR activation by siRNAs [79]. In mice, injection of naked siRNA did not
show detectable induction of an IR in one study while another study showed sequence-
dependent induction of innate immunity [79, 80].
3. Applications of RNAi
RNAi has been used to generate model systems to identify novel molecular targets [81], to
study gene function [82], and to create a new niche for clinical therapeutics [83]. Many
researchers reported that siRNAs have successfully been tested in various disease animal
models. Recent reports reviewed the therapeutic potential of synthetic siRNAs in various
human diseases and disorders [84].
3.1. Application for therapy with RNAi in vivo
Applications, such as gene function analysis, target identification and validation, and thera‐
peutic agents, are the main spots of this new technology [26]. Although RNAi is an efficient
technique for in vitro studies, there are some challenges for in vivo applications. siRNAs have
undesired characteristics, such as non-specific silencing of non-targeted genes and dose-
dependent immunogenic response [85]. In addition, it is extremely complicated to avoid the
OTEs due to spatiotemporal gene expression pattern of these molecules [73]. Furthermore, age,
sex, tissue, organ, tumor, and individual-specific specificity should be also considered as other
variables [86]. Prediction of susceptible off-target domains that can influence silencing
efficiency is the first step for applying in vivo therapy [73, 87]. Some studies recommend
utilization of more sensitive alignment algorithms or siDirect instead of BLAST database [85,
88] to predict a target for siRNA matching without cross-reactivity [89].
The administration route for siRNA, such as oral or intravenous, is not feasible and not
efficiently delivered the siRNA into target cells. A single injection of naked siRNA into the
brain parenchyma failed to good efficacy [90]. A study reported that continuous infusion of
siRNA into the ventricular CSF success with very high concentration [91]. To penetrate the
blood–brain barrier (BBB) and reach the target cells in the interesting site, receptor-specific
pegylated immunoliposome (PIG) is used. PIGs encapsulate the plasmid vector–encoding
siRNA or shRNA and are administered with peripheral route to the brain. This tool has been
tried in brain cancer animal model and successfully worked [92]. Another study showed
effective and long-term knock down of endogenous tyrosine hydroxylase (TH) in rodent brain
using shRNA-expressing adeno-associated virus (AAV) [93]. There have been many successful
in vivo studies with using viral vector. They are included two models of autoimmune hepatitis
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[94], hepatitis B virus [95], respiratory viruses such as influenza virus [96], respiratory syncytial
virus [97], parainfluenza virus, and sexually transmitted disease such as herpes simplex virus-2
[98]. Both non-viral and viral shRNA delivery systems have been trailed.
3.2. Application for therapy with RNAi in brain diseases
Many works using RNAi to suppress dominant disease genes have occurred primarily in cell
culture models [99, 100]. Allele-specific silencing aims to suppress the disease gene without
affecting any other normal genes. The possible therapeutic applications of RNAi for neuro‐
logical diseases are broad, ranging from acquired diseases, such as viral infections, to purely
genetic disorders.
Particularly, one attractive group of candidate diseases for RNAi therapy is the dominantly
inherited neurodegenerative diseases, including polyglutamine disorders such as Hunting‐
ton’s disease (HD) [101], amyotrophic lateral sclerosis (ALS) [102], familial Alzheimer’s disease
(AD) [103], and frontotemporal dementia caused by tau mutations [104]. HD has been
approaching with animal model mimicking the human disease to provide some therapeutic
clues with various ways. In the new preclinical study, single injection of a cholesterol conju‐
gated-siRNA was targeting mutant Huntingtin (mhtt), and, subsequently, the pathologic
symptoms containing behavioral dysfunction were improved [105].
The exciting recent works have taken place in vivo in mouse models of neurodegenerative brain
disease. The best example of RNAi-mediated therapy to date is in spinocerebellar ataxia type-1
(SCA-1) [106]. As another case, RNAi-mediated therapy was tried on DYT1 dystonia with
animal disease model. DYT1 dystonia is another inherited dystonia. DYT1 dystonia is caused
by deletion of GAG that is coding TOR1A, which results in one of a pair of glutamic acid from
the carboxyl terminal of the torsin A (TA) protein-coding region [107].
Prion disease is one of the brain diseases that is invariably fatal, and no therapy is available.
Once serious damage to the brain has already occurred, clinical symptoms manifest after the
untreatable brain damage. Causing this reason, prion disease treatments have aimed not to
cure the disease but to slow disease progression [108]. Prion disease is caused by prions, in
which a self-replicating, infectious protease resistant form of PrP (termed PrPSc), is the only
essential component identified to date. PrPSc multiplies through conversion of the normal
cellular PrP (PrPC) [109]. Some reviews are presenting that lentivector-mediated anti-PrPC
shRNA expression effectively suppressed prion replication in a murine neuroblastoma cell
line, and researchers created chimeric mice using embryonic stem cells, which were transfected
with a lentiviral vector carrying an anti-PrPC shRNA. Results showed that the survival time
after prion inoculation was markedly prolonged [110, 111].
4. Prospects of RNA therapeutics in CNS disease
The current phamaceuticals required more knowledge to decipher potentials of the RNAi in
spite of flourishing future. It is crucial that each disease has not only a unique pattern but also
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the understanding for pathogenesis relating pathways and activating or inhibiting factors
[112]. To introduce the DNA therapeutics into the CNS is much more complicated due to the
BBB, which can be only permeable to lipophilic molecules of less than 400 Da [113]. Using
human viruses, DNA delivery system has been extensively trailed for over three decades.
However, the results have been not satisfactory. Therefore, a critical goal for clinical neuro‐
science is to develop the efficient RNAi therapy to prevent the neuronal damage [77]. We
categorized the neurological disease containing cancers in below sections.
4.1. Genetic neuronal disease-familial neurological disease
The application of siRNA has been advanced in development of various incurable disease
therapies, apart from the widespread usage of RNAi in fundamental biological application.
Particularly, dominant inherited disorders are major application field. Among familial
neurobiological diseases, HD has been tried to lots of therapies based on RNAi and may be
beneficial effect from the therapy using siRNA. In the N171-82Q transgenic HD mouse model,
a study using shRNA showed a 50–55% decrease in the N171-82Q mRNA when injected to
striatum and a complete elimination of mHtt protein inclusions from the neuronal cells [114].
There was also a rescue of motor dysfunctions. siRNAs against the “R6/2 huntingtin (htt)
mRNA” reduced brain atrophy and neuronal inclusions in the R6/2 transgenic mouse model
[115]. With using a rAAV5 vector and administrating to the striatum, long-term expression of
a mHtt-siRNA partially reduced in neuropathology condition [116].
Besides AAV, there is lentiviral vector that can be applied after onset of symptoms [117]. Using
lentivirus vector decreased htt protein expression by up to 35% and altered htt-related
pathways but did not reduce cellular viability for at least 9 months after treatment. To enhance
cellular uptake of siRNA, cholesterol-conjugated duplexes (cc-siRNA) have been applied to
target htt mRNA [118]. Allele-specific targeting of mhtt helped to overcome the side effects of
RNAi where ASO or single nucleotide polymorphisms (SNPs) in the mHtt allele have been
used to specifically target only the mutant gene product [119]. Intra-cellular antibody frag‐
ments bind to abnormal aggregations, and allele-specific siRNA disrupts mhtt gene [120,
121]. Targeting of just three SNPs with five siRNAs covered most of the HD patients in the
population studied [122].
Tuberous sclerosis is a common, dominantly inherited disorder caused by mutations in the
tumor suppressor complex-1 (TSC1) or tumor suppressor complex-2 (TSC2) genes [123]. The
proteins hamartin (encoded by TSC1) and tuberin (encoded by TSC2) form a complex. This
protein complex represses mTOR-S6K-4E-BP signaling pathway [123]. Mutated TSC1 and
TSC2 lead to loss of activity resulting in unchecked cell growth and hamartoma formation in
the CNS. Recent studies propose that the target may be the GTPase Rheb [124]. RNAi sup‐
pression of Rheb might respond the dysregulated cell proliferation in tuberous sclerosis.
Particularly, allele-specific silencing is apt for inherited neurological diseases. DYT1 is the most
commonly inherited dystonia [125]. Although the pathogenesis of DYT1 is unclear, several
facts make DYT1 a good candidate to explore the therapeutic potential of RNAi [77]. The three
nucleotide difference between the wild type and the mutated gene has been enough to allow
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allele-specific silencing against mutant TA (the mutated protein in DYT1) in cultured cells
using in vitro synthesized siRNA [107].
Allelic discrimination has also been demonstrated for superoxide dismutase (SOD) mutations
responsible for familial ALS [100], and also a mutation in an acetylcholine receptor subunit
causes congenital myasthenia [126]. In a tau mutation responsible for fronto-temporal
dementia, siRNAs can act by discriminating between sequences differing by a single nucleo‐
tide [99].
An important role for RNAi in the brain is also presented for Fragile X syndrome (FXS) in
human [127]. FXS is the one of the most common forms of inherited mental retardation caused
by mutations in Fragile X Mental Retardation Protein (FMRP), a protein influencing synaptic
plasticity [127]. FXS is stemmed from mutations in FMRP and is supported by the involvement
of the RNAi process in human neurological disease [127]. Increasing evidences from different
studies support the view that FMRP regulates protein translation by regulating RNAi in
neurons [128, 129].
4.2. Sporadic neurodegenerative diseases
Neurodegenerative diseases are age dependent, and many of them are inherited. However,
non-genetic neurological diseases, such as sporadic AD or migraine, are much more common
than diseases due to single-gene mutations.
The most common sporadic neurodegenerative disease, AD, is also the best studied with
siRNA therapy. Many studies of AD pathogenesis investigate an essential role for β-amyloid
(Aβ) in familial and sporadic forms of AD [130]. Different RNAi strategies have been applied
to regulate this pathogenic cascade. Researchers tried by directly silencing of amyloid
precursor protein (APP) [131], by silencing of β-secretase (BACE1) that is one of two proteases
required for Aβ production but not essential gene in mice [132], or by silencing of tau expres‐
sion that is a component of the neurofibrillary tangles of AD neurons. Therapeutic use of RNAi
is now being tested in animal models of AD targeting these proteins.
Migraine, one of the most common neurological disorders, is caused by diminished production
of calcitonin gene-related peptide (CGPR) in the trigeminal system. CGPR can protect from
migraine attacks [133]. The CGPR-limited animals are normal, but the paroxysmal nature of
this disorder necessitates to use promoters for CGPR. From the beginning of the pathogenic
cascade, expression of the shRNA targeting CGPR can terminate the growing pain of this
disease. This pain alleviating therapy for migraine is limited because of high threshold dose
needed for RNAi [133].
4.3. Motor dysfunction disease
A viral delivery of shRNA was used to achieve a long-term RNAi in the CNS. In some reports,
the delivery of shRNA-expressing lentivirus showed a rescue of spinal motor neurons with
behavioral and histopathological phenotypes in a mouse model having dominant familial
ALS [134].
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Parkinson’s disease (PD) is the second most common neurodegenerative disease. Patient brain
of PD is often littered with Lewy body, which is abnormal protein aggregate primarily of alpha-
synuclein (α-syn) [135, 136]. parkinsonism is linked to hereditary to a single-point mutation
in the α-syn as well as genetic duplication or triplication of the α-syn (SCNA) [104]. The studies
targeting the α-syn expression revealed RNAi as a therapeutic approach to PD [30, 137]. To
date, conflicting results were reported. Regarding the effectiveness and tolerability, there is a
report that nigrostriatal degeneration was detected after depleting the α-syn level in the brain
[138]. It can be inferred that RNAi approaches can be used to validate them in genetic and
sporadic models of PD.
4.4. Neurovascular disease
RNAi can be applied to cardiovascular and cerebrovascular diseases. Cardiovascular disease
results from the progressive occlusion of arteries, and it is most common in a process called
atherosclerosis, which can ultimately culminate in a myocardial infarction or stroke [139]. It
may be a trigger for the death of cardiac muscle cells or neurons [139]. Although some of the
cells die rapidly by necrosis, many other cells die more slowly by apoptosis in such cardiac
myocytes and brain neurons [140, 141]. RNAi technology may be used to intervene in athero‐
sclerosis or to reduce the damage of heart tissue and brain cells following a myocardial
infarction or stroke [142].
Another vascular disease is an ocular disease. Representatively, there were two RNAi clinical
trials. The trials performed direct intra-vitreal injection of siRNAs that are targeting VEGF or
the VEGFR to test for the safety and efficacy in ocular diseases [143]. siRNAs, targeting VEGF
and VEGFR1, are currently in the early stages of clinical trials. The direct injection approach
can also prove its usefulness for the other ocular diseases.
4.5. Cancer
A chemo-resistance or radio resistance is a major obstacle in cancer treatment. Targeted
therapies that enhance cancer cell sensitivity have the potential to increase drug efficacy while
reducing toxic effects on untargeted cells (144). Actually, oncogenes expressed at abnormally
high levels are attractive targets for RNAi-based therapies against cancers [145], and such
approaches have effectively inhibited tumor growth in vivo in mouse models.
In nasopharyngeal carcinoma, hyaluronan receptor (CD44) gene silencing resulted in pro‐
found reduction of malignant potential of the cells: tumorigenesis and metastasis of tumors in
nude mice [105, 146]. It is also suggested a possible therapeutic effect of direct introduction of
siRNA to CD44 into some human solid tumors with high expression of the CD44 gene [146].
Although the role of epidermal growth factor receptor (EGFR) in altering tumor chemosensi‐
tivity has not yet been fully elucidated, selectively targeting EGFR supplies the reversal
possibility of chemoresistance in many tumor types [147]. Reduction of EGFR expression and
increased chemosensitivity to docetaxel are emerging an effective strategy for the sensitization
of cancer cells to taxane chemotherapy [147]. siRNA-PG-Amine polyplexes can be systemically
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delivered to tumors in mice [148], and siRNA-nanocarrier system can efficiently inhibit
expression of a specific gene in tumor cells. Once the intact siRNA molecule moves to the target,
the gene of interest gets silenced. The PG-amine-based delivery system actually combines both
tumor passive targeting with the sequence selectivity of siRNA [148].
The limiting point of targeted therapy is alternative pathway compensation by gene amplifi‐
cation. The “synthetic lethality” is proposed idea to overcome the above problem [149]. This
concept suggests that two genes may be considered to have a synthetically lethal relationship
[150]. When a mutation is existed either of the two genes alone has no effect on cell survival,
but when mutations in both genes cell death is triggered at the same time. By genome-wide
RNAi library screening, some synthetic lethal molecules have been discovered. Anaphase-
promoting complex/cyclosome (APC/C) and polo-like kinase (PLK) are synthetically lethal
with the RAS oncogene in colorectal cancer [151]. The STK33 gene is also synthetic lethal
interacting with a RAS mutation in multiple cancer cells from different tumor types [152].
Modified EGFR (amplification or truncation) and hyperactivation of AKT play a major role in
the development of glioblastoma, one of the extreme malignancies [153]. There are approaches
to develop the siRNA delivery efficiency such as the use of dsRNA-binding domain (DRBD)
with a TAT peptide transduction domain (PTD) delivery peptide [154]. These facilities are
stable and efficient delivery of siRNAs into cells [155].
5. Conclusions
Small RNAs and non-coding small RNAs were important discovery for molecular cell biology;
these small RNAs have a vital role in gene regulation that can be controlled by RNA interfering
technology. Presently, attempts to integrate gene expression profiling and protein interaction
mapping are the main research objectives. The proof-of-principle studies in vivo have clearly
demonstrated that both viral and non-viral delivery methods can provide selective and
efficient target gene suppression without any clear toxic effects. Initial results have been very
promising, and many pharmaceutical companies are already focusing on commercialization
of various disease-specific RNAi drugs. Despite successful trials in a large number of animal
model studies including brain diseases, to develop an efficient therapeutic application, there
are numerous hurdles and concerns regarding targeted delivery of siRNAs into brain subre‐
gions that must be overcome before wide clinical application of RNAi as a new therapeutic
solution. The OTEs, competition with endogenous cellular RNAi components, and effective
delivery in vivo remain to be optimized. Although recent research has improved the safety and
toxicity from the OTEs, it still remains a crucial issue and needs to be addressed before RNAi-
based drugs are ready for clinical use. Translational research using RNAi has taken place with
an unprecedented speed, and already there are several RNAi-based human clinical trials in
progress that will provide breakthrough therapeutic tools for effective treatment human CNS-
related disease.
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Abstract
Therapies for blood genetic diseases can be divided into different categories, including
chemotherapy, radiotherapy, gene therapy, and hematopoietic stem cell transplantation.
Among these treatments, gene targeting is progressively becoming a therapeutic alterna‐
tive that offers the possibility of a permanent cure for certain blood genetic diseases. In
recent years, gene therapy has played a more important role in curing genetic blood dis‐
orders. RNA interference (RNAi) is one of the directions for gene therapy, which was in‐
tensively studied in the past decades for its potentials in the treatment of diseases. In
order to provide useful references and prospective directions for further studies concern‐
ing RNAi-based gene therapy for blood genetic diseases, current RNAi-based gene thera‐
pies for several typical blood genetic diseases have been summarized and discussed in
this chapter.
Keywords: RNA interference, gene therapy, mechanism, therapeutic strategy, blood ge‐
netic diseases
1. Introduction
Conceived in the 1960s, gene therapy did not produce any meaningful results until recent
reports of success appeared in clinical studies. Gene therapy attempts to treat inherited
diseases using normal copies of the defective genes. Insertion and expression of specific
exogenous genetic materials via the transfer of nucleic acids directly in vivo, or through
modified cells in vitro, correct a cellular dysfunction or provide a new cellular function. It has
the potential to cure any genetic disease with long-lasting therapeutic benefits [1, 2]. Gene
therapy can be classified into (i) germ line and (ii) somatic line gene therapy types. In the
former, genomes of germ cells (sperms or eggs) are integrated by exogenous functional genes,
which can be carried onto the patient’s offsprings. In the latter, therapeutic genes are intro‐
duced into somatic cells and the effects will only be limited to the individual patient [3].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
According to the mechanisms, gene therapy may include three major categories: (a) direct
modulation of the disease-causing gene, which can be applied to monogenic hereditary
diseases; (b) indirect treatment through gene modulation, which can be applied to multifac‐
torial diseases; and (c) immunotherapy by gene modulation (DNA vaccines), which leads to
the synthesis of the relevant antigen or an adjuvant [1].
RNA interference (RNAi) can be used for gene therapy. It was intensively studied in the past
few decades for its potential in the treatment of blood genetic diseases. RNAi-based gene
therapy possesses several therapeutic advantages such as high efficiency, sequence specificity,
and potentially less immunogenicity. Less immunogenicity is largely due to the use of non-
protein-coding “gene products” to trigger RNAi, which makes gene therapy less likely to be
potentially hampered by the host immune system [4, 5]. Compared to traditional small
molecules and protein drugs, the target specificity and universal treatment spectrum make
RNAi-based gene therapy an ideal treatment for blood genetic diseases. However, there are
still obstacles that remain, such as barriers in the blood circulation system and the diseased
tissues that block the actualization of the RNAi effects [6]. RNAi technology is a relatively new
discovery, and it has already become a potent method for gene regulation. In order to provide
useful references and prospective directions for further studies, current RNAi-based gene
therapies for blood genetic diseases have been summarized and discussed in this chapter.
2. The mechanism of RNAi-based gene therapy
Being a well-described gene regulatory mechanism, RNAi not only suppresses transcription
by transcriptional gene silencing (TGS) but also activates a homology-based mRNA degrada‐
tion process by post-transcriptional gene silencing (PTGS). Both silencing pathways resulted
in the decrease of the coding transcript level (mRNA) [7]. We will focus on PTGS due to its
important role in RNAi-based gene therapy. Two distinct mechanisms regulate PTGS. The first
one is the repression and degradation of mRNAs with imperfect complementarity. Endoge‐
nous microRNAs (miRNAs) belong to this category. They induce translational repression and
mRNA degradation when the guide (antisense) strand has limited complementarity to the
target mRNA. The second one is the sequence-specific cleavage of perfectly complementary
mRNAs. Exogenous small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) belong
to this category. They have perfect or near-perfect base-pairings with the intended target
mRNA. The miRNAs production and processing rely on host machinery that is guided by
complementary miRNA strands to the target mRNA [8, 9]. During the process, double-
stranded RNAs (dsRNA) of the target gene are produced and then processed into 21–24 non-
coding small RNA duplexes with the help of RNaseIII enzyme dicer and its homologs. These
siRNAs are then incorporated into a multi-subunit endonuclease silencing complex called
RNA-induced silencing complex (RISC). siRNAs are associated with the defense against
parasites, heterochromatin formation, transposon and transgene silencing, and PTGS. These
siRNAs, loaded into the RISC, are used as the guide to recognize and degrade or suppress the
complementary gene or mRNA utilizing the endonucleases activity of RISC. Gene silencing
by RNAi can be used in different biological situations when sequence-specific knockdown of
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gene expression is required, thus providing a convenient tool for analysis of gene function as
well as gene therapy [10, 11, 12].
Recent reports have shown that off-targeting can commonly occur during RNAi, despite the
belief that initial gene silencing through RNAi was thought to be specific. Because nonspecific
hybridization of siRNAs with non-target transcripts can induce undesired effects, it should be
guaranteed that the dsRNA and corresponding siRNA sequences do not exert off-target effects
that negatively influence host physiology. Off-target silencing is determined by the similarity
of sequences between siRNA and non-target genes, or mRNA sequences not selected for RNAi,
as well as the size of siRNA and transitive RNAi. Thus, off-targeting effects can be avoided by
using highly specific sequences in siRNA expressed under specific and inducible promoters.
In addition, it is important to examine the off-targeting effects of RNAi at multiple levels, since
undesired effects on the host may occur through the silencing of genes associated with
regulatory functions and multiple metabolic pathways, such as transcription factors or
signaling molecules [10].
3. RNAi-based gene therapy for blood genetic diseases
3.1. Blood diseases
Blood diseases refer to the disorders in the hematopoietic system or plasma components. The
development of blood disorders is always thought to be related with inheritance, the envi‐
ronment, drugs, and biological factors where the changes in chromosome and/or genes play
a critical role in some specific hemopathies. Therapeutic approaches for blood diseases can be
divided into different categories, including chemotherapy, radiotherapy, RNAi-based gene
therapy, and hematopoietic stem cell transplantation. Among these, RNAi-based gene therapy
is progressively becoming a therapeutic alternative which offers the possibility of a permanent
cure for some blood diseases [13].
3.2. Hemophilia
Hemophilia A and B are X-linked monogenic bleeding disorders resulting from deficiencies
of factor VIII and IX, respectively. Gene therapy, utilizing both viral and non-viral delivery
vectors in vivo and ex vivo, has been attempted for the treatment of both hemophilia A and B
[14, 15]. Given its recent clinical success, adeno-associated vector (AAV)-mediated hepatic
gene transfer could be primarily used for the treatment of hemophilia B. However, a number
of problems, such as current immunosuppressive regimen and pre-existing neutralizing
antibodies, limit the broad applicability of this approach. For hemophilia A, while AAV-
mediated gene therapy has potential, a number of limitations reduce its desirability, such as
packaging capacity and inefficient expression. While a number of transgene modifications
have increased the expression levels, the vector doses require the corrective F.VIII expression
to remain significantly higher than the F.IX. These expression limitations lead to further
concerns about immune responses to both the capsid and, if expression levels are not sufficient,
the transgene. As such, ex vivo gene transfer may be more effective for hemophilia A due to its
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ability to enhance expression through cellular division. While a number of promising gene
therapies for hemophilia have been elucidated, there are clearly numerous problems that still
need to be addressed to develop approved gene therapies, especially RNAi, for both hemo‐
philia A and B in humans [16]. RNAi-based gene therapy for hemophilia is still in its early
stages of development.
3.3. β-Thalassemia
The globin chains have an extremely precise structure, ensuring their function of loading,
delivering, and unloading oxygen. The globin chains are coded by genes in the chromosome
16 (α-gene) and 11(β-gene). The normal structure of globin is based on the balanced match
between α-chains and β-chains. When the condition is not met, there will be a complete or
partial defect in one or both allelic globin genes, such as β-thalassemia [17]. β-Thalassemia is
a worldwide-distributed inherited hemoglobin disorder resulting in severe, chronic anemia
[18, 19]. It is a heterozygous condition in which only a single β-globin gene is affected and
results in the absence or reduced β-globin chain synthesis. The defects of β-globin synthesis
lead to an excess of unmatched α-globin, which release free iron, non-heme iron, or hemi‐
chrome. These iron species promote a severe red cell membrane oxidative stress and lead to
abnormal β-thalassemic red cell features. The abnormal red cells are finally removed by the
macrophage system and results in anemia [20, 21].
Blood transfusion is a primary way to treat the most severe forms of β-thalassemia. Appro‐
priate goals and optimal safety of transfused blood are necessary for routine administration
of red blood cells to patients. The problem is that the high frequency of blood transfusion can
lead to iron overload. In its less severe form, chronic transfusions are not required, but iron
overload may still develop due to the chronic suppression of the synthesis of the iron regula‐
tory hormone hepcidin by ineffective erythropoiesis. Untreated iron overload can be fatal,
resulting in cardiac complications [3, 22]. Therefore, handling iron overload is a key factor for
the successful treatment of this disease. TMPRSS6, a serine protease expressed predominantly
in the liver, can inhibit an iron-responsive bone morphogenetic protein-mother against the
decapentaplegic (BMP-SMAD) signaling pathway, resulting in the downregulation of
hepcidin transcription. Researchers found that therapeutics with the lipid nanoparticle (LNP)-
formulated RNAi targeting of TMPRSS6, in conjunction with oral deferiprone therapy, is
superior to monotherapy with dietary iron deficiency and iron chelate for reducing hepatic
iron storage [22].
3.4. B-lineage lymphoid malignancies
B-precursor acute lymphoblastic leukemia (BPL) is the most common form of cancer in
children and adolescents. A dysfunctional CD22 is expressed in BPL cells due to the deletion
of Exon 12 (CD22ΔE12) resulting from a splicing defect related to homozygous intronic
mutations. CD22 is a negative regulator of multiple signal transduction pathways critical for
the proliferation and survival of B-lineage lymphoid cells, and CD22ΔE12 leads to uncontrol‐
led proliferation and the survival of B cells. Recently, researchers have found that CD22ΔE12
is especially associated with therapy-refractory clones in pediatric BPL, thus implicating the
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impact of the CD22ΔE12 genetic defect on the aggressive biology of relapsed or therapy-
refractory pediatric BPL. At the same time, forced expression of CD22ΔE12 in transgenic mice
causes fatal BPL, demonstrating that CD22ΔE12 alone is sufficient as an oncogenic driver lesion
for malignant transformation and clonal expansion of B-cell precursors [23].
Recent studies have demonstrated that B-lineage lymphoid malignancies in children and
adults are characterized by a high incidence of the CD22ΔE12 genetic alterations. Moreover,
the relationship between CD22ΔE12 and aggressive biology of BPL cells is also reported
through the demonstration that siRNA-mediated knockdown of CD22ΔE12 in primary BPL
cells is associated with a remarkable inhibition of their carcinogenicity. A unique polypeptide-
based nanoparticle formulation of CD22ΔE12-siRNA is described as a first-in-class RNAi
therapeutic candidate targeting of CD22ΔE12. This formulation is capable of delivering siRNA
cargo into the cytoplasm of leukemia cells, leading to a remarkable inhibition of leukemic cell
growth [24]. It is expected that further development of this nanoparticle may promote an
effective therapeutic RNAi strategy of aggressive or chemotherapy-resistant B-lineage
lymphoid malignancies [23].
3.5. Myeloid leukemia
Leukemia arising from genetic alterations in normal hematopoietic stem or progenitor cells
results in the impaired regulation of proliferation, differentiation, and apoptosis, as well as the
survival of malignant cells. Overall, the relative 5-year survival rate for various leukemias is
only around 50% [25]. Leukemia is still a worldwide health problem, although various
therapies have been explored to cure the disease. Among them, chemotherapy is always
considered to be a frontline treatment, mainly containing a broad spectrum of cytotoxic agents
and therapeutic molecules. Although leukemic cells respond well to chemotherapy at the onset
of treatment, over a period of 6–12 months the drugs might lose effectiveness in a considerable
fraction of patients. Moreover, significant side effects of traditional cytotoxic agents are
inevitable at efficacious doses, which limit its function with the progression of the disease. For
example, in chronic myeloid leukemia (CML), resistance to current frontline therapy of
imatinib and failure to a complete cytogenetic response may occur in 24% of patients within
18 months. With a better understanding of molecular changes in leukemia, the treatment
targeting tumor-specific changes, such as RNAi, is expected to make a difference in the
therapeutic effectiveness of the disease [26].
Researchers have explored the suitability of RNAi in suppressing the growth and proliferation
of myeloid leukemia cell lines including HL-60, U937, THP-1, and K562, which express c-raf
and bcl-2 genes. The results were exciting, as the siRNA duplexes succeeded in significantly
decreasing the level of target proteins by eliminating the expression of c-raf and bcl-2 genes.
This led to the inhibition of the differentiation and programmed cell death suppression of
myeloid leukemia cells. These results demonstrated the possibility of RNAi as a novel
therapeutic approach to myeloid leukemia [27]. In recent years, based on the molecular
alteration of CML, two clinical trials of RNAi therapy have been conducted to target the
aberrantly expressed isoforms of the BCR-ABL fusion protein. In one case, there are no
publishable outcomes. In the other case, silencing aberrant proteins with RNAi have been
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found to be less prone to drug resistance [28]. In another in vivo application of targeted and
non-virally delivered synthetic bcr-abl siRNA, a remarkable apoptosis of CML cells was found
in a female patient with a recurrent Philadelphia chromosome with positive CML. The patient
was resistant to imatinib and chemotherapy after hematopoietic stem cell transplantation.
There were no clinically adverse events, implying feasibility and safety of the application of
RNAi-based gene therapy for CML [29].
Furthermore, RNAi-based gene therapy also proves to be effective in acute promyelocytic
leukemia (APL). APL is the M3 type of acute myeloid leukemia characterized by a clonal
proliferation of abnormal promyelocytes in bone marrow and has a severe bleeding tendency.
In 98% of APL patients, a balanced translocation between chromosomes 15 and 17 [t(15;17)
(q22;q21)] was found, which leads to the formation and fusion of promelocytic leukemia
protein (PML) and retinoic acid receptor alpha (RARα) [30, 31]. A variety of chromosomal
aberrations have been identified in APL including t(11;17)(q23;q21), t(5;17)(q35;q12-21),
t(11;17)(q13;q21), and der(17), in which the RARα gene is fused to the PLZF, NPM, NuMA,
and STAT5b genes, respectively [32]. The differentiation of leukemic cells and complete
remission of APL may occur after treatment with ATRA (all-trans retinoic acid). However, the
alternative strategies of specific targeting of APL are required because of the ATRA resistance
in patients with PLZF-RARα fusion mutation and a treatment of relapse. It has been found
that the siRNA targeted knockdown of fused PML-RARα mRNA can induce differentiation
and apoptosis of human APL cells; moreover, an injection of pretreated APL cells with anti-
PML-RARα siRNA greatly inhibits the progression of APL in mice. Therefore, a targeted RNAi
for PML-RARα fusion might be a promising treatment strategy for ATRA-resistant APL
patients [33].
At present, several technological requirements and mechanistic challenges (i.e., targeted
delivery of siRNAs) for efficient clinical trials have to be explored and overcome to make RNAi-
based gene therapy readily applicable for the treatment of myeloid leukemia [26].
3.6. Multiple myeloma
Multiple myeloma (MM) of clonal plasma cells in bone marrow can cause damage to multiple
organs. MM is the second most common hematological malignancy. Chromosomal abnor‐
malities, oncogene activation, and growth factor dysregulation contribute to the development
of MM. Like leukemia, chemotherapy is the most common treatment for MM right now.
However, it is remarkably resistant to chemotherapy [34]. Molecular therapy became an
alternative treatment, and the introduction of bortezomib has contributed to the improved
survival of patients with MM. Resistance to this therapy inevitably occurs, and the clinical
efficacy of bortezomib is significantly diminished. At present, RNAi is found to be helpful in
sensitizing tumor cells to chemotherapy and radiation. Bmi-1, an oncogene, has been impli‐
cated in the pathogenesis of MM and might influence the response to bortezomib in MM
patients. Bmi-1 has been silenced in two MM cell lines using shRNA targeting Bmi-1 (shBmi-1).
The cell cycle progression and apoptosis of MM cells are evaluated. The prolonged G1 phase
and enhanced apoptosis were observed that suggest RNAi-derived knockdown of Bmi-1
reducing the resistance to bortezomib. Therefore, Bmi-1-specific RNAi may serve as an
important treatment strategy for MM [35].
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4. Conclusions and future perspectives
As a powerful and novel treatment of blood genetic diseases, RNAi-based gene therapy has
propelled the clinical testing of siRNAs for a variety of diseases at early stages. It is still too
early to determine whether the RNAi-based therapeutics will be an efficient tool for the
treatment of blood genetic diseases. Therefore, understanding the basic mechanisms of a
targeted gene RNAi and its interconnection with genetic, biochemical, and physiological
pathways, as well as “off-targets” and “side effects,” are the most important factor for
developing an efficient therapeutic RNAi strategy. It is highly possible that the RNAi-based
gene therapy can be readily and efficiently used for clinical treatment in conjunction with other
therapies. The power of sequence-specific suppression of gene expression without “off-
targets” and undesired side effects makes RNAi-based gene therapy very promising. Although
progress has been made [36], major obstacles, such as the development of methods for efficient
targeted delivery of siRNAs in patients, still remain a critical task. In addition, uncovering
target domains of genes related to blood genetic diseases and the discovery of more blood
genetic disease-causing genes are also key research areas for developing RNAi-based gene
therapy for important blood genetic diseases.
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Abstract
RNA interference represents a promising therapeutic strategy for the silencing of specific
target genes in cancer therapy. Small interfering RNAs and DNA-based vectors encoding
short hairpin RNAs provide sequence-specific post-transcriptional gene silencing by
binding to its complementary RNA. For the therapeutic use of siRNA in cancer, efficient
intracellular delivery is necessary. The efficient cancer therapy with RNAi is not still ac‐
complished because of internalization and intracellular trafficking problems such as low
transfection efficiency, enzyme degradation, inappropriate subcellular localization, and
endosomal trapping of siRNAs in cells. Cancer is a complex disease including multiple
genes and pathways. The most important benefits of siRNA therapy are high target spe‐
cificity and non-toxicity compared with chemotherapy. The uptake of siRNA by cells
without a carrier system is possible, but naked siRNA is mostly degraded with nucleases
and activates the immune responses. Development of appropriate delivery systems is an
important issue in the use of siRNA-based therapeutics. Non-viral delivery systems have
great potential for safe and effective delivery of siRNA therapeutics to tumor cells. Nano‐
carriers such as nanoplexes, lipoplexes, nanoparticles, and liposomes have been common‐
ly used for siRNA delivery. This chapter highlights the importance of non-viral delivery
systems in vitro and in vivo cancer therapy.
Keywords: Cancer, non-viral vectors, RNAi, siRNA, shRNA
1. Introduction
RNA interference (RNAi) is a conserved endogenous cellular process for post-transcriptional
regulation in sequence-specific gene silencing. The regulatory RNA molecules include small
interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs) provide the specific degrada‐
tion of target mRNA in mammalian cells [1]. siRNAs are the products of long double-stranded
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
RNA (dsRNA) molecules in cells, which are expressed transgenically or delivered exogenous‐
ly. Synthetic siRNAs can be transfected into cells that specifically silence the expression of
target genes. In the RNAi pathway, dsRNA (over 100 nt) molecules are cleaved into 21- to 23-
nucleotide duplexed RNAs, termed as siRNA duplex, by endoribonuclease Dicer or RNAse
III-type enzyme. The cleaved siRNA duplexes contain 5′-phosphate and two-base 3′ over‐
hangs. siRNAs are incorporated into the endogenous RNA-induced silencing complex (RISC).
One of the two strands of siRNA duplex is guide (antisense) strand, and the other is passenger
(sense) strand. siRNA duplex is unwinded by RNA helicase activity. While the guide strand
binds to the RISC, the passenger strand is degraded. The activated RISC binds to mRNA with
base-pairing for sequence-specific degradation of complementary mRNA. The mRNA
fragments cleaved by Argonaute (Ago) proteins are released from RISC and degraded by other
endogenous nucleases. After mRNA degradation, the active RISC is rebuilt and can participate
in another RNAi pathway [2, 3]. In the event, RNAi process decreases specific mRNA levels,
and thus decreases target gene expression.
Among the nucleic acid–based drugs, siRNAs as potential novel drug candidates are offered
a highly promising strategy in cancer therapy. The knockdown of abnormal gene overexpres‐
sion, occuring in cancer by using siRNA, has been used in therapeutic applications [2]. Targets
of chemical drugs are limited to certain classes of receptors, ion channels, and enzymes. In the
treatment with siRNA, known sequence of any gene of interest is sufficient and its target choice
is unlimited [4].
The potential advantages of siRNA treatment compared with other treatment methods are that
siRNAs [5–7] (i) provide sequence-specific gene therapy; (ii) can specifically target many
undruggable genes or downregulate gene products; (iii) are considered the safe therapeutics;
(iv) are potent and efficient molecules and possess high gene silencing activity; and (iv) can be
easily designed for any disease.
RNAi might be a promising new pharmaceutical area for treatment of incurable and severe
diseases such as cancers and infections. RNAi applications have been recently achieved by
using synthetic siRNAs and vector-based siRNA expression systems or short hairpin RNAs
(shRNAs) synthesized within the cells by vector-mediated production. The expressed shRNAs
from plasmid and viral vectors in nucleus are cleaved by Dicer in cytoplasm and siRNAs are
formed. There both strategies have advantages and disadvantages. Vector-based siRNA
expression systems have several advantages for applying RNAi compared to synthetic
siRNAs. Both permanent and transient transfection with vector-based systems can be ach‐
ieved, and thus vector-based system increases the period of siRNA-mediated inhibition of gene
expression [8]. In addition, shRNA constructs are more stable than siRNAs [9]. Low amount
(nM) of siRNA and less than five copies of shRNA are sufficient for stable transfection and for
acheiving gene silencing effect [10]. The synthetic siRNAs can be easily synthesized in large
amounts and chemically modified to improve stability, permeability, efficacy, and transfection
control; however, the modified siRNAs are highly expensive [11]. siRNAs are not integrated
into host genome. The modification of vector-based shRNA systems is difficult, but shRNA
expression systems can be regulated or induced by appropriate promoters and termination
sequences. Choice of promoter, loop structure of shRNA, length and arrangement of sense and
RNA Interference202
RNA (dsRNA) molecules in cells, which are expressed transgenically or delivered exogenous‐
ly. Synthetic siRNAs can be transfected into cells that specifically silence the expression of
target genes. In the RNAi pathway, dsRNA (over 100 nt) molecules are cleaved into 21- to 23-
nucleotide duplexed RNAs, termed as siRNA duplex, by endoribonuclease Dicer or RNAse
III-type enzyme. The cleaved siRNA duplexes contain 5′-phosphate and two-base 3′ over‐
hangs. siRNAs are incorporated into the endogenous RNA-induced silencing complex (RISC).
One of the two strands of siRNA duplex is guide (antisense) strand, and the other is passenger
(sense) strand. siRNA duplex is unwinded by RNA helicase activity. While the guide strand
binds to the RISC, the passenger strand is degraded. The activated RISC binds to mRNA with
base-pairing for sequence-specific degradation of complementary mRNA. The mRNA
fragments cleaved by Argonaute (Ago) proteins are released from RISC and degraded by other
endogenous nucleases. After mRNA degradation, the active RISC is rebuilt and can participate
in another RNAi pathway [2, 3]. In the event, RNAi process decreases specific mRNA levels,
and thus decreases target gene expression.
Among the nucleic acid–based drugs, siRNAs as potential novel drug candidates are offered
a highly promising strategy in cancer therapy. The knockdown of abnormal gene overexpres‐
sion, occuring in cancer by using siRNA, has been used in therapeutic applications [2]. Targets
of chemical drugs are limited to certain classes of receptors, ion channels, and enzymes. In the
treatment with siRNA, known sequence of any gene of interest is sufficient and its target choice
is unlimited [4].
The potential advantages of siRNA treatment compared with other treatment methods are that
siRNAs [5–7] (i) provide sequence-specific gene therapy; (ii) can specifically target many
undruggable genes or downregulate gene products; (iii) are considered the safe therapeutics;
(iv) are potent and efficient molecules and possess high gene silencing activity; and (iv) can be
easily designed for any disease.
RNAi might be a promising new pharmaceutical area for treatment of incurable and severe
diseases such as cancers and infections. RNAi applications have been recently achieved by
using synthetic siRNAs and vector-based siRNA expression systems or short hairpin RNAs
(shRNAs) synthesized within the cells by vector-mediated production. The expressed shRNAs
from plasmid and viral vectors in nucleus are cleaved by Dicer in cytoplasm and siRNAs are
formed. There both strategies have advantages and disadvantages. Vector-based siRNA
expression systems have several advantages for applying RNAi compared to synthetic
siRNAs. Both permanent and transient transfection with vector-based systems can be ach‐
ieved, and thus vector-based system increases the period of siRNA-mediated inhibition of gene
expression [8]. In addition, shRNA constructs are more stable than siRNAs [9]. Low amount
(nM) of siRNA and less than five copies of shRNA are sufficient for stable transfection and for
acheiving gene silencing effect [10]. The synthetic siRNAs can be easily synthesized in large
amounts and chemically modified to improve stability, permeability, efficacy, and transfection
control; however, the modified siRNAs are highly expensive [11]. siRNAs are not integrated
into host genome. The modification of vector-based shRNA systems is difficult, but shRNA
expression systems can be regulated or induced by appropriate promoters and termination
sequences. Choice of promoter, loop structure of shRNA, length and arrangement of sense and
RNA Interference202
antisense strands, and orientation of restriction enzyme regions are important for shRNA
expression cassette preparation. Similar to the various RNAi applications for targeted gene
silencing, the chimeric expression cassettes of siRNA and shRNA in the same expression unit
might also be made [12].
Design of optimal siRNA sequence plays a key role for successful siRNA therapy. The choice
of potent and specific siRNA sequences is important for minimization of immune responses
and off-target effects. siRNAs are 19–27 base pairs in length, but mostly preferred to be 21 nt
of siRNAs with a structure of 19 nt duplex region and two nucleotide overhangs at the 3′ end,
usually TT and UU, which are important for recognition by the RNAi machinery. Increasing
the length of the dsRNA may enhance its potency, dsRNAs with 27 nucleotides are up to 100
times more potent than the siRNAs containing 21 nucleotides. The longer (25–30 nt) duplexes
act as a substrate for Dicer (Dicer-subtrate siRNAs). This Dicer-substrate siRNAs are more
efficiently loaded into the RISC over the siRNAs with 21 bp and newly produced siRNAs from
the long dsRNAs directly incorporated into the RISC complex. Thus, gene silencing mecha‐
nism can be facilitated [13, 14]. On the other hand, dsRNAs longer than about 30 bp can lead
to interferon response, which is the defense mechanism against viral infection. The activation
of interferon pathway causes non-specific mRNA degradation and apoptosis [15, 16]. The long
dsRNAs activates innate immune response by interaction with protein kinase receptor (PKR)
and Toll-like receptors (TLR7 and 8 are activated by ssRNA; TLR9 activated by unmethylated
CpG; and TLR3 activated by dsRNA). The activation of these receptors induces interferon (IFN)
and proinflammatory cytokines [10, 17].
In addition to immune responses, another important problem for efficient RNAi therapy is off-
target effects of these molecules. The cause of off-target effects are the suppression of undesired
or unpredicted genes other than the desired target genes. The absence of homolog sequences
between siRNA and its target mRNA can cause cleavage of non-targeted mRNA regions. Off-
target effects of siRNA can lead to problems in the interpretation of gene silencing studies,
serious and unwanted side effects such as potential toxicity and even cell death [18]. There are
many factors and mechanisms leading to occurence of off-target effects. These factors are the
length of dsRNA or siRNA, the length and position of siRNA-target sequence mismatch, and
coding sequences and untranslated regions in genes [19]. The mechanisms leading to off-target
effects of siRNAs are (i) the regulation of unwanted transcripts by seed sequence homology
to the 3′ UTR of cellular mRNAs, (ii) the saturation of RISC by affecting cellular miRNA activity
of siRNAs in large amounts, (iii) the function of miRNAs as siRNAs or shRNAs because of
similarities in gene silencing pathway, (iv) non-specific distribution by non-targeting systemic
delivery, and (v) immunostimulatory motifs in siRNA sequences [14, 17, 20].
Many preclinical studies with siRNA indicated that it is a hopeful molecule for clinical research
of various diseases. Up to date, at least 22 RNAi-based drugs have been evaluated in clinical
trials [21]. The first clinical trial with siRNA was made in 2004 by Opko Health. The clinical
studies of Bevasiranib, that is, siRNA targeting vascular endothelial growth factor (VEGF) to
suppress ocular neovascularization in patients with age-related macular degeneration (AMD),
continued to the phase III trial, but the clinical trials was terminated in 2009 because of its poor
efficacy and causing vision loss. Allergan company has terminated the phase II clinical trials
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of siRNA AGN-745, targeting VEGF because of its off-target effects [21]. The clinical translation
of RNAi can be possible with development of safe and efficient RNAi delivery systems that
lack of off-target effects [7, 21].
Although siRNAs are used as the potential therapeutic molecules in cancer and other diseases,
the most important challenge in the development of RNAi-based drugs is efficient and safe
delivery of appropriate doses to target cells and tissues. Therefore, the development of siRNA-
based viral and non-viral delivery systems are required to have an enhanced efficacy, im‐
proved stability, and minimized non-specific gene silencing such as off-target effects and
immune responses. This chapter focuses on recent improvements in the non-viral siRNA
delivery systems in cancer therapy.
2. RNAi in cancer therapy
Cancer is a multistep genetic disease, which develops as a consequence of changes in the
control of cell proliferation and differentiation. In the transformation of normal cells to tumor
cells, the affected cells undergo mutations such as downregulation of tumor suppressor genes
and overexpression of oncogenes. RNAi-based therapeutics have been extensively used for
knockdown of cancer-associated genes. The in vitro and in vivo studies with siRNA and shRNA
have shown that silencing of genes related to tumor cell growth, invasion, angiogenesis,
metastasis, and chemoresistance in various types of cancer [17]. RNAi technology, as a new
approach for cancer therapeutics, offers many advantages over conventional cancer treatment
strategies. Advantages of gene silencing by siRNA and shRNA are the high degree of specif‐
icity to target tumor cells and tissues, a capacity to inhibit target gene expression, a simple and
rapid design, and synthesis [22]. While non-specific chemotherapy leads to death of cancer
cells, it significantly damages the surrounding healthy tissues and organs, causing extensive
systemic toxicity. The side-effects of chemotherapeutic drugs can be minimized with siRNA
treatment.
Cancer cells have the ability to develop a resistance to chemotherapeutic drugs. RNAi-based
therapeutics can simultaneously target multiple genes in cancer signaling pathway. The
simultaneous silencing of multiple genes in cancer therapy have importance in terms of
minimizing the multiple drug resistance caused by small chemical molecules given in high
dose [23, 24]. This therapy inhibits survival signals and pathways that take part in the
development of multi-drug resistance in cancer cells.
Oncogenes, mutated tumor supressor genes, survival and apoptotic genes, causing tumor
initiation and progression, are major targets for RNAi-based therapy. Simultaneous suppres‐
sion of one target gene or multiple genes has provided a significant advantage in cancer
therapy. siRNAs can be designed for effective gene knockdown by targeting any gene or
multiple genes in cells [25]. siRNAs are likely to be more effective than other antisense
approaches because of many properties such as a highly specific mRNA degradation, cell-to-
cell spreading of gene silencing effect, long silencing activity, improved stability in vivo, and
their efficiency in lower concentrations [26, 27]. A single therapeutic strategy is insufficient for
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the inhibition of cancer growth and progression; RNAi as a new therapeutic strategy may be
used as well as with chemotherapy, immunotherapy, anti-hormone therapy, and radiotherapy
for achieving synergistic therapeutic effect.
In clinical trials, the most of siRNAs have been given by local administration. When siRNAs
are delivered to target tissue locally, lower siRNA doses can be used for pharmacologic effect
(e.g., saline-based formulation, or excipiants such as 5% dextrose) and any drug delivery
approaches (e.g., liposome, nanoparticle, and complexes) [28]. However, systemic drug
administration by intravenous injection is required for cancer diseases [7]. In systemic effect,
siRNAs must encounter several extra- and intra-cellular barriers until it reaches the target cell
and tissue. siRNAs cannot freely cross physiological and cellular barriers because of their high
molecular weight and negative charge. The significant challenges of using siRNA are their
poor cellular uptake, degradation by serum nucleases, and rapid elimination. These factors
and barriers reduce therapeutic effect of siRNA. Therefore, efficient in vitro and in vivo delivery
of siRNA-based therapeutics in cancer is dependent on the development of appropriate
delivery systems. siRNA delivery systems should (a) protect siRNAs against degradation
enzymes and serum proteins, (b) prolong the circulation time of siRNA, (c) provide siRNA
stability in blood serum, (d) avoid sequestration in the reticuloendothelial system (RES), (e)
avoid aggregation in serum, (f) minimize non-specific tissue and cellular uptake, (g) achieve
target-specific siRNA delivery, (h) allow for immune evasion, (i) resist rapid renal clearance,
(j) enhance vascular permeability to reach cancer tissues, (k) promote trafficking to the
cytoplasm and uptake into RISC, and (l) have low or non-toxicity [7, 29, 30].
3. Delivery strategies of RNAi-based therapeutics
siRNAs have large molecular weight (~13 kDa) and are polyanionic nature (~40 negative
phosphate charge) and are easily degraded by enzymes in cells, tissues, and bloodstream. In
addition, siRNAs cannot easily cross the cell membrane [29]. The naked siRNAs are readily
degraded by serum endonucleases. The half-life of circulating naked siRNA is less than 10
minutes because of its rapid clearance by the kidneys, so that they cannot reach to target cell
efficiently. The gene silencing activity of unmodified or uncomplexed siRNAs is little or absent
[31]. To solve this problem, two strategies are used: chemical modifications and conjugation
of siRNA molecules or use of gene delivery systems for increasing efficiency of RNAi-based
therapeutics.
Chemical modification is the major approach to overcome in vivo siRNA delivery problems.
Chemical modifications of naked siRNAs have been performed to (i) enhance siRNA stability,
(ii) protect siRNA from degradation, (iii) avoid recognition by the innate immune system and
minimize immunostimulatory responses, (iv) minimize off-target effects, (v) reduce required
dose for gene silencing, (vi) improve pharmacodynamic properties, (vii) increase delivery to
target cells, and (viii) allow the delivery by systemic administration. The sugar, backbone and
nucleobase modifications of siRNA, can significantly protect siRNA in both serum and
cytoplasm. The commonly used chemical siRNA modifications are the incorporation of locked
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nucleic acids (LNA), phosphorothioate linkages, and 2′-o-methyl, 2′-amine, 2′-fluoro groups
[7, 32, 33]. Chemical modifications must increase the stability of siRNA without affecting its
gene silencing activity [23]. However, these substitutions may lead to off-target effects,
cytotoxicity, reduced RNAi activity, and impaired biological activity [17, 34].
Other chemical strategies for siRNA are cholesterol, folate, and aptamer conjugation and
peptide modification. siRNAs can associate with aptamers, ligands, and antibodies by
electrostatic interaction or direct conjugation. The conjugation of these functional groups
provides cell- or tissue-specific targeting and efficient delivery. As a result, the efficacy of
silencing can be increased [1].
Viral and non-viral vectors have been extensively used in the siRNA-based therapy. Viral
vectors encoding shRNA have a high gene transduction and gene silencing effects. Adeno-
associated viral vectors, lentiviral vectors, and adenoviral vectors have been extensively used
in gene knockdown studies [35]. The transfering of shRNA-encoding vectors into the nucleus
of cells have obtained high and long-term shRNA expression. In addition, viral vectors can
integrate the host genome [14]. Although viral vectors have a high gene transfection efficiency,
the challenges such as inflammatory reactions, strong immunogenicity, insertional mutagen‐
esis, and oncogenic transformation of viral vectors can cause important safety concerns. In
addition, some viral vectors have low capacity for transgene insertion. To overcome these
problems, non-viral vectors have been developed and used in siRNA delivery. Compared to
viral vectors, non-viral vectors have several advantages such as lack of immunogenicity, low
or no integration into genome, large-scale production, and use of wide variety of nucleic acids
size [36]. However, the transfection efficiency of non-viral vectors is not as high as the viral
vectors.
3.1. Non-viral vectors
The non-viral delivery of siRNA and shRNA therapeutics to target tumor cells is a multi‐
step process. To achieve efficient delivery and therapeutic gene silencing, siRNAs should be
stable in biological fluids and must have above mentioned properties [37, 38]. The circulat‐
ing siRNAs after systemic administration must be evaded from the reticuloendothelial system
(RES). Negatively charged siRNAs gain the positive charge after complexed with cationic
charged polymers. This positive charge facilitates cellular internalization of siRNAs; however,
the cationic charge increase non-specific interactions by non-target cells, negatively charg‐
ed serum proteins, and extracellular matrix. As a consequence of these non-specific interac‐
tions, clot-like accumulations or aggregations are formed. Complexes are entrapped in the
endothelial capillary bed or taken up by RES recognition. While RES organs such as spleen,
liver, and bone marrow uptake the major part of injected dose, the minor part of this reaches
to tumors [25, 37, 39].
Non-viral delivery vectors prolong the biological half-life and mean residence time of siRNA,
and they enhance accumulation of siRNA molecules in tumor tissues. siRNA therapeutics can
be accumulated into cancer tissue by enhanced permeability and retention (EPR) effect as a
result of discontinuous vasculature (permeation) and poor lymphatic drainage (retention) in
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the abnormal tumor blood vessels compared to the normal blood vessels. Tumor endothelium
allows penetration of macromolecules [37, 38].
The other challanges of RNAi-based therapeutics delivery to the tumor tissues after systemic
circulation are crossing of cellular membrane, intracellular traffic into the cells with endoso‐
mal/lysosomal compartments, release of siRNA or shRNA from carriers, and nuclear transport
for vector-based siRNA/shRNA therapeutics and entry to cytoplasm for siRNA-based
therapeutics. The cell membrane is an important extracellular barrier for siRNA uptake. The
average size of a single siRNA molecule is less than 10 nm. Despite their small size, polyanionic
nature and hydrophilicity of siRNA make crossing of biological membranes difficult [18]. To
overcome this problem, the complexation of negatively charged siRNA with cationic polymers
or lipids are performed. The net positive charge of this formulations facilitates binding to
negatively charged cell membranes, following internalization by adsorptive pinocytosis. For
cell-type specific delivery, targeting ligands, antibodies, and aptamer-binding non-viral
vectors pass through the cell membrane by receptor-mediated endocytosis [1]. After crossing
from the cell membrane, siRNAs and vector-based siRNAs/shRNAs encounter several
intracellular barriers that include the endosomal trafficking, unpackaging of siRNA, and
nuclear traffic. The intracellular traffic of endosomal content is important for succesful siRNA
delivery. When siRNA released from the carrier reaches cytosol, RNAi mechanism is induced
inside the cells. However, for the onset of RNAi effect, transfer of vector-based siRNA/shRNA
to the nucleus is required. In the delivery process, early release of siRNA from endosome is
required. If siRNA remains inside the endosome for long time, it will be degraded. Therefore,
different agents (fusogenic protein) conjugated with polymers disrupt the endosomal mem‐
brane. In addition, polymers possess proton-sponge effect (polyethyleneimine, PEI), which
have been used to induce osmotic swelling and subsequent disruption of the endosome [15].
3.1.1. Polymer-based RNAi delivery system in cancer therapy
Negatively charged siRNAs or shRNAs can readily bind to cationic polymers or load to the
nanocarriers by ionic interactions. Nanosized complexes or polyplexes by electrostatic
interactions and nanoparticle formulations by encapsulation have been developed for efficient
siRNA/shRNA delivery. Thus, siRNAs can be protected from nuclease attack and cellular
uptake of siRNAs via endocytic pathway faciliated. Many natural and synthetic polymers are
used for gene delivery, such as polyethyleneimine (PEI), poly-l-lysine (PLL), chitosan,
protamine, gelatin, atelocollagen, cationic polypeptides, cyclodextran polymers, dendrimers,
poly-lactide-co-glycolide (PLGA), and polydimethylaminoethylmethacrylate (PDMAEMA)
[34]. In addition, polyethyleneglycol (PEG) is widely used as a linker between polymer and
ligand or nucleic acid or for binding of siRNA onto nanocarrier surface [40].
3.1.1.1. Chitosan
Among the non-viral vectors, chitosan or its derivatives are attractive where chitosan has been
shown to be biodegradable, biocompatible, non-toxic, mucoadhesive, and non-inflammatory
and has low cost of production. Chitosan is a cationic polysaccharide, consisting of N-acetyl-
d-glucosamine and d-glucosamine units. In addition, chitosan has been designated as “Gen‐
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erally Recognized As Safe (GRAS)” by the FDA [41]. It has been widely used in in vivo siRNA
and shRNA delivery applications because of positively charged amines, allowing electrostatic
interactions with negatively charged nucleic acids to form stable complexes. The protonated
amine groups allow transportation to cellular membranes and subsequent endocytosis into
cells. Moreover, the high amounts of chitosan in siRNA complexes may lead to increase cellular
accumulation of siRNA molecules and facilitate release of siRNA from endosomes to cytosol
under high osmotic pressure in the endosomes of cells [42].
Chitosan-based nanocarriers are prepared by three different methods. These include simple
complexation, ionic gelation (siRNA entrapment), and adsorption of siRNA onto the surface
of chitosan nanoparticles [42]. The molecular weight and degree of deacetylation of chitosan
influence its solubility, hydrophobicity, charge density, and thus the interaction ability with
nucleic acids. The N/P ratio (ratio between chitosan nitrogen per siRNA phosphate) of
chitosan/siRNA nanoplexes is an important factor for optimization of complex properties (size
and zeta potential), transfection, and gene silencing efficiency. Increasing the N/P ratio not
only helps to obtain a high transfection efficiency but also enhances toxicity. The excess of free
chitosan in the formulations can interact with cell membrane and cellular process, and thus,
may reduce cell viability [41].
Chitosan has a great potential in siRNA-based cancer therapy studies, because it can be safely
and efficiently delivered to cancer cells. It is reported that chitosan or modified chitosan
nanoplexes and nanoparticles as delivery system exerted antitumoral effects in different
cancers [43–48].
Studies with chitosan formulations in different cancers
Howard et al. [43] developed chitosan nanoparticles using polyelectrolyte complexation
method. The size of nanoparticles was between 40 and 600 nm. The endogenous enhanced
green fluorescent protein (EGFP) silencing efficiency with nanoparticles was found to be 77.9
and 89.3% in human lung carcinoma cells (H1299) and murine peritoneal macrophages. The
siRNA/chitosan nanoparticles reduced EGFP expression (43%) compared to untreated control
in transgenic EGFP mice. They suggested that this chitosan-based system can be used in the
treatment of systemic and mucosal diseases.
Salva and Akbuga [44] studied silencing effect of chitosan/VEGF shRNA nanoplexes in breast
cancer cell lines. A significant VEGF gene silencing (60%) was obtained after nanoplexes
application in MCF-7 cells. Salva et al. [44, 45] demonstrated the successful application of
chitosan/siRNA or shRNA VEGF nanoplexes in in vivo breast cancer models. After intratu‐
moral and intraperitoneal injection, comparison was made and higher tumor inhibition was
obtained with intratumoral injection. qRT-PCR and Western Blot analysis showed that VEGF
mRNA and protein expression was significantly reduced by chitosan nanoplexes.
Salva et al. [46] also studied the IL-4 encoded plasmid (pIL-4) to improve the therapeutic
efficacy of siRNA targeting VEGF because of the anti-angiogenic effect of IL-4 molecule.
Researchers prepared chitosan nanoparticles containing shRNA VEGF and pIL-4, and they
have reported that co-delivery of shRNA VEGF and pIL-4 into chitosan nanoparticles caused
additive effect on breast tumor cell growth in rat model (97% inhibition) [46].
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In another study, Salva et al. [47] obtained enhanced silencing effect by using siRNAs targeting
to VEGF and HIF-1α in different breast cancer cell lines such as MCF-7, MDA-MB-231, and
MDA-MB-435. Two siRNAs were encapsulated into liposome coated with chitosan, and the
co-delivery of siRNA VEGF and HIF-1α into liposomal form have significantly inhibited VEGF
(89%) and the HIF-1α (62%) [47].
Yang et al. [48] reported that chitosan/siRNA VEGF nanoparticles prepared by complex
coacervation method showed spherical morphology with a mean diameter of 110–200 nm and
positively charged surface (20 mV). Chitosan nanoparticles were effectively transfected to
mouse melanoma cells (B16-F10), and they have investigated 40% of the VEGF gene silencing
efficiency in cells without any cytotoxicity.
Wang et al. [49] prepared the chitosan-TPP (tripolyphosphate) nanoparticles by ionic gelation
method for the delivery of shRNA expressing vector to the human rhabdomyosarcoma (RD)
cell line and for the inhibition of TGF-β1 expression. Suppression of TGF-β1 gene by chitosan
nanoparticles containing shRNA has resulted in decrease of RD cell growth in vitro and
tumorigenicity in nude mice.
Huang et al. [50] studied the effect of chitosan/shRNA VEGF nanocomplexes on angiogenesis
and tumor growth in hepatocellular carcinoma (HCC). The administration of low molecular
weight chitosan/shRNA VEGF complexes by intratumoral or intravenous injection demon‐
strated more effective suppression of tumor angiogenesis and tumor growth in the different
HCC models. They showed that LMWC could effectively deliver shRNA into tumor tissue.
shRNA VEGF concentrations in tumor tissue dramatically increased after intravenous
administration of chitosan/shRNA VEGF complexes.
Studies with chitosan derivatives and conjugation with other polymers and ligands in
different cancers
In order to increase the transfection efficiency of chitosan, different modifications are made on
the structure of chitosan. Modified forms of chitosan such as carboxymethyl or trimethyl
chitosan, trisaccharide-substituted chitosan oligomers, and succinated or galactosylated
chitosan are formed. Chitosan is also conjugated with folic acid or PEG [51].
Jere et al. [52] used chitosan-graft-polyethylenimine (CHI-g-PEI) copolymer for delivery of
shRNA Akt1 expressing plasmid in lung cancer cells. The formed complexes were silenced
Akt1 onco-protein and significantly reduced the survival, proliferation, and growth progres‐
sion of lung cancer cell. Akt1 silencing induced apoptosis in cancer cells. The suppression of
Akt1 oncoprotein decreased A549 cell malignancy and metastasis. The therapeutic efficiency
of CHI-g-PEI-shRNA Akt was found higher than PEI25K-shRNA Akt compared to carrier.
Noh et al. [53] prepared a copolymer containing additional cationic moieties linked with
chitosan to enhance the cationic charge of chitosan. Therefore, chitosan derivation with poly-
l-arginine (PLR) and polyethyleneglycol (PEG) (PLR-grafted CS) polyplexes were used for in
vitro and in vivo delivery of siRNA RFP. PLR alone can be cytotoxic, thus conjugation of PLR
to chitosan both decreased cytotoxicity of PLR and enhanced siRNA delivery efficiency. The
pegylation of cationic polymers reduces the charge of polymers and limits the interaction with
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cell membranes. PEG-CS-PLR did not significantly reduce the cellular delivery of siRNA.
Three intratumoral injections of 120 μg of PEG-CS-PLR/siRNA RFP complexes to B16F10-RFP
tumor-bearing mice had decreased RFP expression at 90% level in tumor tissues. It is indicated
that PEG-CS-PLR can be a useful carrier for delivery of oncogene-specific siRNAs.
Fernandes et al. [54] investigated folate conjugation to improve gene transfection efficiency of
chitosan. When chitosan was conjugated with folate, the folate-chitosan-siRNA complexes
have increased gene silencing efficiency because of promoted uptake in HeLa and OV-3 cell
lines, which are known to have high folate receptor expression. Higher transfection efficiency
and lower toxicity of folate-chitosan complexes are reported in folate receptor–positive cells.
Cell penetrating peptide-based systems may improve cellular uptake and gene silencing
efficiency of siRNAs without side effects. Protamine is a cationic, non-toxic polypeptide that
has membrane translocation and nuclear localization activities because of its arginine-rich
amino acid sequences. In addition to its stabilization enhancing properties, protamine is
known to exhibit cell penetrating activity and is an important compound for several cancer
targeting systems [55].
Salva et al. [46] have developed ternary nanoplexes of chitosan/protamine/siRNA targeting
VEGF in breast cancer cell lines for efficient siRNA uptake and inhibition effect. Ternary
nanoplexes showed the highest cellular uptake than binary nanoplexes.
Erdem-Cakmak et al. [56] reported that addition of protamine to chitosan complexes increased
the silencing of VEGF genes after using chitosan/shRNA/protamine nanoplexes. In terms of
the gene silencing and transfection, when the molecular weight of chitosans were compared
at the different cell lines including HEK293, HeLa, and MCF-7, low molecular weight chitosan
(70 kDa) proved more efficient than medium molecular weight chitosan. Gene inhibition
values in cell lines after transfection of binary and ternary complexes followed the rank
HEK293>HeLa>MCF-7. In addition, any cytotoxicity was not found after the complexes.
Song et al. [57] used protamine/antibody fusion protein to deliver siRNAs targeting c-my,
MDM2, and VEGF specifically to HIV envelope-expressing B16 melanoma cells and envelope-
expressing subcutaneous B16 tumors. The positively charged protamine served as binding
partner for negatively charged siRNA and showed cell internalization and release of the siRNA
cargo. The antibody-protamine delivery system can target siRNA specifically to cells.
Choi et al. [58] reported that complexes prepared with low molecular weight protamine
(LMWP) inhibited cell growth by suppressing VEGF expression in hepatocarcinoma cancer
cells. In tumor tissues, the expression of VEGF was inhibited through the systemic application
of peptide complex, thereby suppressing tumor growth.
3.1.1.2. Polyethylenimine
Polyethylenimines (PEIs) are water-soluble cationic synthetic polymers. They can be synthe‐
sized in different lengths and different molecular weights such as branched (bPEI) or linear
(lPEI) and low molecular weight (<1000 Da) or high molecular weight (>1000 kDa). PEI has a
high cationic charge density because of the protonation of its primary, secondary, and tertiary
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amine groups positioned at every third nitrogen [59]. While in linear PEI all nitrogen atoms
are protonable, in the branched form, two-thirds of nitrogens can be charged. PEI can lead to
proton accumulation in endosome, which was brought in by endosomal ATPase with an influx
of chloride anion. Proton accumulation in endolysosome counteracts pH decrease, inhibits
nucleases and unbalances endosome osmolarity depend on CI concentration and results in
osmotic swelling of endosome. This effect of PEI is named as “proton sponge effect”. PEI may
enhance intracellular delivery by facilitating endosomal escape and induce lysosomal dis‐
truption, endosomal release, and DNA/siRNA protection from lysosomal degradation by
buffering endosomes [60].
The molecular weight of PEI is important in the development of gene delivery and level of
cytotoxicity in cells. The high molecular weight PEI has higher transfection efficiency than low
molecular weight PEIs. PEI has a high electrostatic capacity, which can provide strong
electrostatic interactions with the siRNA and contribute to cell membrane binding and
internalization. Especially, the 25 kDa bPEI is one of the most effective non-viral vectors in
gene silencing because of efficient endosomal escape. However, the high positive charge of
bPEI leads to severe cytotoxicity and non-specific interactions with serum proteins [61, 62].
The cytotoxicity of PEIs can be decreased with modification of free amine groups or conjuga‐
tion of cell binding and targeting ligands. Therefore, graft copolymers have been usually
preferred as a delivery system.
Schiffelers et al. [63] prepared PEGylated PEI nanoplexes with Arg-Gly-Asp (RGD) peptide
ligand containing siRNA targeting VEGFR-2 and investigated the effect of angiogenesis and
tumor growth in tumor-bearing mice. This study indicated that nanoplexes containing siRNA
VEGFR-2 reached tumor tissues after systemic administration. This delivery system has
sequence-specific inhibition effect and reduced the tumor growth.
Jiang et al. [64] studied anti-VEGF siRNA/PEI-HA complex prepared by PEI-hyaluronic acid
(PEI-HA). Complexes at the dose of 4.5 μg of siRNA/mouse were applied intratumorally to
C57BL/6 mice by daily injection for 3 days. At 24 hours post-injection, the siRNA VEGF
formulations were distributed mainly in the tumor, spleen, lung, heart, liver, and kidney. This
study suggested that siRNA VEGF/PEI-HA complexes can be used for the treatment of cancer
in the tissues having HA receptors such as the liver and kidney.
Park et al. [61] synthesized siRNA/(PEI-SS)-b-HA complexes and, after characterization,
applied to in vitro and in vivo gene silencing for target-specific tumor treatment. This delivery
system demonstrated an excellent in vitro gene silencing efficiency (50–80%). siRNA VEGF/
(PEI-SS)-b-HA complexes were administrated intratumorally to colorectal tumor bearing mice
every 3 days. After the treatment of tumor, VEGF gene silencing and reduction in tumor growth
were seen.
3.1.2. Other non-viral delivery systems
Among cationic polymers, poly (l-Lysine) (PLL) is one of the mostly studied polymers used
for nucleic acid delivery. It formed complexes with DNA smaller than 100 nm. Its complexes
can target different cells after binding suitable ligands. PLL can be easily produced in large
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scale and is physiologically stable and biosafe [65]. PLL may protect siRNA from degradation
effect of nucleases. However, PLL has some hurdless that impade its clinical application. PLL
does not have the proton buffering ability to enhance lysosomal release of transported siRNA.
It can be modified also by addition of ligands [66].
The ternary copolymer mPEG-b-PLL-g(ss-IPEI) was used for siRNA delivery to SKOV-3
ovarian cancer treatment. Nanocomplexes were administered to SKOV-3-implated Balb/c mice
and tumor growth inhibition was observed [67].
Dendrimers are highly branched spherical and synthetic multifunctional macromolecules. The
surface functional groups of dendrimers can be modified to enhance biocompatibility and
decrease toxicity. Polycationic dendrimers such as poly(amidoamine) (PAMAM) and
poly(propyleneimine) (PPI) dendrimers, because of the high density of positive charges on the
surface, are highly attractive for delivery of negatively charged pDNA, antisense oligonucleo‐
tide (AsODN), and siRNAs. PAMAM dendrimers have primary amine groups on their surface
and tertiary amine groups inside. Their amine groups are complexed with siRNAs. Thus,
compact structure promote cellular uptake of siRNA and tertiary amine groups initiate the
proton sponge effect to enhance endosomal release of siRNA [68, 69].
Waite et al. [70] conjugated cationic PAMAM dendrimers with RGD targeting peptides to
enhance the delivery efficiency of siRNA to glioma cells. They suggested a promising strategy
of RGD-conjugated dendrimers for siRNA delivery to solid tumors.
Liu et al. [71] investigated in vitro characterization and anticancer effect of PAMAM dendrimer-
mediated shRNA against human telomerase reverse transcriptase (hTERT) in oral cancer.
Dendriplexes had 110 nm size and +30 mV zeta potential which were favorable parameters for
escape from the vasculature and intracellular delivery. shRNA hTERT dendriplexes were
applied by intratumoral administration to tumors. Dendrimer-mediated shRNA TERT
resulted in cell growth inhibition and apoptosis in vitro and tumor growth inhibition in vivo in
the xenograft model. In addition, expression of HTERT and PCNA proteins was reduced in
tumors.
Atelocollagen, which is produced from bovine type I collagen, has biomaterial properties such
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scale and is physiologically stable and biosafe [65]. PLL may protect siRNA from degradation
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xenograft model. The knockdown of VASH2 with atelocollagen/siRNA VASH2 complexes
exerted a significant antitumor effect and helped in tumor vascularization.
PLGA has been widely used as gene delivery system because of its biodegredability, biocom‐
patibility, and non-toxic properties. FDA has approved PLGA as a pharmaceutical excipient.
PLGA nanoparticles enter the cells efficiently by specific and non-specific endocytosis.
Nanoparticles can release the encapsulated drug slowly leading to sustained drug effect [25].
Murata et al. [78] investigated anti-tumor effect of long-term sustained release of PLGA
microspheres encapsulating anti-VEGF siRNA. The release of siRNA from microspheres was
sustained for over one month. Intratumoral injection of PLGA microspheres containing siRNA
VEGF inhibited tumor growth.
Su et al. [79] prepared PEI-coated PLGA nanoparticles loaded with paclitaxel and Stat3 siRNA.
PLGA-PEI nanoparticles more rapidly released Stat3 siRNA than paclitaxel. Thus, decrease of
Stat3 expression by siRNA in human lung cancer cells (A549) and A549-derived paclitaxel-
resistant A549/T12 cell lines reduced resistance of cell to paclitaxel. The released paclitaxel
from nanoparticles killed the cancer cells that induce microtubule aggregation. In summary,
inhibition of Stat3 expression decreased cell viability, increased apoptosis, and reduced cellular
resistance to paclitaxel.
3.1.3. Lipid-based siRNA delivery systems in cancer therapy
Cationic lipids are used as carrier for siRNA delivery. Liposomes and lipoplexes, as lipid-based
delivery systems, have been widely used in local and systemic siRNA or shRNA delivery.
Liposomes are microscopic vesicles that consist of single or multiple lipid bilayer, form in a
sphere with an aqueous core. Nucleic acids can either be entrapped in the aqueous core of
liposomes or attached to the lipid surface for delivery. The advantages of liposomes as delivery
system include a high gene transfection efficiency, enhanced stabilization, easy penetration
into cell membranes, efficient in vivo delivery, and flexible and versatile physicochemical
properties. The disadvantages of liposomes are the short half-life in serum, lack of tissue
specificity, rapid liver clearence, and cell toxicity [17]. Three different liposomes, such as
neutral, anionic, and cationic liposomes, are used in the siRNA delivery studies [22]. Cationic
liposomes for siRNA delivery can easily cross the cell membrane, promote escape from the
endosomal compartment, and reach the target genes with good biocompatibility. However,
cationic lipids can induce an interferon response and cause unwanted interactions with
negatively charged serum proteins because of its high cationic charge density [32, 67].
Interferon responses can lead to not only change in gene expression but also show dose-
dependent cytotoxicity and pulmonary inflammation [80, 81]. The toxicity and transfection
efficiency of cationic lipids depend on length and structure of hydrocarbon chains of lipids [82].
Neutral lipids lead to less cellular toxicity and do not induce immune responses without the
down-regulation of gene expression. However, neutral liposomes have shown low transfec‐
tion efficiency because of their lack of surface charges [17]. The commonly used cationic lipids
for siRNA delivery include 1,2-dioleoyloxy-3-trimethylammonium propane (DOTAP) and 1,2-
di-o-octadecenyl-2-trimethylammonium propane (DOTMA) have combined with neutral
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lipids such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). This combination can
enhance transfection efficiency. Because neutral lipids facilitate fusion to the host cell’s
membrane, cationic lipids can facilitate electrostatically complexation with siRNA to obtain
more stable formulation and entry to cells more easily [18]. Liposomes are usually more stable
than lipoplex in biological fluids [5].
Lipid-based siRNA delivery strategies have shown as promising in cancer therapy. Tumor-
targeting approaches have been used to enhance antitumor efficacy of these delivery systems.
Specific delivery to target cells can be achieved by conjugation of ligands or molecules such as
transferin or PEG on the surface of liposomes [20]. The targeting and prolonged circulation
half-life of liposomes allow for the enhanced permeability of tumor vasculature, increased
delivery to tumor tissue, and reduced side effects [34, 82]. Cationic liposomes containing
siRNA targeting tumor-associated genes have been used to inhibit tumor growth and prolif‐
eration, induce apoptosis, and enhance the radiosensitivity of tumor cells [83–85].
Cationic lipids can interact with negatively charged siRNA by ionic interactions. Thus, self-
assembly formed lipoplexes protect siRNA from enzymatic degradation, enhance cellular
uptake of siRNA by endocytosis, enhance the release of siRNA from endosomal/lysosomal
entrapment, and thus, promote siRNA accumulation in the cytosol [16]. Commercially
available cationic lipid formulations such as Lipofectin®, Lipofectamine® (Invitrogen),
Dharmafect® (Dharmacon), RNAifect® (Qiagen), and TransIT TKO® (Mirus) have been
studied as tranfection reagents for siRNA delivery in vitro [86]. The ratio of lipid and siRNA
(lipid/siRNA ratio) affects the colloidal properties of the lipoplexes (particle size and zeta
potential). Lipid/siRNA or shRNA ratio is important to facilitate the cellular internalization of
lipoplexes and to dissociate the nucleic acids in the cytosol. Lipid/siRNA ratio can be optimized
in terms of biological activity [16]. Developing a lipid-based delivery system, choice of lipids,
and appropriate formulations are essential to decrease cytotoxicity and increase the transfec‐
tion efficiency of formulation.
To overcome the drawbacks of lipoplexes and liposomes, different nanostructures such as
neutral lipid-based nanoliposomes, stable nucleic acid lipid particles (SNALP), and solid lipid
nanoparticles (SLN) have been developed as siRNA delivery system. SNALPs are composed
of cationic, neutral, and fusogenic lipid mixture. SNALPs increase cellular uptake and
endosomal release of siRNA [4]. PEG-conjugated SNALPs represent exciting lipid-based
systemic RNAi. The PEG-lipid conjugate improves the retention time to >10 hours [87].
Recently, Tekmira Pharmaceuticals [88] has developed siRNA-based drugs that are encapsu‐
lated in the SNALPs for delivery of siRNAs to target tissue by intravenous injection. SNALP-
encapsulated siRNA targeting PLK1 initiated phase I trial in December 2010. Alnylam
Pharmaceuticals [89] has developed first dual-targeted siRNA drug, SNALP-encapsulated
siRNAs targeting VEGF, and kinesin spindle protein (KSP) for the treatment of hepatocellular
carinoma. Phase I trial was initiated in April 2009 [90].
Tekedereli et al. [91] indicated that knockdown of Bcl-2 by intravenously administered
nanoliposomal-siRNA Bcl2 (150 μg siRNA/kg) twice a week lead to antitumoral activity in
breast tumors of orthotopic xenograft models. In addition, nanoliposomal-siRNAs have
enhanced the efficacy of chemotherapeutic agents in the breast cancer therapy.
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Landen et al. [92] studied neutral nanoliposomes incorporating siRNA targeting EphA2 in
orthotopic mouse model of ovarian cancer. Three weeks of treatment with EphA2-targeting
siRNA nanoliposomes (150 μg/kg twice weekly) reduced tumor growth. The combination
therapy with paclitaxel reduced tumor growth.
Salva et al. [47] investigated the effect of co-delivery of siRNA HIF1-α and VEGF in liposomal
form in the breast cancer cell lines. Chitosan-coated liposomal formulation for co-delivery of
siRNA VEGF and HIF1-α were developed. The co-delivery of siRNA VEGF and HIF1-α was
greatly enhanced in vitro gene silencing efficiency in the breast camcer cell lines (95%). In
addition, chitosan-coated liposomes showed 96% cell viability. Salva et al. has suggested that
siRNA-based therapies with chitosan-coated liposomes may have some promises in cancer
therapy [47].
In conclusion, siRNA-based therapeutics are new and potential targets in cancer studies. In
cancer, different mechanisms including angiogenesis, and cell growth were studied as target
pathways. However, siRNAs have different hurdles in treatment because of their short
biological life in blood, instability, and poor cellular internalization. In order to overcome these
hurdles two solutions are present: one is modification of siRNA and the other is use of suitable
siRNA delivery system. In cancer treatment, viral and non-viral delivery systems are evaluated
as siRNA delivery. Although limited information is available related to in vivo delivery, more
papers are present in literature. Viral delivery systems have serious problems. Therefore, non-
viral systems are more attractable than viral systems for siRNAs. Cationic lipids, liposomes,
and polymers such as chitosan, PEI, PLL, and PLGA are used as non-viral siRNA delivery
system. However, more suitable carriers are needed for siRNA delivery systems.
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Abstract
siRNA therapy has great potential in humans, and its applications have been significantly
improved. The kidney is a comparatively easy target organ of siRNA therapy due to its
unique structural and functional characteristics. Here, we reviewed recent achievements
in the design, delivery, and utilization of RNAi with a focus on kidney diseases, in partic‐
ular acute kidney injury. In addition, the perspectives and challenges of siRNA therapy
such as increasing its serum stability and immune tolerance, targeting single/double/
multiple genes, cell/allele-specific delivery, time-controlled silencing, and siRNA-modi‐
fied stem cell therapy were also discussed. Finally, selecting target genes and therapeutic
time windows were addressed.
Keywords: Small interfering RNA, kidney diseases, delivery, off-target effects, compen‐
sative responses
1. Introduction
Acute kidney injury (AKI) is very common and critical in clinical practice. The incidence of
hospital-acquired AKI is increasing, and many patients require renal replacement therapy [1].
AKI significantly increases the risk of chronic renal disease, end-stage renal disease (ESRD),
and death, presenting a major burden to the patient and the health care system. Because of
high metabolic activity in handling and transporting ions, amino acids, and other small
molecules, the kidney is highly susceptible to acute injuries from lack of sufficient perfusion,
exposure to, and accumulation of nephrotoxic substances. Despite numerous clinical trials,
AKI remains a cause of significant morbidity and mortality for which there is no effective
intervention [2].
RNA interference (RNAi) is a highly conserved biological phenomenon in all eukaryotes,
including renal cells. Although RNAi naturally exists, synthetic artificial siRNA exerts similar
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
effects as natural endogenous microRNA (miRNA). Both sense and antisense strands of siRNA
can be synthesized separately and annealed to form double stranded siRNA duplexes in
vitro. After the siRNA is delivered into the cytoplasm, the artificial siRNA silences the target
gene using similar biological processes as endogenous miRNA. Since the introduction of 21-
nucleotide artificial siRNAs that triggered gene silencing in mammalian cells [3], synthetic
siRNA has generated much interest in biomedical research, in which the kidney is one of
important key players. siRNA as a strategic molecule has been highly expected in the field of
innovative therapy. Because siRNA is highly efficient at gene silencing, it is possible to develop
specific siRNA-based drugs that could target any genes, including those that have unknown
pharmacological antagonists or inhibitors. Different types of synthetic siRNA have been tested
for their efficacy in various disease models, including cancer [4], autoimmune disorders [5],
cardiovascular injuries [6], and organ transplantation [7], including native and transplanted
kidney injuries [8].
As siRNA is a posttranscriptional regulator, it must first be absorbed into the target cells.
Therefore, the kidney could be an excellent target organ for siRNA therapy because it benefits
from rapid and vast blood flow physically, subsequent glomerular filtration, and tubular
absorption. In fact, the systemic administration of siRNA leads to rapid uptake by the kidney,
yielding a significant decrease of target protein expression [8]. Consequently, RNAi by siRNA
has advantages for the treatment of renal diseases due to the unique urological system [9]. In
addition, the preservation of donor kidneys before transplantation also provides a suitable
time window for the intervention of siRNA.
In this chapter, we highlighted the design and delivery of siRNA and its therapeutic effects
with a focus on kidney diseases. We also discussed future challenges of siRNA therapy,
targeting single/double/multiple genes, cell/allele specific delivery, time-controlled silence,
and siRNA-modified stem cell therapy.
2. Current principle of siRNA design
The design of potent siRNAs has been greatly improved over the past decade. The basic criteria
for choosing siRNAs include the consideration of thermodynamic stability, internal repeats,
immunostimulatory motifs, such as GC content, secondary structure, base preference at
specific positions in the sense strand, and appropriate length [10].
Chemical modifications significantly enhance the stability and uptake of naked siRNAs.
Importantly, siRNAs can be directly modified without crippling the silencing ability. Chemical
modifications have been rigorously investigated for virtually every part of siRNA molecules,
from the termini and backbone to the sugars and bases, with the goal of engineering siRNA
to prolong half-life and increase cellular uptake. The most common chemical modification
involves modifying the sugar moiety. For example, the incorporation of 2′-fluoro (2′-F), -O
methyl, -halogen, -amine, or -deoxy can significantly increase the stability of siRNA in serum.
Locked nucleic acid (LNA) has been also applied to modify siRNA. The commonly used LNA
contains a methylene bridge connecting the 2′-oxygen with the 4′-carbon of the ribose ring.
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This bridge locks the ribose ring in the 3′-endo conformation characteristic of RNA [11].
Additionally, recent studies, including ours [12], have proven the efficacy of LNA-modified
siRNA in terms of prolonged half-life in serum, but without detectable adverse effects,
suggesting that the natural RNAi machinery could accommodate a certain degree of alterations
in the chemical structure of siRNAs [13].
3. siRNA delivery
The biggest obstacle faced by siRNA therapies is the in vivo delivery of genetic materials. The
systemic delivery of synthetic siRNA has the most medical and commercial potential. This
type of delivery, however, remains a major challenge for translating siRNA from the research
to the clinic. Overcoming the delivery challenge requires effective siRNA delivery vehicles.
The virus-based delivery system, while efficient, may be fatally flawed due to raised safety
concerns, such as inducing mutations and triggering immunogenic and inflammatory
responses [14]. Therefore, extensive research had been performed to develop efficacious
nonviral delivery systems, including direct chemical modification of siRNA (as described
above) and/or optimization of delivery materials, such as liposome formulation, nanoparticle
conjugation and antibodies that target cellular moieties [14].
To date, studies on synthetic siRNA therapy have been performed in a variety of cell culture
and rodent models [15] that produced exciting results and were cost effective but failed to
faithfully mimic human diseases. Therefore, large animal models, such as porcine models, are
indispensable to compensate for the limitations of rodent models due to their greater similarity
to human beings. The investigations on siRNA conducted in our laboratory have reflected this
trend in the field [7, 12, 16].
3.1. Direct delivery of synthetic siRNA in vitro/ex vivo
The siRNA could be easily transduced into various cells for scientific research. For example,
we transfected synthetic caspase-3 siRNA in porcine proximal tubular cells (LLC-PK1) using
cationic lipid-based transfection reagent. The caspase-3 siRNA inhibited apoptosis and
inflammation in LLC-PK1 cells that were subjected to hydrogen peroxide stimulation [17]. In
addition to in vitro delivery of siRNA, ex vivo/in vivo siRNA delivery to target organs is an
indispensable step before its clinical application. If it was directly delivered into the kidneys,
siRNA could obtain higher local concentrations, which would result in improved gene
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directly infused into the renal artery (locally) and autologous blood perfusate (mimic systemic
delivery) before 24-h cold storage (CS), followed by a further reperfusion for 3 h. The results
demonstrated that the caspase-3 siRNA improved ischemia reperfusion (IR) injury with
reduced caspase-3 expression and apoptosis, better renal oxygenation, and acid–base homeo‐
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stasis [16]. These promising proof-of-principle observations provide valuable guidance for
further development before siRNA used in clinical practice.
3.2. Local or systemic delivery of siRNA in vivo
Delivery of siRNA via ex vivo route can be applied in donor kidneys, but most renal diseases
need in vivo delivery. Based on the anatomical and physiological characteristics of the kidney,
local delivery can be achieved through several routes: (1) renal artery, first targeting the
glomeruli or tubules [18, 19]; (2) renal vein, predominately targeting tubulointerstitium [20];
(3) intraureteral, administered into the renal pelvis and interstitium [21]; and (4) subcapsular
administration, achieves intraparenchymal silencing [22]. Due to the rich blood flow through
the glomeruli, siRNA injection via the renal artery followed by electroporation could silence
specific genes in the glomeruli, such as TGF-β1, which subsequently ameliorates matrix
expansion in an experimental glomerulonephritis model [18].
We then used naked caspase-3 siRNA in a porcine kidney autotransplant model for the first
time. The left kidney was retrieved from mini pigs and was infused with University of
Wisconsin solution, with or without 0.3 mg of naked caspase-3 siRNA, via the renal artery,
which was followed by renal artery and renal vein clamping for 24-h cold storage (CS,
mimicking donor kidney preservation before transportation in clinic). After right nephrecto‐
my, the left kidney was autotransplanted into the right nephridial pit for 48 h without systemic
siRNA treatment (Figure 1). The expression of caspase-3 mRNA and active caspase-3 protein,
as well as its precursor, was downregulated by siRNA in the post-CS kidney. In the siRNA
preserved posttransplant kidney, however, caspase-3 precursor was further decreased while
caspase-3 mRNA, and its activated subunits were upregulated, which resulted in increased
apoptosis and inflammation. This study indicated that the naked caspase-3 siRNA was
effective for cold preservation but was not effective at protecting posttransplant kidneys,
which may be due to systemic compensative responses overcoming local effects. Therefore, to
overcome the systemic response and to prolong the therapeutic time window, we subsequently
utilized a novel, serum-stable caspase-3 siRNA, both locally as before and systemically via a
pretransplantation intravenous injection, and observed the animals for up to 2 weeks post‐
transplantation. The effectiveness of the novel caspase-3 siRNA was confirmed by downre‐
gulated caspase-3 mRNA and protein in the post-CS and/or posttransplant kidneys, as well as
reduced apoptosis and inflammation. More importantly, renal function, associated with active
caspase-3, HMGB1, apoptosis, inflammation, and tubulointerstitial damage, was improved by
this novel, serum-stable caspase-3 siRNA [12].
It has also been revealed that an injection of a single-dose Fas siRNA through the renal vein
post ischemia provided a survival advantage in a murine IR model, which was due to the
antiapoptosis and antiinflammation effects of the Fas siRNA [20]. Unilateral ureteral obstruc‐
tion (UUO) is a well-established model for tubulointerstitial fibrosis. Xia et al. injected the
siRNA of heat shock protein 47 once via the ureter at the time of UUO preparation, leading to
significantly reduced fibrosis-related protein expression and a remarkable alleviation of the
accompanying interstitial fibrosis [21]. Subcapsular administration is still used in some
experiments due to its unique advantages, although it requires an invasive procedure and has
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limitations in clinical practice. Cuevas et al. reported that an infusion of DJ-1 (an antioxidant)-
specific siRNA into the subcapsule silenced DJ-1 expression in the renal cortex and increased
ROS production [22].
Systemic delivery is a common and convenient clinical practice, although current clinical trials
using siRNAs are almost directly administered to the target site, such as the nostril, eye, and
lung, thereby avoiding the complexity of systemic delivery [23]. The most common method of
systemic siRNA delivery is a hydrodynamic intravenous injection with hydraulic pressure to
assist siRNA cell entry. However, the pharmacokinetic metabolism of siRNA is more compli‐
cated during systemic delivery because siRNAs can be rapidly degraded by nucleases in the
serum and cleared by the kidney and liver. To enhance the in vivo efficacy of siRNA treatment,
a variety of approaches have been attempted for both siRNA itself and delivery techniques
[22–24], as mentioned above.
Due to its anatomical and physiological characteristics, the kidney is the most preferable target
organ of systemic siRNA administration. siRNA access to the kidney is thought to be depend‐
ent on the filtration and reabsorption functions of the kidney. Proximal tubule cells (PTCs) are
Figure 1. Schematic drawing showed a series of our studies using caspase-3 siRNA. The caspase-3 siRNA was first
used to protect porcine renal tubular epithelia cells against hydrogen peroxide-induced injury [17]. The renoprotection
of naked caspase-3 siRNA with the same sequences was further validated in a porcine ex vivo isolated reperfusion
model and showed that the siRNA was effective for cold preservation [16], but not in autotransplanted kidneys with‐
out systematic siRNA treatment [7, 12, 16]. Finally, the chemically modified siRNA of caspase-3 via locked nucleic acid
stabilized the siRNA in serum and significantly protected autotransplanted kidneys [7, 12, 16].
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the primary site for rapid and extensive endocytic uptake of siRNA within the kidney
following glomerular filtration. In an AKI model, naked synthetic siRNA targeting p53 that
was intravenously injected 4 h after renal ischemic injury significantly reduced upregulated
p53 expression and protected both the PTCs and kidneys [25]. In another study performed by
Zheng et al., siRNA was systematically injected to target complement 3 (C3) and caspase-3 in
a murine renal IR injury model. The results showed that the level of serum creatinine and blood
urea nitrogen was significantly decreased in the siRNA-treated mice [26]. As most of AKI may
be not associated with renal surgery, the systemic siRNA delivery might be a desirable
approach. However, for kidney transplantation, in which IR injury is inevitable, local siRNA
delivery via any above-mentioned method is feasible and more effective.
3.3. Cell-specific delivery
As proposed by precision medicine, individual person should receive customized healthcare
including diagnosis and intervention. The dysfunctional cells are the true targets for siRNA
delivery. For instance, it is known that p53 in PTCs promotes AKI, whereas p53 in other tubular
cells does not [27]. It is also expected that apoptosis-inducing siRNA should be directly
delivered into tumor cells rather than the surrounding normal cells. Therefore, the cell-specific
delivery method is our key point in the next generation of siRNA development.
Recently, antibody conjugation technology has made tumor-targeting drug delivery systems
available. The conjugate can be regarded as a “guided molecular missile” that specifically
targets unique antigens [28]. Inspired by cancer therapy strategies, siRNAs have also been
“packed” to be delivered to target organs, even cells. Recently, a type of asymmetric liposome
particle (ALP) has been developed, which highly efficiently encapsulates siRNA without
nonspecific cell penetration. The ALPs protected siRNA from ribonuclease degradation. ALPs
without any surface modification elicited almost no uptake into cells, while the polyarginine
peptide surface-modified ALPs induced nonspecific cell penetration [29]. Leus et al. delivered
siRNA targeting vascular cell adhesion molecule-1 (VCAM-1) into inflammation-activated
endothelium using anti-VCAM-1-SAINTPEGarg formulated with additional 2 mol% DOPE-
PEG2000 in vivo. The antibody recognizes VACM-1, which can create specificity for inflamma‐
tion activated endothelial cells. The siRNA homed to VCAM-1 protein expressing vasculature
in TNF-α-treated mice without any kidney and liver toxicity [30]. These results represent great
progress in siRNA delivery system development. Antibody-mediated specific recognition
rather than virus-mediated recognition may be a mainstream in the future.
3.4. Allele-specific RNAi
RNAi, in addition, discriminates between two sequences only differing by one nucleotide
conferring a high specificity of RNAi for its target mRNA. This property was used to develop
a particular therapeutic strategy called “allele-specific RNAi” devoted to silence the mutated
allele of genes causing dominant inherited diseases without affecting the normal allele.
Therapeutic benefit was now demonstrated in cells from patients and animal models, and
promising results of the first phase Ib clinical trial using siRNA-based allele-specific therapy
were reported in pachyonychia congenita, an inherited skin disorder due to dominant
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mutations in the keratin 6 gene [31]. The allele-specific siRNA silencing of the mutant keratin
12 allele was also applied in corneal limbal epithelial cells grown from patients with Mees‐
mann’s epithelial corneal dystrophy [32, 33]. It has also been shown that modified siRNAs
conferring allele-specific silencing against disease-causing ALK2 mutants found in fibrodys‐
plasia ossificans progressiva, without affecting normal ALK2 allele [34].
3.5. Delivery of siRNA using a cargo system
Although lentivirus vectors as vehicles together with liposome reagents are widely applied in
the transduction of siRNA, nanoparticle systems have emerged in last few years as an
alternative carrier for advanced diagnostic and therapeutic applications. The nanotechnology
offers many merits and overcomes the range of challenges/barriers summarized in the
previous section, such as the bioavailability and biodistribution of therapeutic agents. Recent
reports have demonstrated that the kidney, the glomerulus especially, is a readily accessible
site for nanoparticles. Zuckerman at al. intravenously administered nanoparticles containing
polycationic cyclodextrin and siRNA/CDP-NPs, most of which deposited in the glomerular
mesangial areas. Furthermore, the cultured mouse and human mesangial cells could rapidly
internalize siRNA/CDP-NPs. This process could be accelerated by attaching targeting ligand
mannose or transferrin to the nanoparticle surface [35].
Complex nanoparticles, especially cationic polyplexes/lipoplexes and liposomes, dominat‐
ed the scene in the early days of RNAi therapeutic development. Their main advantage lies
in their endosomal release activity and their ability to concentrate multiple RNAi triggers
in  one  particle  [36].  Forbes  and  Peppas  cross-linked  polycationic  nanoparticle  formula‐
tions using ARGET ATRP or UV-initiated polymerization. The advantage of this method
is  the  one-step,  one-pot,  and surfactant-stabilized monomer-in-water  synthesis,  which is
simpler and faster compared with traditional complicated multistep techniques involving
toxic organic solvents [37].
Regardless of how much each mechanism plays in the transport of the drug, cell entry remains
a focus for drug design and discovery. An exciting and relatively new approach to transporting
pharmaceutical agents into cells is making use of cell-penetrating peptides (CPPs). CPPs are
relatively short peptides, typically less than 30 amino acids, and could be vectors for the
delivery of genetic and biologic products. CPPs provide a safe, efficient, and noninvasive mode
of transport for various cargos into cells [38]. Recently, van Asbeck et al. discovered that CPP/
siRNA complexes with the most negative zeta-potentials in serum were the most resistant to
siRNA release over a 20-h incubation period compared to less negatively charged complexes
[39]. They also found that the zeta-potential of CPP/siRNA complexes in serum did not
correlate with improved cellular association, which might demonstrate the importance of
serum proteins or CPP conformation on the ability of CPP/siRNA complexes to associate with
the cell membrane. Huang et al. designed a bifunctional peptide named RGD10-10R, by which
siRNA was delivered in vitro and in vivo. Because of their electrostatic interactions with
polyarginine (10R), negatively charged siRNAs were readily complexed with RGD10-10R
peptides, forming spherical RGD10-10R/siRNA nanoparticles. This is also a novel siRNA
delivery tool [40].
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Gemini or dimeric lipids (GCLs) are a recent type of amphiphilic molecules that contain two
polar headgroups linked by a rigid or flexible spacer that may be hydrophobic or hydrophilic.
As each headgroup has a hydrophobic moiety, GCLs may be considered as two conventional
monomeric surfactants connected by a spacer group [41]. GCLs have been proved as promising
candidates to transfect nucleic acids in gene therapy. The molecular structure of the GCLs
offers a high number of alternatives to develop and to improve their capability as transfecting
agents.
4. siRNA therapy in AKI
To date, siRNA therapy has been successfully applied in a variety of acute kidney injuries. IR
injury is the primary cause of AKI, particularly during kidney transplantation, in which the
kidney is exposed to hypoxia and experiences a series of oxidative, inflammatory and apoptotic
responses [42, 43]. Consequently, specific siRNAs targeting critical molecules that are involved
in the processes of oxidation, inflammation, and apoptosis have been developed.
Caspase-3, which mediates apoptosis and inflammation, is upregulated by IR injury. Multiple
pharmacological interventions against caspase-3, including enzyme inhibitors and genetic
modification, have been investigated. In recent years, our group studied the delivery and
efficacy of caspase-3 siRNA in in vitro, ex vivo, and in vivo kidney injury models. The synthetic
caspase-3 siRNA was initially tested in porcine PTCs (LLC-PK1), with or without hydrogen
peroxide (H2O2) stimulation. Apoptotic cells and activated IL-1β protein expression were
significantly reduced by the caspase-3 siRNA, with improved cell viability [17]. This outcome
led to siRNA application in an isolated organ perfusion system, as described above, and the
efficacy of caspase-3 siRNA was further proven, in terms of silenced caspase-3 mRNA and
protein expression, attenuated inflammation and apoptosis, and improved renal function and
histology [16].
The porcine kidney preserved by caspase-3 siRNA was then autotransplanted in a 2-day
model. However, the transplanted kidney was not protected without systemic treatment of
the recipient. Moreover, new serum-stabilized caspase-3 siRNAs were applied locally in
kidney preservation and intravenously in recipient in a 2-week autotransplant model. The
transplanted kidneys were protected without significant off-target effects. These serials of step-
by-step studies provided promising evidence to support siRNA treatment to be further applied
in clinic.
p53, another pivotal protein in the apoptotic pathway, has been identified as a mediator of
transcriptional responses to IR injury [44]. Molitoris et al. revealed that intravenously injected
p53 siRNA attenuated ischemic and cisplatin-induced AKI [25]. Fujino et al. also tested the
efficacy siRNA targeting p53 via transarterial administration siRNA injected into the left renal
artery immediately after ischemia improved tubular injury and downregulated GSK-3β
expression [45]. In a diabetic mouse model, p53 inhibition by siRNA also reduced ischemic
AKI [46].
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Silencing of other important transcription factors or immunity related receptors using siRNAs
have also been studied. Renal IR injury and inflammation are related to postsurgical healing
and both processes can be influenced by toll-like receptor (TLR) signals. Effective TLR9
silencing by siRNA decreases renal cell apoptosis, mitigates AKI severity, and increases the
mice survival [47]. NF-κB, a pro-inflammatory transcription factor induced by TLR and other
signals, plays a key role in AKI. NF-κB activation depends on the activation of the inhibitor of
κB kinase β (IKKβ). Wan et al. demonstrated that silencing IKKβ using siRNA diminished
inflammation and protected the kidneys against IR injury [19]. These studies clearly demon‐
strate the therapeutic potential of siRNA-induced silencing of key AKI mediators, which are
activated and involved in the pathways of apoptosis, inflammation, immunity, etc.
5. Off-target side effects and toxicities of siRNA
The siRNA has been likened to a “magic bullet” due to this potency and specificity, but off-
target side effects and toxicities create additional challenges for researchers. The induction of
various side effects may be caused by unexpected perturbations between RNAi molecules and
cellular components. The off-target effects of siRNA were first reported by Jackson and
colleagues in 2003 [48]. Broadly speaking, off-target effects can be siRNA specific or nonspe‐
cific. The former are caused by limited siRNA complementarity to nontargeted mRNAs. The
latter, resulting in immune- and toxicity-related responses, are due to the construction of the
siRNA sequence, its modification, or the delivery vehicle.
The off-target effects associated with siRNA delivery fall into three broad categories: (1)
miRNA-like off-target effects, referring to siRNA-induced sequence-dependent regulation of
unintended transcripts through partial sequence complementarity to their 3′UTRs; (2)
inflammatory responses through the activation of TLR triggered by siRNAs and/or delivery
vehicles (such as cationic lipids and viruses); and (3) widespread effects on miRNA processing
and function through the saturation of the endogenous RNAi machinery by exogenous siRNAs
[49, 50].
5.1. miRNA-like off-target effects
The siRNAs and miRNAs share similar machinery downstream of their initial processing.
Using several different siRNAs targeting the same gene, microarray profiling showed that each
siRNA produced a unique, sequence-dependent signature. Sequence analysis of off-target
transcripts revealed that the 3′ UTR regions of these transcripts were complementary to the 5′
end of the transfected siRNA guide strand [48]. It is now understood that for the off-targeting
effects to occur, a perfect complementarity between the seed region of the antisense strand
such as nucleotide positions 2–7 or 2–8 and the 3′ UTR of the transcript is necessary [49, 51].
Silencing the set of original off-target transcripts could be induced by base mismatches in the
5′ end of siRNA guide strands. However, a new set of off-target transcripts within 3′ UTRs
that were complementary to the mismatched guide strand could be generated [49].
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RNAi regulation by miRNAs involves partial complementarity between the targeting RNA
and miRNA. Because miRNAs cause gene silencing through mRNA degradation and trans‐
lation inhibition, the siRNA-mediated off-target effects may also be acting at two levels. For
this reason, there should be greater emphasis on improving siRNA design as well as moni‐
toring gene and protein levels following RNAi therapy to account for any off-target effects.
5.2. Recognition and stimulation of the innate immune system
The recognition and stimulation of the immune system arenonspecific off-target effects of
siRNA therapy. The RNA-sensing pattern recognition receptors (PRRs), localized in endo‐
somes, are the most important components of the innate immune system. The responses of
PRRs to siRNAs are either TLR-mediated or non-TLR-mediated. The PRR responses are also
associated with siRNA sequence-specific side effects and have recently attracted many
attentions from researchers [52]. RNA-sensing TLRs (TLR3 and TLR7) are predominantly
located intracellularly and recognize nucleic acids released from invading pathogens. The non-
TLR-mediated innate immune responses triggered by siRNA binding are linked to RNA-
regulated expression of protein kinase (PKR) and retinoic acid inducible gene 1 (RIG1), which
further induce caspase-3 and NF-κB expression, respectively. The activation of PRRs generates
excessive cytokine release and subsequent inflammation [53].
Based on this second type of off-target RNAi effects, our group further investigated the
mechanism of how short-acting caspase-3 siRNA impaired posttransplanted kidneys. The
results suggested that the amplified inflammatory responses in caspase-3 siRNA preserved
autotransplant kidneys were associated with TLR3, TLR7, and PKR activation, which may be
due to systemic compensative responses, although persistent actions initiated by short-acting
caspase-3 siRNA cannot be completely excluded [54]. Other studies have also indicated that
the horseshoe-like structure of TLR3 facilitates dsRNA recognition [55, 56]. Interactions
between TLR3 and dsRNA were originally reported in 2001 when TLR3-deficient mice
exhibited reduced immune responses to dsRNA viruses [57].
Several studies have demonstrated that the immune response to siRNAs is cell type-dependent
due to the selective expression of TLRs. siRNAs stimulate monocytes and myeloid dendritic
cells through TLR8 to produce proinflammatory cytokines, or activate plasmacytoid dendritic
cells through TLR7 to produce type I interferons [58–60]. In addition, the volume of hydrody‐
namic naked siRNA delivery influences immune activation. Rácz et al. compared the immune
responses induced by 50 μg siRNA dissolved in either low-volume (1 mL/mouse) or high-
volume (10% of body weight, 2.5 mL/mouse in average) physiological salt solution delivered
in vivo. Low-volume hydrodynamic injection induced slight alanine aminotransferase (ALT)
elevation and mild hepatocyte injury, whereas high-volume hydrodynamic injection resulted
in higher ALT levels and extensive hepatocyte necrosis. High-volume hydrodynamic injection
also led to a time-dependent slight increase in IFN-related gene expression [61]. Collectively,
these studies suggest that there is a need for improving siRNA design, establishing experi‐
mental controls and carefully interpreting results.
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these studies suggest that there is a need for improving siRNA design, establishing experi‐
mental controls and carefully interpreting results.
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6. From bench to bedside: Clinical trials
The numbers of RNAi-based preclinical studies and clinical trials have grown over the past
several years. To date, there have been 27 registered clinical trials using siRNA worldwide.
These studies include retinal degeneration, dominantly inherited brain and skin diseases, viral
infections, respiratory disorders, metabolic diseases, and of particular note, kidney diseases.
In 2011, Quark Pharmaceuticals completed a phase I, randomized, double-blind, dose
escalation, safety, and pharmacokinetic study (NCT00554359) on QPI-1002, also designated
I5NP, which was a synthetic siRNA that temporarily inhibits p53 expression that is in early
development for acute kidney failure therapy. I5NP is the first siRNA to be systemically
administered in humans. Based on the preclinical data obtained from animal models, the
siRNA was intravenously injected within 4 h to bypass surgery patients. Pharmacokinetic data
were collected during the first 24 h, and safety and dose-limiting toxicities were monitored
until hospital discharge and 6–12 months after surgery. Recently, Quark initiated a subsequent
clinical trial to determine whether a single administration of I5NP can prevent delayed graft
function in kidney transplant recipients. Data from this study will be used to identify I5NP
doses for follow-on efficacy studies (NCT00802347). Another ongoing phase I trial investigat‐
ing solid tumors, including Renal cell carcinoma (RCC), was conducted by Calando Pharma‐
ceuticals. The investigators used CALAA-01, whose active ingredient is a type of siRNA, to
inhibit tumor growth and/or reduce tumor size. This siRNA inhibits the expression of the M2
subunit of ribonucleotide reductase and resists nuclease degradation by using a stabilized
nanoparticle that targets tumor cells (NCT00689065).Besides, there is an ongoing study, in
which patients with melanoma, kidney cancer, pancreatic cancer, or other solid tumors that
are metastatic or cannot be removed by surgeryare treated by APN401, siRNA-transfected
autologousperipheral blood mononuclear cells.These cells were modified by siRNA targeting
factors inhibiting the killing ability of immune cells in vitro and transfused back into the body,
in order to kill more cancer cells (NCT02166255, the above clinical trials can be found at
ClinicalTrials.gov, Table 1).
Study Target/siRNA drug Status Disease
NCT00554359 I5NP Phase I, completed Kidney injury; acute renal failure
NCT00802347 I5NP Completed Delayed graft function in kidney
transplantation
NCT00689065 CALAA-01 Phase I, terminated Solid tumor cancers including RCC
NCT02166255 APN401 Phase I, recruiting Melanoma, kidney cancer, pancreatic
cancer, or other solid
Table 1. Clinical trials of siRNA therapy in kidney diseases.
7. Perspectives and challenges
Despite the enormous potential advantages of siRNA therapy, additional research must be
performed before its large-scale clinical application.
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7.1. Target gene selection
Genome-wide or pathway-specific siRNA libraries have become available using high-
throughput screening approaches. Establishing in vitro prescreening leads to signaling
pathway prediction and target validation in in vivo renal disease. However, choosing one or a
set of reasonable target genes is the key for designing specific siRNA treatments. The patho‐
physiological changes during kidney disease, like any other disease, refer to a complex gene
and protein regulation network. For example, the network that exists during kidney trans‐
plantation involves the original conditions of the donors and the interactions between the
donor kidneys and the recipients, which could direct the progression, as well as the recovery,
of the injury. Fortunately, transcriptome measurements of the transplanted kidney may
provide a comprehensive understanding of gene regulation and would be beneficial for target
gene selection.
Mueller et al. analyzed the transcriptome of postreperfusion implant biopsies in living donors
(LD) and deceased donors (DD). Hundreds of mRNAs were identified that predicted delayed
graft function [62]. In a recent prospective study using human posttransplant kidney biopsies,
20 mRNAs and two miRNAs were identified as molecular signatures of AKI. Elevated
secretory leukocyte peptidase inhibitor in AKI allografts was validated and miR-182-5p was
identified as a molecular regulator [63]. These genes could be used as potential targets of siRNA
therapy. We recently identified 3 times more differentially expressed genes in renal allograft
biopsies between living donors and cadaveric donors at 30 min than 3 months posttransplan‐
tation. The majority of these differentially expressed genes are responsible for acute responses
at 30 min, but also involved in inflammation, nephrotoxicity, and proliferation at 3 months.
These divergent transcriptome signatures between two types of donors might be linked with
not only the initial injury of the donors, but also the immune responses of the recipients.
Another method for selecting target genes is by identifying their translation product proteins.
To find a single or a set of crucial proteins involved in kidney allograft rejection, Wu et al.
explored potential transcriptional factors and regulation networks in 352 kidney transplant
recipients, of which 85 suffered from acute rejection (AR). The results demonstrated that the
dominant processes and responses were associated with inflammation and complement
activation in AR. A number of transcription factors were identified in AR patients, including
NF-κB, signal transducer, and activator of transcription (STAT) 1 and STAT3 [64]. Their recent
study further revealed inflammation-derived kidney allograft injury, such as AR, chronic
rejection, and impaired renal function without rejection. Wu et al. 12 common proteins and 11
level-specific proteins from the phenotype-related protein–protein interaction networks [65].
These potential biomarkers also provide valuable targets for siRNA design relating to the
treatment of transplant-related injury.
7.2. Timely application
Compared with shRNA, an advantage of siRNA for AKI therapy is time-controlled, transient
treatment. Silencing the target gene for a short time or a long time should be assessed before
RNAi application. The silenced genes may be multifunctional according to the surrounding
milieu. For example, caspase-3, generally considered an executor in cellular apoptosis, should
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be inhibited in injured tissues. However, it is also a loyal scavenger in malignantly transformed
cells, which could be an unavoidable side effect in any caspase-3-targeting siRNA therapy. For
AKI, siRNA ineffectiveness is needed after the therapeutic time window. Additionally, siRNA
application avoids intracellular traffic. In certain circumstances, shRNA delivery could be
harmful to the organ or even fatal.
A study from Grimm et al. investigated the long-term effects of sustained high-level shRNA
expression in the livers of adult mice. An evaluation of 49 distinct adeno-associated virus/
shRNA vectors, with unique lengths and sequences that were directed against six targets,
showed that 36 vectors resulted in dose-dependent liver injury, with 23 ultimately causing
death. The observed morbidity was associated with the downregulation of liver-derived
miRNAs, indicating possible competition of the latter with shRNAs (through saturation of the
endogenous RNAi machinery by the exogenous siRNAs) for the limited cellular factors
required for the processing of various small RNAs [66]. Therefore, controlling intracellular
shRNA expression levels will be imperative, but siRNA would not influence the endogenous
process of RNA degradation mediated by miRNAs.
7.3. siRNA targeting single, double or multiple genes
The knockdown of two or more genes simultaneously using siRNA cocktail has been recently
reported. Many applications of siRNA cocktail have demonstrated significant benefits
compared with siRNA targeted to a single gene, particularly in anticancer and antiviral therapy
[67, 68]. A high concentration of individual siRNAs may represent the key off-target effect in
terms of competition for endogenous miRNA biogenesis machinery. Therefore, the other
advantage of siRNA cocktail is the relatively low concentration of each siRNA, which may also
reduce off-target signatures without sacrificing silencing potency [69].
7.4. Cell-specific siRNA targeting
We have showed that the apoptosis of different types of cells leads to different outcomes. For
instance, the apoptosis of inflammatory cells is associated with inflammation clearance and
tissue remodeling, whereas the apoptosis of renal parenchymal cells is link to tubular atrophy
and renal fibrosis. Therefore, using the genetic material such as siRNA targeting specific cell
at particular time frame is crucial to achieve high efficacy of treatment in AKI and also avoid
site-effects [12, 54].
It is still challenging to administrate siRNA cell specifically, but it is feasible as there were a
few studies showed delivering siRNA into liver cells and antigen-presenting cells [70–72] using
carbon nanotubes and mannose-conjugated liposomes. In addition, surface pegylation and
cell-specific targeting ligands incorporation in the carriers may improve the pharmacokinetics,
biodistribution, and siRNA selectivity. Choosing appropriate siRNA carriers has to consider
the safety, effectiveness, ease of manufacturing, off-target effects [12], and innate immune
responses. Of course, the efficacy of siRNA is still a most important factor dominating the
selection of its carriers [54].
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7.5. siRNA-modified stem cell therapy
Mesenchymal stem cell (MSC) transplantation has attracted much attention in cell therapy in
different organ systems such as myocardial infarction. One of the limitations is the poor
survival of grafted cells in the ischemic microenvironment. To tackle this issue, a novel siRNA-
mediated prolyl hydroxylase domain protein 2 (PHD2) silencing system has been developed
based on arginine-terminated generation 4 poly (amidoamine) nanoparticles. This system, for
the first time, exhibited effective and biocompatible siRNA delivery and PHD2 silencing in
MSCs in vitro. After transplant PHD2 siRNA-modified MSC in myocardial infarction models,
MSC survival and paracrine function of IGF-1 were enhanced significantly in vivo, with
decreased cardiomyocyte apoptosis, scar size, and interstitial fibrosis, and increased angio‐
genesis in the diseased myocardium, which ultimately attenuated ventricular remodeling and
improved heart function. This study demonstrated that a great potential of siRNA-modified
stem cells in therapeutic applications, which, of course, might be used in AKI [73].
8. Conclusions
The kidney is a comparatively easy target organ for siRNA therapy due to its unique structural
and functional characteristics. siRNA intervention is effective, feasible, and has great potential
for fighting against kidney diseases. For the next-generation siRNA development, cell-specific
precise delivery should be pursued. Although the safety of siRNA therapy has been proven
by rapidly emerging clinical studies, off-target and compensative responses still need be
overcome via various modification strategies. The time for realizing the therapeutic potential
of RNAi has come because optimized siRNA therapy, in conjunction with advanced genetic
screening technologies, could facilitate timely and specific treatment of kidney as well as other
organ diseases in the near future.
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Abstract
RNA interference (RNAi) is a posttranscriptional mechanism of gene regulation present
in eukaryotic cells. Inducers of RNAi are small molecules of RNA that act in the cyto‐
plasm where they are able to impair translation of a specific mRNA to protein, hence
modifying gene expression. The discovery of this mechanism in mammals led to the de‐
velopment of a new class of therapeutics with the aim of exploiting this endogenous
mechanism of action. In the last decade, great efforts have been put into understanding
RNAi and translating this accumulated knowledge into the design of modern therapeu‐
tics. With several compounds in phase III clinical development, the field is getting closer
to its first market authorization. Here we make a thorough overview of the field of RNAi
therapeutics in ophthalmology, one of the fields in which RNAi has been most successful.
Keywords: RNAi, eye diseases, ophthalmology, drug development
1. Introduction
Short interference RNAs (siRNA) are small molecules of double-stranded RNA of around 21
base pair long that specifically downregulate the expression of a target gene [1]. This mecha‐
nism of endogenous gene expression regulation, present in most eukaryotic cells, has been
thoroughly used to study gene function [2]. SiRNAs exert their function in the cytoplasm of
the cell, where they assemble with a several proteins to yield the RNA-induced silencing
complex (RISC), a multimeric RNA–protein complex that recognizes complementary messen‐
ger RNAs (mRNA) and promotes their degradation, thus blocking the synthesis of specific
proteins. RNAi may be activated by endogenous siRNAs synthesized in the nucleus of the cell
and generated by subsequent processing within the cell cytoplasm to yield siRNAs. Alterna‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
tively, siRNAs can be exogenously introduced to mimic the action of endogenous RNAi
triggers [3]. Among the benefits of RNAi are the potential of transiently silencing any given
gene at any stage of development and to affect gene expression in specific anatomical regions
without affecting nontargeted regions. These benefits are being used as a basis to develop a
new class of innovative drugs that may reach the market in the next five years; the present
report highlights the advances made in RNAi therapeutics on the field of ophthalmology.
2. The special environment of the eye: advantages and disadvantages
The eye has traditionally been considered a good organ for proof-of-concept studies to assess
the efficacy of innovative therapies. It has a very particular anatomy that allows the transfor‐
mation of sensory information into electrical signals that can be thereafter interpreted by the
brain. Transformation and partial processing of sensory information takes place in the retina,
located at the back of the eye. The correct function of the eye requires light to travel through
several anatomical structures in order to reach the photosensitive retina; hence, these struc‐
tures have to be transparent or semi-transparent to allow passage of light. The environment
of the eye is extremely specialized to ensure that transparency is maintained, and there are
several mechanisms in place to ensure that this specialized environment is preserved. One of
the anatomical characteristics of the eye to allow light to travel through its structures is
restricting the blood flow to regions where transparency is not strictly required.
In addition, access to the innermost regions of the eye is controlled by several barriers; these
barriers isolate the eye from external aggressions and pathogens to but also limit the access of
therapeutics. The influence of the particular anatomical features of the eye on drug delivery is
further explained in Section 4 of this review. The barriers of the eye do not only isolate this
organ from external aggressions or substances but also limit the access of internal elements;
as such, the immune system has only limited access to the eye making the eye a partially
immune-privileged region. Finally, the aqueous humor, the clear liquid that fills the eye and
maintains its shape and pressure, has a very low content in proteins compared to serum.
Among the proteins that are significantly reduced compared to other tissues are RNases and
elements of the complement cascade. The reduced concentration of RNases increases the half-
life of RNAs used as therapeutics, and reduction in the elements of the complement cascade
further decreases the likelihood of an unwanted immune reactions to drugs.
In order to preserve its integrity, the eye has efficacious barriers to block the entrance of
pathogens and substances that could potentially affect its sensory function. The eye has
developed specific features that ensure that light travels through its tissues; this specialization
of tissues to preserve visual function is also observed by the immune system [4]. Immune
responses change the local environment of tissues and are frequently associated to tissue
inflammation. In order to avoid these potentially harmful changes, the eye has a relatively
immune privileged status. This immune privilege status is maintained by several mechanisms.
Absence of lymphatic and blood vessels in certain areas and abundance of immunosuppressive
factors in the aqueous humor are among these mechanisms [5]. On the other hand, the eye
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needs to be able to respond to situations in which its integrity can be compromised such as
viral or bacterial infections. The innate immune response is the first system activated in
response to aggressions; it acts like a watchdog mechanism recognizing pathogen-associated
molecular patterns (PAMP). Depending on the molecular characteristics and location of the
PAMP, different effectors of the innate response are activated; these responses can be mediated
by toll-like receptors (TLR) or independent of these receptors. Toll-like receptors discriminate
self-motifs from non-self-motifs [6]. There are ten known TLRs, and they differ in their
subcellular localization and in the type of non-self-pattern they recognize. TLR1, TLR2, TLR4,
TLR5, and TLR6 recognize components of bacterial walls and are located in the cell surface,
whereas TLR3, TLR7, TLR8, and TLR9 recognize oligonucleotides and are sequestered in
intracellular compartment. TLR3 binds to single- and double-stranded RNA, TLR7 binds to
single-stranded RNA, and TLR9 binds to unmethylated CpG motifs, usually found in bacterial
DNA. In the eye, the expression pattern of each TLRs varies depending on the anatomical
structure; all TLRs are present in the corneal and retinal pigment epithelia; TLR4 is the
predominant TLR in the rest of the eye structures where it localizes in resident antigen
presenting cells [7, 8]. TLR-independent response mechanisms to cytoplasmic oligonucleotides
include dsRNA-binding protein kinase, the RNA helicase (RIG-I), and oligoadenylate synthase
enzyme. These proteins are cytoplasmic dsRNA sensors belonging to the antiviral innate
immune system, which plays an important role in antiviral defense in response to viral
infection and replication [9].
The first proof-of-concept studies to demonstrate the viability of silencing genes in the eye
showed that the injection of siRNAs into the subretinal space or vitreous cavity could indeed
downregulate specific genes. In these experiments, the downregulation of genes of the vascular
endothelial growth factor (VEGF) family with siRNAs correlated with the inhibition of ocular
neovascularization [10, 11]. The first set of these experiments used an adenoviral vector that
codified for an siRNA designed against VEGF1. The subretinal injection of this vector 36 h after
the induction of coroidal neovascularization (CNV) by laser reduced the areas of neovascula‐
rization compared to areas of mice injected with vector codifying for a scrambled siRNA [10].
In a subsequent study, Campochiaro and coworkers [10] demonstrated that the inhibition of
ocular neovascularization could also be achieved by injecting a VEGFR1 siRNA directly,
without an expression vector, into the vitreous cavity. The siRNA used in this study had the
so-called canonical design, which comprises a 21-nucleotide guide strand and a complemen‐
tary passenger strand annealed to form an siRNA duplex with a 19-bp dsRNA stem and 2
nucleotide 3′ overhangs at both ends [11].
In 2008, Kleinman and coworkers published a study in Nature demonstrating that the effect
of siRNAs on CNV was mediated by activation of TLR3 rather than an effect on target [12].
The  results  of  these  studies  showed  that  the  effect  of  the  siRNAs  on  CNV  was  dose-
dependent but not dependent on sequence. In addition, the authors demonstrated that a
minimum length of the siRNA was required in order for the molecules to have an effect
on CNV; this length was show to be at least 21 nucleotides. The study also showed that
the internalization of the siRNAs was not required for the inhibition of CNV as cells of the
retinal pigment epithelium (RPE) abundantly express TLR3 on the cytoplasmic surface. The
authors  used  several  sequences  to  point  out  that  the  inhibition  of  CNV  was  mediated
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through an off-target  effect.  Using docking models,  the  authors  showed that  TLR3 and
siRNAs were indeed able to interact with each other but the interaction was unstable when
siRNAs were shorter than 21 nucleotides. A subsequent study by the same group showed
that activation of TLR3 by IVT siRNAs led to caspase-3-mediated degeneration of the RPE
questioning the safety these compounds as therapeutics for back of the eye diseases [13].
The findings of Kleinman and coworkers boosted research on alternative designs that could
successfully  block  immune  recognition;  among  the  most  commonly  used  strategies  are
incorporation of delivery systems and 2’-ribose modifications.
Finally, exogenous RNAs are quickly degraded by RNases present in tissues and body fluids
[14]. These enzymes cut RNA into smaller components that are subsequently incorporated into
the route of degradation of nucleotides. RNAses are present at high concentrations both in
tissues, such as in spleen, liver, and pancreas, and in biological fluids, such as in serum [15].
In the eye, the tear fluid is rich in nucleases but the presence of these enzymes is considerably
lower in most eye tissues, thus allowing for increased half-life of the siRNAs used for thera‐
peutic purposes.
3. Efficacy studies: Animal models to study the eye
Proof-of-concept studies are required in order to demonstrate that a particular drug has the
proposed activity. siRNAs are designed using bioinformatics tools to target specific regions of
the human genome. Therefore, assessing the activity of these molecules in animal models
requires that the siRNA has biological activity in the species chosen to perform the proof-of-
concept study. With the sequencing of the genome of most animal models used in biomedical
research, evaluating the homology of a given sequence between two species is nowadays
common practice, but this does not warrant finding a fully homologous siRNA for all targeted
genes. In cases where homologous sequences cannot be found, a surrogate compound can be
used to perform animal efficacy studies; this entails designing a compound that targets the
exact same region as the human version but with the sequence of the gene of the animal species
to be used. Several animal models can be used to assess the activity of a compound. Here we
highlighted the animal models used in the developmental programs of products included in
the ophthalmic siRNA pipeline.
3.1. Ischemic optic neuropathy
Ischemic optic neuropathy is a sudden loss of vision caused by interruption or decreased blood
flow in the optic nerve. There is a disagreement as to its pathogenesis, clinical features, and
management because ischemic optic neuropathy is not a unique disease, but a spectrum of
different types [16]. Ischemic optic neuropathy can be primarily of two types: anterior (AION)
caused by the interruption of blood flow in the optic nerve head and posterior (PION)
involving the posterior part the optic nerve. Both types can be further classified into different
subtypes. AION comprises arteritic (A-AION) caused by giant cell arteritis and nonarteritic
(NA-AION) caused by other than giant cell arteritis. NA-AION is by far the most common
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research, evaluating the homology of a given sequence between two species is nowadays
common practice, but this does not warrant finding a fully homologous siRNA for all targeted
genes. In cases where homologous sequences cannot be found, a surrogate compound can be
used to perform animal efficacy studies; this entails designing a compound that targets the
exact same region as the human version but with the sequence of the gene of the animal species
to be used. Several animal models can be used to assess the activity of a compound. Here we
highlighted the animal models used in the developmental programs of products included in
the ophthalmic siRNA pipeline.
3.1. Ischemic optic neuropathy
Ischemic optic neuropathy is a sudden loss of vision caused by interruption or decreased blood
flow in the optic nerve. There is a disagreement as to its pathogenesis, clinical features, and
management because ischemic optic neuropathy is not a unique disease, but a spectrum of
different types [16]. Ischemic optic neuropathy can be primarily of two types: anterior (AION)
caused by the interruption of blood flow in the optic nerve head and posterior (PION)
involving the posterior part the optic nerve. Both types can be further classified into different
subtypes. AION comprises arteritic (A-AION) caused by giant cell arteritis and nonarteritic
(NA-AION) caused by other than giant cell arteritis. NA-AION is by far the most common
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type and typically affects individuals between 55 and 67 years of age. The incidence of AION
has only been thoroughly studied in the USA where there are 2.3–10.3 cases per 100,000
inhabitants; for the nonarteritic type, the numbers are lower: 0.36 per 100,000 inhabitants. NA-
AION is characterized by visual loss, optic disc swelling, sometimes with flame hemorrhages
on the swollen disc or nearby neuroretinal layer, and sometimes with nearby cotton wool
exudates. Visual loss is usually sudden and may progress over several hours to days and even
weeks [17].
Animal modes of this disease are used to assess efficacy of pharmaceuticals in development
for these conditions and include the optic nerve crush model and the photoembolic stroke
model. The optic nerve crush model is a general model in which surviving of the ganglionar
cells can be studied in response to a physical damage to the optic nerve [18]. In the photoem‐
bolic stroke model, a photosensitive dye, such as rose bengal, is injected intravenously, and
laser is specifically applied to the optic nerve head to activate the dye. The activation of the
dye results in damage to the endothelial cells of the optic nerve vascular system that ultimately
leads to thrombosis of vessels and edema of the optic nerve head [19].
3.2. Glaucoma
Glaucoma is  a  group of  progressive  optic  neuropathies  characterized  by  vision  impair‐
ment  and degeneration of  retinal  ganglion cells  that  if  left  untreated can lead to  blind‐
ness. Glaucoma is the second leading cause of global irreversible blindness, and it has been
estimated that 60.5 million people were affected by primary open-angle glaucoma (POAG)
and  primary  angle–closure  glaucoma  (PACG)  globally  in  2010,  a  number  expected  to
increase to nearly 80 million by 2020 [20]. The degeneration of the optic nerve is thought
to be produced as a result of changes in intraocular pressure (IOP), but specific molecu‐
lar  mediators  of  these  changes  have  yet  to  be  identified.  Because  glaucoma  may  be
asymptomatic until a relatively late stage where the nerve damage has already occurred,
early diagnosis and treatment are crucial for halting the progression of the condition [21].
Reduction  of  IOP is  the  only  proven  strategy  to  treat  the  disease;  thus,  first-line  treat‐
ments are aimed toward achieving this goal. There are several compounds currently used
to lower IOP, and although most of them are efficacious in lowering IOP, they all come
with their  own set  of  side effects  and tolerance to  the drug is  a  frequent  phenomenon.
Tolerance or reduced response of  the drug requires change of  drug regimen, frequently
increasing the dose or combining the prescribed pharmaceutical with another drug [22, 23].
Depending on the specific phase of the disease one wants to model, several animal models can
be used [24]. If studying the degeneration of the retina is the main objective, the models
mentioned in the previous section can be used. For assessing the IOP lowering efficacy of
pharmaceuticals, models with increased IOP are generally used. The increased IOP model
induced by oral water overloading in rabbits is a very easy and physiologic model to screen
compounds. The basis behind this model is to give the animal an oral overload of water that
will result in a transient increase in IOP [25]. Although the specific mechanism behind the
increase in IOP following water overloading is uncertain, the model has been extensively used
to perform rapid screens of IOP-lowering compounds. The main advantage of this model over
other existing models of increased IOP is that the anatomical structure and physiology of eye
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structures are preserved allowing a normal response to hypotensive drugs. Other models of
increased IOP include laser photocoagulation, intracameral injection of latex microspheres,
topical application of prednisolone, light-induced reduced outflow facility, subconjunctival
injection of betamethasone, or episcleral vein occlusion [24].
3.3. Dry eye disease
Dry eye disease (DED) is a multifactorial disease of the tear-fluid and ocular surface that results
in symptoms of discomfort, visual disturbance, and tear film instability. It is accompanied by
increased osmolarity of the tear film and inflammation of the ocular surface [26]. Common
symptoms of this condition include blurry vision, tearing, and ocular pain. There are several
factors that contribute to the etiology of the disease, among them are insufficient tear secretion,
excessive evaporation, and alteration in the composition of the tear film [27]. Temporary
changes of the composition of the tear film can cause an acute form of DED; if changes persist,
the condition can turn into chronic DED. Damage to the ocular surface is usually more severe
in the chronic forms than in the acute types. DED is frequently associated to other conditions
such as Sjögren’s disease or lachrymal gland dysfunction, but it can also be caused by vitamin
deficiency, contact lens wear, and use of several prescription drugs. Acute DED is handled
with lubricants and avoiding preservatives in concomitant eye drops. If DED persists,
treatment options include procedures that favor tear retention such as punctal occlusion,
moisture chamber spectacles, contact lenses, or pharmacologic agents that stimulate tear
secretion. More severe forms may require the use of anti-inflammatory therapy [28]. Although
some advances have been made toward alleviating some of the symptoms of DED, pain
associated to this condition is not usually addressed. Pain in the eye results from stimulation
of sensory axons of the trigeminal ganglion neurons innervating the cornea [29]. Animal
models to assess the efficacy of ocular analgesics are extremely complex in terms of interpreting
efficacy outcomes [30]. One of the commonly used models to study pain is the capsaicin-
induced ocular pain model developed by Gertrudis and colleagues [31]. This model is based
on the evaluation of animal behavior after topical ocular administration of capsaicin, a selective
agonist of transient receptor protein vaniloid type 1 (TRPV1). Capsaicin applied locally to the
eye activates TRPV1 inducing palpebral closure. Latency to open the eye and time required
for complete palpebral opening can be used as measurements of the discomfort caused by
capsaicin. Reference products used in this model include analgesics, in particular, capsazepine,
the antagonist of TRPV1 channels.
3.4. Ocular allergy
Ocular allergies constitute a heterogenic group of diseases with a broad spectrum of clinical
manifestations and include mild forms such as seasonal allergic conjunctivitis (SAC) and
perennial allergic conjunctivitis (PAC), and more severe manifestations such as vernal
keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjuncti‐
vitis (GPC). The severe forms can be associated to complications such as corneal damage and
may cause vision loss. SAC and PAC are commonly IgE-mast cell-mediated hypersensitivity
reaction to external allergens, whereas AKC and VKC are characterized by chronic inflamma‐
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tion involving several immune cell types. In SAC and PAC, allergens, with the help of antigen
presenting cells, trigger a Th2-predominant immune response that induces B cells to release
IgE. In SAC and PAC, allergen-induced local release of IgE prompts infiltration and degranu‐
lation of mast cells in Ca2+-dependent mechanism. Mast cells liberate preformed inflammatory
mediators such as histamine and leukotriene 4 that subsequently attract eosinophils amplify
the allergic response [32]. The prevalence of ocular allergies in the general population is
estimated to be around 40% in the United States [33] and up to 35% in Europe and the Middle
East [34], but it is probably underestimated in most epidemiologic studies [35]. The primary
treatment for ocular allergies includes avoidance of allergens, cold compresses, and lubrica‐
tion. In persisting cases, symptoms can be treated using topical and oral decongestants,
antihistamines, mast-cell stabilizers, or anti-inflammatory agents [36]. Allergic conjunctivitis
can be modeled in animals by exposing them to allergens in the presence of an adjuvant [37].
The model developed by Magone and coworkers uses Female Balb/C mice that are sensitized
with short ragweed and alum and several days later animals receive a topical dose of short
ragweed pollen in the eye. A prescreening of mice can be performed in order to select only
those animals that respond to allergens.
3.5. Age-related macular degeneration with choroidal neovascularization
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in indi‐
viduals over 50 years of age [38, 39]. AMD is caused by a combination of genetic and environ‐
mental factors. Risk factors include hypertension, cardiovascular disease, smoking, and high
BMI. Among the genetic factors that confer susceptibility to developing AMD are variants in
genes encoding complement pathway proteins [40, 41].
The underlying cause for AMD is accumulation of drusen or residual material produced by the
renewal process of the external part of the photoreceptors of the retina in the retinal pigment
epithelium (RPE). The accumulation of this material in the RPE leads to the production of
inflammatory mediators that cause photoreceptor degeneration in the macula and severe vision
loss [42]. In the early stages of the disease, accumulated drusen are small; the size and amount
of this material increase as the disease progresses and central vision deteriorates.
There are two types of AMD: dry or wet. Dry AMD is characterized by the degeneration of the
RPE and photoreceptors along with changes in pigmentation of the RPE. In the wet form, or
choroidal neovascularization (CNV), fragile blood vessels of the choriocapillaris grow into the
RPE and frequently leak blood and fluid that accumulate between RPE and choriocapillaris.
As a result of these abnormal growths, dense scars are formed in the macula, and the RPE can
detach. The wet form is more severe than the dry form and sometimes dry AMD can develop
into wet AMD [43].
The characteristic invasion of leaky blood to the RPE in wet AMD is mediated by VEGF. The
discovery of the relationship between VEGF and changes in vasculature in AMD led to the
development of different approaches aimed to decrease the levels of this growth factor.
Antibodies targeting VEGF are currently the first-line treatment for wet AMD [44]. The
hallmark of wet AMD is CNV; thus, this is the lesion most extensively modeled in animals to
assess efficacy of compounds targeting this disease. The laser-induced CNV model is by far
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the most used animal model. This model, initially developed for nonhuman primates (NHP),
was later adapted into rodents. The basis for this model is to induce a break in Bruch’s
membrane using a high-energy laser. The experimental CNV can be analyzed in vivo using
fluorescein angiography or optical coherence tomography or postmortem studying the retina
explants. The model has been successfully transferred and validated to rat and mouse, and in
both species, the chain of events taking place after lesion induction resembles the events that
tale place in humans with the disease. Other models include the injection of subretinal
materials such as Matrigel, angiogenic substances, macrophages, lipid peroxides, or polyethy‐
lene glycol. Although these models are promising, they have yet to be appropriately validated
in order to be used as a proof of concept tools [45].
3.6. Diabetic retinopathy
Diabetic retinopathy (DR) is an ocular complication of diabetes mellitus characterized by
microaneurysms in the retinal vasculature that eventually lead to ischemia and macular
edema. Changes in the retina can cause rapid vision loss, and this complication is the main
cause of visual loss in working-age individuals [46, 47].
The initial phase of DR, known as nonproliferative DR, is characterized by the thickening of the
capillary basement membrane and apoptosis and migration of pericytes. These microchanges
cause microaneurysms and small leakages in the vessels that irrigate the retina. As the disease
progresses, interaction between endothelial cells and pericytes weakens and the capillaries
become permeable; subsequent accumulation of fluids in the macula leads to edema. The
microaneurysms in the retinal capillaries cause occlusions that compromise blood flow through
the  retina  and  cause  ischemia.  Local  hypoxia  upregulates  angiogenic  factors  that  cause
capillaries to grow into the retina,  preretinal space,  and vitreous cavity;  stage known as
proliferative DR [48]. Among the upregulated angiogenic factors, one of the most critical is
VEGF; the newly formed vessels are structurally deficient and very responsive to this growth
factor. As such, antibodies used to treat AMD are also used for the treatment of diabetic
retinopathy. DR is usually treated with laser photocoagulation, a procedure that does not cure
the disease but mitigates the damage. IVT steroids can also be used to reduce accumulation of
fluids within the retina. If accumulation of blood in the vitreous humor physically impedes laser
photocoagulation, a vitrectomy has to be performed in order to remove the blood accumulat‐
ed in the vitreous prior to laser photocoagulation.
There are several animal models of diabetic retinopathy, each of them comes with its own set
of advantages and disadvantages. One of the most extensively used is the streptozotocin (STZ)-
induced diabetes model. Intravenous or intraperitoneal injection of STZ causes a rapid and
selective destruction of β-pancreatic cells leading to hyperglycemia and development of type I
diabetes. The model has been used successfully in several animal species including rat, mouse,
rabbit, dog, and monkey. Nonproliferative DR develops in this model, but microaneurysms
and neovascularization are seldom observed; hence, this model can be complemented with the
laser-induced CNV model explained in the AMD section. Larger animal models can be generated
by surgically removing the pancreas, but this model is significantly more complicated to
generate than the STZ model and has the same drawbacks. Alternatively, animals can be fed a
high-galactose diet, but the induction of diabetes is considerably slower [50].
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4. Biodistribution studies
Despite the extraordinary potential that RNAi technology displays in the treatment of ocular
conditions, the transition of siRNAs programs to the clinical setting still presents challenges.
The in vivo efficacy of therapies based on siRNAs depends on the ability of a given siRNA to
reach the cytoplasm of its target cell in sufficient quantities to achieve its desired biological
effect. The intrinsic characteristics of siRNAs such as their sensitivity to degradation by
endogenous enzymes, their relative large size, and its negative charge limit their ability to cross
biological barriers and reach the cytoplasm. Approaches used to overcome the hurdles
associated to the use of siRNAs range from delivery strategies to chemical modifications aimed
towards improving the pharmacological properties of the therapeutic siRNAs.
Drug delivery into the eye is challenging due to the presence of static and dynamics barriers
that protect the internal tissues. The eye consists of two anatomically differentiated regions:
the anterior and posterior segments. The anterior segment includes the cornea, conjunctiva,
iris, ciliary body, lens, and anterior and posterior chambers; this segment occupies approxi‐
mately the anterior third of the eyeball. The posterior segment is of greater size and comprises
the sclera, choroid, retina, and vitreous cavity. There are significant anatomical, molecular,
and immune differences between the two segments; thus, strategies to deliver molecules to
the eye will be very different depending on the targeted segment [51]. The anterior region of
the eye is protected from exterior aggressions by the cornea and tear film. The former is a
specialized tissue composed of five layers that constitutes the main physical barrier to external
molecules; the latter is an enzyme-rich fluid that degrades many biological molecules,
lubricates the eye surface, and washes away materials from the cornea. In addition, many
components of the tear film impede adhesion of molecules to the eye surface further restricting
the access of external molecules to the inside of the eye.
Topical ocular administration of drugs is a patient-friendly administration route typically used
for the treatment of pathologies affecting the anterior segment of the eye. However, molecules
applied as eye drops are quickly cleared from the ocular surface being the bioavailability of a
compound administered via this route less than 5% of the initially applied dose. The standard
volume of a commercial eye drop is approximately 40 μL whereas the normal volume of the
tear fluid in the ocular surface is 7-9 μl. Once an eye drop is instilled in the inferior conjunctival
sac, there is a transient increase of volume that activates the blinking reflex and increases the
turnover of the tear film. Most of the content of the eye drop is spilled out by the blinking
process or drained via the nasolacrimal duct, drastically reducing the amount of compound
available to the eye.
The cornea is a specialized tissue covering the anterior part of the eye whose main functions
are protecting against harmful agents and provide the eye with a refractive surface that allows
the entrance of light. The human cornea is approximately 0.5–0.8 mm thick, and it is comprised
of three layers: the outer five cell layer-epithelium, a thick stroma rich in type I collagen fibrils
and glycosaminoglycans, and the innermost endothelium consisting in a single layer of
cuboidal cells. The corneal epithelium is separated from the stroma by the Bowman´s mem‐
brane, while the stroma and the corneal endothelium are separated by the Descemet´s
Preclinical Development of RNAi-Inducing Oligonucleotide Therapeutics for Eye Diseases
http://dx.doi.org/10.5772/61803
253
membrane. There are no blood vessels irrigating the cornea; this provides the required
transparency for the transmission and refraction of light. Drugs can take two paths to penetrate
the corneal epithelium: the intracellular path crossing through the cells or the paracellular path
bypassing between cells. The cells of the corneal epithelium are tightly attached to each other
with gap and tight junctions that restrict the diffusion of large molecules between them [52–
54]. The cross-cellular pathway requires molecules to be able to cross cell membranes; thus,
lipophilic molecules have an easier access through this route. The stroma is an aqueous matrix
composed mainly of hydrated collagen and proteoglycans with few keratinocytes interspersed
[55]. The hydophilicity/lipophilicity index determines the diffusion of molecules through this
layer [56]. The remaining layers of the cornea do not significantly hamper the diffusion of
molecules.
Contrary to the cornea, the conjunctiva is a highly vasculated tissue that covers the sclera and
lines the inner surface of the eyelids. Its main functions are producing mucus and tears to
lubricate the eye surface and preventing the entrance of pathogens. The human conjunctiva is
composed of three layers: the outer epithelium, the substantia propia, containing nerves and
blood vessels, and the submucosa layer, which provides a lightweight attachment to the
underlying sclera [57]. The histology of the stratified outer epithelium varies among the different
regions of the conjunctiva, but it is always its apical portion that controls the permeability of
the conjunctiva. The conjunctiva offers an attractive route for drug delivery when compared to
the cornea as it presents an extended exchange surface as well as a superior rate of permea‐
tion to large hydrophilic molecules. The sclera is structurally continuous with the cornea and
extends posteriorly from the limbus. The composition of the sclera is similar to that of the corneal
stroma, mainly collagen and mucopolysaccharides leaving numerous channels through which
drugs can freely diffuse [58]. The sclera is poorly vascularized and significantly more permea‐
ble than the cornea but less permeable than conjunctiva. There are contradictory reports on the
ability of charged molecules to cross the sclera. Some authors suggest that this layer is more
permeable  to  negatively  charged molecules  [59,  60],  whereas  other  studies  suggest  that
positively charged molecules  cross  the sclera more easily  [61,  62].  Ranta and colleagues
suggested that the negative charge of mucopolysaccharides in the sclera prevented the diffusion
of negatively charged molecules as a consequence of charge repulsion. Other studies have shown
that negatively charged molecules are indeed able to cross the sclera, pointing out that size is
the limiting factor in drug diffusion through this layer [52]. It should be noted, however, that
scleral drug binding does not necessarily impair drug delivery to inner structures of the eye; it
can also act as a drug-depot if the molecules are subsequently released [63].
Ophthalmic drugs topically administered to de eye can thus be absorbed through two
pathways: crossing the cornea to reach the aqueous humor or through the conjunctival-scleral
pathway reaching the uvea. The relative quantity that enters through each of the above-
mentioned routes varies significantly depending on the size and hydrophilic/lipophilic ratio
of the molecule. Generally, the conjunctival route is favored for large hydrophilic molecules,
whereas small lipophilic drugs are mainly absorbed through the cornea. The ability of siRNAs
to penetrate the cornea has been thoroughly demonstrated as well as the ability of these
compounds to enter the cytoplasm of cells within the cornea. However, the capacity of siRNAs
to cross the cornea is limited, as shown by the limited amount of siRNAs detected in the
aqueous humor following eye drop instillation [64].
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to penetrate the cornea has been thoroughly demonstrated as well as the ability of these
compounds to enter the cytoplasm of cells within the cornea. However, the capacity of siRNAs
to cross the cornea is limited, as shown by the limited amount of siRNAs detected in the
aqueous humor following eye drop instillation [64].
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Increasing the amount of compound in the anterior part may be of interest for treating specific
conditions. For this purpose, several strategies can be used in order to improve delivery: (a)
increasing the residence time of the compound within the eye surface, (b) directing the
molecule to a specific region to increase the concentration locally, and (c) increasing absorption
by using physical methods. Increasing the contact time of the molecule with the eye surface
can be achieved by the use of formulations or depots. Formulations that increase viscosity and/
or mucoadhesion of ophthalmic solutions are generally believed to increase absorption into
the eye. Polymers such as methylcellulose or polyvinyl alcohol can be added to solutions to
increase viscosity and consequently increase residence and reduce clearance time. Mucoad‐
hesion may be increased by formulating the oligonucleotides in polymers such as chitosans.
These polymers have been used to deliver DNA vectors into the eye [65]. Encapsulation in
liposomes and in thermosensitive gels has also been attempted as a means to increase the
absorption and residence time of oligonucleotides in the eye [53]. In these studies, a 16-mer
was formulated in liposomes, a thermosensitve 27% poloxamer gel, and HEPES; the results of
these studies showed that the amount of compound reaching external tissues such as the
conjunctiva or the cornea was higher when the compound was prepared in HEPES. By contrast,
access to deeper regions of the anterior chamber such as the sclera or the iris benefited from
the increased viscosity of the gel formulation [53]. One of the main drawbacks of biodistribu‐
tion studies to assess the fate of a given siRNA in a formulation is that most of these studies
focus on the fate of nanocarrier rather than on that of the oligonucleotide and the relative
distribution of the molecule among the tissues of the eye. Therefore, thorough biodistribution,
studies are required to address the specific characteristics required for improving delivery for
specific conditions. Targeting has scarcely been used to deliver oligonucleotides into the eye;
there are a few reports using dendrimers with the goal of increasing the intracellular concen‐
tration of therapeutic oligonucleotides in specific regions of the eye, but advances toward this
goal are as of today very limited [66]. Physical methods such as iontophoresis have also been
studied aiming to increasing the amount of molecule that crosses the cornea and/or the sclera.
Although iontophoresis certainly increases the amount of transcorneal and transcleral delivery
of oligonucleotides mainly to the anterior chamber but also to some degree to the posterior
chamber, the use of this method has not been extensively used most likely because the
equipment required to apply the required current would entail in-office administration, which
would significantly complicate repeated administrations [67].
Drugs administered systemically enter the eye from the bloodstream crossing the capillaries
of the choroid. The choroid is a vascular layer composed of capillaries and supported by
Bruch’s membrane, a connective membrane of 2–4 μm thickness. Bruch’s membrane separates
the choroid from the retina, forming the main barrier to permeation across the choroid-Bruch’s
bilayer [68]. The permeability of Bruch’s membrane is relatively high; charge and size do not
generally affect drug diffusion through this membrane unless molecules are very big; in this
particular case, size can reduce the rate of permeation [52]. The choroid is a thin and permeable
membrane that is rich in melanin. Melanin has the ability to bind and retain many drugs
hampering their entrance to the retina and inner tissues. Other drug-binding proteins,
depending on the kinetic of binding/unbinding retention of drugs by melanin, can completely
block the entrance or act as a reservoir for slow release [69]. Studies to assess the binding of
oligonucleotides to melanin have yielded different results suggesting that at least some
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oligonucleotides bind to melanin reducing the rate of entrance to the retina; this is however
not the case for all oligonucleotides [52, 70].
The main restriction to free permeation of molecules from systemic circulation to the eye is the
blood–retinal barrier (BRB). The BRB is composed of the inner BRB and the outer BRB. The
former includes the vessels of the retina, whereas the latter is constituted by the retinal pigment
epithelium (RPE). Both barriers possess cells with well-developed intercellular junctions that
control the permeation of substances through them. Larger molecules, such as proteins and
nucleic acids, are mostly able to permeate through the choroid but have limited ability to cross
the inner BRB; thus, drugs need to exit the choroid and penetrate the eye crossing the outer
BRB. Crossing through the outer BRB usually requires high systemic doses increasing the
likelihood of systemic side effects [71]. Delivery to the posterior segment of systemic or
topically applied drugs requires thus crossing several biological barriers. Therefore, invasive
administration procedures are frequently used to deliver drugs to the posterior segment. In
addition, the outflow mechanisms of the eye rapidly remove drugs from the posterior chamber;
thus, reaching clinically meaningful concentrations is challenging. Most of the programs
developing siRNAs for eye conditions target the back of the eye; consequently, the route of
administration is IVT injection. The concentration of siRNAs administered IVT is highest in
the vitreous body, but they are also found in the RPE, choroid, and retina. Depending on the
stability of the siRNAs, the compound can also be found in systemic circulation.
There are numerous reports describing strategies that can be of benefit for increasing the
concentration of drugs in the back of the eye. Several nonbiodegradable (Retisert™, Illuvien™,
and Vitrasert®) and one biodegradable (Ozurdex™) intravitreal ocular inserts are currently
used in the clinical practice for delivering small molecules to the back of the eye. It is expected
that these advances be soon incorporated into the pipelines of larger molecules such as proteins
and oligonucleotides.
5. Toxicology
siRNAs are chemically synthesized oligonucleotides and are considered New Chemical
Entities (NCEs) by the US and European Regulatory Authorities since 2009 when the European
Commission excluded siRNAs from the definition of advanced medicinal products [72].
Toxicology assessment of RNAi-based drugs should be carried out following guidelines for
NCEs, and the complete toxicology battery is usually performed following the recommenda‐
tions of the ICH M3 (R2) guideline [73]. The guideline recommends the assessment of toxicol‐
ogy in two species, a rodent and a nonrodent, at three dose levels and for a duration that should
be similar or superior to the clinical trial to be carried out. This assessment should include
acute or maximum tolerated toxicology studies and repeated-dose toxicity studies. Addition‐
ally, pharmacokinetics, safety pharmacology, genotoxicity, carcinogenicity, and specific
toxicology studies should be carried out depending of the nature, indication, and route of
administration of the product. On the other hand, some aspects of RNAi-based products are
closer to new biological entities (NBEs) rather than NCEs; therefore, some of the requirements
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of the ICH S6 guideline also apply to the design of their developmental programs [74]. As such,
a tailored toxicology assessment program should be designed combining the recommenda‐
tions outlined in the above-mentioned guidelines and the accumulated experience of numer‐
ous compounds tested in preclinical and clinical development.
Toxicology of ocular products depends on their biodistribution and on their biological activity.
Moreover, the disease process, age, sex, or eye pigmentation are other potential factors
affecting the toxicity profile of the ocular drug assessed. Additionally, the bioavailability of
the RNAi compound will depend mainly on the route of ocular administration (topical versus
injected) and on the physicochemical characteristics of the drug.
Toxicities arising from oligonucleotides, including siRNAs, can be classified into hybridiza‐
tion-dependent toxicities and hybridization-independent toxicities. Hybridization-dependent
toxicities can be caused by (a) exaggerated pharmacology: excessive activity on the intended
target or by (b) off-target effect: modulating gene expression of an unintended target by an
RNAi-mediated mechanism. Hybridization-independent toxicities are often associated to the
chemistry of the siRNA. Identified hybridization-independent toxicities include prolongation
of activating partial thromboplastin time (aPTT), complement activation, and immunostimu‐
lation [75, 76, 77].
5.1. General toxicology
Up to date, numerous siRNAs indicated for different eye conditions have entered clinical trials
(Table 1); the administration route of four of these compounds is by IVT injection, whereas the
remaining two compounds are topically administered in eye drops. The toxicology assessment
of these products follows the traditional schedule for NCEs; this schedule entails general
toxicology studies in two species, a rodent and a nonrodent species of variable length. Most
programs up to date have used NHP as the nonrodent species; this is because siRNAs are
species specific, and it is likely that the assessment of toxicology was performed in the only
species in which the compound was pharmacologically active. The rabbit is very frequently
used to assess toxicology of compounds under development for eye conditions. Many sponsors
of programs using NHP or dog as nonrodent species chose to use the rabbit as second species,
although this animal is not a rodent per se. Reasons behind this choice include the similarity
of the volume of the eye to that of humans and the difficulty of administering controlled doses
to smaller animals. This is particularly relevant when the compound is administered by IVT
injection. This rationale has also been followed for developing siRNAs for eye conditions; only
in one case, PF-04523655, rats were used as the rodent species, and the rest of the programs
developing siRNAs for eye indications used the rabbit (New Zealand White rabbits or Dutch
Belted rabbit) as second species for toxicology assessment.
Most programs developing siRNAs for eye conditions include acute/maximum tolerated dose
and repeat-dose toxicology studies. The length of these studies is determined by the indication,
stage of development, and envisioned duration of treatment. In addition, most programs do
not only perform toxicology studies using the envisaged route of administration but also
include studies using intravenous route to challenge the systemic exposure to the drug and
assess potential dose limitations and target organs.




As mentioned in the previous section, both the ICH M3 (R2) and the ICH S6 guidelines apply
to programs developing siRNAs [73]. The ICH S6 states that the range and type of genotoxicity
studies routinely conducted for NCEs are usually not applicable to NBEs; pointing out that
performance of these studies is only required when there is a cause of concern. The European
Medicines Agency (EMA) issued a reflection paper on the assessment of the genotoxic potential
of antisense oligodeoxynucleotides in January 2005. This paper recommends addressing at
least two issues in regards to oligonucleotides which may indicate a cause of genotoxic concern:
(a) analyzing the potential of incorporation of phosphorothioated (PS) oligonucleotides into
the DNA and (b) addressing the potential of triplex formation of oligonucleotides with the
DNA fiber [78]. Several years of experience with siRNAs indicate that full-length molecules
are very unlikely to interact with the DNA. Thus, the potential cause of concern may arise from
the genotoxic potential of metabolites or chemical contaminants. The metabolism of nonmo‐
dified oligonucleotides yields naturally occurring nucleotides that are subsequently incorpo‐
rated to the natural degradation pathways of endogenous nucleic acids; thus, toxicities derived
from these degradation products are not expected. Modified oligonucleotides, on the other
hand, incorporate very frequently backbone modifications to reduce nuclease activity and
improve other pharmaceutical properties of the molecule. The most commonly used backbone
modification is the replacement of a nonbridging oxygen on the backbone between two
ribonucleotides with a sulfur to create a PS linkage [79]. Extensive genotoxicity studies
performed with Vitravene, a PS antisense oligonucleotide administered by IVT injection,
indicate that oligonucleotides with a PS backbone do not pose genotoxic potential [80, 81].
These results are in line with those obtained in the analysis of over 30 compounds studied in
the standard battery, all of which have yielded negative results. Other modified nucleotides
could potentially be incorporated into nucleotide pools and be thereafter used to synthesize
DNA. The standard battery of tests would detect eventual damaging potential of theses
degradation products.
The EMA reflection paper also recommends assessing the potential of triplex formation with
the DNA fiber. For this to happen, siRNA molecules would have to enter the nucleus of the
cell and their structure should include an uninterrupted homopurine stretch of at least 10–12
base pairs that should be homologous a given region of the DNA. In silico design of siRNAs
usually addresses these issues and candidates with the ability of forming triplex are avoided
prior to lead selection.
5.3. Carcinogenicity
Standard carcinogenicity studies are generally not required for NBEs, but these studies may
be required for siRNAs depending on their chemical structure, clinical dosing, patient
population, or biological activity. If the in vitro test genotoxic studies indicate that there is
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For RNAi products under development for eye conditions, the systemic bioavailability of these
products is usually very low, and a waiver to perform these studies may be justified. Strategies
should be discussed in a case-by-case base with the competent health authorities.
5.4. Reproductive and developmental toxicity
The assessment of reproductive and developmental toxicity is required to support the use of
a given pharmaceutical in pregnant women, women of childbearing potential, or children.
These studies are regulated by the ICH S5 guideline [82], which recommends assessing the
effect of drugs on all phases of the reproductive cycle. These recommendations apply to siRNA-
based products. Nevertheless, due to the unique features of these compounds, a case-by-case
approach should be followed for each product, and the requirements for these studies should
be discussed with the competent authorities. The target, indication, chemical modifications,
and systemic bioavailability of the RNAi-based drugs are features that may influence in the
nature of the required studies.
Because the toxicity of siRNAs can be caused by exaggerated pharmacology whenever
reproductive toxicity studies are required, they should be performed in a pharmacologically
active species. Standard reproductive toxicity species in rodents or rabbits can give information
on toxicity related to chemical structure. However, if the compound is not active in these
species or if the biological activity is not deemed to be equivalent to the foreseen activity in
humans, the assessment of reproductive risk may be conducted using an active analog or in a
nonrodent species in which the compound has biological activity. If the former strategy is
chosen, the toxicity and toxicokinetic profile of the surrogate should be taken into account
when interpreting the results. If the compound is only active in NHPs, studies should only be
performed in cases where there is cause for concern. In these particular cases, the number of
animals should be optimized, and a combined enhanced pre-and postnatal developmental
study can be performed as recommended for NBEs. In NHP studies, the assessment of
reproductive toxicology is usually studied by histopathologic examination of the reproductive
organs as part of the general toxicology studies of at least three months. The timing of
reproductive and developmental studies depends on when women of childbearing potential
are to be included in clinical trials. If NHPs are required for the assessment, the timing is more
flexible due to the length and complexity of the studies [83].
5.5. Local tolerance
Local tolerance studies are required for all topically administered drugs. In most cases, the
potential adverse events caused by local tolerance issues are evaluated in the single or
repeated-dose toxicology studies, reducing the number of animals required for the program.
5.6. Safety pharmacology
According to ICH S7A, safety pharmacology studies can be reduced or eliminated for locally
applied products as well as for NBEs that achieve highly specific receptor targeting [84]. For
siRNAs under development for ophthalmology indications, separate safety studies are not
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usually required; instead, functional safety end points are incorporated into the repeated-dose
toxicity studies. If the results of the toxicology studies indicate that there is cause of concern,
separate safety pharmacology studies should be performed.
6. Programs in development and future ahead
Table 1 summarizes the status of siRNA-based therapies under development for ocular
conditions. As mentioned in Section 1, the eye offers multiple advantages for developing
innovative therapies; therefore, studies in the eye pioneered the field of siRNA therapeutics.
The first siRNA to enter clinical development for an ophthalmology indication was bevasiranib
in 2004 shortly followed by sirna-027. Bevasiranib targeted VEGFA, whereas sirna-027 targeted
VEGFR1. These compounds were being developed for the treatment of AMD as both showed
a dose-dependent inhibition of experimental CNV in animal models that correlated with
knockdown of their respective target genes [10, 85]. As mentioned in Section 1, in 2008
Kleinman and coworkers published a study demonstrating that the effect of siRNAs targeting
VEGF and VEGFR on CNV was not mediated by an on-target effect but by activation of TLR3
[12]. The results of these studies indicated that the effect of the compounds on CNV was
sequence-independent and mediated by siRNAs of 21 base pairs or longer. The study also
showed that the internalization of the siRNAs was not required for the inhibition of CNV as
cells of the RPE abundantly express TLR3 on the cytoplasmic surface. The authors used several
sequences, including those of the siRNAs undergoing clinical trials at the time, to point out
that the inhibition of CNV by both bevasiranib and sirna-027 was mediated through an off-
target effect. A subsequent study by the same group showed that activation of TLR3 by IVT
siRNAs led to caspase-3-mediated degeneration of the retinal pigment epithelium (RPE)
questioning the safety of these compounds as therapeutics for back of the eye diseases [13].
The clinical development of bevasiranib was halted in 2007 and of sirna-027 in 2009 both as a
result of not reaching or being unlikely to reach their respective efficacy end points in phase
III trials.
The findings of Kleinman and coworkers boosted research on alternative designs that were
not able to activate TLR3, and as result, a new generation of compounds is currently under‐
going clinical trials. Currently, the most advanced siRNAs-based programs for ocular indica‐
tions are Quark’s QPI-007 and Sylentis’ bamosiran (SYL040012). QPI-007 is a 19-nt modified
siRNA-targeting caspase 2 currently in phase II/III for the treatment of nonarteritic anterior
ischemic optic neuropathy (NAION) [86]. QPI-1007 has shown to be safe when IVT injected to
animal models and humans. The ongoing phase II/III trial for this compound analyzes the
potential of multiple IVT doses to improve visual acuity in patients suffering NAION [87, 88].
Bamosiran is a canonical-designed naked siRNA-targeting β2-adrenergic receptor (ADRB2)
under development for the treatment of increased IOP associated to glaucoma [64, 89–91].
Glaucoma is a degenerative, chronic disease of the optic nerve that can lead to blindness if left
untreated [92]. The mechanistic details of optic nerve degeneration observed in glaucoma are
yet to be fully detailed, but it is well established that reduction of intraocular pressure avoids
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development of the disease. ADRB2 controls the production and release of aqueous humor.
The aqueous humor is responsible for maintaining optimal IOP. Treatment with topic beta-
blockers has shown to efficiently reduce intraocular pressure, but currently approved beta-
blockers are small molecules and are thus able to reach systemic circulation and systemic
organs were they cause unwanted effects. The rationale behind bamosiran is developing a
locally active compound that efficiently knocks down ADRB2 in the eye but that is not able to
reach systemic tissues reducing the likelihood of side effects. The compound is administered
in eye drops and has been shown to be well tolerated in animal models and humans [64, 93].
Three different doses of bamosiran are currently being studied in an active controlled phase
IIb trial. Previous clinical trials with this compound have shown promising results in healthy
individuals and patients with ocular hypertension [91, 93].
SYL1001 is a naked 19-bp siRNA-targeting transient receptor potential vanilloid-1 (TRPV1) for
the treatment of ocular pain. TRPV1 is a cation channel permeable to calcium activated by heat,
low pH, and capsaicin among other signals. This receptor is present in several structures of
the eye where it has been related, among other roles, to nociception [94]. SYL1001 has shown
to be safe when administered in eye drops to animals and humans and to have analgesic effect
in the capsaicin-induced eye pain model. The compound is currently undergoing a phase I/II
for the treatment of ocular pain associated to dry eye disease, a condition for which no specific
treatment currently exists [89].
PF-655 is a chemically stabilized siRNA-targeting RTP801, a stress-induced adaptor protein
that inhibits mTOR function upstream to TSC1/TSC2 complex in response to a variety of
stresses. Expression of RTP801 is upregulated in response to ischemia, hypoxia, and/or
oxidative stress. Intravitreal injection of PF-655 in preclinical animal models of laser-induced
CNV leads to silencing of RTP801 via a RNAi mechanism without TLR activation and
reduction of CNV volume, vessel leakage, and infiltration of inflammatory cells into the
choroid [95–97]. This compound has undergone phase II clinical trials for the treatment of
diabetic macular edema and wet AMD. Treatment with PF-655 of patients with diabetic
macular edema over a period of 12 months caused a dose-dependent improvement in visual
acuity compared to the visual acuity observed in patients treated with laser photocoagulation
[98]. A subsequent phase IIb trial was conducted with a new set of doses but terminated
because the primary end point was not likely to be achieved. The compound was thereafter
tested in combination with ranibizumab, a monoclonal antibody fragment that targets VEGF
and is the current gold standards for treatment of the disease. The results of this study have
not yet been disclosed. PF-655 has also been studied in patients suffering wet AMD. In this
indication, the compound did not show improvement as a single agent or in combination with
ranibizumab in mean visual acuity after 3 months of dosing.
Self-delivery rxRNAs (sd-rxRNAs) incorporate 2’-F and 2-’O-Me modifications and a sterol
conjugate on the sense strand with the goal of improving stability and cellular uptake. These
compounds have a 19-nt antisense strand and a sense strand usually shorter than 15 nt
resulting in an asymmetric duplex with a phosphorothioated single-stranded tail on the
antisense strand [99]. These compounds have been tested in vitro where they have shown to
be able to induce target knockdown in different cell lines. In vivo analysis of their activity
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showed these compounds are readily taken-up by retinal cells and that the compound is evenly
distributed throughout the mouse retina. Several of these compounds are under development
for different eye conditions and are expected to enter clinical development shortly.
SYL116011 is a naked 19-bp siRNA targeting the calcium release-activated calcium modulator
1 (ORAI1). Store-operated Ca2+ entry (SOCE) is activated in response to depletion of endo‐
plasmic reticulum Ca2+ pools. Activation of SOCE induces Ca2+ entry from extracellular
compartments, and this is mediated by store-operated CRAC channels. CRAC channels are
composed of calcium sensing proteins called STIM (stromal interaction molecule) and pore-
forming subunits named ORAI [100]. Mammalian cells have three ORAI isoforms: ORAI1,
ORAI 2, and ORAI3; although ORAI2 and 3 fulfill the same role as ORAI1, the Ca2+ currents
generated by these proteins are around two- to threefold smaller than the ones generated by
ORAI1 [101]. There is growing evidence that indicates that short-term and long-term activation
of immune cells in allergic responses is mediated by influx of Ca2+ to immune cells from the
extracellular compartment. Short-term responses include the degranulation of mast cells and
the activation of effector cytolitic T cells. Indeed, mast cells lacking either STIM1 or ORAI1
show a considerable defect in degranulation [102, 103]. Long-term responses involve the
modulation of gene expression that controls B and T cell proliferation and differentiation.
SYL116011 is being developed for the treatment of ocular allergies and has shown to reduce
immediate clinical signs in a mouse model of ragweed pollen-induced ocular allergy. The
decrease in clinical signs was accompanied by a reduction in the number of infiltrating
eosinophils in the conjunctiva and reduction of allergy biomarkers.
TT-211 is an AAV‐encapsidated construct that expresses a single shRNA modeled into a
miRNA backbone that inhibits the expression of VEGF‐A for the treatment of wet AMD. VEGF-
a protein is responsible initiating a signaling cascade that stimulates the growth of new blood
vessels, a hallmark of wet AMD. TT-231 is a second-generation candidate designed to express
three shRNAs, which target three different genes, VEGF receptor 2, PDGF-β, and human
complement factor B, proteins that play a major role in the progression of wet AMD. Both these
compounds are yet in a preclinical phase; IND filing is planned for 2017.
STP601 is a multitargeted siRNA cocktail nanoparticle formulation administered by IVT
injection under development for treatment of wet AMD, proliferative diabetic retinopathy,
and herpetic stromal keratitis. The cocktail includes three 25-mer siRNA duplexes targeting
VEGF, VEGFR1, and VEGFR2. Inhibiting this clinically validated pathway at the endothelial
cells lining the interior of the growing blood vessels is thought to halt the progression of AMD.
This product is currently in preclinical stage.
AQA001 is a single-stranded long chain nonmodified ribonucleotide connected by a proline-
derived linker that self-anneals to form a shot-hairpin structure within the molecule. The
compound targeting periostin acts through an RNAi mechanism and is being developed for
the treatment of diabetic retinopathy. The compound has shown positive result in a proof-of-
concept study of CNV [104].
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showed these compounds are readily taken-up by retinal cells and that the compound is evenly
distributed throughout the mouse retina. Several of these compounds are under development
for different eye conditions and are expected to enter clinical development shortly.
SYL116011 is a naked 19-bp siRNA targeting the calcium release-activated calcium modulator
1 (ORAI1). Store-operated Ca2+ entry (SOCE) is activated in response to depletion of endo‐
plasmic reticulum Ca2+ pools. Activation of SOCE induces Ca2+ entry from extracellular
compartments, and this is mediated by store-operated CRAC channels. CRAC channels are
composed of calcium sensing proteins called STIM (stromal interaction molecule) and pore-
forming subunits named ORAI [100]. Mammalian cells have three ORAI isoforms: ORAI1,
ORAI 2, and ORAI3; although ORAI2 and 3 fulfill the same role as ORAI1, the Ca2+ currents
generated by these proteins are around two- to threefold smaller than the ones generated by
ORAI1 [101]. There is growing evidence that indicates that short-term and long-term activation
of immune cells in allergic responses is mediated by influx of Ca2+ to immune cells from the
extracellular compartment. Short-term responses include the degranulation of mast cells and
the activation of effector cytolitic T cells. Indeed, mast cells lacking either STIM1 or ORAI1
show a considerable defect in degranulation [102, 103]. Long-term responses involve the
modulation of gene expression that controls B and T cell proliferation and differentiation.
SYL116011 is being developed for the treatment of ocular allergies and has shown to reduce
immediate clinical signs in a mouse model of ragweed pollen-induced ocular allergy. The
decrease in clinical signs was accompanied by a reduction in the number of infiltrating
eosinophils in the conjunctiva and reduction of allergy biomarkers.
TT-211 is an AAV‐encapsidated construct that expresses a single shRNA modeled into a
miRNA backbone that inhibits the expression of VEGF‐A for the treatment of wet AMD. VEGF-
a protein is responsible initiating a signaling cascade that stimulates the growth of new blood
vessels, a hallmark of wet AMD. TT-231 is a second-generation candidate designed to express
three shRNAs, which target three different genes, VEGF receptor 2, PDGF-β, and human
complement factor B, proteins that play a major role in the progression of wet AMD. Both these
compounds are yet in a preclinical phase; IND filing is planned for 2017.
STP601 is a multitargeted siRNA cocktail nanoparticle formulation administered by IVT
injection under development for treatment of wet AMD, proliferative diabetic retinopathy,
and herpetic stromal keratitis. The cocktail includes three 25-mer siRNA duplexes targeting
VEGF, VEGFR1, and VEGFR2. Inhibiting this clinically validated pathway at the endothelial
cells lining the interior of the growing blood vessels is thought to halt the progression of AMD.
This product is currently in preclinical stage.
AQA001 is a single-stranded long chain nonmodified ribonucleotide connected by a proline-
derived linker that self-anneals to form a shot-hairpin structure within the molecule. The
compound targeting periostin acts through an RNAi mechanism and is being developed for
the treatment of diabetic retinopathy. The compound has shown positive result in a proof-of-
concept study of CNV [104].
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Name Indication Target Route Sponsor Status
Bevasiranib AMD with choroidal
neovascularization
VEGFA IVT Opko Health Halted in Phase III
Sirna-027 AMD with choroidal
neovascularization
VEGFR1 IVT Allergan Halted in Phase III




PF-655 AMD with choroidal
neovascularization
RTP801 IVT Quark/Pfizer Completed, Phase
II
Diabetic macular oedema Completed, Phase
IIb
SYL040012 Glaucoma β2 ADR Eye Drop Sylentis Completed, Phase
IIb
SYL1001 Ocular pain associated to
dry eye disease
TRPV1 Eye Drop Sylentis Active, Phase IIa
Undisclosed Retinal scaring Undisclosed Intraocular RXi Preclinical
Undisclosed Corneal scaring Undisclosed Eye Drop RXi Preclinical
Undisclosed Macular degeneration Undisclosed Intraocular RXi Preclinical
SYL116011 Ocular allergy ORAI1 Eye Drop Sylentis Preclinical
TT-211 AMD VEGF-A IVT Benitec Preclinical
TT-231 AMD VEGF-A, PDGFβ
and CFB
IVT Benitec Preclinical
STP601 AMD and retinopathy VEGF-VFGFR1-
VEGF2
IVT Sirnaomics Preclinical
AQA001 Diabetic macular oedema Periostin IVT Aqua TherapeuticsPreclinical
Table 1. siRNAs in development for ocular indication.
7. Conclusion
RNA interference is on the verge of becoming a new class of therapeutics [105]. The field of
ophthalmology has played a major role in advancing siRNAs from laboratory tools to the clinic.
In the last few years, significant advances have been made in the understanding of how these
molecules enter and exert its action in the eye and in the identification of the main hurdles that
still need to be addressed. The introduction of chemical modifications as well as the under‐
standing of the immune activation in the eye has significantly improved the pharmaceutical
properties of compounds for eye conditions. However, the following years will tell whether
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improvements on these molecules are enough to be of therapeutic value in the field of
ophthalmology or not.
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Abstract
RNA interference has a close relationship with the host defense system including adap‐
tive immunity. It is not only involved in regulating immune cells at different stages of the
immune response but also directly induces or enhances antigen presentation and subse‐
quent immune responses. We have previously reported that a small hairpin RNA
(shRNA) targeted the downstream site of a dominant cytotoxic T lymphocyte (CTL) epit‐
ope of human papillomavirus (HPV) type 16 oncogene E7 can stimulate an immune re‐
sponse against E7 expressing tumors in C57BL/6 mice. This results in the elimination of
tumor growth in vivo, whereas an shRNA that targets the upstream site does not. Our re‐
cent data further confirm the long half-life of the 5'-mRNA fragment after shRNA degra‐
dation and its involvement in protein synthesis. This chapter summarizes these findings
and provides some updated explanations for the findings.
Keywords: RNAi, shRNA, immune response, HPV E7, miRNA
1. Introduction
RNA interference (RNAi) is a conserved gene-regulation mechanism in all eukaryotic cells,
where small RNAs including small interfering RNA (siRNA), small hairpin RNA (shRNA),
and micro-RNA (miRNA, miR) interact with message RNAs (mRNAs) in a sequence-specif‐
ic manner and cause the cleavage or translational blockage of a gene [1, 2]. Because of its
specificity and efficiency, it has been widely utilized as a routine tool for gene functional
studies in biology laboratories worldwide. In addition, since RNAi blockage is very specific
and at the transcriptional level, RNAi-based gene therapy (RNAi therapy) is thought to hold
a great potential for treating many diseases, especially viral infections and genetic disorders.
Synthesized siRNA is thus regarded as a specialized drug for gene therapies. So far, promis‐
ing results have been obtained with RNAi therapy in various diseases and many are being
tested in clinical trials, including viral infections, cancers, and genetic or inflammatory dis‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
orders [3-7]. As cancers and other emerging diseases such as dementia and super-bug infec‐
tions become major public health issues, RNAi therapy can offer a new solution and has the
additional ability to overcome drug resistances.
Beside the fundamental gene-silencing and gene-regulating roles of RNAi, which will also
regulate the gene functions of immune cells and thus the immune responses, RNAi pathway
itself has an additional function and involvement in inducing adaptive immunity. This func‐
tion has not been well-studied, and the mechanism is not clear. Its relationship with the im‐
mune system in terms of antigen reactivation and antigen presentation is still a new area to
be investigated. Indeed, in plants and primitive species, RNAi is a part of the defense sys‐
tem against viral infections. However, in mammals, RNAi seems not directly involved in the
immune system, probably due to the development of an advanced and sophisticated im‐
mune system. This chapter summarizes the evidence of RNAi-induced immunity against tu‐
mors and provides some updated possible explanations for the findings. The possible link
between miRNA and its degraded products with the immune system has been also dis‐
cussed. Exploring the relationship between RNAi and the immune system may lead to new
discoveries in RNAi biology and approaches for more effective cancer immunotherapy or
treatment for viral and intracellular pathogen infections.
2. The discovery of RNAi-induced adaptive immunity against tumors
In 2009, we reported a discovery about RNAi-induced immunity [7]. We investigated two
shRNAs encoded by lentiviral vectors on their ability to suppress tumor cell growth and
stimulate antitumor immunity in vivo. One shRNA targeted the downstream site of a domi‐
nant cytotoxic T lymphocyte (CTL) epitope of the oncogene E7 of human papillomavirus
(HPV) type 16 (termed downstream shRNA), while another shRNA targeted the upstream
site of this epitope (termed upstream shRNA). Both shRNAs were equally effective at silenc‐
ing E7 gene expression (in mRNA and protein levels) and led to the inhibition of tumor cells
growth in vitro and in vivo [7]. In spite of this, TC1 tumor cells (expressing HPV E6 and E7)
treated with downstream shRNA stimulated an immune response against E7 in C57BL6
mice and resulted in elimination of tumor growth in vivo, whereas cells treated with the up‐
stream shRNA did not. When untreated TC1 tumor cells were injected to the same mice
(challenging tumors), the group of downstream shRNA exhibited a total inhibition of chal‐
lenging tumor growth, whereas no inhibition was observed in the upstream shRNA group.
This ability of downstream shRNA was absent in Rag-/- mice (lack of T- and B-cells), suggest‐
ing adaptive immune response or T-cell response was required. To prove that the immune
response was antigen-specific, we carried out a same animal experiment by immunizing
C57BL/6 mice with TC-1 cells treated with these shRNAs but challenged with another tumor
cell line C2, which has the E7 expression and H-2b genetic background as C57BL/6 mice.
Again, we observed that only mice immunized with downstream shRNA treated cells had a
loss of tumor formation, indicating tumor clearance was specific to E7. Our data indicate
that a more effective treatment can be developed for cervical cancer by combining RNAi
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treatment with immunotherapy. Our results also reveal that RNAi may be widely used as
an antitumor immunity stimulator or enhancer (Fig 1).
Figure 1. Schematic diagram shows RNAi targeting site and 5' mRNA fragment. It is known that in cervical cancer
HPV E7 and mouse lymphoma EG7/OVA (ovalbumin) models, the shRNA targets the downstream site of the CTL
epitope that produce the 5' fragment of mRNA. This makes immature proteins and further induces an immune re‐
sponse.
To prove the applicability of immune response to general tumor antigens, we tested a model
antigen ovalbumin (OVA) expressed in EG7 cells that are a mouse thymoma cell line with
C57BL6 genetic background. We chose the major CTL epitope of OVA, SIINFEKL, as the tar‐
get site and designed two upstream shRNAs OVA-1 and -2 and a downstream shRNA
OVA-3. The shRNA-treated EG7 cells were used to immunize the mice, which were subse‐
quently challenged with untreated EG7 cells. We observed that only mice inoculated with
OVA-3-shRNA treated cells had significantly reduced tumor formation but not with OVA-1
and -2 shRNAs.
3. Confirmation of mRNA fragments and truncated proteins in treated cells
To determine if the RNAi-induced immune response was actually from degraded products




outside the targeting sites of upstream shRNA (E6-1) and downstream shRNA (E7-1, Fig
2A). If an inside fragment was present while the outside fragment was absent, it would indi‐
cate that the mRNA had been cleaved by shRNA at the target site. The cells were treated
with E6-1 and E7-1 shRNAs and incubated for 2–4 days before real-time RT-PCR was car‐
ried out. As expected, the shortest PCR fragment, R3, was observed in all samples (Fig 2B).
The full-length R1 PCR fragment was only observed in untreated TC1 cells or cells infected
with the lentiviral vector control (PLL, Fig 2B). In cells treated with both E7-1 and E6-1, R1
was not found, indicating that shRNA-mediated cleavage was occurring. Of most interest
was the R2 fragment which was found in all samples except cells treated with E6-1. These
results suggest that R2 or R3 short fragments of E6-1 and E7-1 existed in the cells, at least
temporarily at the time we isolated RNA. These short-form mRNAs may act as templates for
short-form proteins (truncated proteins) and trigger antigen presentation to CD8+ T-cells
and a CTL immune response to E7.
Apart from our data, a previous study reported that degradation of the 3' mRNA fragment
resulting from siRNA-mediated cleavage was blocked for some mRNAs, leaving an mRNA
fragment that could act as a template for cDNA synthesis. They suggested that this could
give rise to false negative results and that this phenomenon may be avoided by the careful
design of RT-qPCR primers for each individual siRNA experiment [8]. This report further
confirms that mRNA fragments from RNAi do sometimes exist in the cells. In addition, it
was noticed by researchers that un-degraded fragments of an siRNA-targeted mRNA may
cause false positive effects of microarray analysis [9]. To avoid this, they developed a qRT-
PCR protocol, which allowed for the determination of the optimal time point for mRNA
analyses, indicating mRNA fragments after RNAi can be present in cell for a certain time.
What is the functional role of these mRNA fragments after RNAi? Our data demonstrated
that they can be involved in translational machinery and produce truncated proteins. To ex‐
perimentally prove this, we utilized the OVA-expressing EG7 cell model again. The cells
were treated with downstream and upstream shRNAs and further treated with the protease
inhibitor MG132 to reduce protein degradation before immunoblotting was performed. The
blots were probed with an antibody against the N terminus of OVA protein. The predicted
size of a truncated protein produced by the cleavage of OVA-2 shRNA was 14.7 kDa. We
observed a protein band about 15-kDa in cells treated with the OVA-2 shRNA but not in un‐
treated and OVA-1 or OVA-3 shRNA treated cells. It proves that truncated proteins can be
produced in cells by the translation of mRNA fragment cleaved by shRNA. The predicted
truncated product by shRNA-OVA3 was not observed due to cross-reacting proteins on the
blot [7].
Our recent data (unpublished) showed that the cleaved 5’ and 3’ fragments of human papil‐
lomavirus type 16 (HPV-16) E6/7 mRNA after shRNA treatment were unevenly degraded.
The 5’ mRNA fragment was more abundant and displayed a greater stability than the corre‐
sponding 3’ fragment in the treated cells. Further analysis revealed that the 5’ fragment was
polysome-associated, indicating its active translation, and this was further confirmed by us‐
ing tagged E7 protein to show that C-terminally truncated proteins were produced in treat‐
ed cells (Singhania et al. submitted).
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inhibitor MG132 to reduce protein degradation before immunoblotting was performed. The
blots were probed with an antibody against the N terminus of OVA protein. The predicted
size of a truncated protein produced by the cleavage of OVA-2 shRNA was 14.7 kDa. We
observed a protein band about 15-kDa in cells treated with the OVA-2 shRNA but not in un‐
treated and OVA-1 or OVA-3 shRNA treated cells. It proves that truncated proteins can be
produced in cells by the translation of mRNA fragment cleaved by shRNA. The predicted
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blot [7].
Our recent data (unpublished) showed that the cleaved 5’ and 3’ fragments of human papil‐
lomavirus type 16 (HPV-16) E6/7 mRNA after shRNA treatment were unevenly degraded.
The 5’ mRNA fragment was more abundant and displayed a greater stability than the corre‐
sponding 3’ fragment in the treated cells. Further analysis revealed that the 5’ fragment was
polysome-associated, indicating its active translation, and this was further confirmed by us‐
ing tagged E7 protein to show that C-terminally truncated proteins were produced in treat‐
ed cells (Singhania et al. submitted).
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Figure 2. The shRNA targeting sites and primer design for HPV E6/E7 mRNA (Adapted from Gu et al 2009). (A) The
shRNA and primer sites on E6/E7 mRNA. (B) The PCR products on an agarose gel. Notes: TC1, the untreated cell con‐
trol. PLL, lentiviral vector control. *: indicates the site of CTL epitope. F: forward primer, R: reverse primer.
4. Possible models for explaining RNAi-induced immunity
It is well established that miRNAs play an important role in regulating innate and adaptive
immune responses as a part of their gene-regulating roles. Evidence has accumulated that
miRNAs are involved in the adaptive immune responses by regulating T-cells, B-cells, and
antigen-presenting cells (APCs). For example, miR-214 was reported to target phosphatase
and tensin homolog (PTEN) and increase proliferation and the activation of T-cells [10],
while miR-150, -155, and let-7 have been shown to be involved in the development of T-cells
into memory cells [11]. In addition, miR-184 was shown to inhibit nuclear factor of activated
T-cells-1 (NFAT-1) in the activation of CD4 T-cell in the early stage of adaptive immune re‐
sponses [12] and miR-181-a could promote CD4 and CD8 double positive T-cell develop‐
ment [13]. For B-cells, miR-155 is required for their normal function such as production of
isotype-switched, high-affinity antibodies and for memory responses [14]. It has also been
demonstrated that miR-155 is induced by B-cell receptor (BCR) [15]. However, overexpres‐
sion of miR-155 can immortalize B-cells and lead to transformation, for instance, EBV was
shown to have induced miR-155 expression and transformed B-cells [16, 17]. In addition,
miR-150 is important in B-cell development [18] and so is miR-17 [19, 20].
For dendritic cells (DCs), a recent review summarized the need of miRNAs in their lineage




plasmacytoid DCs and conventional DCs [21]. Liu et al. (2010) used software to predict and
then conducted experiments to confirm that three members of the miR-148 family,
miR-148a, miR-148b, and miR-152 are negative regulators of the innate immune response
and antigen-presenting capacity of DCs. They showed that miR-148/152 expression was up‐
regulated in DCs on maturation and activation induced by TLR3, TLR4, and TLR9 agonists.
These miRNAs in turn inhibited the production of cytokines including IL-12, IL-6, TNF-al‐
pha, and IFN-beta and upregulation of MHC class II expression and DC-initiated antigen-
specific T-cell proliferation by targeting Calcium/calmodulin-dependent protein kinase II
alpha (CaMKIIα) [22]. In addition, miR-150 and miR-223 has been shown to play an impor‐
tant regulatory role in Langerhans cells (LCs) by cross-presenting a soluble antigen to anti‐
gen-specific CD8(+) T-cells [23, 24]. Beside APCs such as DC and LC, miRNA is shown to be
directly involved in antigen presentation. For example, Bartoszewski et al. (2011) demon‐
strated that the mRNA of human endoplasmic reticulum (ER) antigen peptide transporter 1
(TAP1) is a direct target of miR-346. They showed that the 3'-UTR (un-translational region)
of TAP1 contains a 6-mer seeding region for miR-346 and the ER stress-associated reduction
of TAP1 mRNA and protein levels could be reversed by inhibitory miRNA of miR-346 [25].
As TAP plays an important role in MHC class I-associated antigen presentation, their data
provide an insight for miRNA-regulating MHC class-I-associated antigen presentation dur‐
ing ER stress.
The above-highlighted results clearly indicate miRNA’s regulatory role in many aspects of
adaptive immunity. However, is it possible that miRNA also takes part in host immunity
through mRNA fragments produced after RNAi just like shRNA described in section 2 and
3? Normally, miRNAs target the 3' UTR and lead to the translation block or degradation of
the targeted mRNAs. So when they degrade mRNAs, it is supposed to produce long 5'
mRNA fragments and may also produce truncated proteins. If this is true, the translated de‐
fective proteins could be treated as truncated protein and be processed by proteasome. If
there is a CTL epitope in the defective structure, it could be coupled with the MHC class I
molecule and presented to T-cells by DCs through antigen cross-presentation, as described
above with shRNA. This could be a link between RNAi pathway and antigen presentation
or adaptive immune response.
In the shRNA case discussed above, the target should be at the downstream of a CTL epit‐
ope to induce immunity. When miRNAs target 3' UTR, a site certainly at the downstream
site of any possible CTL epitopes, it is assumed to have the ability to produce truncated pro‐
teins and so to induce immune responses. Therefore, an important question for miRNA biol‐
ogy is whether miRNAs can routinely induce immune responses by degrading mRNA at 3'
UTR and generating 5' mRNA fragments or truncated proteins that contain CTL epitopes?
So far, there is no answer for this question. Another critical question is: what is the differ‐
ence between blocking and degrading mRNA by miRNAs at 3' UTR? Does this relate to an‐
tigen presentation of different proteins?
Because it has been shown that miRNA can act as siRNA and shRNA can be produced in
the same pathway as miRNA [26], it is important and interesting to investigate if miRNA
can induce the same immune response as shRNA. The systems of HPV 16 E7/TC1 and
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OVA/EG7 can be used as good models to investigate this. As miRNAs are routinely transcri‐
bed and involved in interacting with mRNA, this mechanism can be considered as a routine
way in cells to generate CTL containing truncated proteins. However, because most mRNAs
in cells are for self-proteins, their CTL epitopes will not be presented to T-cells. This leaves
the question of whether this is a mechanism just for cells that express viral genes (such as
HPV E7 in TC1 and C2 as above) or for cells expressing foreign genes/antigens (such as
OVA in EG7)? The next question is: can this be generalized to any tumor antigens including
self-antigens? This is an interesting subject to investigate and will facilitate our understand‐
ing of how RNAi pathways interact with and are involved in adaptive immune responses
(antigen presentation) to utilize them for cancer immunotherapy.
Although some miRNA are highly conserved between lower animals and higher animals,
mammals have far more miRNAs compared to nonmammals. This suggests that during evo‐
lution, as gene regulation became so complex and important in higher animals, miRNA or
RNAi pathway gradually specialized into gene regulation. At the same time, as the adaptive
immune system became well developed and highly specialized, these two systems got sepa‐
rated, but as described above, they still have some links. Future investigations leading to in‐
sight into these links will provide answers to the above questions.
5. Conclusion
In summary, RNAi-induced immunity opens a new perspective in which to explore the rela‐
tionship between RNAi pathways and the immune system, especially its involvement in an‐
tigen presentation in the adaptive immune response. For RNAi biology, it will provide an
insight into the understanding of function roles of RNAi (including miRNA and siRNA) in
host defense. In the field of gene therapy for cancers, RNAi can be used as an approach to
silence oncogenes as well as a strategy to enhance immunity against cancer antigens (at least
viral infection related cancers) and further explored as a novel cancer immunotherapy. Fi‐
nally, for intracellar pathogens, it can be used as a strategy for developing new vaccine
through RNAi reactivating their antigens to the immune system.
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Abstract
RNA interference (RNAi), mediated by short interfering RNA (siRNA), vector-derived
short hairpin RNA (shRNA) and microRNA (miRNA), brings about revolutionary fea‐
tures to basic biomedical research and clinical application. New drugs based on RNAi
have been developed for therapeutic applications. The family of RNAi molecules are effi‐
cient agents to modulate mammalian immune system, and many studies reported that
these molecules could manipulate immune defence, surveillance and homeostasis. Both
perfect match of siRNA/shRNA and non-perfect match of miRNA could be beneficial for
designing RNAi-based drugs for treatment of tumour and viral infection. This chapter
provides a view to control or utilize the immune regulation of various small RNAs that
should help researchers to understand the successful clinical application of RNAi.
Keywords: RNA interference, siRNA, miRNA, immunopharmacology, immunotherapy
1. Introduction
RNA interference (RNAi) is a conserved mechanism against exogenous nucleic acid and
transposon transcripts in plants and lower animals. No matter of transfected siRNA, vector-
delivered shRNA or pre-miRNA (transcribed mainly by Pol II) , Dicer (DCLs) and Agronaute
(AGO) family proteins efficiently process small RNAs into short double-stranded
RNA(dsRNA). Further, dsRNAs assemble into the RNAi-induced silencing (protein) complex
(RISC) to guide and cleave target mRNA, promote mRNA degradation or inhibit mRNA
translation. The great potential of RNAi is to specifically repress the expression of disease-
causing genes while avoiding undesirable effects.
It is well accepted that siRNA can be recognized by endosomal pathways, Toll-like receptor 3
(TLR3), TLR7, TLR8 and cytoplasmic pathways, retinoic acid-inducible gene I (RIG-I),
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
melanoma differentiation-associated antigen 5 (MDA-5) and RNA-activated protein kinase
(PKR), resulting in immune activation [1–5]. For example, it has been demonstrated that siRNA
can cause activation of at least three key transcription factors, including NF-κB, interferon
regulatory factor 3 (IRF-3) and IRF-7, and stimulate interferon (IFN) secretion. This activates
T cells and dendritic cells (DCs) in the spleen in a TLR7-dependent manner [2,6]. Furthermore,
5′-triphosphate siRNA was demonstrated to activate RIG-I signal pathway, and then natural
killer (NK) cells and DCs were activated [7,8]. In most circumstances, immune system
stimulation is regarded as an unwanted side effect; therefore, siRNA-induced immune
response should be controlled by using proper delivery system or chemical modification,
although immune stimulation has been proved to be essential in cancer treatment and viral
infection.
miRNAs are critical in regulating the development, differentiation, function and destiny of
immune cells, including DCs, granulocytes, monocytes/macrophages, NK and natural killer
T (NKT) cells and B and T lymphocytes. miRNAs influence both innate and adaptive immune
defence and individual miRNAs may contribute their implications to various immune-
mediated diseases. Furthermore, pattern recognition receptors (PRRs), kinases, adaptors,
inflammatory factors and IFN could all be targets of miRNAs. Extra effort has been made to
develop miRNA-based oligos or vectors for anti-infection purpose by manipulating corre‐
sponding immune genes.
In addition to silencing of targeted genes in a sequence-specific manner, components of RNAi
technology often induce immune response. Several strategies were reported to design RNAi
molecules with gene silencing and immune regulatory properties. Bifunctional molecules rely
on the activation of PRRs such as TLR7/8, TLR9 or RIG-I, or just rely on down-regulation of
target gene. This chapter summarizes RNAi-involved immune responses in the past 10 years
and discusses the anticipated therapeutic application.
2. Chemically synthesized siRNA and vector-derived shRNA
2.1. RNAi drugs based on targeting specific immune genes
Immune disorders, both autoimmune diseases and immune defective or deficiency, are always
caused by high-level overexpression of certain immune genes. A variety of immune inhibitory
genes can serve as targets for RNAi-mediated gene silencing. Targeting specific immune
suppressor could re-balance immune network and subsets.
Elevated activity  of  signal  transducer  and activator  of  transcription 3  (STAT3)  has been
found in several kinds of human tumours. Use of RNAi to knockdown STAT3 expression
and inhibit its activation would reduce the tumour cell growth such as pancreatic cancer,
colorectal cancer, melanoma and hepatocarcinoma cells. STAT 3 knockdown could induce
bystanders immune response in vitro and in vivo, where CD4+, CD8+ and NKT cells were
activated as well as the secretion of interferon-γ (IFN-γ), interleukin-12 (IL-12) and tumour
necrosis factor alpha (TNF-α) was increased significantly [9–11]. siRNA-STAT3, synthetical‐
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ly linked to CpG (agonist of TLR9), was demonstrated to silence immune suppressor STAT3
gene in TLR9+ myeloid cells  and B cells.  This  strategy of  therapy leads to activation of
various  populations  of  immune  cells,  including  DCs  and  macrophages,  that  ultimately
induce potent anti-tumour immune responses [10,12].  Hossain DM et al.  recently report‐
ed that CpG-siRNA-STAT3 conjugates could efficiently silence the target expression, and
abrogate inhibition of CD8+ T cells in patients who received myeloid-derived suppressor
cells (MDSCs) [13]. Researchers proved that immune-stimulation-inducing CpG(A)-STAT3-
siRNA was non-toxic for normal human leukocytes [14]. In another experiment, Luo Z et
al. [15] generated a nano-vaccine loaded with poly I:C (a TLR3 agonist) and STAT3 siRNA.
Researchers found this kind of siRNA could promote the maturation of DC and reverse
immunosuppression in the tumour micro-environment; the function of inhibitory cells in
tumour-draining lymph nodes were inhibited; thus, anti-tumour immune responses were
potently  induced;  and  the  survival  were  prolonged  [15].  Therefore,  STAT3  siRNAs  are
expected to be a promising immunomodulatory drugs to improve the treatment efficacy of
cancer vaccines by abrogating tumour immunosuppression.
Suppressor of cytokine signalling 1 (SOCS1) is a negative regulator of antigen-presenting cell
(APC)-based immune response. Silencing of SOCS1 gene expression by RNAi is essential for
DCs to enhance Ag-specific anti-tumour immunity [16]. SOCS1-silenced bone marrow
dendritic cells (BMDCs) were more potent in suppressing tumour growth [17]. When SOCS1
was silenced, maturation of DCs (i.e. expressions of CD80, CD40, CD86 and major histocom‐
patibility complex II [MHC II]) was significantly accelerated. As a result, SOCS1 inhibition up-
regulated the expression of IFN-γ and IL-12, and decreased IL-4 secretions, which induced
Th1 cell differentiation and thereby affected the development of Th2 cell. The combined
nanoparticle (NP) delivery, which can render both tumour antigen and siRNA-SOCS1 to
BMDCs, simultaneously could enhance immunotherapeutic effects in BMDC-based cancer
therapy [16,18]. DC-targeted delivery of SOCS1 siRNA has been shown to enhance antifungal
immunity in response to Candida albicans in vitro and HIV-specific cytotoxic T cell in mice [16,
19]. This evidence suggests the use of SOCS1–siRNA, as a potent adjuvant to improve immune
response.
A20 is  usually regarded as an attractive target  for  siRNA-mediated gene knockdown in
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cytes (CTLs), T helper cells that produced IL-6 and TNF-α were also activated by siA20-
DC.  A20  silencing  in  DCs  can  enhance  the  immune  response  against  self-tumour-
associated  antigens  [20,21].  Furthermore,  A20-silenced  DCs  were  proved  to  overcome
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has enabled DCs to gain a potent ability to activate CTLs and Th cells, and inhibit Treg,
providing a novel strategy to promote a tumour immune response.
Programmed  death  ligand  (PD-L)  is  another  exciting  target  on  the  surface  of  antigen-
presenting cells (APCs); PD-L/PD-1 interactions were related to functional impairment and
exhaustion of tumour antigen-specific CD8+ T cells. Although PD-L antibody exerts a potent
anti-tumour effect,  previous reports [24] have demonstrated that PD-L1-siRNA-PEI were
preferentially and avidly engulfed by tumour-associated CD11c+PD-L1+ tolerogenic DCs at
ovarian  cancer  locations.  This  kind  of  nanoparticle  uptake  stimulated  multiple  TLRs
signalling,  mainly  via  myeloid  differentiation  factor  88  (MyD88).  Then,  regulatory  DCs
activated into potent stimulators of CTLs that led to significant anti-tumour immunity in
mouse models of ovarian cancer. Most importantly, PD-L knockdown DCs showed superior
potential  to  expand minor histocompatibility antigen (MiHA)-specific  CD8+ effector  and
memory T cells from leukaemia patients early after donor lymphocyte infusion and later
during relapse. Combined PD-L1 and PD-L2 knockdown resulted in improved prolifera‐
tion of CD4+ T cells and enhanced cytokine production [25,26]. In addition, another report
demonstrated the improved effector functions of tumour-specific CD4+ and CD8+ human
T cells by siRNA-mediated silencing of PD-1 ligands, PD-L1 or PD-L2 [27]. These results
suggest  that  siRNA-mediated  knockdown of  PD-L  is  a  fascinating  strategy  to  inhibit  a
negative regulatory mechanism of tumour-specific T cells.
siRNA-CD40, delivered by a novel delivery system with a poly-dA extension at the 5'-end of
the siRNA sense strand that was stably incorporated into 1,3-β-glucan, was captured and
incorporated into DCs through its receptor, Dectin [28]. This strategy could induce antigen-
specific Tregs, resulting in the permanent acceptance of mouse cardiac allografts. CD40
knockdown significantly suppressed Th1-type cytokines and induced Th2-type cytokines in
rats with myocarditis. Knockdown of CD40 in experimental autoimmune myocarditis (EAM)
rats promoted Foxp3 gene expression and increased Treg cells [29].
In addition, when silencing of CD40 or CD80/CD86, DCs exhibited suppressed allostimulatory
activity with impaired APC function. In the well-established collagen-induced arthritis (CIA)
model, multigene-silenced DCs were capable of delaying onset of joint pathology. Therapeutic
effects of gene-silenced DCs were mediated by the inhibition of collagen II-specific Ab
production and suppression of T cell recall responses. Also, multigene-silenced DCs inhibited
Th1 and Th17 response, demonstrating IFN-γ and IL-2 inhibition [30]. Thus, inhibition of
specific co-stimulatory molecules of DCs reveals a promising approach of suppressing
immune responses in autoimmunity. These findings highlight the potential of immunomo‐
dulation of siRNA-CD40, and have important implications for developing RNAi-based clinical
therapy in the transplantation field.
It is well documented that tumours could secrete immunosuppressive molecules, including
the cytokines transforming growth factor β (TGF-β) and IL-10. This creates an immunosup‐
pressive environment, which inhibits anti-tumour immunity. The suppression of Treg cell,
induced by targeting TGF-β1 using siRNA, can enhance the efficacy of a DC vaccine against
a poorly immunogenic tumour in mice [31]. Nanoparticle-delivered TGF-β siRNA enhances
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vaccination against advanced melanoma, and the tumour micro-environment was modified
with increased levels of tumour-infiltrating CD8+ T cells and decreased level of regulatory T
cells [32]. siRNA targeting IL-10 receptor α (siIL-10RA) initiated the significant antigen-specific
CD8+ T cell immune responses. Concordantly, the combination of knockdown of IL-10RA and
TGF-βR in DCs showed significant up-regulation of MHC I, enhancing co-stimulatory
molecules CD40, CD80, CD86 and chemokine CCR7 after lipopolysaccharide (LPS) stimula‐
tion. It induced the strongest anti-tumour effects in the TC-1 P0 (a cervical cancer model
expressing the human papillomavirus [HPV]-16 E7 antigen) tumour model, and even in the
immune-resistant TC-1 (P3) ones [33]. These data revealed that siRNA co-targeting immuno‐
suppressive molecules enhance the potency of DC-based immunotherapeutics.
High-mobility group box 1 (HMGB1) is highly expressed in tumour cells and increased levels
of HMGB1 in tumour cells are usually associated with a greater tumour angiogenesis, growth,
invasion and metastasis. Knockdown of tumour cell-derived HMGB1 by shRNA did not affect
tumour cell growth, while naturally acquired long-lasting tumour-specific IFN-γ- or TNF-α-
producing CD8+ T cell responses were induced, and ability to induce Treg was attenuated.
This led to naturally acquired CD8 T cell-dependent anti-tumour immunity [34].
Foxp3, a master gene that controls the development and function of Treg cells, contributes to
pathogenesis of several different tumours. Owing to the intracellular localization of Foxp3,
RNAi technology was employed to knockdown its activation to suppress Treg activity in vivo.
Tsai et al. [35] performed a study targeting silencing Foxp3 gene expression by shRNAs-
mediated RNAi using a lentivirus vector in a murine model of leukaemia. The lentiviral vector
was used to overcome poor transfection efficiency. Lentiviral-mediated Foxp3 RNAi showed
suppressive effects on tumour growth and prolonged the survival of tumour-transplanted
mice. Furthermore, Foxp3 knockdown mediated by siRNA increased the ratio of Th1/Th2 in
chronic hepatitis B patients; transcription factors T-bet and GATA-3 may be partly involved
in this progress [36]. This strategy provides a novel view about how to decrease the number
of Treg cells and weaken its function.
Selective knockdown of CCL22 and CCL17 expression in monocyte-derived DC (MoDC) by
siRNA decreased the ratios of CD4+ to CD8+ as well as lowered the frequency of Tregs
recruited by MoDC. Furthermore, intratumoural injection of MoDC, which was transfected
with siCCL22 and siCCL17, significantly reduced the number of Tregs while inducing CD8+
T cells infiltration in thymic nude mice with human tumour xenografts [37]. Using siRNA to
selectively silence chemokines may lead to a new strategy for DC vaccine development to
improve cancer biotherapy.
High expression of indoleamine 2, 3-dioxygenase (IDO) in DCs leads to the suppression of T
cell responses. Gene silencing by siRNA or shRNA of IDO in DC would up-regulate IL-12 and
IFN-γ and inhibit apoptosis in CD8 and CD4 T cells as well as Treg cells; IL-10 expression was
significantly down-regulated, thus finally restraining tumour growth. DC-based vaccine with
IDO silence was demonstrated to augment and enhance the anti-tumour response against
breast cancer, melanoma, bladder tumour and liver cancer [38–40]. A novel APC-targeted
siRNA delivery system using mannosed liposomes (Man-lipo) with encapsulated siRNA-IDO
Perspectives on RNA Interference in Immunopharmacology and Immunotherapy
http://dx.doi.org/10.5772/61575
289
(Man-lipo-siIDO) was demonstrated to preferentially silence IDO in APCs and efficiently
enhance anti-tumour immune response [41–43].
It was reported that natural killer group 2, member D (NKG2D) activation was involved in
NK cell and CD8+ cell-mediated liver inflammation, and blockade of NKG2D by silencing of
multiple NKG2D ligands on hepatocytes was considered efficient in liver disease intervention.
Huang et al. [44] constructed a plasmid containing the three shRNA sequences (shRae1-
shMult1-shH60). After hydrodynamic injection into mice, they found that the expression of all
three NKG2D ligands on hepatocytes was down-regulated, and fulminant hepatitis mediated
through NKG2D in NK cell was attenuated. Furthermore, simultaneous knockdown of
multiple human NKG2D ligands (MHC class I polypeptide-related sequence B/A(MICA/B),
UL16-binding protein 2 [ULBP2] and ULBP3) also significantly attenuated NK cell cytolysis.
Simultaneous knockdown of multiple ligands of NKG2D is a potential therapeutic approach
to treat liver diseases induced by NKG2D-expressing NK cells and CD8+ cells. Furthermore,
inhibition of human leukocyte antigen-G (HLA-G) by siRNA boosted NK cell lytic function
[45,46].
Among several molecules involved in immune response, the choice of targets should be
carefully reviewed and validated comprehensively according to the emerging knowledge
about their function.
2.2. Advantage of non-target immune effect of siRNA/shRNA drugs
siRNA/shRNA have the potential to recruit immune receptors specialized in RNA sensor, such
as TLR3, TLR7/8 [2,3]. 5′-triphosphate siRNA (3p-siRNA) was demonstrated to be detected by
RNA sensors RIG-I. These immunostimulatory siRNA or shRNA can non-specifically induce
innate immune response, the so-called ‘off-target’ effects that have considerable implications
for clinical application to cure cancer and infection disease.
IFN response is a common side effect of siRNAs and siRNAs with GU-rich sequences, which
are very potent in inducing IFN-α response. A newly published report demonstrated that
siRNA could induce IFN-α responses, and then induced the analgesic effects in the spinal cord.
This off-target analgesia is dose- and sequence-dependent while non-GU-rich sequences also
produced off-target analgesia at high doses, where pain relief by a designed siRNA may not
be attributable to target gene knockdown but IFN response [47].
Early in 2004, Karikó et al. [48] demonstrated that siRNAs and shRNAs induce immune
activation by signalling through TLR3 and activate sequence-independent inhibition of gene
expression. Kleinman et al. [4] showed that non-targeted (against non-mammalian genes) and
targeted (against vascular endothelial growth factor [VEGF] or VEGFR1) siRNAs suppressed
choroidal neovascularization (CNV) via cell-surface TLR3 and its adaptor TIR-domain-
containing adaptor-inducing interferon-β (TRIF), leading to the induction of IFN-α and IL-12.
The effect of non-targeted siRNA to suppress dermal neovascularization in mice was as
effective as vascular endothelial growth factor (VEGF) siRNA. This finding showed that two
investigational siRNAs in clinical trials owe their anti-angiogenic effect in mice, which was
not due to target knockdown but due to TLR3 activation. The efficiency of RNAi by siRNA is
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believed to be comparable with anti-VEGF antibodies. Kleinman’s group then concluded that
a 21-nucleotide (nt) non-targeted siRNA suppresses both hemangiogenesis and lymphangio‐
genesis in mouse models of neovascularization, induced by corneal sutures or hindlimb
ischemia, as efficiently as a 21-nt siRNA targeting VEGF-A [1].
Among 15 siRNAs, Khairuddin et al. [49] identified an extremely immunostimulatory siRNAs,
targeting the HPV, which exerted potent anti-tumoural function. This bifunctional siRNA
could reduce growth of established TC-1 tumours in C57BL/6 mice, and its effect was TLR7
dependent, where ablation of TLR7 recruitment via 2′O-methyl modification of the oligo
backbone reduced these anti-tumour effects. Flatekval et al. [40] designed either monofunc‐
tional siRNAs devoid of immunostimulation or bifunctional siRNAs with IDO silencing and
immunostimulatory activities. They showed that bifunctional siRNAs were able to knock‐
down IDO expression and induce cytokine production through either endosomal TLR7/8 or
RIG-I.
In the past 10 years, several studies reported that bifunctional 3p-siRNA (Exp:targeting Bcl2/
TGF-β/Survivin/Glutaminase/IDO) with target silencing and an innate immunity stimulation
via RIG-I activation could confer potent anti-tumour efficacy. This is illustrated for the first
time by the work of Poeck et al. [8], who reported that bifunctional siRNAs, with 5′-triphos‐
phate targeting Bcl2 (3p-siRNA), led to better melanoma tumour reduction than OH-siRNA
or 5′-triphosphate siRNAs containing target mismatches. Poeck and his colleagues revealed
that siRNA with 5′-triphosphate ends could be recognized by RIG-I and activate an innate
immune cells such as DC; then, expression of IFNs was directly induced, leading to apoptosis
in tumour cells. These bifunctional 3p-siRNAs with RIG-I activation and RNAi-mediated Bcl2
silencing could provoke massive apoptosis of tumour cells in lung metastases in vivo. This
was the first report demonstrating that 3p-siRNA represents a single molecule-based approach
in which RIG-I function activates immune cell and gene silencing, leading to a key molecular
event. Researchers subsequently found that 3p-TGFβ1-siRNA combining RIG-I activation with
gene silencing of TGF-β1 induced profound tumour cell apoptosis and revealed potent anti-
tumour efficacy in pancreatic cancer. This kind of 3p-siRNA induces a Th1 cytokine profile,
demonstrating IFN-γ induction and IL-4 inhibition. High level of IFN and CXCL10 recruited
more activated CD8+ T cells to the tumour. Frequency of immunosuppressive CD11b+ Gr-1+
myeloid cells was reduced after 3p-TGFβ1-siRNA treatment [50].
In addition, 3p-siRNA against survivin gene was designed and generated. This finding
demonstrated that 3p-survivin-siRNA inhibited lung cancer cell proliferation and induced a
RIG-I-dependent type-I interferon response [7]. Recently, 5′-triphosphate siRNA combining
glutaminase (GLS) silencing with RIG-I activation was demonstrated to induce more promi‐
nent anti-tumour responses than RIG-I ligand or GLS silencing capability alone. 3p-siRNA-
GLS effectively induced intrinsic proapoptotic signalling, and GLS silence sensitized
malignant cells to apoptosis induced by RIG-I activation. Moreover, cytotoxicity was en‐
hanced, resulting from disturbed glutaminolysis induced by GLS silencing. Finally, RIG-I
activation by 3p-siRNA-GLS blocked autophagic degradation, leading to dysfunction of
mitochondria, whereas GLS silencing severely impaired reactive oxygen species (ROS)
scavenging systems, leading to a vicious circle of ROS-mediated cytotoxicity [51]. Immature
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monocyte-derived DCs had been transfected with siRNA-bearing 5′-triphosphate-activated T
cells [40].
In addition, 3p-siRNA can inhibit hepatitis B virus (HBV), Influenza A Virus and Coxsackie‐
virus, by gene silencing and RIG-I activation. RNAi provides a promising approach for the
specific treatment of HBV infection. Our laboratory has previously demonstrated that 3p-HBx-
siRNA and shRNA-HBx not only directly inhibit HBV replication but also stimulate innate
immunity against HBV, which are both beneficial for the inversion of HBV-induced immune
tolerance [52]. In HBV-positive hepatoma HepG2.2.15 cells, 3p-HBx-siRNA combining RIG-I
activation with HBx gene silencing induce stronger type I IFN response than non-target 3p-
scramble-siRNA, indicating that a potent immunostimulatory effect may partly contribute to
the reversal of immune tolerance through decreasing HBV load; 3p-HBx-siRNA more strongly
inhibited HBV replication and promoted IFN production than HBx-siRNA in primary HBV(+)
hepatocytes, and this effect was mediated by RIG-I activation [52]. This was consistent of the
other two reports [53,54]. Our dually functional vector containing both an immunostimulatory
single-stranded RNA (ssRNA) and an HBx-silencing shRNA could reverse HBV-induced
hepatocyte-intrinsic immune tolerance; TLR7 signalling pathway was attributed to this
progress [55].
Lin et al. [56] designed and tested a 3p-mNP1496-siRNA against influenza virus. They found
that 3p-mNP1496-siRNA could activate the RIG-I-mediated IFN-β pathway and significantly
reduce virus load and virus-induced pathogenesis. The inhibition effect was in an siRNA- and
RIG-I-dependent manner, demonstrating siRNA playing dual antiviral roles: viral gene-
specific silencing and non-gene-specific RIG-I activation. This strategy was also proved to elicit
potent antiviral effects in coxsackievirus myocarditis, and virus-specific 3p-siRNA was
superior to both conventional virus-specific siRNA and non-target 3p-siRNA in inhibiting viral
replication and subsequent cytotoxicity [57].
In the attempt to inhibit the expression of woodchuck hepatitis virus (WHV), Meng et al. [58]
found that innate immune responses could be enhanced by RNAi through the PKR- and TLR-
dependent signalling pathways in primary hepatocytes. The immunostimulation by RNAi
may contribute to the antiviral activity of siRNAs in vivo.
Furthermore, siRNA can also synergistically enhance DNA-mediated type III IFN (a newly
characterized antiviral interferon) response in non-immune or primary immune cells. This
enhancement is mediated by crosstalk signalling pathway between RIG-I (RNA sensor) and
IFI16 (DNA sensor) [59].
Designing with GU sequences, addition of triphosphate motifs to siRNA, co-treatment with
CpG oligos are believed to activate innate immunity when siRNA was applied in vitro and in
vivo. Accumulating evidence suggests these bifunctional siRNAs could activate NK cells and
CD8+ T cells in different models. Thus, specific clinical applications of RNAi can benefit from
a concurrent activation of the immune system.
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3. miRNA
It has been well discussed how miRNAs regulate signalling pathways, and the dynamics of
the immune response, tolerance and homeostasis. Here we summarize and explore updated
achievements of special miRNAs in immunopharmacology.
3.1. miRNAs as intrinsic targets in antiviral immunity
In addition to the conventional innate and adaptive immune responses, even in the earlier
phase after virus invasion, the host cell suppresses viral replication by evolving the profile of
special and constitutively expressed genes. These cell-intrinsic antiviral approaches based on
host restriction factors may be no less important than in considerations of conventional
immunity. At the same time, viruses also gain some countermeasures or adapt the unique
phenotype of their hosts substantially to survive. Moreover, miRNAs may also be involved in
the inextricably intertwined relationship between viruses and their hosts.
In 2005, a liver-specific miRNA, miR122, which is involved in cholesterol and lipid metabolism
[60], was illustrated to be necessary for hepatitis C virus (HCV) accumulation in cultured liver
cells [61]. Researchers found that miR122 directly binds to two close sites in the 5′ non-coding
region of the HCV genome and promote HCV translation [62–64]. This miRNA kept conserved
among all HCV subtypes [65,66]. Even in non-hepatic cell, miR122 could boost HCV replication
[67]. Moreover, miR122 was further proved to be significantly reduced after IFN-β treatment,
and miR122 mimics neutralized IFN-induced anti-HCV effect [68]. Epidemiological and
genomic researches further suggested that the level of miR122 in individuals with HCV might
be an ’indicator’ for IFN therapy, and only those patients with high levels of miR122 responded
well to IFN therapy [69,70]. Therefore, miR122 antagonist would also be called as IFN ’sensi‐
tizer‘ in HCV immune treatment.
Santaris Pharma designed and synthesized an LNA-based miR122 inhibitor, named Miravirs‐
en (or SPC3649), to eradicate HCV. The product was first evaluated in preclinical studies in
mice [71], cynomolgus monkeys [72], green African monkeys and chimpanzees [73,74]. Here
the key concern is that whether miR122 inhibitor can effectively lower the level of free miR122
and inhibit HCV replication without disturbing normal cholesterol and lipid metabolism or
without any potential chemical toxicity. Interestingly, although there was a reduction of
cholesterol levels in plasma by nearly 40%, Miravirsen caused a dose-dependent reduction of
miR122 and maintained ∼5-week-long half-life in the liver of monkeys and chimpanzees [73,
74]. Moreover, in the high-dose treatment group, Miravirsen decreased HCV subtype 1a or 1b
more than 2 orders of magnitude compared to control group. In all animal species, Miravirsen
was reported to be safe, without serious adverse effects or dose-related toxicities in rats,
monkeys and human [75,76].
In May 2008, Miravirsen was put into human clinical trials as the first miRNA-based drug
(https://clinicaltrials.gov/ct2/show/NCT00979927). There was a significant, dose-dependent
reduction and sustained decrease of HCV viremia after drug administration in human subjects,
and several patients became even HCV undetectable during the study. At the same time, only
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infrequent and moderately adverse effects were caused to some volunteers and did not
influence the trial process [77]. Because miR122 is only liver enriched in physiological condi‐
tions and there is high amount of miR122 in adult human liver, it may be an ideal target to
design highly specific anti-HCV drugs with good resistance to HCV infected person, particu‐
larly to those who have no tolerance to traditional treatments. In the following years, miR196
[78], let-7b family [79] and some other miRNAs were then proved to influence HCV life cycle,
providing new target to restrict hepatitis C infection and avoid chronic infection.
Besides HCV, some other kind of viruses also encode miRNAs or regulate the miRNAs
expression in host cells to disturb the expression of many immune-associated genes directly
and/or indirectly, so that they can be critical regulators for viral life cycle. For example, in
HEK293T cell, prototype foamy virus I (PFV-1) encodes Tas protein to counteract cell-encoded
miR32, which could inhibit PFV-1 gene expression and accumulation [80]. Kaposi’s sarcoma-
associated herpesvirus (KSHV)-induced miR132 could silence p300 expression, which is
critical for the transcription initialization of many antiviral genes, to help themselves maintain
long-time latency [81]. The hematopoietic-cell-specific miR142-3p potently restricts the
replication of eastern equine encephalitis virus in myeloid-lineage cells by binding to the 3′-
untranslated region (UTR) of viral genome [82]. Even Drosha, the enzyme that processes
miRNA biogenesis and maturation, was an independent factor for limiting RNA virus
replication along with canonical type I IFN system in particular cell type [83]. Above of all, it
is much likely that miRNA mimics (for viral inhibitory miRNAs) or antagonists (for viral
beneficial miRNAs) can be effective antiviral strategies as intrinsic immune drugs.
3.2. miRNA regulation antimicrobial and anti-tumour immunity
3.2.1. miRNA in antimicrobial innate immunity
Of the known PRRs, TLRs and RIG-like receptors (RLRs) have been well studied in mediating
antimicrobial and inflammatory responses during infections, which may be targets of patho‐
gens or host-encoded miRNAs.
The first PRR targeting miRNA let7i was reported in 2007 [84], which targeted TLR4 mRNA
in a MyD88/NF-κB-dependent way during Cryptosporidium parvum infection, controlling the
production of inflammatory factors. During Bacillus Calmette-Guérin (BCG) infection, miR124
exerts  its  function  by  targeting  multiple  components  of  the  TLR  signalling  pathway,
including TLR6, MyD88, TNF receptor-associated factor 6 (TRAF6) and TNF-α in mouse
lung cell [85]. After HCV infection, miR373 was induced and negatively regulated the type
I  IFN signalling pathway by suppressing Janus kinase 1(JAK1) and IRF9 in hepatocytes
[86].  Experimental  evaluation using miR124 inhibitors  or  miR373 knockout up-regulated
BCG-induced pro-inflammatory factors  or  type I  IFN and so as  to inhibit  BCG or HCV
more efficiently.  Besides using host  miRNAs,  human cytomegalovirus (HCMV) targeted
TLR2 by encoding its own miRNA, miR-UL112-3p, and reduced the expression of IL-1β,
IL-6 and IL-8 upon stimulation with a TLR2 agonist [87]. Neutralizing this miRNA might
recover normal cytokines production.
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Besides immune inhibitory miRNAs, dengue virus (DENV)-induced miR30e* up-regulated
IFN-β and the downstream IFN-stimulated genes (ISGs) by suppressing IkBα and promoting
NF-κB-dependent IFN production [88]. The transfection of miR30e* would increase the
expression of 2′-5′-oligoadenylate synthetase 1(OAS-1), myxovirus resistance A (MxA) and
interferon-induced transmembrane protein (IFITM). In 2014, miR526 [89] was proved to
enhance RIG-I-induced viral replication by suppression of the expression of cylindromatosis
(CYLD), which suppresses RIG-I K-63-linked polyubiquitin. Moreover, Enterovirus 71(EV71)
inhibited miR526 transcription in an IRF-dependent way and so as to attenuate virus-triggered
type I interferon production. These studies suggested that recruitment or increase of miR30e*
or miR526 would stimulate type I IFN expression and inhibit virus more quickly.
3.2.2. ’Immune miRs‘ as immunopharmaceutic agents
With the general knowledge of immunologically relevant miRNAs established in the past 10
years, many miRNAs have been intensively investigated using gain- and loss-of-function
methods, showing how this novel class of small non-coding RNA participates in mammalian
immunity. And individual immune miRNA might contribute its implications to various
immune-mediated diseases.
The role of miR125b in immune signalling may be paradoxical. After stimulation with LPS,
miR125b was down-regulated and TNF-α, one of miR125b targets, was overexpressed in
RAW264.7, which is essential for antimicrobial activity. Moreover, during M. tuberculosis
infection, the overexpression of miR125a significantly attenuated the antimicrobial effects in
macrophages through targeting UV radiation resistance–associated gene (UVRAG) [90].
Nevertheless, in diffuse large B cell lymphoma (DLBCL), miR125a and miR125b directly target
a negative NF-κB regulator tumour necrosis factor alpha-induced protein 3(TNFAIP3) and
present a positive self-regulatory property to maintain prolonged NF-κB activity. Taken
together, whether overexpression or inhibition of miR125b in an anti-infection therapeutic
study depends on concrete circumstances.
miR146a also acts as a negative regulator in immune sensing. Both in mouse and human,
miR146a was always exploited by virus to attenuate innate and adaptive antiviral immunity
mainly in DC [91], lymphocyte [92] and hepatocytes by inhibiting interleukin-1 receptor-
associated kinase 1(IRAK1), TRAF6 [93], son of sevenless homolog 1 (SOS1) [94] and STAT1
[95]. Silencing of miR146a via the delivery of sponge or antagomiR could restore the expression
of inflammatory factors, augment type I IFN production and promote clearance of vesicular
stomatitis virus (VSV) [96], dengue virus [97], enterovirus 71 (EV71) [94,98] and HBV [95].
Because miR146a was also abnormally expressed in hepatocellular carcinoma (HCC) and
exerted negative anti-tumour effects by up-regulation of immunoinhibitory cytokines such as
TGF-β, IL-17, VEGF, miR146a may also be a novel immunotherapeutic target for HCC [99].
Unlike miR146a, miR155 always promotes immune signal transduction, enhances immune
function or speeds lymphocyte proliferation. Mice lacking miR155 have impaired CTL cell
responses to infections with lymphocytic choriomeningitis virus and the intracellular bacteria
Listeria monocytogenes because of insufficient activation of Akt pathway after TCR cross-linking
[100]. miR155 knockout mice died soon after Erdman (a variant from severe acute respiratory
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syndrome [SARS]) infection and held higher level of colony-forming units (CFU) in lungs than
wild-type mice [101]. During HIV infection, miR155 inhibited the HIV-activating effects of
tripartite motif-containing protein 32 (TRIM32), and therefore, it might promote a return to
latency in CD4+ reservoir cells [102]. In addition, in NK cells, miR155 might regulate T cell
immunoglobulin-3 (Tim-3)/T-bet/STAT-5-signalling axis, and following cytokine expression
that balanced antiviral response and immune injury during chronic HCV infection [103]. A
remarkably ectopic up-expression of miR155 can be observed by delivering hepatotropic
adeno-associated virus 8 (AAV8) vectors to the liver of mice, and then high level of miR155-
enhanced GAP’s protective capacity against parasite [104]. These studies imply miR155 as an
immune-augmenting adjuvant in improving the antigenicity of vaccination.
miR223 was already proved to be of importance in myeloid progenitor cells proliferation and
responsiveness to pathogenic stimuli in neutrophils by targeting myocyte-specific enhancer
factor 2C (MEF2C), acting as a fine-tune regulator both in normal granulocytes generation and
in preventing aberrant expansion and over-activated inflammatory responses. In recent years,
miR223 was involved in inflammasome response by targeting NLR family pyrin domain
containing 3 (NLRP3) in human [105]. Moreover, Epstein–Barr virus (EBV) encoded a mimic
of hsa-miR223, called miR-BART15, targeting the same site within the NLRP3 3’-UTR to repress
inflammasome activation. Furthermore, this miRNA can be secreted from EBV-infected B cells
into exosomes to rheostat NLRP3 inflammasome activity in non-infected cells [106]. miR223
sponge would balance the amount of NLRP3 and ‘absorb’ EBV-miR-BART15 in macrophages
and DCs.
It is noteworthy that two groups of miRNAs, which shaped NK-mediated cytotoxicity, have
potent value for developing antiviral and anti-tumour biodrugs. First, NKG2D–NKG2D-L
interaction plays a predominant role in ‘NK cell–abnormal cell’ recognition. MICB/A, ULBPs
targeting miRNAs, are not only encoded by human genome as stress regulators but also
synthesized by some virus (e.g. HCMV-miR-UL112 [107], EBV-miRBART2 [108], KSHV-miR-
K12-7 [108] and BK virus (BKV)-miR-B1-3p, JC virus (JCV)-miR-J1-3p[109]), to escape from NK
cell killing. Meanwhile, viral infected cell and tumour cell always express low MICA/B because
of up-regulated MICB/MICA, targeting miRNAs such as miR20a, 93, 103, 106b [110] to
maintain a compromised micro-environment. Furthermore, non-classical human leukocyte
antigen G (HLA-G) is known as an inhibitory ligand, which suppresses the cytotoxic activity
of T and NK cells. Studies demonstrated a strong post-transcriptional gene regulation of the
HLA-G by miR148a, miR148b and miR152, and lower expression of these miRNAs in renal
carcinoma [111] and placental choriocarcinoma cells [112]. Stable manipulation of these
activating and inhibitory miRNAs may enhance NK and LAK cell-mediated cytotoxicity
against infected and tumour cells. Therefore, it could be concluded that modulating the
expression or inhibition of specific miRNAs could boost immune response during viral
infections or against cancers.
3.3. miRNA in maintaining immune homeostasis
Because several miRNAs participate in immune cell development and differentiation,
abnormal expression of miRNA may cause a disturbance of homeostasis by changing the ratio
of helper and regulatory cell subsets, or perturb the functionality and survival of effect-
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memory cells that lead to lymphoproliferative disease. Utilization of miRNA interference
techniques may recover regular immune balance.
3.3.1. miR17-92, miR146a and miR155 in Systemic Lupus Erythematosus (SLE)
In 2007, a unique mouse strain, ‘sanroque’, presented a pattern of lupus pathology, revealing
the core role of T follicular helper (Tfh) in systemic autoimmunity [113]. miR17-92 was found
to regulate Tfh cell differentiation, which is essential for maintenance of the germinal centre
formation and sustained antibody responses. Overexpression of this miRNA in T cells would
enhance Tfh cell proliferation and survive an autoantibody production [112]. Similarly, miR155
increased IL-21-mediated STAT3 signalling in T cell [114], which might accelerate Tfh differ‐
entiation and maturation as well. Moreover, miR155 deficiency ameliorates autoimmune
inflammation of SLE by targeting s1pr1 in mice [115]. Therefore, miR17-92 and miR155 might
be a new target to restrain aggressive autoimmune response in SLE.
3.3.2. miR29 and miR146 in type 1 diabetes
Type 1 diabetes (T1D) is a chronic autoimmune disease that results from the persisting
destruction of pancreatic β-cells by autoreactive CD8+ T cell and Th1 cytokines. Dicer 1 deletion
in β-cell would disrupt normal β-cell development and survival, lead to impairment of insulin
secretion and diabetes development [116], apparently suggesting that miRNAs network is
necessary for normal glycometabolism. Recently, endogenous miR29b released from pancre‐
atic β-cells within exosomes stimulated TNF-α secretion in spleen cells isolated from diabetes-
prone non-obese diabetic (NOD) mice. Delivery of miR29b to mice activated myeloid cell and
pDCs to induce IFN-α, TNF-α and IL-6 production [117]. Abnormal expression of miR146 is
associated with high serum titers of glutamic acid decarboxylase antibody in T1D patients,
indicating the involvement of miR146 in the sustained immune imbalance during T1D
progress [118]. These findings raised the possibility of developing a new clue for T1D immu‐
notherapy using miRNA-based agents.
3.3.3. miR146a and miR155 in rheumatoid arthritis
The role of miR146a in controlling Treg-mediated decrease of Th1 responses has been dem‐
onstrated [119]. In contrast, miR155 promoted Th1 and Th17 differentiation and cell formation
and lowered T cell sensitivity to IFN-γ-driven proliferation by targeting C-MAF and IFNγRα
[120]. Therefore, imbalance of miR146a and miR155 may be an epigenetic phenotype for
autoimmune response. In rheumatoid arthritis (RA), decreased expression of miR146a
contributes to an abnormal Treg phenotype and allows Th1/Th17 skewing while low level of
miR155 failed to support effective Th2 immunity [121]. Systemic administration of miR146a
has potential therapeutic intervention for preventing bone destruction by inhibited Th1 and
Th17 cells, as well as IL-1β, IL-6 and TNF-α [122].
3.3.4. miR15 and miR326 in multiple sclerosis
Multiple sclerosis (MS) is manifested by chronic and progressive inflammatory demyelination
of the central nervous system and is one of the main causes of regressive neurological diseases.
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Study on MS animal model illustrated that mice with fewer Th17 cells were less susceptible to
experimental autoimmune encephalomyelitis (EAE) [123]. Therefore, Th17-targeting biother‐
apeutic approaches may be a promising way to cure multiple sclerosis. Gang Pei’ s laboratory
[124] found that miR326 promoted Th17 differentiation by targeting Ets-1 (a negative regulator
of Th17 polarization) and antagonizing miR326 by sponge vector that resulted in fewer Th17
cells and Th17 cytokines and remitting EAE symptom. Inversely, increased miR155 in primary
human microglia up-regulated pro-inflammatory cytokine secretion and co-stimulatory
surface marker expression suggested that miR155 inhibition in myeloid cell might be useful
to suppress allogeneic T cell responses [125]. In conclusion, reverse pathological expressed
miRNAs and re-balance dysregulated immune genes are of consideration to treat multiple
sclerosis.
4. Conclusion
RNAi technology holds promise for treating various human diseases. It is becoming apparent
that clinical outcome of cancer immunotherapy and infectious diseases can be improved by
targeted strategies to abrogate tumour-induced immunosuppression. Anti-tumour strategies
using siRNA/shRNA/miRNA for both silencing of oncogenes and recruiting of innate recep‐
tors were designed. The present researches highlighted the potential therapeutic applications
of this new generation of siRNAs in immunotherapy.
Additionally, but importantly, siRNA/shRNA or miRNA drugs with regard to pharmacody‐
namic difficulties and unwanted side effects are even more complicated compared to low
molecular weight drugs and hard to be delivered into immune cells. This requires more
extensive procedure than any other traditional drugs. Considering clinical challenges for RNA-
based nucleic acid drugs, including barriers and RNases, the advanced tissue-directed delivery
systems with safety, high efficiency and specificity, long-term function and controllability are
required. Although the exploration of such tiny regulators causally bring pharmacists a
considerable effort to draw up individualized and tailor-made strategies, we believe that
immunoregulation triggered by siRNA/shRNA/miRNA can be used to regulate the host
immunity against cancers or viruses. The development of multifunctional RNAi molecules
will greatly contribute to the future arsenal of tools to combat not only microbial pathogens
but also hard-to-treat cancer.
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Abstract
Remarkable progress in the experimental and clinical applications of cell-based therapies
has identified stem cells and their derived products as potential candidates for regenera‐
tive therapies for many disorders. The use of autologous stem cells as source for regener‐
ative therapeutic products is strongly limited by their low availability. Therefore, the
future applications of in vitro pharmed therapeutic cell products will most likely occur in
an allogeneic manner. However, the high variability of the human leukocyte antigen
(HLA) represents a major obstacle to the application of off-the-shelf products. We have
developed a strategy to decrease the immunogenicity of in vitro generated cell products
by silencing HLA expression using RNAi. HLA expression was permanently silenced in
CD34+ hematopoietic stem and progenitor cells and induced the pluripotent stem cells to
generate HLA-universal cells sources, which were then used for the differentiation of low
immunogenic cell products. In this chapter, we will provide an overview about an RNAi-
based strategy to reduce the immunogenicity of cell-based therapies, and in particular in
the generation of HLA-universal platelets and tissues.
Keywords: HLA, immunogenicity, transplant rejection, blood pharming
1. Introduction
The high variability of the human leukocyte antigen (HLA) constitutes a major hurdle in
allogeneic transplantation and to the application of off-the-shelf cell products in regenerative
medicine. Recently, remarkable progresses in the field of stem cell biology, cell pharming, and
tissue engineering have made feasible the differentiation of cells and tissues that might serve
as a bridging strategy or even an alternative to the very scarce donated tissues and organs.
However, HLA incompatibility may pose a threat to the applicability of such in vitro generated
cell products by increasing the risk of immune rejection after the transplantation.[1] To
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
overcome this major hurdle in the fields of transplantation, cell and tissue engineering, we
have developed an RNA interference (RNAi)-based approach to reduce the immunogenicity
of cells and tissues, allowing their application in an universal manner. A lentiviral vector
encoding for specific short hairpins RNA (shRNA), targeting HLA transcripts were used to
achieve a permanent silencing of HLA expression. As HLA residual expression is crucial to
prevent the natural killer (NK) cell activity, RNAi appears as a superior tool in comparison to
gene editing technologies that cause a complete gene deletion such as the transcription
activator-like effector nuclease (TALEN) or clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 systems.[2-4] By decreasing the immunogenicity of cells and tissues,
the need for immunosuppressive regimens might be reduced after HLA-mismatched trans‐
plantation. Furthermore, as HLA plays a pivotal role in the recognition of virus-infected cells
and cancer cells, the combination of conditional promoter systems allows the re-expression of
HLA and constitutes a safety mechanism. The generation of low immunogenic cells and tissues
would bring enormous benefits to the patients and open novel horizons in the field of
transplantation and regenerative medicine.
2. The HLA system
Evolution conferred highly refined mechanisms to all animals from sponges to mammals to
distinguish self from non-self, and thereby allowing an immune response against potential
pathogens. In humans, a tight interplay between adaptive and innate immune systems allows
their defense against virtually all pathogens and cancer cells.[5, 6] Nevertheless, those
sophisticated surveillance mechanisms pose a major hurdle to allogeneic transplantation. The
alloimmune responses are mainly based on the recognition of mismatched major histocom‐
patibility complex (MHC) antigens by antibodies and T-cells. In humans, the MHC is known
as HLA and it comprises a group of linked genes. MHC class I and II regulate the immune
response through the presentation of peptides to T-cells. Allogeneic MHC in the graft’s
antigen-presenting cells (APCs) is recognized after transplantation through a direct pathway.
Afterwards, own patient APCs process and present the allogeneic antigens to T-cells by an
indirect alloantigen recognition pathway.[7, 8] HLA loci are encoded on the short arm of
human chromosome 6. Based on their structure, HLA molecules are grouped into class I and
class II (Figure 1). HLA class I classical genes comprise the A, B, and C loci, and are expressed
in the majority of cells. HLA class II genes include DR, DQ, and DP and are constitutively
expressed only in professional APCs.[9] The non-self recognition mediated by the engagement
of the T-cell receptor with the donor HLA is the basis for the allogeneic immune response.
2.1. HLA incompatibility increases the risk of rejection
Despite the progresses in the field of transplantation, graft rejection remains the major concern
regarding the application of off-the-shelf products. HLA comprises the most polymorphic loci
of the entire human genome. The probability to find a complete HLA-matched donor for a
specific patient is very low and, therefore, in most of the cases, patients will be treated with
partially HLA-mismatched tissues and organs. In addition, even in fully HLA donor/recipient
RNA Interference312
overcome this major hurdle in the fields of transplantation, cell and tissue engineering, we
have developed an RNA interference (RNAi)-based approach to reduce the immunogenicity
of cells and tissues, allowing their application in an universal manner. A lentiviral vector
encoding for specific short hairpins RNA (shRNA), targeting HLA transcripts were used to
achieve a permanent silencing of HLA expression. As HLA residual expression is crucial to
prevent the natural killer (NK) cell activity, RNAi appears as a superior tool in comparison to
gene editing technologies that cause a complete gene deletion such as the transcription
activator-like effector nuclease (TALEN) or clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 systems.[2-4] By decreasing the immunogenicity of cells and tissues,
the need for immunosuppressive regimens might be reduced after HLA-mismatched trans‐
plantation. Furthermore, as HLA plays a pivotal role in the recognition of virus-infected cells
and cancer cells, the combination of conditional promoter systems allows the re-expression of
HLA and constitutes a safety mechanism. The generation of low immunogenic cells and tissues
would bring enormous benefits to the patients and open novel horizons in the field of
transplantation and regenerative medicine.
2. The HLA system
Evolution conferred highly refined mechanisms to all animals from sponges to mammals to
distinguish self from non-self, and thereby allowing an immune response against potential
pathogens. In humans, a tight interplay between adaptive and innate immune systems allows
their defense against virtually all pathogens and cancer cells.[5, 6] Nevertheless, those
sophisticated surveillance mechanisms pose a major hurdle to allogeneic transplantation. The
alloimmune responses are mainly based on the recognition of mismatched major histocom‐
patibility complex (MHC) antigens by antibodies and T-cells. In humans, the MHC is known
as HLA and it comprises a group of linked genes. MHC class I and II regulate the immune
response through the presentation of peptides to T-cells. Allogeneic MHC in the graft’s
antigen-presenting cells (APCs) is recognized after transplantation through a direct pathway.
Afterwards, own patient APCs process and present the allogeneic antigens to T-cells by an
indirect alloantigen recognition pathway.[7, 8] HLA loci are encoded on the short arm of
human chromosome 6. Based on their structure, HLA molecules are grouped into class I and
class II (Figure 1). HLA class I classical genes comprise the A, B, and C loci, and are expressed
in the majority of cells. HLA class II genes include DR, DQ, and DP and are constitutively
expressed only in professional APCs.[9] The non-self recognition mediated by the engagement
of the T-cell receptor with the donor HLA is the basis for the allogeneic immune response.
2.1. HLA incompatibility increases the risk of rejection
Despite the progresses in the field of transplantation, graft rejection remains the major concern
regarding the application of off-the-shelf products. HLA comprises the most polymorphic loci
of the entire human genome. The probability to find a complete HLA-matched donor for a
specific patient is very low and, therefore, in most of the cases, patients will be treated with
partially HLA-mismatched tissues and organs. In addition, even in fully HLA donor/recipient
RNA Interference312
pairs, disparities at the minor histocompatibility antigens (mHAg) derived from other
polymorphic proteins and presented at the HLA complexes are capable of triggering antigen-
specific immune responses that cause graft rejection. Improved use of post-transplant immu‐
nosuppression to prevent acute and chronic rejection allowed allogeneic transplantation as a
widespread, successful therapy.[10-13] However, graft rejection remains a major concern in
the field of transplantation. The registry of the International Society for Heart and Lung
Transplantation (ISHLT) reported that within the first year after lung transplantation, up to
55% patients need to be treated for acute rejection and only 50% are alive after five years.[14]
Also, the number of HLA mismatches between a donor/recipient pair is associated with
stronger immunosuppressive regimens. In particular, the number of HLA-DR mismatches and
the number of HLA-A and -B mismatches as well as rejection treatment showed significant
associations with the dose of maintenance steroids. Although immunosuppression allows the
acceptance of the allogeneic graft, it has severe side effects that may contribute to death even
with a functioning graft.[15] The occurrence of post-transplant complications related to the
immunosuppressive therapy such as cancer, opportunistic infection, toxicity, and hip fractures
have indicated the necessity to develop alternative strategies to allow the therapeutical use of
off-the-shelf HLA and mHAg-mismatched cell-based products.[16] Furthermore, due to the
shortage of organs and tissues for transplantation, there is a high demand regarding the
development of in vitro pharmed cell products, and engineered tissues or organs. Progresses
in the fields of stem cell biology and tissue engineering have demonstrated the feasibility to
generate in vitro potential alternative cell-based products that might serve as an alternative or
overcome the need for using donated tissues. Nevertheless, the future use of such products
will occur in an allogeneic manner, and therefore, it will be required that those products will
be able to escape an allogeneic immune response.
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Figure 1. Structure  representation of  (A) HLA class  I  (HLA‐B) and  (B) HLA class  II  (HLA‐DQ) molecules. The 
structures were designed using the software http://www.mh‐hannover.de/institute/transfusion/histocheck/. 
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2.2. RNAi-mediated HLA targeting as a strategy to decrease the cell immunogenicity
Rejection of allogeneic grafts is based on the recognition of the HLA complexes by the specific
pre-formed complement-binding anti-HLA antibodies or by the engagement of the T-cell
receptor, which leads to T-cell activation and the initiation of the immune response.[17, 18]
RNA interference is an invaluable technique in cell biology and regenerative strategies to
silence the target gene expression. Our studies have focused on the downregulation of HLA
class I and class II expression on the graft cells. So far, several strategies have been developed
to induce the acceptance of the allogeneic graft. Similar to the immunosuppression, those
strategies involve the modulation of immune responses and aim the induction of tolerance to
the graft. In our studies, we genetically modify the graft to silence its HLA expression to
prevent the recognition of the allogeneic graft as non-self by the recipient’s immune system.
In this approach, we do not induce tolerance toward the allogeneic graft, but we generate a
condition of immunological blindness in which the recipient’s immune system is not able to
recognize the allogeneic cells (due to the missing HLA) but is fully capable of defending the
patient against common clinical conditions associated with the use of immunosuppressive
drugs such as opportunistic infections and leukemia. To prevent the recognition of the grafted
cells as off the shelf, we have downregulated the expression of HLA class I and class II antigens
using RNAi. We have constructed lentiviral vectors encoding for short-hairpin RNA sequences
targeting β2-microglobulin (shβ2m) or the alpha-chain of HLA-DR (shDRA) to silence the
expression of HLA class I and class II antigens, respectively. Our studies demonstrated the
feasibility to stably downregulate HLA class I and II expression in several cell lines (e.g., B-
LCL, MonoMac-6, HeLa) as well as in primary cells (e.g., endothelial cells, CD34+ progenitor,
induced pluripotent stem cells). Cell transduction for the delivery of shRNAs targeting specific
HLA transcripts resulted in a decrease by up to 90% of β2m or HLA-DRA transcript levels and
HLA class I expression. In vitro assays have shown that HLA class I-silenced cells were
protected against the antibody-mediated complement-dependent cytotoxicity. Furthermore,
in T-cell cytotoxicity assays, significantly lower cell lysis rates were observed when HLA-
silenced cells were used as targets in comparison to fully HLA-expressing cells. In addition,
HLA-silenced cells demonstrated to induce significantly lower T-cell proliferation, pro-
inflammatory cytokine secretion, and degranulation. The residual HLA class I expression
showed to be sufficient to prevent NK cell cytotoxicity. Altogether, HLA-silenced cells showed
a protective effect against the humoral and cellular allogeneic immune response.[2, 3, 19]
2.3. MHC-silenced cells survive after fully HLA-incompatible transplantation
Despite the widespread use of immunosuppressive regimens to prevent graft rejection, their
therapeutic window is very narrow. Immunosuppressive drugs frequently cause adverse
effects including thrombocytopenia, leukopenia, hypercholesterolemia, stomatitis, nephro‐
toxicity, and diarrhea, and they lead to an increased risk for infections and cancer.[20, 21]
Silencing HLA expression using RNAi may represent an alternative to immunosuppression;
hence it has the potential to offer many benefits for the patients. In addition, silencing HLA
expression may allow the future application of HLA-mismatched off-the-shelf products in a
universal manner independently of the genetic background of the donor and recipient. In an
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in T-cell cytotoxicity assays, significantly lower cell lysis rates were observed when HLA-
silenced cells were used as targets in comparison to fully HLA-expressing cells. In addition,
HLA-silenced cells demonstrated to induce significantly lower T-cell proliferation, pro-
inflammatory cytokine secretion, and degranulation. The residual HLA class I expression
showed to be sufficient to prevent NK cell cytotoxicity. Altogether, HLA-silenced cells showed
a protective effect against the humoral and cellular allogeneic immune response.[2, 3, 19]
2.3. MHC-silenced cells survive after fully HLA-incompatible transplantation
Despite the widespread use of immunosuppressive regimens to prevent graft rejection, their
therapeutic window is very narrow. Immunosuppressive drugs frequently cause adverse
effects including thrombocytopenia, leukopenia, hypercholesterolemia, stomatitis, nephro‐
toxicity, and diarrhea, and they lead to an increased risk for infections and cancer.[20, 21]
Silencing HLA expression using RNAi may represent an alternative to immunosuppression;
hence it has the potential to offer many benefits for the patients. In addition, silencing HLA
expression may allow the future application of HLA-mismatched off-the-shelf products in a
universal manner independently of the genetic background of the donor and recipient. In an
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allogeneic transplantation rat model, we have confirmed the improved capacity of MHC-
silenced cells to survive in allogeneic environment upon transplantation and even in the
absence of immunosuppression. A lentiviral vector encoding for a shRNA sequence targeting
rat MHC class I (RT1-A) and the sequence for firefly luciferase as a reporter gene was used to
silence MHC class I Lewis rat-derived fibroblasts. In contrast to nonmodified fibroblasts, MHC
class I-silenced fibroblasts were able to survive after subcutaneous transplantation in a
complete MHC-mismatched setting. MHC class I-silenced fibroblasts were able to engraft and
were detectable during the entire monitoring period (8 weeks). Nonmodified cells were
rejected in all animals.[22] This study showed the superior performance of MHC-silenced cells
after MHC-incompatible transplantation.
2.4. Generation of HLA-silenced platelets
Since the 1950s, blood transfusion therapy has become routine clinical practice; however, the
concept of blood pharming – ex vivo production of mature blood cells – is quite new. In
humans, platelet production is sustained by a well-regulated process known as thrombopoi‐
esis. In the bone marrow, CD34+ progenitor cells differentiate into polyploid megakaryocytes
(the precursor of platelets). Megakaryocytes lack the expression of CD34, but express several
glycoproteins essential for the platelet function.[23, 24] In general, platelet numbers in blood
range from 150 x 109 to 400 x 109 per liter, and an estimated 1 x 1011 platelets are produced each
day in the adult human. Thrombocytopenia and severe thrombocytopenia characterized as
platelet counts less than 50 x 109 and 10 x 109 per liter, respectively, increase the risk of
spontaneous bleeding and represent a threat for the patient’s life.25 Platelet transfusion has
been widely used to prevent and treat life-threatening thrombocytopenia; however, prepara‐
tion of a unit of concentrated platelets for transfusion requires at least 4–6 units of whole blood,
thereby significantly increasing the risk of blood-borne infections and adverse immunologic
reactions. Furthermore, platelet transfusion refractoriness – lack of adequate post-transfusion
platelet counts – remains a major complication often observed in patients receiving multiple
transfusions. This condition is frequently caused by the development of antibodies specific to
HLA. Currently, platelet transfusion relies on volunteer blood donation; however, the demand
for blood products in particular of platelets often exceeds their availability.[25]
The potential of multipotent progenitor and stem cells in regenerative medicine has been
recognized.[26, 27] Platelet transfusion refractoriness due to the presence of anti-HLA
antibodies constitutes a life-threatening risk for many patients suffering from hematological
disorders, and hence require multiple platelet transfusions. Thus, it would be highly desirable
to produce HLA-deficient platelets to facilitate the management of severe alloimmunized
thrombocytopenic patients. In our studies, we have combined the concept of blood pharming
with RNAi as a strategy to downregulate HLA gene expression. The ultimate goal of this
approach is the large-scale production of platelets in vitro that may be used as an alternative
to the conventional donated blood platelets. In addition, we aim for the production of
genetically modified platelets with the capacity to survive even under platelet transfusion
refractoriness.
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In our studies, CD34+ hematopoietic progenitor cells and induced pluripotent stem cells
(iPSCs) were used to produce HLA-silenced platelets in vitro. CD34+ cells or iPSCs were
transduced with a lentiviral vector encoding for the shRNA sequence targeting β2m which
induces HLA class I silencing. We have demonstrated the feasibility to generate HLA-universal
CD34+ cells and iPSCs which might be used for the differentiation of HLA-silenced cell-
products. In our studies, we have differentiated HLA-silenced megakaryocytes and platelets
from both cell sources. In our previous studies, we have demonstrated the possibility to
generate HLA-silenced platelets with comparable function to blood-derived platelets. How‐
ever, in contrast to blood-derived platelets, in vitro generated HLA-silenced platelets were able
to escape antibody-mediated complement-dependent cytotoxicity as well as cellular-depend‐
ent cytotoxicity. Also, in a platelet transfusion refractoriness mouse model, HLA-silenced
platelets showed the capacity to survive and were even detectable 10 days after transfusion.
[28] The limited availability of CD34+ cells derived from G-CSF mobilized donors is a major
obstacle to the large-scale production of in vitro pharmed platelets. The breakthrough Nobel
Prize–winning research by Yamanaka and colleagues to induce pluripotency in somatic cells
has reshaped the field of stem cell research. Human iPSCs can be used for studying embryo‐
genesis, disease modeling, drug testing, and regenerative medicine.[29] In contrast to CD34+
cells, iPSCs represent an unlimited cell source for the in vitro production of a variety of cell-
based products including platelets. Therefore, we have recently established an efficient
protocol for the differentiation of megakaryocytes and platelets from iPSCs (Figure 2). First,
we have generated an HLA-universal iPSC line. Then, the lentiviral vector containing the
shRNA targeting β2-microglobulin was used to silence HLA expression on iPSCs. A significant
and durable reduction of HLA expression was observed even after passaging. Nevertheless,
the HLA-silenced iPSC line showed comparable expression of pluripotency markers (such as
SSEA-4 and Tra-1-60) as the original HLA class I-expressing iPSC line (Figure 3). The data















Figure 2. Schematic representation of the differentiation of HLA-silenced platelets from iPSCs. A lentiviral vector en‐
coding for an HLA-specific shRNA is used to transduce the iPSCs. Afterward, HLA-silenced iPSCs will be differentiat‐
ed using a cytokine cocktail containing thrombopoietin (TPO) until the release of platelets.
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Figure 3. Generation of an HLA-universal iPSC line. (A) iPSCs were adapted to monolayer culture conditions and 
transduced with a lentiviral vector encoding for a nonspecific shRNA (shNS) or a β2-microglobulin-specific 
shRNA to silence the expression of HLA class I; (B) expression of SSEA4 and Tra-1-60 on nonmodified and 
shβ2m-expressing iPSCs; (C) expression of HLA class I of a HLA-silenced shNS-expressing iPSC lines. Cells were 
stained with an HLA class I antibody (W6/32) and the expression of HLA was measured by flow cytometry after 
different number of passages. Mean fluorescence intensities (MFI) detected on HLA-silenced iPSCs were 
















































Figure 3. Generation f an HLA-universal iPSC li e. ( ) iPSCs were adapted t  monolayer culture c ditions and
transduced with a lentiviral vector encoding for a nonspecific shRNA (shNS) or a β2-microglobulin-specific shRNA to
silence the expression of HLA class I; (B) expression of SSEA4 and Tra-1-60 on nonmodified and shβ2m-expressing
iPSCs; (C) expression of HLA class I of a HLA-silenced shNS-expressing iPSC lines. Cells were stained with an HLA
class I antibody (W6/32) and the expression of HLA was measured by flow cytometry after different number of passag‐
es. Mean fluorescence intensities (MFI) detected on HLA-silenced iPSCs were normalized to the MFI measured on
shNS-expressing iPSCs at the same passage.
In addition, the future application of iPSCs will occur most likely in an allogeneic manner to
facilitate their availability during the time of need and standardization of the protocols. Hence,
the use of HLA-silenced iPSCs may facilitate the application of HLA-mismatched iPSC-
derived cell products. For megakaryocyte differentiation, HLA-silenced iPSCs were cultured
in monolayer in the presence of vascular endothelial growth factor (VEGF) and BMP-4 for
mesoderm induction and afterward in the presence of TPO. During ontogeny, definitive
hematopoietic cells are generated de novo from a specialized subset of endothelium, known
as hemogenic endothelium. Endothelial-to-hematopoietic transition during embryogenesis
provides the first long-term hematopoietic stem and progenitor cells in the embryo.[30] In our
differentiation cultures of iPSCs into megakaryocytes, structures resembling the hemogenic
endothelium were observed (Figure 4). In suspension, megakaryocytes could be detected by
an increase in DNA content higher than 4n and the expression of typical megakaryocytic
markers such as CD41 and CD42a. In addition, the megakaryocytes showed the capability to
build pro-platelets. Moreover, the shRNA-mediated silencing effect was maintained during
the entire differentiation. Importantly, iPSC-derived megakaryocytes and pro-platelets
showed a significant reduction of β2-microglobulin and HLA class I antigens in comparison
to those differentiated from iPSC expressing a nonspecific shRNA (control) (Figure 5).
Differentiation rates of iPSC into megakaryocytes by up to 82% were observed (Figure 6).
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Figure 4. Formation of hemogenic‐like endothelium during the differentiation of iPSCs into megakaryocytes. The 
photos display an island of hemogenic‐like endothelium at a magnification of (A) 10x; (B) 20x. 
Figure 4. Formation of hemogenic-like endothelium during the differentiation of iPSCs into megakaryocytes. The pho‐



























Figure 5. Differentiation of HLA-universal megakaryocytes from HLA-silenced iPSC. (A) The histogram represents the
flow cytometric analysis of HLA-silenced iPSC-derived megakaryocytes after staining with propidium iodide; (B) light
microscopic and (C) fluorescence microscopic analysis of an iPSC-derived megakaryocyte after staining with 4′,6-Dia‐
midin-2-phenylindol (DAPI, blue); (D) light microscopic analysis of pro-platelets indicated with white arrows; (E) real-
time PCR analysis of β2-microglobulin levels in megakaryocytes derived from iPSCs transduced with a lentiviral
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Figure 6. Phenotypic analysis of HLA-universal megakaryocytes derived from iPSCs. The expression of the megakar‐
yocyte markers CD41 and CD42a was measured by flow cytometry in the cells harvested from the iPSC differentiation
cultures at different time points. The gates in the dotplots indicate megakaryocytes characterized by the double expres‐
sion of CD41 and CD42a.
The complement-dependent cytotoxic (CDC) crossmatch is an informative assay that detects
alloantibodies in pre- and post-transplant patients, which may guide the most appropriate
clinical management of transplant patients.[31] The capacity of in vitro generated HLA-
silenced megakaryocytes and platelets to escape antibody-mediated complement-dependent
cytotoxicity was evaluated in CDC tests. HLA-silenced megakaryocytes incubated with
specific HLA antibodies and complement showed comparable cell lyses rates to the megakar‐
yocytes incubated with nonspecific HLA antibodies. In contrast, significantly higher cell lysis
rates were observed when HLA-expressing megakaryocytes were incubated with specific anti-
HLA antibodies (Figure 7). These data suggest that HLA-universal iPSC-derived megakaryo‐
cytes are protected from anti-HLA antibody-mediated complement-dependent cytotoxicity
and have the potential to survive under refractoriness conditions.















Figure 7. HLA-silenced megakaryocytes are protected from antibody-mediated complement-dependent 
cytotoxicity. HLA-expressing (shNS) or HLA-silenced (shβ2m) iPSC-derived megakaryocytes were incubated 
with a nonspecific antibody (NC) or an HLA-specific antibody and complement. Cell lysis was detected by flow 
cytometric analysis upon staining with propidium iodide. The bar graph represents means and standard 
deviations of three independent experiments. Statistical significance was calculated using Student’s t-test (*p< 
0.05, **p< 0.01; ***p< 0.001). 
 
 
2.5. Generation of HLA-silenced tissues 
Due to the high variability of the HLA loci and the shortage of organs and tissues for transplantation, it is very 
difficult to find a complete HLA-matched graft for a given recipient. The number of HLA mismatches between 
the graft and the recipient are associated with a higher risk for graft rejection and even morbidity and mortality 
due to immunosuppression-related side effects. Thus, it would be desirable to engineer the grafts in order to 
decrease their immunogenicity by silencing HLA expression. Worldwide, the demand for organs and tissues for 
transplantation is very high and it is not possible to satisfy all needs. This discrepancy is even accentuated in the 
Middle East and countries in the East such as India and China. According to the World Health Organization 
(WHO), there are over 10 million people in the world who are blind in one or both eyes due to corneal injury or 
disease and up to 45 million people could benefit from corneal transplants. However, according to data from eye 
banks and health agencies, less than 150,000 corneal transplants are done annually worldwide due to the shortage 
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2.5. Generation of HLA-silenced tissues
Due to the high variability of the HLA loci and the shortage of organs and tissues for trans‐
plantation, it is very difficult to find a complete HLA-matched graft for a given recipient. The
number of HLA mismatches between the graft and the recipient are associated with a higher
risk for graft rejection and even morbidity and mortality due to immunosuppression-related
side effects. Thus, it would be desirable to engineer the grafts in order to decrease their
immunogenicity by silencing HLA expre sion. Worldwide, the demand for organs and tissues
for transplantation is very high and it is not possible to satisfy all needs. This discrepancy is
even accentuated in the Middle East and countries in the East such as India and China.
According to the World Health Organization (WHO), there are over 10 million people in the
world who re blind in o e or b th eyes due to corneal injury r disease and up to 45 million
people could benefit from co neal transplants. Ho ever, according to data from eye banks and
health agencies, less than 150,000 corneal transplants are done annu lly w rldwi e d e to the
shortage of human cadaver corneas. Furthermore, during the first five years after penetrating
keratoplasty, rejection is responsible for 28–35% of total corneal graft loss. High risk-corneal
recipients even showed increased rejection rates (30–56%).[32, 33]
The corn  presents a s m le anatomical structure, in which the endothelium is easily
accessible to the shRNA- ncoding viral vector cont ining supern tant (Figure 8). The integrity
of the endothelial cell layer is crucial for the transparency of the cornea and it is the major
target for rejection. Therefore, silencing HLA expression on the corneal endothelium may














Figure 7. HLA-silenced megakaryocytes are protected from antibody-mediated complement-dependent 
cytotoxicity. HLA-expressing (shNS) or HLA-silenced (shβ2m) iPSC-derived megakaryocytes were incubated 
with a nonspecific antibody (NC) or an HLA-specific antibody and complement. Cell lysis was detected by flow 
cytometric analysis upon staining with propidium iodide. The bar graph represents means and standard 
deviations of three independent experiments. Statistical significance was calculated using Student’s t-test (*p< 
0.05, **p< 0.01; ***p< 0.001). 
 
 
2.5. Generation of HLA-silenced tissues 
Due to the high variability of the HLA loci and the shortage of organs and tissues for transplantation, it is very 
difficult to find a complete HLA-matched graft for a given recipient. The number of HLA mismatches between 
the graft and the recipient are associated with a higher risk for graft rejection and even morbidity and mortality 
due to immunosuppression-related side effects. Thus, it would be desirable to engineer the grafts in order to 
decrease their immunogenicity by silencing HLA expression. Worldwide, the demand for organs and tissues for 
transplantation is very high and it is not possible to satisfy all needs. This discrepancy is even accentuated in the 
Middle East and countries in the East such as India and China. According to the World Health Organization 
(WHO), there are over 10 million people in the world who are blind in one or both eyes due to corneal injury or 
disease and up to 45 million people could benefit from corneal transplants. However, according to data from eye 
banks and health agencies, less than 150,000 corneal transplants are done annually worldwide due to the shortage 
























Figure 7. HLA-silenced megakaryocytes are protected from antibody-mediated complement-dependent cytotoxicity.
HLA-expressing (shNS) or HLA-silenced (shβ2m) iPSC-derived megakaryocytes were incubated with a nonspecific
antibody (NC) or an HLA-specific antibody and complement. Cell lysis was detected by flow cytometric analysis upon
staining with propidium iodide. The bar graph represents means and standard deviations of three indepe dent experi‐
ments. Statistical significance was calculated using Student’s t-test (*p < 0.05, **p < 0.01; ***p < 0.001).
2.5. Generation of HLA-silenced tissues
Due to the high variability of the HLA loci and the shortage of organs and tissues for trans‐
plantation, it is very difficult to find a complete HLA-matched graft for a given recipient. The
number of HLA mismatches between the graft and the recipient are associated with a higher
risk for graft rejection and even morbidity and mortality due to immunosuppression-related
side effects. Thus, it would be desirable to engineer the grafts in order to decrease their
immunogenicity by silencing HLA expre sion. Worldwide, the demand for organs and tissues
for transplantation is very high and it is not possible to satisfy all needs. This discrepancy is
even accentuated in the Middle East and countries in the East such as India and China.
According to the World Health Organization (WHO), there are over 10 million people in the
world who re blind in o e or b th eyes due to corneal injury r disease and up to 45 million
people could benefit from co neal transplants. Ho ever, according to data from eye banks and
health agencies, less than 150,000 corneal transplants are done annu lly w rldwi e d e to the
shortage of human cadaver corneas. Furthermore, during the first five years after penetrating
keratoplasty, rejection is responsible for 28–35% of total corneal graft loss. High risk-corneal
recipients even showed increased rejection rates (30–56%).[32, 33]
The corn  presents a s m le anatomical structure, in which the endothelium is easily
accessible to the shRNA- ncoding viral vector cont ining supern tant (Figure 8). The integrity
of the endothelial cell layer is crucial for the transparency of the cornea and it is the major
target for rejection. Therefore, silencing HLA expression on the corneal endothelium may
improve cornea survival in high-risk patients after allogeneic keratoplasty.
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Figure 8. Anatomy of the cornea. Optical coherence tomography of a mouse cornea showing the three main layers.
We have silenced HLA expression in human and mice corneas. The tissue was transduced for
8 h with the lentiviral vector encoding for the MHC-specific shRNAs as described above. We
were able to silence the MHC expression on the cornea endothelium, which is the major target
during graft rejection. In this study, we demonstrated the feasibility to generate HLA universal
tissues in their original 3D structure (Figure 9). Silencing HLA expression on tissues is expected
to significantly improve graft survival rates in high-risk keratoplasty patients.
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We have silenced HLA expression in human and mice corneas. The tissue was transduced for 8 h with the 
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Figure 9. Generation of MHC-silenced corneas. A mouse cornea was explanted and transduced with a lentiviral vector
encoding the shβ2m to cause a downregulation of MHC class I antigens and the expression of green fluorescence pro‐
tein (GFP) sequences. (A) Light microscopic and (B) fluorescence microscopic analyses of a transduced mouse cornea.
2.6. Conclusion
Recently, gene regulation or editing strategies have emerged as powerful tools to improve the
design and efficacy of personalized cell-based therapies. In the field of histocompatibility and
transplantation, RNAi seems to be a favorite approach to reduce the immunogenicity of
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allogeneic and in vitro generated cells and tissues. The lentiviral vector-mediated delivery of
shRNAs targeting HLA transcripts prevents the activation of cellular and humoral allogeneic
immune responses that cause the rejection of the foreign cells. However, this RNAi-based
strategy permits the residual expression of HLA class I antigens which are crucial to inhibit
NK cell cytotoxicity. With the establishment of iPSCs, the concept of cell pharming came one
step closer to reality as iPSCs may serve as unlimited cell sources for different cell products
such as platelets. The combination of RNAi-mediated HLA silencing and the capacity to
generate platelets in vitro may represent a novel therapeutic approach for the management of
alloimmunized thrombocytopenic patients with an increased risk to develop refractoriness to
platelet transfusion. Furthermore, our results also indicate the feasibility to reduce MHC
expression in the 3D original structure of tissues. Abrogating the histocompatibility barrier
between donors and recipients may improve therapeutic efficacy, reduce the adverse events
associated with strong immunosuppressive regimens, and improve transplant patient life’s
quality. In conclusion, RNAi-mediated silencing of HLA expression may open new avenues
in tissue engineering and transplantation.
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Abstract
MicroRNAs (miRNAs) are small, noncoding RNA molecules that have emerged as im‐
portant posttranscriptional regulators of gene expression. miRNA provides intracellular
immune defense when the body is faced with challenges from transgenes, viruses, trans‐
posons, and aberrant mRNAs. miRNA molecules trigger gene silencing in eukaryotic
cells. To date, more than 3,000 different human miRNAs (hsa-miRs) have been identified,
and it is generally agreed that cellular gene regulation is significantly impacted by the
presence of miRNAs. A single miRNA has the complex capacity to target multiple genes
simultaneously. In a viral infection context, miRNAs have been connected with the inter‐
play between host and pathogen, and occupy a major role in the host–parasite interaction
and pathogenesis. While numerous viral miRNAs from DNA viruses have been identi‐
fied, characterization of functional RNA virus-encoded miRNAs and their potential tar‐
gets is still ongoing. Here, we describe an in silico approach to analyze the most recent
Ebola virus (EBOV) genome sequences causing West African epidemics. We identified
numerous “candidate” miRNAs that can be utilized to quell the Ebola virus. Future ap‐
proaches will focus on experimental validation of these miRNAs during quelling the Ebo‐
la target transcripts for further elucidating their biological functions in primates and
other animal models.
Keywords: Ebola virus, gene alignment, miRNA, prevention, vaccine
1. Introduction
1.1. Inhibition of Ebola virus by anti-Ebola miRNAs In silico
Since the HIV-1 pandemic of the 1980s and more recent outbreaks of bird flu, severe acute
respiratory syndrome (SARS), and Middle East respiratory syndrome-Corona Virus (MER-
CoV), it has been widely believed that there would be new pandemics of highly pathogenic
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
viruses [1]. Fortunately, until recently, many of the new emerging pathogenic agents, such as
Ebola virus (EBOV) and Marburg virus (MARV), have failed to demonstrate the transmissi‐
bility or animal reservoirs required to become true pandemic threats [2, 3]. Few, if any,
antivirals can claim to be specific enough to halt the epidemic. Recently, a whole EBOV
replication-defective vaccine—EBOVdVP30—has been found to be very effective in nonhu‐
man primates, while two others are in Phase II trials [4].
The testing of the recently developed replication-defective recombinant chimpanzee adeno‐
virus type 3–vectored ebolavirus (cAd3-EBO) vaccine is based on a demonstration of efficacy
in a nonhuman primate model [5]. However, a curious finding has puzzled the investigators
—preexisting neutralizing antibodies against cAd6 and cAd68 in human serum samples were
found in ~40% of Ugandans and in 15% of the US and European volunteers. The increased
prevalence of neutralizing antibodies against chimpanzee adenoviruses in sub-Saharan Africa
may indicate cross-species transmission of these viruses from chimpanzees to humans. The
possibility of fairly high levels of neutralizing antibodies against cAd3 may complicate the
evaluation of the effectiveness of Ebola vaccines currently underway.
1.2. Virology of Ebola virus
Filoviruses are taxonomically classified within the order Mononegavirales, a large group of
enveloped viruses whose genomes are composed of a nonsegmented, single-stranded minus
[2, 3] RNA molecule. Following their discovery, filoviruses were originally grouped with
rhabdoviruses, as the appearance of these virus particles appeared similar [3]. However,
subsequent filamentous morphology and extensive genetic, physiochemical, and virologic
studies of Marburg virus (MARV) and Ebola virus (EBOV) revealed distinctive characteristics,
and these viruses were placed into a separate family, the Filoviridae [3]. Further characterization
of these agents demonstrated that EBOV and MARV represent divergent lineages of filovi‐
ruses, and that their variances were significant enough to warrant the formation of the two
genera, MARV and EBOV [4]. Subsequent to the International Committee on Taxonomy of
Viruses recommendation, the MARV genus contains a single species, the Lake Victoria
Marburg virus, as this strain exhibits only limited genetic variation.
EBOV is the causative agent of Ebola virus disease (EVD) [6]. The mortality rate can vary from
40% to 93% depending on the strains [6]. The viral life cycle begins with host cell entry through
a mechanism that is still poorly understood. The incubation period for EVD is 2–21 days, and
typical early symptoms include fever, chills, malaise, and myalgia (all of which could be
misdiagnosed as malaria, which is highly prevalent in West African nations), followed by the
onset of symptoms indicative of multi-organ stress and subsequent failure, sometimes
followed by hemorrhagic episodes that can easily be misdiagnosed as Lassa fever.
EBOV is a negative, single-stranded RNA virus with an unusual, variable-length, filamentous,
branched morphology whose helical capsid is enclosed inside a membrane. The mechanism
of attachment and entry into the cell is still not completely defined (see discussion below).
Once inside, the viral RNA polymerase (L protein) begins to copy the negative strand (–ve)
RNA to make the positive strand (+ve) transcripts that mimic the structure of mRNA and are
translated by host ribosomes. Replication is thought to occur in the cytoplasm. An unusual
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feature of the transcription and translation of the Ebola genes is the fact that the glycoproteins
(GP) are only expressed through transcriptional editing. The genome of the Zaire Ebola virus
(EBOV), the most pathogenic among all species of EBOV, is 18,959 nucleotides (nts) in length
and contains seven transcriptional units that guide synthesis of at least nine distinct primary
translation products: the nucleoprotein (NP), virion protein (VP) 35, VP40, glycoprotein (GP),
soluble glycoprotein (sGP), small soluble glycoprotein (ssGP), VP30, VP24, and the large (L)
protein. L is the catalytic subunit of the viral polymerase complex (Figure 1). Similar to other
nonsegmented negative-sense (NNS) RNA viruses, EBOVs encode a multiprotein complex to
carry out replication and transcription. In the case of EBOV, viral RNA synthesis requires the
viral NP, VP35, VP30, and L proteins. Transcription of filovirus mRNAs is presumed to occur
as in other NNS viruses, where there is a gradient of viral mRNAs with the abundance of each
mRNA transcript decreasing as the polymerase transcribes toward the 5′ end of the template
[7]. Each EBOV mRNA is presumed to be efficiently modified with a 5′–7’-methylguanosine
(m7G) cap and a 3′p (A) tail [8].
Figure 1. The genome of EBOV, 18 9 kb in length, has the following gene order: 3′ leader nucleoprotein (NP), virion
proteins (VP) VP35-VP40, membrane glycoprotein (GP), viral polymerase (VP) VP30-VP24, viral polymerase L protein,
and 5′ trailer.
The Ebola virus genus possesses greater diversity, and four viral species have been recognized:
Zaire Ebola, Sudan Ebola, Reston Ebola, and Ivory Coast Ebola (EBOV-Z, EBOV-S, EBOV-R,
and EBOV-IC, respectively). Each of the EBOV species has a different degree of pathogenicity
and mortality rate [9]. Therefore, EBOV-S and EBOV-Z, which are the predominant EBOVs
associated with known outbreaks, are more pathogenic than EBOV-R and EBOV-IC [10].
EBOV-IC has only caused a single nonfatal human infection, but EBOV-R has caused fatal
infection in nonhuman primates [8]. However, EBOV-S, EBOV-Z, and EBOV-B often cause
severe hemorrhagic diseases with markedly high case fatality rates (40–90%) [10]. The EBOV
genome is 18.9 kb in length with the following gene order: 3′ leader nucleoprotein (NP), virion
protein (VP) 35-VP40, glycoprotein (GP), VP30, VP24, polymerase (L), and 5′ trailer. The GP
differences between any two species range from 37% to 41% at the nucleotide level and from
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34% to 43% at the amino acid level [40]. However, variations within EBOV-Z species are very
low (∼2–3%) [11]. Thus, GP nucleotides are usually used in the phylogenetic analysis of EBOV
(Figure 2).
Figure 2. The Ebola Pandemic Map depicts the history of Ebola in Africa. The sporadic cases of Ebola were common in
the central African countries such as the DRC (988 cases with 767 fatalities), Uganda (606 cases with 283 fatalities),
South Sudan (335 cases with 180 fatalities), Gabon (214 cases with 150 fatalities), the Republic of the Congo (248 cases
with 210 fatalities), and South Africa (2 cases with 1 fatality).
Because of their high mortality rate, which can vary from 40% to 93%, and their potential
for  person-to-person transmission and lack of  an approved vaccine or  antiviral  therapy,
MARV  and  EBOV  are  classified  as  biosafety  level  4  (BSL-4)  viruses  by  World  Health
Organization [12, 13]
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1.3. History of MARV and EBOV
Viruses are obligate intracellular parasites and essentially rely on host cells for raw materials,
replication, transcription, and translations of their genetic codes. Until a few years ago, we
assumed that the major intracellular defenses against viral pathogens were interferons [13].
Since the discovery of RNA interference (RNAi) and miRNAs, we know that one of the
fundamental functions of miRNAs is to prevent replication of foreign viruses by pre- and
posttranscriptions and suppressions of viral expression [12]. Therefore, besides endogenous
gene regulation, miRNAs are the primary intracellular immune defense system [13]. Viruses
have also evolved to counter the antiviral effects of miRNAs by viral miRNAs (vmiRNAs).
Recently, Li and Chen [14] have conducted molecular epidemiologic analyses of presently
extant  Ebola viral  genomes to ascertain their  evolutionary viral  history.  Of  considerable
potential importance are interpretations derived from a dataset that is between 1,000 and
2,100 years old and includes four Ebola species (EBOV-Z, EBOV-S, EBOV-TF, EBOV-R) [15].
Logically, one could assume that over the past 2,000 years, humans have evolved counter‐
measures  to  the  Ebola  virus  via  innate,  adaptive,  and  miRNA-based  immunity.  The
identification in a  human database of  71 miRNAs capable of  potentially quelling EBOV
strongly suggests that Homo sapiens already have developed primary intracellular defens‐
es to quell EBOV infection [16]. This raises a question: Why have EBOVs been circulating
for about 2,000 years, and yet they seem to have emerged only recently? The earliest known
cases of Ebola date to the 1970s. One theory proposes that EBOV-Z experienced a recent
genetic bottleneck [17].  Before Ebola viral  strains were introduced to primates,  they had
already  been  circulating  among  small  mammals,  including  bats,  rodents,  marsupials,
shrews, and so on [16]. Although these bats and other animals were infected [15, 16], no
evidence demonstrated that such infections were fatal to them [18]. This indicates that a
natural  balance  had  been  achieved  between  the  viruses’  pathogenicity  and  the  host’s
immune system, especially at the intracellular levels where miRNAs provide immunologi‐
cal protection [19].  This homeostasis,  this balance, apparently was broken in 1900, when
EBOV genetic diversity experienced a dramatic drop [16].  Accordingly,  most lineages of
the various EBOV species became extinct because of such influences as threatening human
activities,  climate  change,  and  a  steep  decline  in  the  number  of  animals  to  serve  as  a
reservoir for viral replication. Probably due to altered patterns of positive selection in the
glycoprotein (GP), which diversified substantially and was found to be part of fusion and
receptor  binding  within  cellular  membranes,  infection  patterns  through  direct  exposure
were changing. Therefore, by about 1970, few lineages that possessed broader tropism and
enhanced  fitness  had  the  capacity  to  infect  primates  via  direct  exposure  [16].  Similar
examples can be seen in the emergence of HIV-1, which appeared to have surfaced in the
1950s through a zoonotic event that involved common infections among chimpanzees (i.e.,
SIV) and then accidentally jumped to humans [16–18].  Due to the paucity of  significant
differences in EBOV genetic diversity since 1970, the decreased number of surviving viruses
may have become the only circulating lineages in primates and viral reservoirs. EBOV-Z
has the ability to traverse a long distance through bats, which serve as a migratory reservoir.
Outbreaks with their epicenter in Congo have been caused by the EBOV-Z species [20–23].
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Through analysis of miRNA numbers that demonstrate high homologies in seed sequences
and that show high identity to EBOV species, we have deduced that the genetic variations at
the GP may serve as a type of Achilles’ heel. After all, only one miRNA showed identity to GP,
while eight proved capable of blocking polymerase steps. This indicates that minor variations
within the GP amino acid sequence could allow for viral entrance into host target cells in
humans. The subsequent transcription of negative-stranded RNA viruses into positive RNA
strands occurs amid a struggle to overcome the miRNAs with quelling potential that can halt
this process. It is possible that at the time of exposure to EBOV, all of the protective miRNAs
may not be present in the target cells, or may be present, but not in sufficient quantities to block
early EBOV replication [24].
Figure 3. The illustration depicts a simplified structure of Ebola virus. The functions of various viral proteins are de‐
scribed in the text. GP, glycoprotein; NP, nucleoprotein; VP40, matrix protein; VP30, transcription factor; and polymer‐
ase enzyme.
Figure 3 shows the VP24, VP30, VP35, VP40, and L nucleoproteins that constitute the nucleo‐
capsid, which is crucial in both the transcription and viral replication processes [25, 26]. The
glycoprotein is located in the lipid membrane of the Ebola virus; this is also the place in the
host target cells where receptors that facilitate viral entry are embedded [27]. Viral matrix
proteins VP40 and VP24 are essential to viral budding, stability, and structure. VP40 is the
primary matrix protein, and is the viral protein that is expressed most abundantly. It plays a
central role in the process of Ebola budding from the plasma membrane. For example, in
mammalian cells, the mere expression of VP40 is sufficient to create virus-like particles (VLPs)
with morphological characteristics that are similar to those of the actual Ebola virus [28, 29].
Given VP40’s absence, studies have found that the nucleocapsid was not transported effec‐
tively into the plasma membrane, and as this membrane is the site of assembly, budding, and
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may not be present in the target cells, or may be present, but not in sufficient quantities to block
early EBOV replication [24].
Figure 3. The illustration depicts a simplified structure of Ebola virus. The functions of various viral proteins are de‐
scribed in the text. GP, glycoprotein; NP, nucleoprotein; VP40, matrix protein; VP30, transcription factor; and polymer‐
ase enzyme.
Figure 3 shows the VP24, VP30, VP35, VP40, and L nucleoproteins that constitute the nucleo‐
capsid, which is crucial in both the transcription and viral replication processes [25, 26]. The
glycoprotein is located in the lipid membrane of the Ebola virus; this is also the place in the
host target cells where receptors that facilitate viral entry are embedded [27]. Viral matrix
proteins VP40 and VP24 are essential to viral budding, stability, and structure. VP40 is the
primary matrix protein, and is the viral protein that is expressed most abundantly. It plays a
central role in the process of Ebola budding from the plasma membrane. For example, in
mammalian cells, the mere expression of VP40 is sufficient to create virus-like particles (VLPs)
with morphological characteristics that are similar to those of the actual Ebola virus [28, 29].
Given VP40’s absence, studies have found that the nucleocapsid was not transported effec‐
tively into the plasma membrane, and as this membrane is the site of assembly, budding, and
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incorporation into the virions, considerable attention should be given to the role of this matrix
protein [30]. The utilization of miRNAs that specifically target VP40 mRNA degradation is
important to our understanding of just how VP40 functions and what potential roles it might
play in the regulation of VLP assembly in both in vitro and live cell settings. hsa-miR-4692 and
hsa-miR-548-az effectively target VP40; therefore, the overexpression of these particular
miRNAs within host cells could totally disrupt the viral life cycle and may have a decisive
impact in the categorization of therapeutic targets (data unpublished). The tendency of Ebola
VP40 to assemble virus-like particles (VLPs) presents an appealing model for analysis of the
Ebola viral assembly at biosafety level 2 made possible by the noninfectious nature of geneti‐
cally engineered VLPs [31].
VP40’s association with the plasma membrane is of fundamental importance [30]; it is here
that assembly is initiated as well as oligomerization [31], and nucleoprotein recruitment.
Besides membrane association, VP40 also associates or otherwise interacts with host cell
factors, including the endosomal sorting complex that supports transport (ESCRT) machinery
[27, 29], the vesicle coat II proteins (COPII) [24], as well as the protein actin [25, 30]; these host
cell factors, respectively, have been shown to enable VP40 budding, transport, and movement.
Moreover, host cell protein kinases could contribute to Ebola infectivity as c-Abl1 can phos‐
phorylate Tyr13 in VP40 [32, 33]. Still we have an inadequate understanding of how VP40
actually assembles on the plasma membrane before virion release occurs. Localization of VP40
in the plasma membrane is believed to be important as studies give evidence that hydrophobic
residues located within the C-terminal domain, including Leu213, are essential in the localiza‐
tion and budding processes [32]. Detection of VP40 oligomers in VLPs and UV-inactivated
virions has occurred [34, 35]; they have been detected mainly in filamentous structures
stemming from the plasma membrane [36]. Therefore, VP40 oligomerization apparently occurs
on the same plasma membrane in which oligomers selectively have found to reside [37]. In
terms of structure, VP40 has predominantly been found to oligomerize into either hexamers
or octamers [38, 39]. These share a comparable monomer–monomer (or intradimeric) antipar‐
allel interface. However, the detection of oligomeric structures in live cells suggests that these
structures, too, could exert a critical influence on both viral assembly and egress [40]. We
discovered that hsa-miR-4692 and hsa-miR-548-az both target VP40 (data unpublished).
The formation of virus-like particles (VLPs) requires VP40 oligomers; these are associated with
membranes that are resistant to detergent [41], which underscores the active part that the
plasma membrane may play in VP40 oligomerization. Moreover, on the plasma membrane,
matrix protein oligomerization may function as a scaffold in host protein recruitment, and also
supply the force needed to effect the formation of virus particles and the deformation of
membranes. A comprehension of VP40 plasma membrane association thus becomes crucial to
our understanding of how the formation of protein buds occurs on the plasma membrane.
Gupta K [42] recently investigated the role that the VP40 C-terminal domain plays in mem‐
brane association as well as in membrane penetration. These investigators utilized the
monolayer penetration methodology to conduct in vitro research into the molecular basis of
the penetration of the VP40 membrane. To study VP40 assembly and its associated egress in
cells, they employed a multipronged methodology that blended cellular imaging, number and
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brightness (N&B) analysis, analysis of the egress of virus-like particles, site-directed muta‐
genesis, and total internal reflection (TIRF) microscopy. N&B analysis permitted them to
ascertain the average number of molecules and also the brightness within each pixel within a
fluorescence microscopy image. This permitted them to detect the oligomeric status of proteins
that are labeled fluorescently. They concluded that within the VP40 C-terminal domain, a
hydrophobic interface actually penetrates the plasma membrane, which plays a key role in the
oligomerization of VP40. The knocking out of plasma membrane penetration by hydrophobic
mutants also substantially reduces the egress of VLPs [38, 39]. Therefore, degradation of VP40
mRNA by a two-pronged attack from hsa-miR-4692 and hsa-miR-548-az can stop Ebola.
A distinguishing characteristic of filovirus genomes is their 3′- and 5′-UTRs that are long
related to other RNA viruses of the nonsegmented negative-strand (NNS) variety [40]. Of
particular note, Kochetov AV [41] concentrated on the 5′-UTRs in the mRNA of seven EBOV
viruses, due to the critical importance of the 5′-UTRs in translation initiation. In four of these
seven mRNAs, small alternate upstream open reading frames (uORFs) were identified, but
their significance is yet to be fully characterized. In cellular mRNAs, uORFs are known to be
a common feature; they are critical in modulating translation of primary ORFs (pORFs), which
was accomplish by reducing the efficiency and quantity of the scanning ribosomes associated
with the reinitiation that occurs at the start codon of pORFs [42]. At a uAUG, rather than a
pAUG, translation initiation frequency is affected by a variety of factors, including the strength
of the Kozak consensus sequence that surrounds the uAUG. Moreover, between the pAUG
and the upstream open reading frame (uORF) is an intercistronic space that, combined with
the phosphorylation status of and the eIF-2α [43, 44], controls whether translation takes place
at the principal protein initiation site (pAUG) or at the termination codon (uAUG).
When eIF-2α∼P is absent, cap-dependent translation has been found to be efficient, which
permits higher ribosome initiation rates at the uORF [45]. When eIF2α∼P is enhanced,
impairment of translation initiation occurs, which causes a ribosome to continue scanning
beyond the uAUG; in this case, initiation occurs at the pAUG. In short, when cell stress occurs,
eIF2α∼P facilitates translation initiation of select mRNAs that possess uORFs at the primary
open ready frame (pORF) [46].
They characterized how the EBOV 5′-UTRs modulate translation. Mutating any of the four
uAUGs present in the EBOV genome enhances translation at the corresponding pORF. The
most dramatic effect was with the L gene where the L uAUG can potently suppress pORF
translation; however, in response to eIF2α∼P, the L uAUG maintains L translation. Modulat‐
ing viral polymerase levels is biologically significant as ablating the L uORF in a recombinant
EBOV reduces viral titers 10- to 100-fold in cell culture, severely impairs viral RNA synthesis,
and functions to maintain virus titers in cells treated with stress-inducing agents. These data
suggest that a uORF in the EBOV L mRNA regulates polymerase expression in response to the
status of the cellular innate immune response and is required for optimal virus replication.
It would be relatively easy to incorporate a combination of relevant miRNAs in a miRNA-
expression vector to test the utility of these miRNAs in genetically engineered VLP cell models
in vitro that can be performed in a BSL-2 facility, and then to extend these studies in animal
models utilizing safe vectors in a BSL-4 environment.
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Currently,  there are several  genetically engineered vaccines containing genes for surface
proteins (GP) that  are in clinical  trial.  The first  among these is  a  vaccine that  Ebola GP
genes stitched into a weakened chimpanzee adenovirus that serves as a vector. The second
vaccine  contains  the  Ebola  surface  protein  gene  inside  a  weakened version of  vesicular
stomatitis  virus  (VSV),  which commonly infects  farm animals.  The potential  dangers  of
employing of  VSV are  obvious:  it  can save men but  potentially  harm livestock in West
Africa. The chimpanzee adenovirus will be a zoonotic event itself, and its potential danger
cannot be underestimated [47, 48].
The third vaccine uses a vector known as MVA, a modified version of the smallpox vaccine
virus, and involves protection from an Ebola virus “challenge” 10 months after the last
vaccination.
We noted that none of these three approaches mentioned a simple and well-tested method
of human and animal vaccination. What happened to the simple, whole formalin-killed or
UV-killed, less pathogenic EBOV vaccines that have been tried in so many viral vaccina‐
tions [49, 50]?
With viruses like the major Ebola strands, where the mortality rate is over 50%, it will be
difficult to find a reasonable and ethical way to carry out an unbiased clinical trial. However,
if one can prepare a “dead Ebola virus” with antigenicity intact, it would be easy to immunize
“high risk groups” without utilizing unusual vectors as exemplified by “harmless” chimpan‐
zee adenovirus, VSV or MVA (modified smallpox virus), each with unknown long-term risk
factors and accompanied by immediate concerns of viral vector-induced antigenic competition
that may potentially quell proper immune responses to the Ebola antigens [51]. We believe
that a dead vaccine may induce the protective miRNAs and quell the pandemic. Increasingly,
miRNA-induced intracellular immunity is being better understood, and several clinical trials
are under way to treat viral diseases and cancers [52–55]. The cost of each of these vaccines
would run into millions of dollars and would be prohibitively expensive to any of the
individuals who are predicted to be infected with the virus in West African nations. In contrast
to the proposed recombinant vaccines, each of the more traditional “killed vaccines” has been
very inexpensive to produce and has benefited billions of humans [56].
2. Conclusions
The current ongoing Ebola outbreaks in West Africa that began almost three years ago in March
2013 have already claimed 11,000 lives and over 27,000 cases. The rapid spread of the infection
demands the need for rapid prevention methods. Currently, there are several vaccines that are
in different phases of clinical trials. In this report, we highlight an alternative to the standard
vaccine for Ebola prevention. We show that a preventive method based on miRNAs could be
utilized and tested in nonhuman primates. Some of the lessons that we have learned from the
recent West Africa Ebola outbreaks is to test the vaccine and other preventive methods that
are currently available against Ebola before the major outbreaks occur. Therefore, we recom‐
mend that vaccines and preventive methods must be developed to the point that the measures
Utility of Potent Anti-viral MicroRNAs in Emerging Infectious Diseases
http://dx.doi.org/10.5772/61687
333
correlate for human protection (Phase I level), so when the outbreaks occur, the vaccine and
other measures can be rolled out quickly to prevent the spread of the disease.
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Abstract
RNA interference (RNAi) has progressed swiftly in the past decade to become a conven‐
ient and dominant genetic tool that has immense utility in diverse fields. The entomologi‐
cal research, ranging from functional genomics to agriculture, has gained enormous
momentum due to this technology. RNAi tool helped to discover the functions of new
genes and study the complicated genetic networks, thus providing an evolutionary in‐
sight into various processes. RNAi is also becoming a method of choice for controlling in‐
sect pest populations. It is envisaged as tailor-made insecticide, which is highly species
specific. However, the efficiency of this mechanism is limited by various factors such as
the stability of the trigger molecule, the candidate gene selection, delivery system adopt‐
ed and, most importantly, the choice of the target species. Apart from the successful im‐
plication in diverse areas, there are certain drawbacks of this technology such as ‘off-
target’ effects, lack of sensitivity of various species, etc. Further research would relieve
these limitations and support the manifestation of this genetic tool with much more relia‐
bility.
Keywords: RNAi, insects, pest management, efficiency of RNAi
1. Introduction
RNA interference (RNAi) is a highly conserved, sequence-specific mechanism of gene silencing
which is triggered by the presence of double-stranded RNA (dsRNA). Since its discovery in
1998, RNAi has attained the status of a powerful genetic tool [1]. This reverse genetics
technique is now immensely used in biomedical research, functional genetics and many other
areas of biological research. Broadly, all the reactions that take place for RNA silencing are
initiated when a long dsRNA is processed into small dsRNAs of about 21 to 24 bp by the
RNaseIII enzyme, called Dicer. These small dsRNAs are called small interfering RNA (siRNA),
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
which when unwound using ATP-dependent activity are incorporated into the multi-subunit
RNA-induced silencing complex (RISC). Here, the siRNA guides the RISC complex to degrade
cellular RNA molecules that are complementary to its sequence [2]. Earlier this process was
described in the experimental RNAi studies, and now it is the most accepted tool for gene
knockdown studies.
The advent of RNAi also revolutionised the entomological research, as novel gene functions
were efficiently discovered. In 1998, Kennerdell and Carthew were the first to use RNAi in vivo
to study the genes Frizzled and Frizzled-2 in Drosophila melanogaster [3]. The tremendous success
of RNAi in model organisms has prompted its use for research in other insect species as well.
In genomics and post-genomics era with the availability of a large amount of sequence
information, RNAi further provides an opportunity to investigate the vital functions and
crucial interactions that are of importance in both biomedical research and agriculture [4–6].
RNAi studies on insects of economic importance would provide new insights into unravelling
the molecular interactions between various disease vectors and ultimately helping in the
discovery of novel vaccine and drug targets. Disease vectors such as mosquito, ticks, mites,
lice and others were studied extensively using RNAi [7]. These insects cause many serious
diseases in humans and animals.
Among other applications, this genetic tool is also gaining popularity as a promising technol‐
ogy in controlling a wide array of agricultural pests. There is a substantial amount of literature
available which documents the success of RNAi as a feasible and sustainable strategy in
managing the agricultural pests [8–11]. The core RNAi machinery being present in all the
insects makes it possible to silence a wide variety of target genes to produce diverse physio‐
logical, developmental and reproductive restrains. The sequence specificity of endogenous
RNAi pathway allows the targeted suppression of genes essential for insect survival and thus
offers the development of a specific, logical and sustainable strategy to combat against insect
pests.
Agricultural pests are notorious and they cannot be efficiently managed by employing a single
control agent or technique. Most commonly, the integrated pest management (IPM) strategies
are utilised for combating the diversity of insect pests in the agro-ecosystem [12]. Along with
mechanical, cultural, biological and chemical methods, the transgenic technology should also
be embraced in the IPM regime. In this regard, RNAi can play an important role along with
the available insecticidal molecules. Among various transgenic approaches to manage insect
pests, Bacillus thuringiensis (Bt) toxin has shown spectacular success [13]; however, many
important insect pests (primarily sap-sucking pests) are not amenable to Bt protection [14].
RNAi can be harnessed to defend crops against insect pests. Successful application of RNAi
technology in agricultural pest management requires (i) suitable candidate gene where its
silencing can cause mortality of the insect and (ii) an effective method of dsRNA delivery.
Nevertheless, prior to field application, many aspects of this multi-faceted technology
including safety and possible risks to environment need to be evaluated in detail.
In this chapter, we discussed the potential of this technology in gene silencing experiments to
study the gene function as well as on opportunity to combat against agricultural pests and
other disease vectors. Further, the factors responsible for a successful RNAi experiment, the
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link with immune response and viral infections have been discussed, highlighting the possible
shortcomings of this strategy.
2. RNAi in insects
RNAi offers species-specific molecules that can be flexibly manipulated and used in under‐
standing various complicated biochemical pathways. The research application of RNAi in
entomology has elucidated the functions of several genes. Decrease in the mRNA levels of a
candidate gene due to introduction of a complementary dsRNA fragment, and the study of
the corresponding phenotype, illuminates a gene function. RNAi has been used to study
various mechanisms related to insect development (embryonic and post-embryonic), repro‐
duction, behaviour and other complicated biosynthetic pathways [15].
Various insect orders have demonstrated amenability to RNAi-mediated silencing. Species of
orders Coleoptera, Lepidoptera, Diptera, Hemiptera, Orthoptera, Blattodea and Hymenoptera
have been studied for various aspects using RNAi technique [15]. The silencing efficiency
ranges from 0% to 100% in different insects. A large majority of the target genes were gut-
specific genes; however, genes from salivary glands, brain and antennae have also been
targeted [16]. RNAi-based studies can be carried out by either in vivo or in vitro studies. The
former method is much easier and involves incubating the cells with the dsRNA added to the
medium. However, the in vivo approach is more useful in the field of functional genomics,
especially in case of non-model organisms. Here, the dsRNA dosage and developmental stage
of insect can be specified. In addition, RNAi can be very helpful in identifying the mutant genes
that are fatal to the organism,. The significance and compilation of various categories of RNAi
experiments in entomology are summarised in Table 1 [17–45].
Experiments Insect Gene and function
RNAi in developmental
biology
Parental RNAi Tribolium castaneum Zygotic genes [16]




It is crucial for many insects
whose eggs are not
accessible




Determination of the role of the gap genes, hunchback and
Krüppel [17,18]
Gryllus bimaculatus Antenna and appendages [19], hedgehog, wingless and dpp in
the initiation of proximodistal axis formation during the
regeneration of insect legs [20]
Nasonia vitripennis Various genes in demonstration of parental RNAi [21]
Tetranychus urticae Distal-less was used, resulting in phenotypes with canonical
limb truncation as well as the fusion of leg segments [22]
Embryonic RNAi T. castaneum Role of wingless (wg) in leg development [23]
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Experiments Insect Gene and function
N. vitripennis Role of bicoid gene in the structural pattern of the anterior
body region. Also in the absence of bicoid gene, orthodenticle,
hunchback and giant genes are responsible for proper head
and thorax formation [24]




T. castaneum (larval RNAi) To study the molecular basis of adult morphological
diversity in various organs [26]
T. castaneum (larval RNAi) Ubx/Utx during hindwing/elytron development [27]
T. castaneum (larval RNAi) Laccase 2 [28]
Bombyx mori (pupal RNAi) Fatty acid transport protein (Bm’FATP) [29]
Schistocerca
Americana (Nymphal RNAi)
The eye colour gene of first-instar nymphs triggered a
suppression of ommochrome
formation in the eye [30]
S. Americana Importance of early retinal genes eyes
absent (eya) or sine oculis (so) in eye development [31]
Blattella germanica (nymphal
RNAi)
RXR/USP, along with EcR, of the
heterodimeric nuclear receptor of 20-hydroxyecdysone
(20E) [32]
G. bimaculatus Mechanisms of leg regeneration [33]
G. bimaculatus period (per)gene for circadian-dependent locomotor activity
rhythm [34]
G. bimaculatus Genes responsible for certain human disorders: fragile X




G. bimaculatus Insect leg regeneration [36]
G. bimaculatus Orthologs of Drosophila hedgehog (Gb’hh), wingless (Gb’wg)
and decapentaplegic (Gb’dpp) are expressed
during leg regeneration and play essential roles in the






a decrease of anticoagulant activity and
less efficient feeding behaviour [38]
Anopheles gambiae Apyrase AgApy in the salivary glands shows important
role in host probing behaviour [39]
D. melanogaster 3-Hydroxy-3-methylglutaryl CoA reductase has been
identified for the control of
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Experiments Insect Gene and function
sexual dimorphism of locomotor activity in [40]]
B. germanica Neuropeptide pigment dispersing factor in
the regulation of locomotor circadian rhythms [41]
Mechanism of insecticidal
action
Mosquitoes NADPH cytochrome P450 reductase led to increased








T. castaneum Chitin synthases CHS1 and CHS2 are crucialexoskeleton
and the midgut peritrophic matrix [28]
Bombyx mori Bombykol is the main component of sexual pheromone, as
well as pheromone-binding
proteins and the receptor of the pheromone
biosynthesis activator neuropeptide [44]
Epiphyas postvittana Silencing of pheromone-binding protein
of the antennae [45]
Table 1. RNAi in the study of gene function in insects.
Apart from deciphering the function of genes involved in various metabolic pathways, RNAi
also finds relevance in other aspects of insect science. It is quite beneficial in maintaining the
beneficial insects and saving them from various parasites and pathogens. Certainly, this is
useful in case of those parasites and pathogens, which have operative RNAi machinery. A
successful study in this regard shows the control of honey bee parasite Nosema ceranae. When
the gene related to energy metabolism was silenced, it was observed that the honey bee
population had reduced infestation of Nosema, and lower mortality [46]. In another study,
multiple genes of an ectoparasite of honey bee Varroa destructor were targeted [47]. It poses a
great threat to the health of bees, and its control is of utmost importance for the rearing
industry. It is a blood-sucking parasite, so the bees were fed on a meal containing dsRNA
against the genes of Varroa. The RNAi-mediated control decreased the mite population by 50%,
causing no evident damage to the bees. RNAi has also been useful in elucidating the impor‐
tance of various immunological pathways in D. melanogaster [48]. Host–parasite relationships
such as that of Anopheles–Plasmodium have also been studied by using RNAi. Early research
was conducted on defensin and it was shown to be important for protecting mosquitoes against
infections of Gram-positive bacteria [49]. Later, the same group demonstrated how the
development of Plasmodium is affected by Anopheles gambiae immune genes [50]. Similarly, in
Manduca sexta haemocytes, knockdown of haemolin (a bacterial recognition protein) decreased
the ability of insects to clear Escherichia coli from the haemolymph. This eventually reduced
their ability to engulf bacteria and highlighted the role of haemolin in the M. sexta immune
response [51].
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3. RNAi in pest control
Plants are damaged by a plethora of insect pests. The losses due to these pests and expenditure
on the chemical pesticides amount to billions of dollars. In an attempt to reduce these losses,
many reports have been published which demonstrate the successful application of RNAi
technique in crop protection. Huvenne and Smagghe [52] have summarised the reports on
insects in which RNAi has been applied through feeding, and they discussed several factors
that influence the success of RNAi on target insects, such as the concentration of dsRNA, the
nucleotide sequence, the length of the dsRNA fragment and the life stage of the target insects.
The downregulation of expression of critical genes, caused by dsRNA/siRNA, eventually leads
to death/growth retardation of the insect and forms the basis of pest control. In this view, the
efficient delivery and uptake of the dsRNA trigger is of prime importance. In contrast to the
study of gene function, pest control strategies cannot depend on injection of the molecule. The
deployment of pest controlling siRNA/miRNA molecules would involve oral exposure, either
as transgenic plants or as sprays. Most of the nutrients from gut lumen are absorbed in the
midgut tissue of the insect; therefore, this tissue is an attractive target for RNAi. After ingestion,
the dsRNA enters into the gut lumen of the insect. Insect gut is divided into foregut, midgut
and hindgut. While both foregut and hindgut are covered with chitin, it is only the midgut
that has exposed cell surfaces. It is the site of nutrient exchange between the haemolymph and
the gut contents. Therefore, midgut epithelium is an attractive target as it is the primary tissue
exposed to dsRNA in the gut lumen. The stability of dsRNA molecule and the efficiency of the
silencing process (discussed in section 5) is determined by the gut pH and nucleases.
A breakthrough research in RNAi-mediated pest control was published in 2007 on the western
corn rootworm, Diabrotica virgifera virgifera (WCRW) [53], and cotton bollworm Helicoverpa
armigera (CBW) [54]. In the former study, a candidate gene was screened based on the complete
cDNA library. Out of a total of 290 dsRNAs, Vacoular ATPase (V-ATPase) subunit A was finally
selected for the development of transgenic corn plants. The larvae reared on transformed
plants caused much less damage to the roots and also showed the reduced expression of the
target gene. The other study of Mao et al. [9] targeted the pesticide detoxifying gene Cytochrome
P450 (CYP6AE14), which provides gossypol tolerance to the insect. Transgenic plants express‐
ing dsRNA corresponding to CYP6AE14 levels of this transcript in insect body was decreased
and the larval growth was retarded. Following these two studies, many research groups started
to consider RNAi as a feasible technique which could be employed in the transgenic ap‐
proaches to manage insects. As we know from the various studies conducted, the Bt (Bacillus
thuringiensis) toxins are effective on lepidopteran and coleopteran pests but fail to work against
hemipteran pests like aphids, whiteflies, phyllids, etc. [55–58].
RNAi-engineered plants can be more useful in case of these phloem-feeding hemipteran pests,
which are notorious not only because of feeding damages but also because of their ability to
transmit plant viruses [59]. The midgut genes of Nilaparvata lugens were downregulated by
feeding on transgenic rice expressing dsRNA against three separate genes, but no lethal
phenotype was detected in this case [60]. Pitino et al. [61] demonstrated RNAi in aphid Myzus
persicae directed towards the receptor of activated kinase (Rack-1) gene by transgenic expres‐
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study of gene function, pest control strategies cannot depend on injection of the molecule. The
deployment of pest controlling siRNA/miRNA molecules would involve oral exposure, either
as transgenic plants or as sprays. Most of the nutrients from gut lumen are absorbed in the
midgut tissue of the insect; therefore, this tissue is an attractive target for RNAi. After ingestion,
the dsRNA enters into the gut lumen of the insect. Insect gut is divided into foregut, midgut
and hindgut. While both foregut and hindgut are covered with chitin, it is only the midgut
that has exposed cell surfaces. It is the site of nutrient exchange between the haemolymph and
the gut contents. Therefore, midgut epithelium is an attractive target as it is the primary tissue
exposed to dsRNA in the gut lumen. The stability of dsRNA molecule and the efficiency of the
silencing process (discussed in section 5) is determined by the gut pH and nucleases.
A breakthrough research in RNAi-mediated pest control was published in 2007 on the western
corn rootworm, Diabrotica virgifera virgifera (WCRW) [53], and cotton bollworm Helicoverpa
armigera (CBW) [54]. In the former study, a candidate gene was screened based on the complete
cDNA library. Out of a total of 290 dsRNAs, Vacoular ATPase (V-ATPase) subunit A was finally
selected for the development of transgenic corn plants. The larvae reared on transformed
plants caused much less damage to the roots and also showed the reduced expression of the
target gene. The other study of Mao et al. [9] targeted the pesticide detoxifying gene Cytochrome
P450 (CYP6AE14), which provides gossypol tolerance to the insect. Transgenic plants express‐
ing dsRNA corresponding to CYP6AE14 levels of this transcript in insect body was decreased
and the larval growth was retarded. Following these two studies, many research groups started
to consider RNAi as a feasible technique which could be employed in the transgenic ap‐
proaches to manage insects. As we know from the various studies conducted, the Bt (Bacillus
thuringiensis) toxins are effective on lepidopteran and coleopteran pests but fail to work against
hemipteran pests like aphids, whiteflies, phyllids, etc. [55–58].
RNAi-engineered plants can be more useful in case of these phloem-feeding hemipteran pests,
which are notorious not only because of feeding damages but also because of their ability to
transmit plant viruses [59]. The midgut genes of Nilaparvata lugens were downregulated by
feeding on transgenic rice expressing dsRNA against three separate genes, but no lethal
phenotype was detected in this case [60]. Pitino et al. [61] demonstrated RNAi in aphid Myzus
persicae directed towards the receptor of activated kinase (Rack-1) gene by transgenic expres‐
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sion in Arabidopsis thaliana. Another important pest, the whitefly, is also now amenable to RNAi
[62]. Its control was demonstrated both by feeding on artificial diet and by feeding on trans‐
genic tobacco plants expressing dsRNA of V-ATPase A gene [11, 63]. RNAi experiments
conducted on agricultural pests as well as on insect vectors of several human diseases are
summarised in Table 2 [53–118].
Insect pests Mode of delivery Gene target
Order Coleopteran
Diabrotica virgifera virgifera Artificial diet and
transgenic plant
a-Tubulin, vacuolar ATPase subunit A [53]
Phyllotreta striolata Plant tissue Arginine kinase [64]
Leptinotarsa decemlineata Artificial diet Vacuolar ATPase subunit A and E [53]
Diabrotica undecimpunctata
howardi
Artificial diet Vacuolar ATPase subunit A and E, a-tubulin [53]
Monochamus alternates Injection Laccase gene [65]
Order Diptera
Aedes aegypti Blood meal
Artificial diet
Feeding
Inverted repeat (IR) RNA derived from the premembrane
protein coding region of the DENV-2 RNA genome [66]
V-ATPase A [67]
ATP-dependent efflux pump [68]
Anopheles gambiae Feeding Chitin synthase [69]
Glossina morsitans morsitans Feeding Midgut protein Tsetse EP; transferrin [70]
Bactrocera dorsalis Feeding and
injection
Rpl19; V-ATPase D subunit; fatty acid









Cimex lectularius Injection Cpr gene[77]
Diaphorina citri Topical
In planta (virus induced)
Abnormal wing disc [78]
Abnormal wing disc [79]
Laodelphax striatellus Feeding Disembodied [80]
Rhodnius prolixus Injection Nitrophorins1–4 [81]
a-Glucosidase [82]
Gap gene giant [83]
Phospholipase A2 [84]
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Inhibitor of apoptosis gene (IAP) [87]
Polygalacturonase (PG) [88]




Circadian clock gene, mammalian-type cryptochrome; Bla [90]
Gland nitrophorin 2 (NP2) [91]




Hexose transporter; carboxypeptidase; trypsin-like serine
protease [92]
ATP synthase subunit [93]
Trehalose phosphate synthase [94]
Cathepsin B-like protease; nicotinic acetylcholine receptors [95]




Snap, Chickadee, CG5885, GATAd [62]
Actin; ADP/ATP translocase; α-tubulin; ribosomal protein L9;
V-ATPase [63]
V-ATPase subunit A [11]
Bactericerca cockerelli Injection/feeding Actin, V-ATPase [97]
Order Hymenoptera
Athalia rosae Injection Ar white gene
Order Isoptera
Reticulitermes flavipes Feeding Endogenous digestive cellulase enzyme, hexamerin storage
protein [98]
Order Lepidoptera
Ostrinia furnacalis Spraying LIM protein 1; myosin 3 light chain;
chymotrypsin-like serine protease;
chymotrypsin-like protease C1;
chymortypsin-like serine protease C3;
hydroxybutyrate dehydrogenase;
Kazal-type serine proteinase inhibitor 1;
fatty acid binding protein 1; unknown;
caboxypeptidse 4 [99]
Ostrinia nubilalis Spraying Chitinase (OnCht); chitin synthase
(OnCHS2) [100]
Epiphyas postvittana Feeding Carboxylesterase gene (EposCXE1);
pheromone binding protein [101]
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Cytochrome P450; gluthatione-S-transferase[9, 103]
Ecdysone receptor EcR [104]
HaHR3 moulting factor [105]
Hyalophora cecropia Injection Haemolin [106]
Manduca sexta Injection Cadherin [107]
Spodoptera litura Injection Vitellogenin receptor [108]
Spodoptera exigua Feeding Chitin synthase gene A [109]
Spodoptera littoralis Injection β-Actin gene [110]












Insulin receptor; insulin receptor substrate;
phosphatase and tensin homolog;
target of rapamycin; PRS6-p70-protein
kinase; forkhead box O; epidermal
growth factor receptor [114]
Nitric oxide synthase gene NOS [115]
Circadian clock gene per [116]
Sulfakinins [117]
Schistocerca americana Eye colour gene vermilion [118]
Table 2. Different insect pests targeted by RNAi.
The choice of a suitable target gene is central to pest control strategy. The gene selection
approaches can be based on choosing the gene with known function such as detoxification
enzymes, cell synthesis, nutrition, metabolism and cytoskeleton structure. These types of genes
can be selected as insect pest control targets. For this, expressed sequence tag (EST) library of
European corn borer (Ostrinia nubilalis) was screened to find out that a chitinase gene (OnCht)
and a chitin synthase gene (OnCHS2), which are very important in regulating the growth and
development of this insect [119]. Likewise, the EST library of Bemisia tabaci was also used to
screen out few important genes for RNAi-mediated control [63]. The cDNA library screening
approach was also used. Mao et al. [9] constructed a cDNA library from RNAs expressed in the
midgut of fifth-instar larvae exposed to gossypol. Several cDNA libraries of WCR (D. virgifera
virgifera) were prepared and considered upon the underlying principle that genes encoding
proteins with essential functions would be the best RNAi targets for causing lethality [8].
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As an extension of the cDNA library screening approach, the next-generation sequencing
(NGS) technologies have led to novel opportunities for expression profiling in organisms
lacking any genome or transcriptome sequence information. It enables the direct sequencing
of cDNA generated from mRNA (RNA-seq) [120, 121]. Hence, it provides the de novo genera‐
tion of the transcriptome for a non-model organism, including various pests. Wang et al. [99]
adopted Illumina’s RNA-seq and digital gene expression tag profile (DGE-tag) to screen
optimal RNAi targets from Asian corn borer (ACB; Ostrinia furnacalis). The same technique
has been used for the grain aphid, Sitobion avenae and Spodoptera litura [122, 123]. It seems likely
that the combination of DGE-tag with RNA-seq is a rapid, high-throughput, cost-effective and
easy way to select for candidate target genes for RNAi, which may not be only limited to the
midgut tissue but can also be selected from the whole insect.
The convenience of RNAi to target specific pests while not harming other species is a perfect
method of pest management. However, target gene selection and efficient delivery methods
are the two major cornerstones of pest management by RNAi. The candidate gene for RNAi
can be tailored to be species specific or they can also have a broad spectrum. Specificity can be
achieved by designing dsRNAs that target the more variable regions of genes, such as
untranslated regions (UTRs). It was first demonstrated in Drosophila where UTR of the gamma-
tubulin gene was targeted and even closely related species could be targeted selectively [75].
However, it can also be possible to target multiple organisms with a single gene. One such
example is of V-ATPase gene, which is an effective target in B. tabaci, D. virgifera and B.
dorsalis [8, 63, 124]; all of these insects belong to different orders. In this case, either a conserved
region can be selected which could affect closely related species or a mixture of dsRNA
fragments from different genes belonging to different species can be selected.
Delivery methods that ensure continuous supply of dsRNA/siRNA will be applicable in the
fields. A more reliable and verified method would be transgenic plants as the dsRNA can be
applied as bait, sprays, or supplied through irrigation systems [125, 126]. The application
approach by spray could be quite practical like the spray of chemical pesticides. Gan et al. [127]
have also demonstrated the control of viral infection using dsRNA spraying. Similar results
were obtained with Asian corn borer, Ostrinia furnacalis. This study showed that larval lethality
or developmental disorders can be achieved by gene-specific RNAi, and spraying can be an
efficient method for continuous supply of dsRNA [99]. The coating of dsRNA molecule with
liposomes is used for delivering siRNA to mammalian cells, specific tissues and some insects
[128, 75]. This coating prevents the degradation of the molecule and enhances its uptake ability;
spraying may also be explored for such particles. Zhang et al. [129] used the chitosan nano‐
particle based RNAi technology to suppress the expression of two chitin synthase genes
(AgCHS1 and AgCHS2) in African malaria mosquito (A. gambiae) larvae. Bacterial expression
or chemical synthesis allows large-scale production of dsRNA at efficient costs [75, 130, 131].
4. RNAi: Link with immunity and viral infections
The RNAi mechanisms evolved primarily as a defence mechanism against viruses and
transposons [132]. Research has established that RNAi pathway also contributes to the innate
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immunity of the insects against the viruses having either dsRNA genome or such replicative
intermediates. It was demonstrated that the Drosophila S2 cells utilise the endocytosis-mediated
pathway involving the pattern recognition scavenger receptors for the uptake of dsRNA from
the surroundings. These receptors are key players in the innate immune responses of the cell
[133, 134]. Saleh et al. [135] demonstrated the strong link of dsRNA uptake pathway and the
activation of the immune response in the infected cells. The normal cells used dsRNA uptake
pathway to internalise viral dsRNA and subsequently showed manifestation of antiviral
response in these cells. On the contrary, the mutant cells (defective genes used for dsRNA
uptake) did not show activation of any antiviral response. Mutants in the core siRNA compo‐
nents Dicer-2, AGO-2 and R2D2 are more susceptible to viral infections [140].
Further, it was also reported that receptors such as Sr-CI and Eater, which contribute to
majority of dsRNA uptake in the Drosophila S2 cells, were significantly down-regulated after
pathogenic virus treatments, and significant changes in phagocytic activity were observed.
The role of RNAi in antiviral defence has also been firmly established in mosquitoes [136].
Viruses can also affect the availability of RNAi machinery for other candidate dsRNA
molecules. They can saturate the RNAi machinery and affect the efficiency of RNAi mecha‐
nism. Many viruses are known to produce viral suppressors of RNA silencing (VSRs), which
bind to the key elements of the RNAi pathway rendering it unavailable. Many of the viral
proteins (viz. B2 protein from Flockhouse virus, 1A proteins from Drosophila C virus and cricket
paralysis virus) are known to interfere in the siRNA pathway of RNA-mediated silencing [137–
140]. These viral proteins may affect the biogenesis of the trigger molecule by binding to
important enzymes such as dicer, which generate the siRNA from long dsRNA or affect the
target cleavage by binding to RISC. The viral proteins may also sequester the dsRNA signal
molecule or form complexes with the replicative intermediates of the siRNA pathway.
Viruses also produce large amount of RNAs and small RNAs that accumulate in the infected
cells. It has also been hypothesised that the occurrence of alternative and effective antiviral
pathway may become important in controlling the viral infections and may supersede the
RNAi pathway. Few of these possible pathways have been worked upon. Goic et al. [141] have
reported the potential interaction of nucleic acid-based acquired immunity with the core RNAi
machinery in the study of persistent infection of S2 cells by Flock House Virus (FHV). The
insects also protect themselves from foreign nucleic acids by becoming refractory to RNAi. In
the oriental fruit fly, Bactrocera dorsalis, orally administered dsRNA-targeting endogenous
genes, resistance to RNAi was seen due to a blockade in the dsRNA uptake pathway. A very
interesting hypothesis is presented by Swevers et al. [142] about the possible impact of
persistent viral infection in the insects. In their work, the authors have analysed various factors
that determine the response to exogenous dsRNA in the background of viral infection.
5. Efficiency of RNAi
Though RNAi is a conserved mechanism in eukaryotes, its efficiency is governed by various
factors. The response of different insect species towards this mechanism of gene silencing is
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imperative for successful implementation in the study of gene function and more importantly
in the pest management programs. Also, the efficacy is governed by many factors which are
not intrinsic to the organism such as the delivery, dosage and choice of the candidate gene.
Comprehending these factors will provide a better insight into designing the experiments for
successful application of RNAi. The available reports indicate that the lower Insecta species
such as that of Blatella show a much robust and persistent RNAi response, while higher Insecta
species belonging to the orders Lepidoptera and Diptera are non-compliant [15]. The sensi‐
tivity could vary within and among the orders. For instance, many Lepidopteran insects are
resistant to RNAi. Terenius et al. [143] have reviewed various factors that may be contributing
to the poor responsiveness of these insects. The efficiency can vary with insect species, target
gene, developmental stage of the organism, expression of RNAi machinery, method of
delivery, stability of dsRNA, etc. A few factors that may be crucial in determining the efficiency
of RNAi are discussed below.
5.1. The RNAi machinery
RNAi evolved in organisms as a defence mechanism against viral infections at the cellular level
[144, 145]. The differences in the expression of core RNAi machinery can be a prime reason
affecting the adequacy of RNAi mechanism. The systemic RNA-interference-deficient 1 (sid-1)
protein forms a gated channel which is selective for dsRNA molecule. Its role is well established
in the systemic spread of the RNAi signal in the model organism Caenorhabditis elegans [146].
The presence of SID-1gene orthologs in insects varies with the insect orders [52]. The dipterans
lack this gene completely. The mosquito Culex quinquefasciatus also lacks sid-1 ortholog but
shows the systemic spread of the dsRNA trigger [147]. On the one hand, honey bee (Apis
mellifera) showed an increase in the expression of SID-1 during the RNAi experiments,
indicating its role in the uptake pathway [148]. On the other hand, in Tribolium castaneum, the
silencing of all three orthologs of SID-1 casted no influence on the efficiency of RNAi [149].
In Bombyx mori, three orthologs are present but no significant success has been found in this
lepidopteran, while mosquitoes show systemic RNAi despite the absence of sid-1 in several
species [149–152]. R2D2, a cofactor of dicer-2 enzyme which cleaves long dsRNA into siRNA
for loading into the RISC, is absent in B. mori making the insect very insensitive to RNAi.
Another important enzyme RNA-dependent RNA polymerase (RdRP), which amplifies the
primary siRNA signal in C. elegans, is entirely not reported in the insects [149]. T. castaneum
showed a robust systemic RNAi, but a wide survey of RNAi related genes did not show any
traces of RdRP [149]. However, RdRP-like activity was substituted in Drosophila cell lines by
certain other enzymatic pathways. In many cases, the absence of certain well-known genes of
the RNAi pathway is directly responsible for the poor response of the organism while in several
other examples, the absence is compensated by other genes/pathways which play key roles of
their counterparts.
5.2. The RNAi molecule
The exogenous dsRNA molecule is the trigger for initiating the RNAi pathway. These
molecules are delivered in the form of dsRNA, siRNA or hairpin RNA. Apart from sequence
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specificity, other parameters are also crucial in determining the efficiency of RNAi experi‐
ments. The study on the administration of dsRNA (feeding by means of artificial diet, natural
diet, droplet method, blood meal, transgenic plants, etc.) in insects has used varied length of
dsRNA molecule. The nucleotide length used in these reports ranges from 134 to 1842 bp, while
most of the studies used 300–500 bp as the optimal length [153]. However, silencing effects
have also been observed in the case of single siRNA synthesised chemically (administration
in H. armigera) or a cocktail of siRNA (obtained by using dicer enzyme to chop the dsRNA
molecule) [154]. In the cell line experiments done on the Drosophila S2 cell line, 211 bp was
found to be the optimum length of dsRNA that could be absorbed by the cells [135]. Not only
the length but also the specificity of the RNAi molecule is a concern. It can be understood by
the reports on Drosophila that feeding specific sequence of V-ATPase dsRNA caused no
silencing in non-target species [75], which implies the specificity of the process. On the
contrary, various other studies report non-specific silencing. Off-target effects were reported
in Rhodnius prolixus [81] and Colorado potato beetle (Leptinotarsa decemlineata) [8]. Single
mismatches are known to impair the RNAi effect in the mammalian cell lines [155]. Further
studies will clarify whether single mismatches show similar impact in insects as well. In case
of pest management programs, long dsRNAs (>200 bp) are generally used which generate
many probable siRNA maximising the RNAi response [153]. The dosage of the dsRNA
molecule also plays an important role in determining the efficiency of the process. Higher doses
are required in case of feeding experiments as compared to injection. The silencing effect in R.
prolixus was enhanced by multiple doses [38]. Therefore, it follows that doses and types of
administration (oral or injectable) also need to be optimised according to the life stage of the
organism and the target tissue.
5.3. Delivery of the molecule/uptake of silencing signal
One of the most decisive factors for inducing RNAi is the efficient delivery of the dsRNA
molecule. The common methods of delivery are by microinjection, soaking, oral delivery and
transgenic technique [156]. Microinjection-based delivery is the most commonly used techni‐
que in studying gene functions. It has proven to work well for Tribolium, Drosophila and many
other lepidopteran insects. Although it works well for larger insects, success with smaller
insects is limited due to the invasive nature of this technique. The survival of aphids after
microinjection procedure is highly dependent on the injected volume [157].
Further, factors such as needle choice, optimal volume and place of injection are very crucial
considerations and tend to vary with organisms and laboratories. Feeding-based experiments
involve either in vitro synthesised or bacterially expressed dsRNA molecules. The success of
oral delivery methods indicates the possible employment of RNAi technique for target pest
control. However, the stability of the molecule will always be a concern in the gut lumen.
Artificial diet mixed with dsRNA could not induce RNAi in Drosophila spp. Ingested dsRNA
against a gut-specific aminopeptidase N gene also failed to develop RNAi response in Spodoptera
litura [43]. Therefore, it can be suggested that oral delivery is not equally suitable for all species.
Another convenient method of delivery is soaking. Nevertheless, this method is more appli‐
cable for cell line experiments rather than whole insects.
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After the delivery of the molecules, the next step is the uptake of the molecules by insects.
Huvenne and Smagghe [52] have elaborately reviewed the basic mechanisms involved in the
uptake of dsRNA in the insects. The spreading of the RNAi signal, i.e., systemic RNAi, is an
important determinant of the efficiency of RNAi. In cases of functional genetics, cell autono‐
mous RNAi has been successfully employed to study the function of genes; however, for
implementation in the pest control programs, non-cell autonomous RNAi is important. The
systemic spread of the silencing signal is absent in the most studied model insect Drosophila.
In contrast, the most studied insect Tribolium shows a powerful systemic silencing effect [149].
5.4. Potency of the silencing signal
The manifestation of the RNAi effect also depends on the stability and persistence of the
dsRNA molecule. In Acyrthosiphon pisum, the silencing effect on the aquaporin gene began to
reduce after five days [157]. The early stability of dsRNA molecule may be disrupted by the
non-specific nucleases as reported in many of the lepidopteran insects [143]. These are
extracellular enzymes different from dicer and digest the trigger molecule, thereby preventing
the RNAi cascade. In certain cases, the activity of dsRNA degrading enzymes have been
studied and their levels were measured in different stages, which was found related to the
developmental stage. The dsRNase activity is also found in the digestive juices of Bombyx
mori, saliva of Linus lineolaris and in haemolymph of Manduca sexta [87, 158, 159]. The existence/
stability/mode of action of these enzymes are not sufficiently studied and future research in
this direction needs to be carried out to comprehend the stability of dsRNA molecule in the
in vivo studies. The choice of gene can also decrease the strength of the silencing signal. Ideally,
the protein whose function is to be silenced should have a short half-life, whilst the mRNA
turnover number should be high. The stability of protein explained the weak RNAi response
in both D. melanogaster and T. casteneum [160]. However, such studies have not been conducted
for the majority of the genes and therefore it can be concluded that expression of RNAi is
limited by many uncovered phenomena.
6. Conclusions
The advent of RNA interference has been a crucial phase of the modern day science. The wide
array of applications in the entomological research has led to many momentous findings. The
functionality of many genes has been understood by this technique. Its implication in func‐
tional genomics is not only restricted to the study of a given set of genes but is also used to
unveil the interaction of different genes in a particular metabolic pathway. The rapid pace of
RNAi-based research suggests that it would soon facilitate better understanding of evolution,
circadian rhythms, behavioural pattern, reproductive biology and interaction between host
and parasites/pathogens. However, successful manifestation of RNAi is dependent on several
factors. The insect species might lack the basic RNAi machinery [161] or may rapidly degrade
alien dsRNA. Such factors could be intrinsic to the concerned tissue or gene. The gene might
have high transcription rate and could evade the effect of RNAi or the target mRNA may be
too transient.
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After the delivery of the molecules, the next step is the uptake of the molecules by insects.
Huvenne and Smagghe [52] have elaborately reviewed the basic mechanisms involved in the
uptake of dsRNA in the insects. The spreading of the RNAi signal, i.e., systemic RNAi, is an
important determinant of the efficiency of RNAi. In cases of functional genetics, cell autono‐
mous RNAi has been successfully employed to study the function of genes; however, for
implementation in the pest control programs, non-cell autonomous RNAi is important. The
systemic spread of the silencing signal is absent in the most studied model insect Drosophila.
In contrast, the most studied insect Tribolium shows a powerful systemic silencing effect [149].
5.4. Potency of the silencing signal
The manifestation of the RNAi effect also depends on the stability and persistence of the
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studied and their levels were measured in different stages, which was found related to the
developmental stage. The dsRNase activity is also found in the digestive juices of Bombyx
mori, saliva of Linus lineolaris and in haemolymph of Manduca sexta [87, 158, 159]. The existence/
stability/mode of action of these enzymes are not sufficiently studied and future research in
this direction needs to be carried out to comprehend the stability of dsRNA molecule in the
in vivo studies. The choice of gene can also decrease the strength of the silencing signal. Ideally,
the protein whose function is to be silenced should have a short half-life, whilst the mRNA
turnover number should be high. The stability of protein explained the weak RNAi response
in both D. melanogaster and T. casteneum [160]. However, such studies have not been conducted
for the majority of the genes and therefore it can be concluded that expression of RNAi is
limited by many uncovered phenomena.
6. Conclusions
The advent of RNA interference has been a crucial phase of the modern day science. The wide
array of applications in the entomological research has led to many momentous findings. The
functionality of many genes has been understood by this technique. Its implication in func‐
tional genomics is not only restricted to the study of a given set of genes but is also used to
unveil the interaction of different genes in a particular metabolic pathway. The rapid pace of
RNAi-based research suggests that it would soon facilitate better understanding of evolution,
circadian rhythms, behavioural pattern, reproductive biology and interaction between host
and parasites/pathogens. However, successful manifestation of RNAi is dependent on several
factors. The insect species might lack the basic RNAi machinery [161] or may rapidly degrade
alien dsRNA. Such factors could be intrinsic to the concerned tissue or gene. The gene might
have high transcription rate and could evade the effect of RNAi or the target mRNA may be
too transient.
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As happens with every phenomenon, this mechanism can also undergo selection pressure.
Viruliferous insects that also have RNAi suppressors would be able to thrive on RNAi-
protected crops. Furthermore, single nucleotide polymorphisms (SNPs) that result in lower
effectiveness of the RNAi could potentially be selected for and lead to the evolution of
resistance [153]. Genetic variations among insect species are already a challenge for RNAi.
Therefore, parallel research must be carried out to develop strategies, which would minimise
the resistance development and selective pressures.
RNAi has proved its utility as a futuristic tool of insect pest management. However, there are
several issues that need to be addressed before the implementation of this technology in fields.
The knowledge gaps underlying large-scale implications of pesticidal RNAi-based crops on
the environment should be identified and bridged. The off-target gene silencing is a serious
concern where unintended organisms are adversely affected [162]. The non-target effects can
be categorised as off-target gene silencing, silencing the target gene in non-target organisms,
immune stimulation and saturation of the RNAi machinery [163]. A balanced approach should
be taken with maximum effects on the target pests with minimal effects on non-target
organisms.
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Abstract
The fast-growing human population requires the development of new agricultural tech‐
nologies to meet consumers´ demand, while minimizing environmental impacts. Insect
pests are one of the main causes for losses in agriculture production, and current control
technologies based on pesticide application or the use of transgenic crops expressing Ba‐
cillus thuringiensis toxin proteins are facing efficacy challenges. Novel approaches to con‐
trol pests are urgently necessary. RNA interference (RNAi) is a gene silencing mechanism
triggered by providing double-stranded RNA (dsRNA), that when ingested into insects
can lead to death or affect the viability of the target pest. Transgenic plants expressing
dsRNA version of insect specific target genes are the new generation of resistant plants.
However, the RNAi mechanism is not conserved among insect orders, and its elucidation
is the key to develop commercial RNAi crops. In this chapter, we review the core RNAi
pathway in insects and the dsRNA uptake, amplification, and spread of systemic silenc‐
ing signals in some key insect species. We also highlight some of the experimental steps
before developing an insect-pest-resistant “RNAi plant”. Lastly, we review some of the
most recent development studies to control agricultural insect pests by RNAi transgenic
plants.
Keywords: Biotechnology, dsRNA, Entomology, Gene silencing, Insect control, RNA in‐
terference
1. Introduction
Agriculture has to continually adapt to rising environmental concerns in conjunction with
meeting the increasing consumers´ demand. The fast-growing human population creates the
need for the sustainable intensification of agriculture throughout the world which can be
acomplished by adopting mechanization and new technologies to close yield gaps while
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
minimizing environmental impacts. In the past few decades, insect pest control has been
mainly conducted by the application of chemical pesticides because of the low cost and
efficacy; but their indiscriminate use has caused escalating problems with the evolution of
insect resistance to the pesticides together with secondary pest outbreaks. The development
of new biotechnological approaches, with the introduction of transgenic crops expressing
Bacillus thuringiensis (Bt) Cry toxin proteins, also known as insect-resistant transgenic Bt-plants,
decreased pesticide utilization in certain key crops, such as cotton and maize, and brought
economical and environmental benefits [1-3]. But once again, insect resistance has arisen, now
against the Bt toxins, and outbreaks of nontarget pests have emerged [1, 4], which makes
necessary the development of novel approaches to control selected agriculture pests.
RNA interference (RNAi) is a gene silencing mechanism at the cellular level triggered by
double-stranded RNA (dsRNA) and is likely to be the new approach underlying the next
generation of insect-resistant transgenic plants. In some studies, successful delivery of dsRNA
molecules to insects by ingestion resulted in the expected essential gene target silencing [5, 6],
which led to death or affected the viability of the target insect, resulting in control of the pest.
In general, long dsRNAs are processed by species-specific RNase-III-like enzymes, resulting
in smaller double-stranded molecules. These shorter RNAs are loaded into RNA complexes
as a guide for finding target mRNAs that are either cleaved or blocked for translation in
posttranscriptional silencing, or inducing histone modifications when involved in transcrip‐
tional silencing response [7, 8]. However, the RNAi systemic spreading mechanism is not
conserved across organisms, and its elucidation is an essential step in developing an efficient
method to control agricultural pests by RNAi technology.
In this chapter, we review how the RNAi mechanism occurs in insects, highlighting the core
RNAi pathway and components, and new developments regarding dsRNA uptake, amplifi‐
cation, and the spread of systemic silencing signals in some key insect species. We also discuss
the critical experimental steps before developing an “RNAi plant” protected against a specific
insect pest, with consideration to application. Lastly, we review some of the most recent
published studies to control agriculturally important insect pests based on RNAi transgenic
plants.
2. RNAi mechanism
RNAi is an important and natural antiviral defense mechanism, protecting organisms from
RNA viruses, or even avoiding the random integration of transposons [9]. Over time, with the
discovery of some aspects of the mechanism, RNAi has become a widely used tool to knock
down and analyze the function of genes. Most of the RNAi pathways have dsRNA as the
precursor triggering molecule that vary in length and origin [7, 8]. In addition, the RNAi
pathways differ not only in the RNA precursor molecule, but also in genes, enzymes, and
effector complexes involved throughout the process. However, some key steps are conserved.
Briefly, RNA duplexes are processed into short RNA duplexes, which are then used to guide
the recognition of their target, either to cleave a complementary mRNA, or to repress their
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target translation at a posttranscriptional silencing level, or to modify the chromatin structure
at the transcriptional level [7, 8].
The RNA precursor molecules from the RNAi pathways, all of which are already identified in
insects, are small RNAs, categorized into three classes [8, 10]: the first two classes are small
interfering RNAs (siRNAs; 20–25 nucleotides) and microRNAs (miRNAs; 21–24 nucleotides)
[7] (Figure 1). Both miRNAs and siRNAs share a common RNase-III processing enzyme, Dicer,
and closely related effector complexes and both can regulate gene expression at the posttran‐
scriptional level [8, 10, 11]. Conversely, the third class of small RNAs, the PIWI-interacting
RNAs (piRNAs; 24–30 nucleotides), are generated independent of the Dicer activity [12].
piRNAs have been reported to play an essential role in germ-line development, stem cell
renewal, transposon silencing, and epigenetic regulation [13-16]. These piRNAs originate from
a diversity of sequences, including repetitive DNA and transposons, and they seem to act both
at the posttranscriptional and chromatin levels [10]. The mechanism that generates and
amplifies piRNAs is not well-understood, but involves slicer activities (Argonaute proteins
associated with cleaving activity) [8, 10, 17]. Considered a specialized subclass of piRNAs,
repeat-associated siRNAs (rasiRNAs; 25-29 nucleotides) were identified in the Drosophila
genome [18], and suggested by Meister and Tuschl [7] to be involved in guiding chromatin
modification in this insect species (Figure 1).
The most recognized RNAi pathways are the siRNA and miRNA; despite being triggered by
different molecules, both precursors are long double-stranded RNAs (dsRNAs). Naturally in
a cell, long dsRNAs can derive from RNA virus replication, from the transcription of conver‐
gent cellular genes or mobile genetic elements, or from self-annealing cellular transcripts [8].
In the siRNA pathway, these long dsRNA are processed by Dicer into siRNA duplexes. By
contrast, in the miRNA pathway, miRNAs are generated from endogenous transcripts
(primary miRNAs; pri-miRNAs) that form stem–loop structures [19, 20]. In the nucleus, these
hairpin regions are recognized and cleaved into precursor mirRNAs (pre-miRNAs) by Drosha,
another RNase-III-family enzyme, and the pre-miRNAs are transported to the cytoplasm
through the nuclear export receptor Exportin-5 (Expo-5) [19, 20]. Subsequently, the pre-
miRNA undergoes another endonucleolytic cleavage, now catalyzed by Dicer, generating an
miRNA duplex [19, 20] (Figure 1).
The siRNA and miRNAs duplex containing ribonucleoprotein particles (RNPs) are subse‐
quently rearranged into effector complexes. Although it is difficult to assign distinct functional
labels, an siRNA-containing effector complex is referred to as an “RNA-induced silencing
complex” (RISC), and an miRNA-containing effector complex is referred to as an miRNP [7].
In these complexes, the regulation is at a posttranscriptional level and every RISC or miRNP
contains a member of the Argonaute (Ago) protein family [7]. For the regulation at the
transcriptional level as guided by rasiRNAs, a specialized nuclear Argonaute-containing
complex, known as the RNA-Induced Transcriptional Silencing complex (RITS) mediates gene
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and then catalyzes the slicing of these targets, either to be cleaved by RISC, to be blocked for
translation in miRNP or by inducing histone modifications in RITS [7] (Figure 1). The mecha‐
nism of miRNA-guided translational regulation is not as well-understood in the case of target-
Figure 1. RNA-mediated gene silencing pathways. In the nucleus, primary miRNA transcripts (pri-miRNAs) are proc‐
essed to mirRNA precursors (pre-miRNA) by the RNase-III-like enzyme Drosha. The pre-miRNA is exported through
the export receptor Exportin-5 (Exp-5) to the cytoplasm, and then processed by Dicer to microRNA (miRNA). These
miRNAs are unwound and assembled into miRNP (miRNA containing effector complex of RiboNucleo Protein parti‐
cles) or RISC (RNA Induced Silencing Complex), triggering silencing responses by translational repression of target
mRNAs or mRNA-target degradation, respectively. In the cytoplasm, long dsRNA are processed to siRNA (small in‐
terfering RNA) by the RNase-III-like enzyme Dicer. The short dsRNAs are unwound and assembled into RISC or RITS
(RNA-Induced Transcriptional Silencing) complexes. The siRNA guides the RNA cleavage by the RISC complex, while
rasiRNA (repeat-associated short interfering RNA) guides the condensation of heterochromatin by the RITS complex.
7mG: 7-methyl guanine; AAAA: poly-adenosine tail; Me: methyl group; P: 5’- phosphate. (Adapted from [7])
RNA Interference374
and then catalyzes the slicing of these targets, either to be cleaved by RISC, to be blocked for
translation in miRNP or by inducing histone modifications in RITS [7] (Figure 1). The mecha‐
nism of miRNA-guided translational regulation is not as well-understood in the case of target-
Figure 1. RNA-mediated gene silencing pathways. In the nucleus, primary miRNA transcripts (pri-miRNAs) are proc‐
essed to mirRNA precursors (pre-miRNA) by the RNase-III-like enzyme Drosha. The pre-miRNA is exported through
the export receptor Exportin-5 (Exp-5) to the cytoplasm, and then processed by Dicer to microRNA (miRNA). These
miRNAs are unwound and assembled into miRNP (miRNA containing effector complex of RiboNucleo Protein parti‐
cles) or RISC (RNA Induced Silencing Complex), triggering silencing responses by translational repression of target
mRNAs or mRNA-target degradation, respectively. In the cytoplasm, long dsRNA are processed to siRNA (small in‐
terfering RNA) by the RNase-III-like enzyme Dicer. The short dsRNAs are unwound and assembled into RISC or RITS
(RNA-Induced Transcriptional Silencing) complexes. The siRNA guides the RNA cleavage by the RISC complex, while
rasiRNA (repeat-associated short interfering RNA) guides the condensation of heterochromatin by the RITS complex.
7mG: 7-methyl guanine; AAAA: poly-adenosine tail; Me: methyl group; P: 5’- phosphate. (Adapted from [7])
RNA Interference374
RNA cleavage, and to make things more complicated, miRNAs can act as siRNAs, and siRNAs
can act as miRNAs [7].
Dicer is one of the enzymes involved in RNAi mechanism that is encoded by a variable number
of genes and presents distinct specificity among organisms [21]. For instance, mammals and
Caenorhabditis elegans, the best characterized animal for RNAi, have each a single Dicer
responsible for functions in both siRNA and miRNA pathways [12], while Drosophila mela‐
nogaster has two paralogues: Dicer-1 (Dcr-1) that preferentially processes miRNA precursors,
and Dicer-2 (Dcr-2) required to process long dsRNA into siRNAs [22]. However, in Tribolium
castaneum, a model organism among insects for systemic silencing by RNAi, Dcr-2 showed an
important role at the RNAi pathway, whereas Dcr-1 is suggested to have an involvement in
wing development, most likely through the miRNA pathway [23].
Another gene family involved in RNAi pathways is the Argonaute proteins (Ago). Ago is a
central protein component of silencing complexes (RISC, RITS, miRNP) that acts in mediating
target recognition and silencing [24]. Argonaute proteins contain two domains: a PAZ domain
involved in dsRNA binding, and a PIWI-domain responsible for RNase activity [23]. In
Drosophila, Ago-1 is involved in the miRNA pathway; Ago-2 in the siRNA pathway; while
Piwi, Aubergine (Aub), and Ago-3 are associated in transcriptional silencing [13, 25-27]. In
Tribolium, a single class of Argonaute was identified (Tc-Ago-1) in the miRNA pathway, while
two classes of Ago-2 paralogues (Tc-Ago-2a and Tc-Ago-2b) were found in the siRNA
pathway, probably deriving from gene duplication in the beetle lineage [23]. This duplicated
Tc-Ago-2 might lead to higher amounts of Ago-2 protein, potentially with the enhancement
of the RNAi response [23]. In the silkmoth Bombyx mori, a Lepidoptera species in which the
RNAi response is considered much less robust [28, 29], AGO genes from all three main RNAi
pathways were identified (BmAGO-1 – miRNA; BmAGO-2 – siRNA; BmAGO-3 – piRNA),
which were shown to be involved in the RNAi response in Bm5 cells [30]. Taken together, these
findings, and other reviews [29], support the idea of a function overlap of the three main RNAi
pathways in B. mori [29].
2.1. Systemic RNAi
Systemic RNAi is described as a silencing signal transmitted widely throughout a treated
organism [5, 31]. The knowledge about the systemic RNAi mechanism in insects is important
as it may affect the approaches adopted to develop “RNAi-mediated pest control” because the
systemic mechanism is not conserved among those organisms. Systemic RNAi has two
important steps to be considered: the uptake of dsRNA by the cells and the systemic spreading
of the signals. Some of the main genes involved in systemic RNAi are presented below and
discussed for the model organisms.
2.1.1. dsRNA uptake
In insects, two types of dsRNA uptake mechanisms have been identified [32]. The first one
involves a multi-transmembrane domain protein, Systemic Interference Defective (Sid). In C.
elegans, Sid-1 is essential and sufficient to mediate uptake and systemic spread of RNAi signal
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in both somatic and germ-line cells [33, 34]; conversely, in insects, Sid-1-like (Sil) proteins
appear to be variable across orders [32]. For instance, Diptera do not present SIL genes, while
Tribolium and B. mori presented three SIL homologues [23, 35]. However, these Tribolium genes
share more identity with another C. elegans gene, TAG-130, not required for systemic RNAi in
C. elegans compared to that with SID-1 [23]. The second dsRNA uptake mechanism involves
endocytosis, specific for dsRNAs acquired from the environment, known as environmental
RNAi [5, 31]. First discovered in Drosophila S2 cells and later in C. elegans, this uptake of dsRNA
by endocytosis appears to be evolutionary-conserved [36-38]. However, we should be cautious
to conclude that all organisms have a dsRNA uptake mechanism based on endocytosis. For
instance, Ulvila and colleagues [38] working with Drosophila S2 cells, which are hemocyte-like,
described high rates of endocytosis as compared to the majority of other cell types in this
species [39].
Other important proteins for systemic RNAi were identified in C. elegans but are specific only
to germ-line cells, such as Rsd-2, Rsd-3, and Rsd-6 [40]. The Rsd-2 protein contains no particular
known motifs but interacts with Rsd-6 that has a Tudor domain, suggesting that these two
proteins act together [40]. The RSD-3 gene encodes a protein that contains an epsin amino-
terminal homology (ENTH) domain, found in proteins involved in vesicle trafficking, sug‐
gesting the involvement of endocytosis in systemic RNAi [40]. In Tribolium, a homologue for
RSD-3 (Tc-RSD3) has been found, but in Drosophila, which does not exhibit a systemic silencing
response, a homologous Rsd-3 protein (Epsin-like) was identified [23]. So, the presence of
Rsd-3 does not seems to determine whether or not systemic RNAi occurs in insects, and it is
possible that the expression level and/or tissue specificity of this gene may affect the degree
of RNAi efficiency and the dsRNA uptake from the environment [23].
2.1.2. RNAi systemic spreading: amplification and maintenance of dsRNA
Once the dsRNA overcomes all the uptake barriers, the silencing signal should be transported
from treated cell to other cells, and spread to other tissues. Further, dsRNA should be con‐
stantly produced, e.g., either by the amplification of dsRNA by an RNA-dependent RNA
polymerase (RdRP), and/or constantly acquired for the maintenance of the silencing responses.
In C. elegans, primary siRNAs processed by Dicer are used as a template for an RdRP activity
to produce secondary dsRNAs [41]. The RdRP activity is key for the RNAi signal amplification.
However, so far in insects, no RdRP-related protein has been found [21, 23], suggesting that
strong RNAi response in insects does not rely on amplification of the trigger dsRNA, and it
must be based on a different mechanism yet to be identified. Alternatively, constant supply of
dsRNA may be provided by RNAi-plants to provide continuous effects.
The presence of the main genes involved in systemic RNAi and amplification in Drosophila and
Tribolium fail to explain the respective absence and presence of systemic RNAi [23]. Never‐
theless, the several differences in the number of these core component genes found between
species suggests an interesting avenue for further investigation [23]. For instance, Ago protein
that have already been shown to determine RNAi efficiency [42], was found to be duplicated
in the Tribolium genome, while Drosophila carries only a copy of AGO-2 gene, suggesting a
relationship between number of AGO copies and RNAi response [23].
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Another component that might affect RNAi efficiency in different insects are the proteins
containing the dsRNA-binding motif (dsRBM), which help small molecules to properly load
inside of the silencing complexes [23]. These proteins act together with Dicer, and seem to be
responsible for determining Dicer specificity in Drosophila [23]. In the T. castaneum genome,
two R2D2-like genes (a particular dsRBM) were found (TcR2D2 and TcC3PO), which might
help Tribolium to be hypersensitive to dsRNA molecule uptake by the cells [23]. However, in
the Anthonomus grandis transcriptome, only an R2D2 contig was identified [21]. The presence
of an additional R2D2-like protein in Tribolium might also allow a longer-lasting RNAi effect,
once dsRBM proteins are known to bind to dsRNAs, and might be involved in the maintenance
of dsRNA in cells [23].
3. Factors affecting the silencing effect and RNAi efficiency as an insect
control method
The RNAi approach to control insect pests had been considered for many years, but application
of this technology was just realized after it was shown that ingestion of dsRNA would trigger
RNAi. The concept of RNAi-plant mediated pest control was demonstrated in 2007 by the
development of transgenic plants producing dsRNAs against specific insect genes, with the
consequent effect on the target species [43, 44]. The main prerequisites to generate successful
RNAi insect-resistant transgenic plants are: (i) identification of a specific gene with an essential
function in the insect that can cause developmental deformities and/or larval lethality when
knocked down or knocked out; and (ii) dsRNA delivery by oral ingestion that must be uptaken
by the insect cells, and spread systemically.
The insect must uptake the dsRNA version of a target gene region by feeding. To silence the
target gene, this specific dsRNA must be taken up from the gut lumen into the gut cells as what
is considered as “environmental RNAi.” If the target gene is expressed in a tissue distinct from
the digestive system, the silencing signal should successfully spread via cells and tissues as a
systemic RNAi. Both environmental and systemic RNAi are considered noncell-autonomous
RNAi, which means that the interfering effect takes places in tissues/cells different from the
location of application or production of the dsRNA. Conversely, in the cell-autonomous RNAi,
the silencing process is limited to the cell in which the dsRNA is introduced [5]. However, the
mechanism of ingested dsRNA uptake and systemic spreading of the silencing signal in the
insect have yet to be fully characterized and understood.
Some factors can affect the efficiency of the dsRNA uptake and systemic silencing spread in
different insects. Here, we highlight important points that must be considered in developing
an RNAi approach against insect pests.
3.1. Target gene
The choice of the target gene should be carefully considered. Each gene requires particular
effort to be silenced. Terenius and colleagues [28] reviewed more than 150 RNAi experimental
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results from RNAi of lepidopterans involving 130 genes, from which only 38% were silenced
at a satisfactory level, while 48% failed to be silenced, and 14% were silenced at insufficient
levels. Among the target genes, those involved in immunity were more effectively silenced,
and, in contrast, genes expressed in epidermal tissues seem to be most difficult. Differences
for RNAi sensitivity among genes in the same tissue was described in [28].
3.2. dsRNA design
The design of the dsRNA determines the one particular target gene to be silenced, but off-
target effects can occur if siRNAs have some sequence similarity with unintended genes.
Tobacco plants expressing Helicoverpa armigera ecdysone receptor (EcR) dsRNA improved
resistance to another insect, Spodoptera frugiperda, due to the high identity shared between the
nucleotide sequence of HaEcR and SeEcR genes [45]. Although this result implies that an RNAi-
plant can control two or even more lepidopteran pests, this can also affect nontarget insects,
becoming a biosafety issue.
3.3. dsRNA length
The length of the dsRNA fragments plays an essential role in the effectiveness of molecular
uptake in insects, which is directly involved in the success of the target gene silencing. In most
of the RNAi experiments, the insects are fed with long dsRNAs [5]. Some experiments showed
that long dsRNAs are more efficiently uptaken than siRNAs [37, 46]. This may be due to the
fact that a long dsRNA, with 100% match of the target mRNA, after processing into siRNA
will provide a greater diversity of siRNAs available to cause specific suppression of target gene
and increase the desired effect, and, additionally, reduce the likelihood of developing resist‐
ance [47]. In contrast, other studies reported suppression of genes in different insects via
incorporation of siRNA in diet instead of dsRNA [48, 49].
3.4. dsRNA concentration
Optimal concentration of dsRNA delivered to the insect is required to induce sufficient gene
target silencing. It is noteworthy to mention that exceeding the optimal dsRNA concentration
may not result in more silencing [50, 51]. However, higher concentration of dsRNA decreased
the duration of dsRNA exposure to reach 50% mortality of Diabrotica virgifera virgifera [46],
suggesting an inverse relationship between dsRNA concentration and duration of exposure.
In cricket (Gryllus bimaculatus), the highest concentrations of dsRNA yielded more efficient
gene knockdown [52]. The amount of dsRNA sufficient to significantly reduce mRNA levels
of PER and CLK genes were one and two μM, respectively. These concentrations reduced the
expression level of the targets, but a higher concentration (20 μM) for the CYC gene was
required, suggesting that the sensitivity to dsRNAs also depends specifically on the gene [52].
3.5. Controls
Empty vector, empty cassette, buffer only, irrelevant or nonspecific control (such as dsGFP –
Green Fluorescent Protein gene region), or any other kind of negative control are essential to
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discriminate specific gene silencing from the simple induction of siRNA processing machinery
by exposure to a dsRNA. Mainly, a negative control should demonstrate the specificity of the
dsRNA designed for a target, not interfering in specific target expression, and even unspecific
effects. Also, any control should have similar size and concentration of the used dsRNA [53].
3.6. Molecular silencing confirmation
An efficient molecular confirmation of the RNAi silencing should be conducted, which
includes target RNA expression, and analyses of protein amount and/or enzyme activity. In
RNA analysis, additional care should be taken for expression analysis. The method of choice
for RNA expression analysis is the quantitative amplification of reversed transcripts or RT-
qPCR, considered a very sensitive and accurate method. To provide precision in RT-qPCR,
some essential care is required, such as the choice of appropriate stable reference genes and
primer pair design with sufficient amplification efficiency. The reference genes should exhibit
stable expression among experimental conditions, providing reliable estimate of gene expres‐
sion results [54]. Additionally, primers should be designed flanking the region used to design
the dsRNA to ensure that the initial cleavage of the mRNA could be detected, thus avoiding
false-positives [55]. Conventional care of RT–qPCR reactions defined by the Minimum
Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines
must be strictly followed [56].
3.7. Protein stability and phenotype analysis
Proteins can exhibit a long half-life and interfere with the phenotypic changes. However,
phenotype changes are not totally related to small decrease of protein levels; haplo-sufficient
genes produce proteins capable of performing the biological processes normally, even at half
of the protein levels [53]. Phenotype changes could be more difficult to be observed in RNAi
responses if the protein product of the target gene has a long half-life. For example, the
reduction of Da6 (nicotinic acetylcholine receptor subunit) expression in both D. melanogaster
and T. castaneum exhibited weak phenotype responses [57], which may be explained based on
the long stability of the nicotinic acetylcholine receptors (nAChRs) [58]. Nevertheless, for most
of the genes, mRNA turnover and protein half-life are unknown and this lack of information
presents one of the principal challenges for the RNAi experiments [39].
3.8. Insect issues, life stage, nucleases, and gut pH
Some insect characteristics should also be considered before starting an RNAi experiment
including the developmental stage of insects. Although handling advanced developmental
stages of insects is more efficient, silencing effects are more prominent in earlier stages. For
instance, in second instar larvae of Rhodnius prolixus, the gene nitropin 2 was knocked down
for 42%, but no silencing was observed in the fourth instar individuals, even though both larval
stages were treated with the same concentration of dsRNA [59]. In Spodoptera frugiperda, fifth
instar larvae presented higher gene silencing as compared to adult moths [60].
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Another consideration that can affect the RNAi silencing efficiency is the presence of insect
nucleases and gut pH. For instance, feeding assays with Lygus lineolaris showed no mortality
effects because the saliva of L. lineolaris contains dsRNA-degrading activity. Thus, dsRNA
ingested did not result in siRNA fragments, rather were completely digested to monomers
[61]. Also, dsRNA degradation is reduced during molting period and further reduced by
starvation in some insects [62]. The stability of the dsRNA in the midgut could be affected not
only by enzymatic but also by chemical hydrolysis [63]. In both cases, gut pH is an important
factor; particularly, it is quite variable among insect orders, with variation even among gut
regions [64]. For example, in general, lepidopterans exhibit a strong alkaline gut (up to pH 10.5
in some species), which provides a highly hostile environment for dsRNA [64]; therefore, this
order is particularly recalcitrant to gene silencing by RNAi.
4. Overview on the use of RNAi to control insects by transgenic plants
Most of the current transgenic crops with specific control against insect pests are based on
Bacillus thuringiensis (Bt) toxins, which act in gut epithelial cell membrane in susceptible insects.
Bt toxins are highly specific against certain orders of insects, where the most successful use
was achieved against Lepidoptera and Coleoptera. However, continuous exposure of those
insects to Bt crops evolved field-resistance, affecting the efficiency in controlling those pests
[4, 65]. Also, there are limitations of Bt transgenics to manage some other important agricultural
pests, such as the sap-sucking insects (Hemiptera). This encouraged the development of new
strategies to help in controlling agricultural pests.
In 2007, two studies demonstrated the concept of plants expressing dsRNAs derived from
hairpin vectors that directed dsRNAs to target gene regions of economically important
agricultural pests: the cotton bollworm (Helicoverpa armigera; Lepidoptera; [44]) and the
Western corn rootworm (WCR; Diabrotica virgifera virgifera; Coleoptera; [43]). After the
demonstration of plants resistant to insects, the application of RNAi by transgenic plants
became a potential new approach to control important agricultural pests, which led to the
flourishing of a new field of research. So far, searches on the publication database “Web of
Science” from Thomson Reuters (August 2015), identified 543 published studies based on the
combination of the topics “RNAi,” “plant” and “insect,” and only one quarter was published
before 2008.
To implement RNAi in agricultural pest control, the target insect should uptake the dsRNA
autonomously, e.g., from transgenic plants expressing dsRNA. This feeding should be
continuous, since insects lack an amplification mechanism based on RdRP, such as C. elegans.
Many of the main agricultural pest species have already been targeted by RNAi technology
using various genes and delivery methods [66]. However, three orders have been the major
focus of the development of transgenic plants expressing target gene regions for RNAi:
Coleoptera, Hemiptera, and Lepidoptera. Here, we list some of the most recently published
RNAi transgenic plants studies performed against those insect orders (Table 1).
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Specie Order Crop Target Gene Remarks Reference
Diabrotica v. virgifera Coleoptera Zea mays vATPase Mortality [67]
Leptinotarsa decemlineata Coleoptera Solanum
tuberosum
β-actin, Shrub Mortality [68]
Helicoverpa armigera
Spodoptera exigua
























MpC001, Rack1 Progeny reduced [72]
Myzus persicae Hemiptera Arabidopsis
thaliana
serine protease Progeny reduced [73]
Myzus persicae Hemiptera Nicotiana tabacum hunchback(hb) Inhibited
reproduction
[74]
Bemisia tabaci Hemiptera Nicotiana rustica vATPase Mortality [75]
Table 1. Overview of the recently published studies on the use of plant-RNAi against different insect pests
4.1. Coleoptera
The coleopterans are likely to be the first target to be controlled by the new generation of
transgenics, the “RNAi-plants.” Diabrotica virgifera virgifera (Western corn rootworm, WCR) is
one of the most important agricultural pests, and this species, along with other coleopterans,
requires little effort to have genes silenced by RNAi, independent of the delivery method and
gene target. The significant breakthrough was demonstrated when WCR presented significant
larval stunting and mortality, causing less injury to maize roots that express a hairpin version
of V-ATPase A [43]. Since then, many studies have been conducted using various target genes,
while not focusing only on pest control, but also to characterize the mechanism of action of the
RNAi [46]. A recent study with WCR demonstrated that long dsRNAs of Dv V-ATPase C
expressed in maize provides highly efficient root protection, but the siRNA population
generated in the transgenic plant does not lead to lethal RNAi responses when consumed by
the insect [67].
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Studies have also been performed in other species, such as the important potato pest Leptino‐
tarsa decemlineata (Colorado potato beetle, CPB). So far, this is the first study to compare efficacy
at controlling pest insects by dsRNAs expressed either in the chloroplast or in the cytoplasm.
Transgenic potato plants expressing hairpin versions of β-actin and Shrub genes (both insectidal
dsRNAs) in the chloroplasts (transplastomic plants) conferred the most potent insecticidal
activity (insects died after 5 days), while the conventional expression from nuclear transgenics
did not affect the beetles [68].
An explanation for this result is that since choroplasts do not have cellular RNAi machinery
[69], the dsRNAs produced inside these organelles are not cleaved by a plant Dicer and the
beetles ingest almost entirely long dsRNA. In contrast, beetles fed on nuclear-transformed
plants consumed mostly siRNAs; previous dsRNA-feeding studies already indicated that
ingested long dsRNAs were much more effective than ingested siRNAs. It should be high‐
lighted that all the other studies have been based on an efficient cytoplasm-derived dsRNA in
various crops, indicating that possibly potato plants process long dsRNA more effective than
the plants from those other studies (Table 1 [69]).
4.2. Lepidoptera
Plants producing Bt proteins were the first generation of transgenic plants to control insects,
and most of the lepidopterans were successfully managed by Bt crops for years. However, the
durability of Bt technology appears to be unsure. The number of pest species that evolved Bt
resistance in the field, reducing transgenic efficacy, increased from one in 2005 to five in 2010
[4]. Among those five species, four are lepidopterans [4]. The lepidopterans could be the first
and main targets for RNAi crops if they were not as recalcitrant to gene silencing, without any
definite explanation for the limited and unstable RNAi responses [28, 29]. For instance, the
concentration of dsRNA necessary to knock down a specific gene by feeding Diatraea saccha‐
ralis (Lepidoptera) neonate larvae is much higher than the one required for the same larval
stage of D. v. virgifera (Coleoptera).
The first successful RNAi plant protected against a lepidopteran (Helicoverpa armigera) was
demonstrated by silencing the CYP6AE14 gene, necessary for detoxifying gossypol from cotton
(Gossypum hirsutum) [44]. Studies have been conducted to explore alternative target genes to
control and understand the RNAi mechanism in lepiopterans. Larval lethality and molting
defects were detected in H. armigera fed with transgenic tobacco plants expressing dsRNA
targeted to the nuclear ecdysone receptor complex (HaEcR), absolutely required for insect
development [45]. The transgenic tobacco expressing dsRNA of HaEcR had an improved
resistance to another lepidopteran pest, Spodoptera exigua. This cross-species effect might
indicate a risk to affect nontarget insects, highlighting the importance of biosafety studies that
should be carefully conducted [45].
The expression of dsRNA in both Escherichia coli and transgenic tobacco plants to silence a
molt-regulating transcription factor gene (HR3) of H. armigera resulted in developmental
deformity and larval lethality [70]. Transgenic Arabidopsis thaliana plants expressing dsRNA
targeted to arginine kinase (AK) of H. armigera (HaAK) led to a 55% mortality rate in first instar
larvae, while retarding growth in surviving larvae [71]. However, no lethal phenotypes were
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observed for the third instar larvae, although transcript levels of HaAK were distinctly
suppressed [71].
4.3. Hemiptera
Hemipterans are characterized as piercing/sucking insects, representing major agricultural
pests that inflict direct damages by sucking sap, or indirectly by acting as a vector of several
viruses and bacterial infections. Since hemipterans feed through sucking the phloem, only
systemic chemical insecticides are effective against these insects, resulting in high residual
toxicity. The problem is further aggravated as no Bt toxin has been identified as exhibiting
adequate insecticidal effects against hemipterans. Transgenic crops based on RNAi offer a
large potential to control hemipteran, requiring expression of target gene dsRNAs on the
phloem. One first report was published in 2011 about developing transgenic Nicotiana
benthamiana and A. thaliana expressing dsRNA targeting genes expressed in Myzus persicae gut
(RACK1) and salivary glands (MpC002) [72]. A reduction of the expression level of the target
genes and a decrease in M. persicae fecundity were observed, but no lethal effects [72].
The same phenotype was observed when M. persicae fed on A. thaliana expressing dsRNA of
a serine protease gene (MySP), with no lethal effects, but reduced fecundity [73]. Once again,
reduced reproduction, but no lethal phenotype was observed when M. persicae was fed on
tobacco plants expressing dsRNA targeting the hunchback gene [74]. A possible explanation for
not achieving the expected phenotypes (mortality) after target gene depletion is that the
dsRNA level produced by RNAi transgenic plants could not be sufficient for an efficient uptake
of dsRNA or siRNA by sap-sucking insects [74]. However, more recently, mortality rates were
observed in Bemisia tabaci fed in tobacco plants expressing dsRNA of v-ATPaseA [75]. This
result provides a proof-of-concept that plants expressing dsRNA, at an efficient level and
targeting crucial genes, could resist the attack of Hemipteran pests [75].
5. Conclusion and future perspectives
Since the concept of a transgenic plant expressing dsRNA targeted to a specific essential gene
in the insect that affects its viability was first demonstrated in 2007, the technology has been
extended to a large number of insect species from various orders. Elucidating the various
mechanisms and components of the RNA interference pathway has progressed, but many
aspects remain to be clarified. Many differences in components and mechanisms among insect
orders and between insects and other organisms still need to be worked out. Some of these
differences (e.g., genes involved, gene number, and level of expression) may explain variation
in recalcitrance among insect species and need to be further investigated. Of particular interest
are the mechanisms of dsRNA uptake, signal amplification, and systemic spread in the major
pest species. Additional insect- or order-specific characteristics, such as gut pH, presence of
dsRNA-degrading activity in digestive system, among others that could be associated with
differences in recalcitrance to RNAi need to be dissected and clarified.
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Due to the variety of RNAi response to RNAi in insects, no single protocol is suitable for all
species. Issues related to the choice of effective target genes, including determining the size of
optimal dsRNA length and ideal gene region. Assuming that the method of choice to deliver
dsRNA is transgenic plants, a major question still to be addressed is the impact of plant dsRNA
processing in the effective RNAi-induced silencing. There is still a need for investigation in
this area. The choice of a suitable inducible promoter for expressing the dsRNA construct is
another point barely explored.
Based on the recent publications reviewed in this chapter, the progress in developing “RNAi-
plants” to control important insect pests widely demonstrated the potential of this technology
to complement or replace Bt crops, providing resistance against a broad variety of insect pests.
However, to be applied on a commercial level, several issues related to the RNAi mechanism
and biosafety still need to be addressed. As a new technology, risk assessments and govern‐
ment regulations still have to be developed. However, RNAi transgenic crops are expected to
have wider acceptance and reduced biosafety requirements for RNAi traits, in comparison to
a protein incorporated into a plant, such as a Bt transgenic [39]. Thus, RNAi-mediated pest
control will open a new paradigm in insect pest management.
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Abstract
RNAi technologies are more environmentally friendly, as the technology provides great‐
er specificity in pest targeting, while reducing the potential negative effects on ecosys‐
tems and leaving beneficial insects and other organisms unharmed in crop ecosystems.
Consequently, the increase in native fauna improves the efficacy of biological control
agents against pests and pathogens. A growing understanding of the ubiquitous nature
of RNAi, along with evidence for efficient, non-transgenic, topical applications has al‐
ready begun to garner support among organic and industry producers. Designing solu‐
tions to agricultural problems based upon the same mechanisms used in nature provides
newer, safer solutions to pests and pathogens for all agricultural industries.
Keywords: Future, Crops, Organic, Non-transgenic, RNAi
1. Introduction
A phenomenon initially reported in plants [1] called the attention of the scientific community,
leading to the discovery of a sophisticated mechanism of gene regulation and protection
against invasive nucleic acids [2–4]. Furthermore, the mechanism described in plants, referred
to as post-transcriptional gene silencing (PTGS), or virus-induced gene silencing (VIGS), had
been described in the 1990s [5] and was often referred to as pathogen-derived resistance [6].
RNAi is a natural process of gene regulation and antiviral defense system of eukaryotic cells.
RNAi is a mechanism that functions as a “gene silencer” by targeting specific RNA sequences.
RNAi results in degradation, and in some situations, translation inhibition, resulting in a
reduction or complete elimination of the expression of a targeted RNA [7]. RNAi is also linked
to suppressing gene expression at transcriptional level by directing epigenetic alterations on
chromatin [8].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
The basic RNAi process consists of the trigger molecule, a long endogenous or exogenous
double-strand RNA (dsRNA) molecule that is expressed in, or introduced into, the cell, which
is processed by Dicer, a ribonuclease III (RNase III) enzyme into small RNA duplexes of 21–
23 nucleotides in length. These duplexes are separated with one strand (the guide strand),
producing a protein complex known as the RNA-induced silencing complex (RISC). The RISC
complex uses the specific sequence of the guide strand to determine potential target messenger
RNAs (mRNA). Once bound to the mRNA, the guide strand directs a RISC-bound endonu‐
clease [called “slicer”, an Argonaute (AGO) protein] to cleave the mRNA which has homology
to the guide strand [9]. Thus, the RISC complex can target the messenger RNA (mRNA), an
invasive virus RNA, or a transposable element transcript (Please note that RNAi cannot
eliminate transposons itself, but its transcripts.) [10]. These components appear to be cosmo‐
politan in their distribution across the RNAi spectrum of the eukaryotic phyla. This implies
that a common ancestor had a functional RNAi pathway [11], estimated to have occurred over
a billion years or more ago [12].
The generation of virus-resistant transgenic plants, by expressing fragments of viral genomes,
was the first demonstration of the beneficial use of the RNAi [13,14]. However, with the
demonstration that ingestion of dsRNAs can robustly silence genes in Caenorhabditis elegans [7],
RNAi became not only an important tool in genetic studies to identify gene function but also
opened a new field of application in plant protection against insects, arthropods, and patho‐
gens.
In this chapter, we outlined some aspects on the development of RNAi-based strategies to
control insects, presenting some considerations and research steps that are important to be
addressed.
2. RNAi-based products for agricultural management of insect pest
Advances in genomics and initiatives to sequence genomes of agriculturally important
organisms created big breakthroughs within the entomology fields of study, including
taxonomy, insect physiology, toxicology, immunology, pest management, and microbe–host
interactions. This new paradigm affected how research could be conducted, to make discov‐
eries and increase the speed by which these could be accomplished. With these breakthroughs,
entomologists, pathologists, and biologists are rapidly advancing toward better, safer, and
more specific pest and pathogen management. Development of gene-based methods was
dependent upon having the knowledge to understand how the cells in a living organism
respond to the threats from viral pathogens, how they regulate their own gene expression, and
how they maintain these natural complex systems throughout their lives.
The initial genomes which were sequenced and annotated to elucidate these very complicated
interactions from: the nematode – C. elegans, the fruit fly – Drosophila melanogaster, the red flour
beetle – Tribolium castaneum, the silkworm – Bombyx mori, the pea aphid – Acyrthosiphon
pisum, the honey bee – Apis mellifera, to bumble bee – Bombus terrestris and including a few
more examples from the world of agriculture [15]. Current genome initiatives, like the i5K
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Arthropod initiative [15] and the Beijing Institute of Genomics, BGI, China, plan to sequence
thousands of arthropod and plant genomes. The enormous amount of new information
produced will also increase the understanding of the genetic basis of the mechanisms nature
uses to solve problems at the cellular and organismal levels.
The number of arthropod species which have had successful RNAi reports continues to
increase, and this trend will carry agriculture into the future, covering five Classes, in four
Subphyla of the Arthropoda phylum, which includes eight insect orders and over 30 insect
species [16–17].
3. Pitfalls and solutions – Relevant considerations for development of
RNAi in insects
Though the use of RNAi strategies to control a desired insect pest seems to be very straight‐
forward; however, some issues should be taken into considerations: (1) for oral treatments the
dsRNA must survive ingestion, then be absorbed by the epithelial cells, and depending upon
the target translocated through the hemolymph to reach other tissues. In insects, the dsRNA
is mainly introduced through feeding, but dermal application has already been reported to
possibly bypass gut issues [18–21]; (2) once inside the body, the dsRNA must enter into the
cell to activate the RNAi mechanism. In insects, cell uptake of dsRNA varies widely between
species, because there are different mechanisms of systemic absorption and translocation of
dsRNAs within and between cells, respectively, leading to differences in response and
influencing the efficiency in silencing the target gene [17,22]; (3) once the RNAi mechanisms
are triggered in a group of cells, it has been demonstrated that a systemic spread of silencing
may also occur, so that other tissues / cells are also affected, which may increase the RNA effect.
Successful studies have shown that dsRNA can circulate in the hemolymph, and cause a
suppression of genes in tissues distant from initial entry sites in the insect gut, affecting cuticle
formation, the nervous system, or ovaries[23–26]. However, in insects results can be highly
variable and research efforts continue to elucidate the effects of systemic signaling.
In theory, any cellular mRNA can be inactivated in a precise and controlled manner. With this
in mind, the use of the RNAi mechanism to manage an insect pest relies on the capacity to
design the dsRNA. The sequence of the dsRNA provides specificity and the researcher must
determine the active concentration needed to obtain the desired RNAi outcome; thus, proper
design and evaluation of the dsRNA becomes critical.
Identification of vitally important (i.e., with high mortality) target genes of a particular insect
is a crucial step toward development of RNAi-based control strategy. Thanks to world science
development and increasing efforts of the research community, the identification of an
essential target can be achieved by an extended literature search and analyses of available
DNA/RNA sequence databases [27]. Once identified, “candidate” target sequences are used
to design potent “RNAi causing structures”. Then, the dsRNAs must be experimentally
validated for functionality, specificity, and stability, toward the specific RNAi target of interest.
Furthermore, the development of an efficient delivery system for “RNAi causing structures”
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is another key step. There are several methods available that include, but are not limited to:
microinjection [28], soaking (for mosquito larvae, and nematodes) [29,30], and feeding
(chewing and piercing-sucking insects) [17,17,27,31,32].
One approach to identify potential target genes which will function under field conditions is
to perform bioassays that closely mimic the conditions in the field, for example, using a
bioassay that mimics the feeding of a hemipteran insect acquiring the dsRNA during the
natural feeding process performed on the crop plant. One problem with delivering dsRNA
through feeding is that, depending on the bioassay, it may be difficult to measure the dose of
dsRNA ingested, from the dose absorbed by the gut cells and the target cells [33].
Oral delivery of dsRNA through feeding can be performed by using artificial diet, detached
plant parts (leaves, buds, roots), or intact plants [17,24,34,35]. Delivering dsRNA through the
diet provides an easy procedure to screen large numbers of dsRNAs in insect larvae and adults
[23,24,34,37]. In addition, it allows addressing different issues, such as effective length of
dsRNA, determine regions of the gene to be target which may provide better suppression, and
to determine the effective lethal concentration (LC50) [23,38].
Although oral feeding provides a more natural screening system, it is important to take into
consideration that for some insect species from across all taxonomic orders, they may not
provide an effective RNAi response when conducting oral feeding bioassays regardless of the
dosage of dsRNA, as the dsRNA may not enter, or be detected in the insect’s body [22]. In
contrast, in these same insects when dsRNA was injected directly into the insect’s body, a
potent RNAi response was observed [23,39,40]. Indeed, lack of positive results using feeding
bioassays does not necessarily indicate that the insect is insensitive to RNAi, but in a majority
of the situations, insects have nucleases in the saliva, in the midgut, or even in the hemolymph
that degrades dsRNA before it can be absorbed by the cells [40–42].
Wynant et al. [40] discussed the interactions of enzymes and RNAi-causing dsRNAs in the
alimentary tract and hemolymph of insects and other arthropods using oral delivery. The
elucidation of the roles of microbes and host enzymes on RNAi efficacy across arthropod
species continues to be a challenging field of research [43].
Where information about absorption of dsRNA or presence of nucleases is not available for a
particular insect species, the use of reporter dsRNAs molecules are useful to clarify possible
issues. It is essential that the dsRNAs sequence should not match with any insect’s transcript
sequence. The dsRNA “movement” can be monitored (detected), or quantified in the insect’s
body by RT-qPCR, showing that the insect has acquired the potent, fully functional, systemi‐
cally spreading dsRNA during feeding (plant, diet, drop of water, etc.) (Figure 1).
When conducting a RT-PCR detection of reporter dsRNA after insect feeding, it is important
to sample a tissue other than the gut such as the hemolymph, fat body, or ovary. Careful
collection of tissues which are not in direct contact with the gut provides evidence that the
dsRNA was truly absorbed by the cells, and you are not just detecting dsRNA just in the
digestive tract.
With small insects, as the Asian Citrus Psyllid (ACP) Diaphorina citri (whitefly or aphids),
collection of material can be difficult without bringing in gut tissues, so another option is to
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let the insects feed on the source of the dsRNA (plant, diet, etc.) for a period of 24–48 h, then
transfer them to an untreated food source. After feeding for 36 h, or more, the insect should
excrete any food residue from the treated food source, which contains dsRNA. After this
period, proceed with sample collection for dsRNA detection.
The reporter dsRNA is designed so that the sequence does not match with any known mRNA
transcript in your insect. This is to avoid off target of other transcripts in the insect. Some
commonly used dsRNAs which are used as negative controls in RNAi experiments are: green
fluorescent protein (GFP), β-glucuronidase (GUS), and enhanced yellow fluorescent protein
(EYFP) [44].
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including: the length of the molecule and the region targeted within the mRNA. The minimal
required length to achieve an RNAi effect will vary depending on insect species [45]. For
example, in Tribolium castaneum, analysis showed that the dsRNA length had a strong influence
on the efficacy of the RNAi response, with longer dsRNA proven to be more effective on
curtailing gene expression [46]. In T. castaneum dsRNA, it was observed that length was crucial
for cellular uptake; a minimum of 70 nucleotides were necessary to achieve the desired
interference. However, other studies in the potato/tomato psyllid, Bactericera cockerelli [47], the
pea aphid Acyrthosiphon pisum [48], and the lepidopteran Manduca sexta [49] have reported
gene suppression using shorter dsRNAs, between 21 and 27 nucleotides in length. These
molecules are called small interfering RNAs (siRNA). Overall, the majority of studies dem‐
Figure 1. Topically applied RNA, provides long dsRNAs for insect ingestion. If absorbed into the plant, then long
dsRNA persists in plant vascular tissues, xylem, and phloem, for several weeks due to lower metabolic activity, fewer
enzymes, and microbes. Once the dsRNA enters a plant or insect cell, the RNAi mechanism is triggered, and the
dsRNA processed [Image: Hunter, W.B., USDA-ARS, 2015].
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onstrate success with dsRNA ranging from 140 to 520 nucleotides in length. Interestingly,
Huvenne and Smagghe [31] reported success using a dsRNA 1,842 nucleotides in length.
dsRNAs longer than 200 nucleotides provide the advantage of resulting in many siRNAs, post-
cleavage against the targeted mRNA, thus maximizing the RNAi response and preventing the
development of individuals with “resistance” due to the natural genetic variation.
There is no consensus on the mRNA region that the dsRNA should match to (e.g., 5′ or 3′). For
example, in the pea aphid, A. pisum, no difference in mortality was observed in groups of
insects that received dsRNA matching the 5′ or 3′ end of the hunchback (hb) gene [27]. In the
mosquito, Aedes aegypti greater RNAi effects were achieved when insect larvae ingested
dsRNA targeting the 3′ end versus 5′ end of an apoptosis gene, AaeIAP1 [18]. These different
results highlight the need to screen several dsRNA molecules across the entire mRNA [50].
In the context of field applications of RNAi for insect management, dsRNAs can be designed
to be highly specific to both the target gene and the insect species. If desired, the RNAs can be
designed to have a broader spectrum to affect several pest species. For example, RNAi
strategies can be designed to remove one aphid species from a cropping system, or be designed
to remove multiple aphid species from that same ecosystem [24,38].
4. Bioassays for dsRNA screening
For RNAi research attempting the development of a viable pest management product. It is of
utmost importance to identify the best delivery mechanisms (i.e., topical sprays, baits, or
transgenic plants) as early as possible; this will expedite the entire process and can cut years
off of the development and commercialization timeline.
The example outlined below highlights RNAi bioassays directed toward two citrus insect
pests, each one with different feeding behaviors: piercing-sucking plant-feeding (the Asian
citrus psyllid Diaphorina citri, Hemiptera) and a chewing beetle pest (the weevil Diaprepes
abbreviatus, Coleoptera). In both situations, the bioassays were designed to evaluate the efficacy
of oral ingestion of dsRNAs under “natural feeding conditions” which mimic conditions the
insects will encounter in the field.
4.1. Bioassays for piercing-sucking insects
The artificial feeding bioassay is being widely used for studies on insect nutrition, pathogen
acquisition, toxicity, and RNAi (Figure 2A) [51–53].
It is notable that liquid feeding bioassays (dsRNAs mixed in a liquid diet or a sucrose solution)
frequently result in high mortality levels in the controls, and increased degradation of dsRNA
in the solution due to bacterial or fungal contaminations [42,57]. In addition, these bioassays
require significantly high dsRNA concentrations to achieve insect mortality. Concentrations
up to 1μg/μL [58–60] cannot be reproduced inside plant vascular tissues.
Hemipteran pests in citrus (psyllids, leafhoppers, aphids, whiteflies) have piercing-sucking
mouthparts that are inserted into the plant vascular system to feed. The development of an
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RNAi control strategy against these insects relies on effective delivery of the dsRNA through
the vascular tissues.
Demonstration of the first dsRNA delivery into full-sized citrus trees and grapevines, without
a delivery vector, expression vector, or transformation event was performed in 2008 [56]. These
results showed that two hemipteran insects, the xylem-feeding leafhopper (H. vitripennis), and
the phloem-feeding Asian citrus psyllid (D. citri), tested positive for ingested dsRNA after
feeding from host plants treated with dsRNA as either a foliar spray or root drench. These
results along with other studies that demonstrated successful RNAi through oral ingestion in
insects [24,34,36,61,62] support the potential for exogenously delivered RNAi control strat‐
egies.
Use of cut plant feeding bioassays for hemipteran pests enables the screening of a large number
of dsRNAs molecules at a reduced cost of materials and time. The bioassay, can use leaf disks,
whole leaf, new growth leaves and stem, or rooted cuttings, to absorb and deliver dsRNAs. In
citrus, the “flush”, which are new growth foliar shoots, are collected from potted citrus
seedlings grown in a glasshouse (USDA-ARS, Fort Pierce, FL). The leaves and stem material
are about 7–8 cm long. The plant material is washed in 0.2% bleach water, for 10 min. Then the
base of each stem is cut at a 45 degree angle while submerged in filtered water. The material
is then placed into a 1.5 mL tube containing 0.5 mL water (Figure 2B and C). The dsRNA
solution, 300 μL, is added to the water, the tube top is wrapped with plastic or Parafilm™ and
placed under artificial lighting to stimulate absorption of dsRNA solution. The next day the
tube is filled with water using a 26 gauge syringe needle and syringed filtered (0.45 μ). The
treated cuttings are then placed into a cage and adult insects provided feeding access for 10
days (Figure 2D). The plant material can remain viable for up to 40 days on average. While
most bioassays may terminate after eight to 10 days of observations for mortality, having a
Figure 2. RNAi feeding assays used at the USDA lab, ARS, Ft. Pierce, FL (2007-2014), to successfully screen dsRNA
constructs rapidly and under controlled conditions: (A) sucrose solutions within artificial membranes (5 ng
dsRNA/μL) [54], (B) rooted okra plant cuttings, (C) citrus flush (5 ng to 100 ng dsRNA/ 0.25 g plant tissue). Plant cut‐
tings absorb dsRNA directly providing systemic movement of dsRNA, (D) insects are given a feeding access period to
ingest the dsRNA across 10 days to observe mortality (Hunter and Andrade, USDA-ARS 2015) [54–56].
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longer feeding access time enables observations on insect oviposition, egg viability, or nymph
development.
Each dsRNA molecules has an optimal concentration. So each dsRNA molecule is evaluated
across a range of total concentrations (i.e., 5, 20, 50, 100 nanograms/ tissue). The bioassay
permits screening for synergistic effects of multiple dsRNAs and to screen a single dsRNA
against multiple insect species. For example, the assay using citrus flush permits screening of
dsRNAs designed against psyllids for off target effects in the citrus aphid (Toxoptera citrici‐
dus) and glassy-winged sharpshooter leafhopper (Homalodisca vitripennis (Germar), two closely
related hemipterans, which also use citrus trees as a host plant.
4.2. Bioassays for chewing insects
For insects which are foliage feeders, the delivery of dsRNA can be achieved as a foliar topical
spray. In this scenario, the dsRNAs are evaluated similarly as topical insecticides. The dsRNA
solution is sprayed on leaves, and then fed to the insects. An example of the effectiveness of
this approach was reported by Bolognesi [45] working with the coleopteran Diabrotica
virgifera, in which dsRNA administered through feeding, silenced genes in tissues far from the
gut epithelium.
Similar results were obtained while developing an RNAi strategy against the Diaprepes root
weevil (DRW), Diaprepes abbreviatus L., (Curculionidae: Coleoptera) (Andrade and Hunter).
The adults feed and oviposition on mature citrus leaves. Topically applied dsRNA was sprayed
on a bouquet of citrus leaves for delivery to DRW adults (Figure 3A). RNA’s have been shown
to move through the plant xylem and phloem [6].
Figure 3. Citrus “leaf bouquet” feeding bioassay for Diaprepes root weevil. (A) Fresh stems with leaves are washed in
0.2% bleach water, rinsed with Nanopure™ filtered water, then the stems are freshly cut while submerged in water.
The leaf bouquets are placed in water-filled containers and placed under artificial lighting for 24 h prior to use. (B)
Topical foliar treatment: the dsRNA is mixed with water and applied using a low-volume aerosol sprayer. (C) After
the leaves dry, the “bouquets” are caged with adult insects.
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A test spray using only water established the volume needed to provide full coverage of leaf
bouquets without excessive run off (Figure 3B). After the leaves have dried, they are caged
with adult insects (Figure 3C). Freshly treated citrus leaf bouquets replaced previous bouquets
every five to seven days for a 5-week period. The total amount of dsRNA to be sprayed over
the leaf bouquet was determined by evaluating a range of concentrations in a pretest experi‐
ment for efficacy. The effects from RNAi in insects usually start to appear within 4 to 5 days
post-ingestion, which suggests there may be a dose response [63]. Since foliage feeding insects
tend to eat a lot of leaf material each day, a low-dose spray may be able to deliver a significant
amount of dsRNA.
5. Final considerations on RNAi applied to agriculture
Efficient delivery and increased stability of dsRNA need to be developed if non-transgenic,
topically delivered, RNAi strategies are to be established. Increased stability and superior
delivery into some insects can be achieved using nanoparticle-mediated RNAi [63–65],
traditional crop improvement strategies, in which plants express hairpin dsRNAs, will
continue to be a mainstay of agricultural approaches [63,65,66].
Transgenic plants have successfully used RNAi strategies to produce crops with improved
virus resistance, increased nutrition and fiber content [67]; biotechnology companies are trying
to move towards a faster, more natural process of topically applied RNAi. dsRNA molecules
are part of naturally occurring processes in all living organisms. They exist in our foods, and
our bodies [66]. The short persistence time of dsRNA in the environment is demonstrated by
the fact that analyses of soils and plant debris, treated with dsRNA have consistently shown
rapid breakdown of dsRNAs within 2–3 days [68], also means less concerns about unintended
contamination of water supplies, soils, or adverse air quality effects. Furthermore, since all
living things have evolved to break down dsRNA and use the nucleic acids as cellular
nutrients, this technology will be safer than conventional chemistries for those who apply
RNAi products, or eat the produce [66–69].
RNAi technologies have greater specificity in pest targeting, which reduces negative impacts
on crop ecosystems by leaving more insects and other organisms unharmed in the field. The
increased fauna consequently improves the efficacy of pollination, and biological control
agents that help suppress a broad range of pests. The increased understanding of the ubiqui‐
tous nature of RNAi, along with evidence of efficient topical application, has already begun
to garner support for this technology among members of the organic grower’s communities,
which desperately need a truly natural, innovative breakthrough, to manage many of the pests
and pathogens which plague the organic industries.
5.1. Cost-effective methods for the mass production and formulation of dsRNA
Cost-efficient methods for mass production of vast amounts of dsRNA are being developed,
and include bacterial, plant, and synthetic production [65]. While small amounts of dsRNA
can be easily produced in the laboratory for research purposes, commercially available kits are
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not a viable, cost-effective method for the production of large quantities of dsRNA [65]. The
costs associated with the commercialization and implementation of RNAi products are
decreasing rapidly. The costs of dsRNA production have dropped from $500,000 USD for 40
g in 2008 to less than $4,000 USD for 40 g today. For example, see [70]. As interests in commer‐
cialization of RNAi-based products increase, better production systems will be developed to
meet the predicted demands of these growing markets [17,65,71]. One of the most cost-effective
methods for production is in bacteria, since for most countries bacteria-produced dsRNA
would provide an affordable production system which could advance RNAi as, “The novel
biological insecticide of the future!” Most agricultural companies interested in the future of
RNAi are working on developing their own technologies that will further reduce production
costs predicted to be near $4 USD per one gram by the end of 2015. For example, see [72].
5.2. Other applications
Future applications of RNAi and other gene-based targeting biotechnologies will add value
to existing beneficial insects (pollinators, predators, parasitoids). A real-world example is a
study conducted over several years in which an RNAi product designed to reduce Israeli acute
paralysis virus replication was fed to honey bees. The treated bees had significantly greater
survival and produced significantly more honey [73]. RNAi strategies have also reduced honey
bee parasites, like Varroa mites [74,75], and internal microsporidian parasites [76] without
deleterious effects to the bees. The highly specific nature of RNAi approaches can be exploited
to reduce pests with no harmful effects on non-target species. The use of RNAi in combination
with beneficial pollinators and natural enemies has the potential to raise the level of all pest
management efforts [17].
Biotechnology has demonstrated the safe production of plants which are more nutritious, less
toxic, more resistant to drought, and more efficient for biofuel production [66, 67]. RNAi has
already been successfully used to produce crops which are virus- and drought-resistant [66].
However, plants expressing dsRNAs while stable and safe take years to develop and millions
of dollars to commercialize [65]. Development of topically applied RNAi, which is a non-
transgenic approach improves crop traits and provides a major step forward for environmen‐
tally sound crop management [66, 67].
6. Conclusions
As more insects and mites develop chemical resistance to one or more insecticides, now
estimated to be over 500 species with resistance to one or more products [77], it is imperative
that new types of pest control are developed. The public would like the world to be filled with
environmentally friendly technologies, safe for human and animal consumption, technologies
which are safe for use around animals and beneficial insects, safe for each type of ecosystem,
forest, field, crop, or backyard, a technology that will not endanger water or food quality, a
more natural solution, with a natural approach toward problem-solving. So enters RNA
interference!
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RNA interference, or gene silencing, is a way to reduce specific mRNAs so that a particu‐
lar protein is either not made or it is reduced. The RNAi mechanism is a natural one which
occurs in the cells of humans, animals, insects, and plants, and appears to have evolved as
a primary defense system against virus replication [78]. Andrew Fire and Craig Mello, won
the Nobel Prize in 2006 [79] for explaining how the RNAi mechanism is triggered, when a
cell  encounters double-stranded RNA, and how this could be used to benefit  humanity.
Humanity’s greatest discoveries have come from observing the natural world; while RNAi
will not solve every problem, it certainly can help improve plant health, reduce insect pests
and pathogens [17,  66,  67,  80].  Some of  the benefits  from developing RNAi as topically
applied products are: 1) The rapid degradation of the molecules ensures low environmen‐
tal risks. All cells have the capacity to degrade dsRNA, and the salvage pathways to recycle
these bases and nucleosides to form new nucleotides. Thus, cells constantly breaking down
DNA and RNA into recycled nucleotides [81]. 2) Topical RNAi applications do not insert
genes, so do not produce proteins. RNAi reduces the expression of the targeted proteins,
a modulation effect of the natural system. 3) RNAi can be designed and tested faster (in
about 2–3 years) than producing transgenic crops, which can take 10 to 20 years and cost
hundreds of millions of dollars [65]. 4) Finally, RNAi strategies as topical sprays would,
for the first time, be able to remove one or two closely related insect species, while leaving
all the other insects unharmed [38]. The ability to design RNAi as highly specific pest control
will  finally  provide relief  to  biological  control  agents  and beneficial  insects  [17,  44,  73],
significantly improving integrated pest management programs.
The advantages and promises from RNAi technology sound amazing. However, serious efforts
in outreach and education are needed to better inform the different stake holders including
the general public, and agricultural industry, leaders as well as decision makers in the
regulatory and political communities to help expedite the release and adoption of RNAi
products and technology.
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Abstract
Ticks (Acari: Ixodida) are blood-sucking arthropods globally recognized as vectors of nu‐
merous diseases. They are primarily responsible for the transmission of various patho‐
gens, including viruses, rickettsiae, and blood parasites of animals. Ticks are second to
mosquitoes in terms of disease transmission to humans. The continuous emergence of
tick-borne diseases and acaricide resistance of ticks necessitates the development of new
and more effective control agents and strategies; therefore, understanding of different as‐
pects of tick biology and their interaction with pathogens is very crucial in developing
effective control strategies. RNA interference (RNAi) has been widely used in the area of
tick research as a versatile reverse genetic tool to elucidate the functions of various tick
proteins. During the past decade, numerous studies on ticks utilized RNAi to evaluate
potentially key tick proteins involved in blood feeding, reproduction, evasion of host im‐
mune response, interaction with pathogens, and pathogen transmission that may be tar‐
geted for tick and pathogen control. This chapter reviewed the application of RNAi in
tick research over the past decade, focusing on the impact of this technique in the ad‐
vancement of knowledge on tick and pathogen biology.
Keywords: Acari, ticks, Ixodidae, RNA interference, tick-borne diseases
1. Introduction
Ticks belong to the class of Arachnida together with spiders, scorpions, and mites. To date,
there are about 900 species of ticks, majority of which are hard ticks belonging to the Ixodidae
family, as well as about 200 species are soft ticks belonging to the Argasidae family, and a
single species belonging to the Nuttalliellidae family [1]. Most of the ticks of medical and
veterinary importance are hard ticks. Through their blood-feeding behavior, ticks can directly
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
affect their host by causing anemia, irritation, and allergic reactions particularly in heavy
infestation. The saliva of some tick species may also contain neurotoxic substances that may
cause the condition termed “tick paralysis” [2]. Additionally, the transmission of pathogens
including viruses, bacteria, and parasitic protozoa also occurs during blood feeding [1]. Ticks
are considered second to mosquitoes in terms of their impact on public health, but they are the
most important vectors of different pathogens in both domestic and wild animals [3]. Tick
infestation and tick-borne diseases (TBDs) continue to have great economic impact on livestock
production, particularly on cattle and small ruminants, in several continents [2]. The annual
loss in cattle production worldwide due to ticks and TBDs has been estimated to be worth
billions of USD [4].
The complete dependence of ticks to host blood for the completion of their life cycle and
generation of offspring is the reason for their notoriety as vectors of several diseases. Depend‐
ing on the species, a tick may utilize one to three hosts during their life cycle. Most of the
pathogens they transmit can be carried on throughout their life cycle through transstadial
(from one stage to the next) transmission and to the next generation through transovarial (from
adults to eggs) transmission [5]. A single tick may carry multiple pathogens [6], thereby having
the potential of infecting a host with a cocktail of pathogens. Most tick-borne infections are
zoonotic in nature, and more of these are being recognized in recent years [1, 7]. Among the
TBDs that are well-known in the veterinary and medical field are anaplasmosis, borreliosis,
rickettsiosis, ehrlichiosis, babesiosis, theileriosis, and tick-borne encephalitis.
The significant impact of ticks and TBDs underscores the importance of tick control. For several
decades, the application of chemical acaricides has been the primary tick control method, and
acaricides were used extensively in livestock production. However, the continuous emergence
of resistant tick strains makes most chemical acaricides ineffective [8]. Moreover, the increasing
concerns for animal product and environmental contamination set limitations for this control
method. To search for new and more effective means of controlling ticks and TBDs, researchers
have actively expanded the understanding on tick biology.
RNA interference (RNAi) is a reverse genetic approach for manipulation of genes that
commonly utilizes double-stranded RNA (dsRNA) to induce post-transcriptional gene-
specific silencing [9]. RNAi has been extensively employed in many studies on tick biology
and pathogen interaction since the first report of RNAi application in the hard tick Amblyomma
americanum [10]. In fact, it is evident that a number of laboratories in different countries
working on tick research are routinely performing RNAi, as shown by an increasing number
of recent publications utilizing this technique. Typically, functional studies using RNAi
involve gene knockdown with subsequent infestation and evaluation of phenotypes, such as
blood feeding and reproduction success (Figure 1). Indeed, RNAi has been particularly useful
in searching for tick proteins that can be targeted for control of tick development and TBDs [11].
This chapter aims to show the extent of RNAi application in tick research, emphasizing the
progress of advanced knowledge on tick biology and tick-pathogen interaction. We first
discussed so far known RNAi mechanisms and the current RNAi inducing methods in ticks;
then, briefly described the studies on tick physiology, immunity, and pathogen interaction that
employed RNAi, highlighting the prospects of applications of RNAi in tick research.
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Figure 1. A typical RNAi experiment in the hard tick Haemaphysalis longicornis. The double-stranded RNA (dsRNA) is
introduced to adult ticks by microinjection. Unfed adult ticks, placed on a double adhesive tape attached on a glass
slide (A), are injected with dsRNA using a pointed microcapillary glass attached to a microinjector (B) through the
membrane of the fourth coxa under a stereomicroscope (C). Successful silencing, as shown by the absence of a band for
the target gene, such as Hlfer1, is confirmed around 4 d post-injection through RT-PCR after adjusting the cDNA level
using an internal control, such as actin (D). Ticks were infested on a host and allowed to feed to repletion (E) and after
dropping, parameters such as engorged body weight (F), survival, egg laying (G, H), and hatch were compared.
2. RNAi pathway in ticks
The mechanism of RNAi has been well studied in the nematode Caenorhabditis elegans and the
fruit fly Drosophila melanogaster [9, 12]. RNAi begins with the uptake of dsRNA by the cell,
followed by its cleavage to produce small interfering RNAs (siRNAs). Cleavage of dsRNA is
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accomplished by an RNAse III enzyme called Dicer. The siRNAs are then incorporated into
RNA-induced silencing complex (RISC), which then drives the degradation or translational
inhibition of the target mRNA that results to gene silencing. This silencing signal may spread
among the cells and different tissues, leading to systemic gene silencing in the whole organism
[13]. The mechanism of RNAi in ticks has not been fully elucidated, but the study of Kurscheid
et al. [14] revealed that several components of RNAi machinery in other invertebrates are also
present in the ticks, and they proposed a putative tick RNAi pathway. Here, we briefly describe
the available knowledge on key components of RNAi machinery in ticks, in comparison of
other invertebrates.
2.1. dsRNA uptake
There are two recognized dsRNA uptake mechanisms in invertebrates: a transmembrane
channel-mediated uptake through systemic RNA interference defective (SID) transmembrane
proteins described in C. elegans, and an endocytosis-mediated uptake described in most
arthropods [15, 16]. Several SIDs identified in C. elegans have been shown to be involved in the
spread of RNAi [17]. SID-1, SID-3, and SID-5, which have wide tissue distribution, are involved
in the systemic spread of RNAi [18–20], whereas SID-2, localized mainly in the gut, is involved
primarily in the intestinal uptake of ingested dsRNA [21]. The multi-domain SID-1 along the
plasma membrane facilitates the traffic of dsRNA into and out of the cells. Homologs of SID-1
are present in some arthropods and vertebrates [18]. Both SID-3, a conserved tyrosine kinase,
and SID-5 have intracytoplasmic localization, the latter being associated with late endosomes
[19, 20]. SID-2 has luminal localization in the intestinal cells, and it was also found in the lower
levels of excretory duct cells [21]. In addition to SIDs, endocytosis has also been also implicated
as a dsRNA uptake mechanism in C. elegans through a protein containing an epsin N-terminal
homology (ENTH) domain [22]. In D. melanogaster, dsRNA uptake in cells is facilitated mainly
by scavenger receptor-mediated endocytosis [23]. Two scavenger receptors, Eater and Sr-CI,
have been identified to be responsible for the majority of dsRNA uptake. These scavenger
receptors are mainly expressed in the plasmatocytes and have a primary role in the phagocy‐
tosis of bacterial pathogens [24, 25].
SID homologues have not been identified in ticks. However, a homologue of ENTH, Epn-I,
has been identified in the hard ticks Rhiphicephalus (Boophilus) microplus and Ixodes scapularis
[14]. A class B scavenger receptor identified in Haemaphysalis longicornis (HlSRB) has been
demonstrated to mediate systemic RNAi in this tick [26, 27]. Combined injection of dsRNA
against HlSRB and other target genes, Vitellogenin-1 (HlVg-1) and Vitellogenin Receptor (HlVgR)
effectively silenced these genes. However, silencing HlSRB prior to injection of dsRNA against
HlVg-1 and HlVgR inhibited the silencing of the latter two genes, suggesting that the uptake
of the injected dsRNA is dependent on HlSRB in ticks. Similar to D. melanogaster scavenger
receptors, HlSRB is also involved in the phagocytosis of bacteria [28], but it is expressed not
only in the hemocytes but also in the other organs such as midguts, salivary glands, and ovary
[26]. The presence of ENTH homologue and scavenger receptor indicates that the uptake of
dsRNA in ticks is through endocytosis. Additionally, the presence of scavenger receptor in
different tick tissues strongly implies its involvement in systemic RNAi, particularly after
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dsRNA injection. Introduction of dsRNA into the hemocoel of ticks directly exposes the
different tick organs to dsRNA, and the scavenger receptor in these organs most likely
mediates the entry of dsRNA into the cells.
2.2. dsRNA processing and RISC assembly
The recommended length of dsRNA to effectively induce silencing of the target gene in non-
mammalian systems is more than 200 bp [15]. A study in R. (B.) microplus showed, however,
that  short  dsRNAs between 100 and 200 bp were also effective in inducing silencing of
Ubiquitin-63E homologue, with minimal off-target effects, but short hairpin dsRNAs were not
able to induce silencing effects [29]. After cellular uptake, dsRNAs are cleaved into 21–25 nt
siRNAs by an RNAse III enzyme called Dicer. In contrast to C. elegans and mammals that have
only one Dicer, D. melanogaster and mosquitoes have two Dicers [15]. Dicer-2 is the one involved
in the generation of siRNA, whereas Dicer-1 acts on stem loop RNA precursors to generate
micro RNA (miRNA). Both, however, are required for siRNA-induced gene silencing due to
their distinct roles in siRISC assembly [30]. Only a single putative Dicer has been identified so
far in the hard tick I. scapularis, which is more similar to mammalian Dicer-1 [14].
The RNAi inhibition of a target mRNA is accomplished by RISC formed by siRNAs and
Argonaute (AGO) proteins. AGO proteins are highly conserved between species, encoded by
multiple genes in most organisms. All AGO proteins are characterized by two domains: the
PAZ domain and the PIWI domain [31]. Upon ATP activation, AGO mediates RISC recognition
of mRNA target that are homologous to siRNAs, subsequently leading to the cleavage of the
mRNA target [9]. In most insects, including D. melanogaster and mosquitoes, five AGO genes
have been identified [15, 31]. In ticks, a homologue of AGO-1 has been identified in I. scapu‐
laris and R. (B.) microplus, and a homologue of AGO-2 has been identified in I. scapularis [14].
However, the functions of these tick AGOs remains to be confirmed.
2.3. Amplification of RNAi signal
The ability to spread throughout the whole organism, inducing total systemic silencing of the
target gene in spite of introducing only a relatively small amount of dsRNA, is an important
aspect of RNAi observed in plants and invertebrates. This systemic RNAi-induced gene
silencing in both plants and C. elegans involves RNA-directed RNA polymerase (RdRP) that
amplifies the RNAi signal [9]. RdRP function in RNAi has not been found in arthropods, but
a putative homologue of RdRP EGO-1 protein of C. elegans has been identified in the hard tick
I. scapularis, and a partial sequence was also identified from R. (B.) microplus [14].
3. Methods of introducing dsRNA in ticks
3.1. Injection
Direct injection is the most widely used technique for introducing dsRNA for in vivo gene
silencing, not only in ticks but also in insects [11, 32]. Through this method, dsRNA is usually
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introduced directly into the hemocoel of ticks allowing the dsRNA to circulate within the
hemolymph. In most reports, a high concentration of at least 1 μg dsRNA per tick has been
shown to be effective in inducing gene silencing [33], but in some reports, lower concentration
has been found to be similarly effective [34–36]. Injection has been accomplished using a 33–
36-gauge needle attached to a Hamilton syringe particularly in large tick species, such as
Amblyomma americanum[37], Dermacentor variabilis, and D. marginatus [38], while microinjection
using a microcapillary drawn to a fine point needle and inserted to a micromanipulator has
been commonly employed in smaller tick species, including Ixodes [39], and Haemaphysalis [26]
ticks. Different injection sites include the lower right quadrant of the ventral surface of the
exoskeleton [40], the groove between the basis capituli and the scutum [37], the ventral torso
of the idiosoma, away from the anal opening [39], and the coxal membrane in the fourth coxae
[26, 41]. In some reports, dsRNA was injected through the spiracle [29, 42, 43] and anal pore;
the latter inducing midgut-specific silencing of the target gene [44]. Injection of dsRNA has
been commonly performed in unfed adult ticks, subsequently allowed to recover for at least
24 h before infestation or use in succeeding experiments. Exceptionally, dsRNA has been also
injected in engorged R. (B.) microplus [42, 45-47], A. americanum, I. scapularis, and D. variabilis
adults [43], which produced significant effects on the eggs and larvae, and microinjection has
also been accomplished in I. scapularis [48-52] and engorged O. moubata nymphs [53].
3.2. Soaking
Soaking in dsRNA has been previously employed to study RNAi in the cell lines of D.
melanogaster [23, 54]. In tick research, this method has been applied to induce in vitro RNAi
not only in cell cultures [55-57], but also in some organs including whole salivary glands [36,
58-60] and midguts [61]. Soaking live Varroa destructor [62] and Dermanyssus gallinae [63] mites,
as well as Aedes aegypti larvae [64] in a solution of dsRNA has been already demonstrated in
producing effective silencing of the target genes in these organisms. However, soaking whole
ticks in a solution of dsRNA has not been commonly performed. Soaking Haemaphysalis
longicornis nymphs in a solution of dsRNA for 24 h resulted to significant transcript reduction
of the target gene, although the effect on the phenotype was not observed in all the nymphs
[65]. In our laboratory, we have attempted to soak H. longicornis larvae, nymphs, and adults
in a dsRNA solution overnight, which resulted to a significant decrease in the mRNA level of
a targeted gene (Galay et al., unpublished results). Soaking offers a simpler and less invasive
method of introducing dsRNA without injuring the ticks and is applicable to immature tick
stages. Furthermore, it does not require injection equipment; therefore, it is less laborious.
3.3. Electroporation
Electroporation is a technique that employs electric impulses to promote DNA uptake of cells
and has been primarily used with in vitro cell transfection [66]. In tick research, this technique
has been first applied to facilitate the introduction of dsRNA in I. scapularis eggs and nymphs
[67]. After electroporation, fluorescein-labeled dsRNA was visualized all over the nymph’s
body and eggs, indicating the successful entry of dsRNA. In a more recent report, the wax
coating of the eggs was first removed using heptane and hypochlorite prior to electroporation
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[68]. Using heptane alone did not significantly decrease the hatching rate. Thus, heptane may
be more helpful in evaluating the effect of a particular dsRNA to egg hatching. This technique
also offers a less invasive method of dsRNA introduction that can be applied to immature tick
stages and eggs.
3.4. Feeding
Feeding dsRNA in insects has been achieved in different species using diets mixed with
dsRNA, liposome-embedded or lipophilic siRNAs, and bacteria and transgenic plants that can
synthesize dsRNA [32, 69]. Although in vitro feeding assays have been shown to be useful in
studying different tick molecules and tick-pathogen interaction [70], its application in RNAi
study in ticks has been limited. A study on the Lyme disease vector I. scapularis employed
capillary feeding of dsRNA to nymphs to suppress anticomplement gene isac [71]. In another
study, adult R. (B.) microplus ticks were capillary fed with ubiquitin dsRNA mixed in whole
blood or Bm86 dsRNA mixed in bovine serum [72]. In both cases, ticks were pre-fed in an
animal host before capillary feeding was performed. While this method may be advantageous
over injection due to very minimal injury, drawbacks may arise from the uncertainty whether
an individual tick will ingest the amount of dsRNA that will effectively induce silencing, and
the possibility of variation in the amount of dsRNA ingested by the ticks within a treatment
group. Furthermore, capillary feeding is difficult to perform and may not be applicable in ticks
with short hypostome.
4. RNAi and study of tick physiology
4.1. Genes related to salivary functions
The saliva is an important arsenal of ticks containing hundreds of pharmacologically potent
substances that facilitate attachment to their hosts and blood-sucking [73]. Different salivary
proteins have redundant functions in counteracting the hemostatic [74], inflammatory, and
immune mechanisms [75] of the host. Aside from its function in tick feeding, the salivary
glands are also involved in osmoregulation and transmission of pathogens [76].
Many studies on characterization of salivary proteins in the recent years employed RNAi
(Table 1). In fact, the first report on the application of RNAi in tick research described a tick
inhibitor of inflammatory mediator, a salivary histamine-binding protein, wherein researchers
induced in vitro RNAi by soaking salivary glands in dsRNA [10, 58]. Soluble N-ethylmalei‐
mide-sensitive factor attachment receptors (SNARE) complex proteins, which mediate
exocytosis in secretory pathways of the salivary glands, have been characterized in Amblyom‐
ma ticks. These include N-ethylmaleimide-sensitive fusion (NSF) protein, Synaptosomal
Associated Protein of 25 kDa (SNAP-25) [77], Ykt6 [65], and vesicle transport through inter‐
action with t-SNAREs (Vti) [78]. Silencing various genes such as Salp14, Salp9pac [39],
Neuronal isoform munc18-1 (nSec1) [59], and synaptobrevin [36] affected the secretion of
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anticoagulant or the anticoagulant activity of salivary gland extracts, indicating that these
genes are important in tick anti-hemostatic mechanism.
Longistatin [79] and acidic chitinases [80] have been found to be important in the formation
of blood pool and tick cement cone, respectively. The attachment site of longistatin-silenced H.
longicornis ticks did not show pathological changes, such as hemorrhagic lesions correspond‐
ing to the blood pool, while the attachment site of ticks simultaneously silenced acidic
chitinases exhibited blood leakage and these ticks can be easily removed. Various protease
inhibitors that have roles in anti-hemostatic, anti-inflammatory, and immunomodulatory
mechanism have been also characterized using RNAi, including a cystatin, sialostatine L [81],
a Kunitz type protease inhibitor, rhipilin [82], and serine protease inhibitors (serpin) [83, 84].
Other salivary proteins with immunomodulatory function, such as the anti-complement
protein, isac [71], and two proteins that can inhibit neutrophil function, ISL 929 and 1373 [85],
have also been knockdowned in I. scapularis. Silencing of isac in nymphs, induced by capillary
feeding of dsRNA, not only reduced blood feeding, but also decreased the load of the spiro‐
chete Borrelia burgdorferi in the tick. Meanwhile, the saliva of ticks devoid of ISL 929 and 1373
had reduced ability in inhibiting host integrin. An osmoregulatory protein aquaporin,
characterized in I. ricinus through RNAi, showed that suppression of this protein impaired the
concentration of blood meal due to failure in removing water [86].
4.2. Genes related to digestion and midgut function
The midgut of ticks houses various kinds of enzymes that act on a large amount of ingested
host blood, which contains great quantities of hemoglobin [151]. Functional studies on these
enzymes and other midgut proteins using RNAi have expanded the understanding of tick
digestive physiology (Table 1). Silencing hemoglobinolytic enzymes, such as leucine amino‐
peptidase [91, 92], longipain [95], and cathepsin L [96, 97] had negative impact on tick feeding.
Moreover, the longipain of H. longicornis was found to have a protective role in Babesia infection
through its babesiacidal activity [95]. Other proteins important in tick digestion that have been
characterized using RNAi are thrombin inhibitors that prevent blood coagulation and serine
proteinase, which induce erythrocyte degradation. Silencing of thrombin inhibitor hemalin
from H. longicornis [93] and boophilin from R. (B.) microplus [47] prolonged the blood feeding
period and decreased the oviposition of these ticks, respectively. Silencing serine protease
reduced the weight of ticks after blood feeding due to impaired erythrocyte degradation [94].
4.3. Genes related to reproductive function
Ticks are known for their high fecundity, laying hundreds of eggs per batch in the case of
soft ticks and up to thousands in the case of hard ticks. A series of physiological events takes
place in female ticks during and after blood feeding that initiate ovarian maturation and
subsequent oviposition. Vitellogenesis, the synthesis and oocyte deposition of the yolk pro‐
tein precursor (vitellogenin), is a key process for ovarian development and oocyte matura‐
tion induced by blood meal in ticks [152]. Three genes encoding vitellogenin have been
identified and characterized in H. longicornis [102].
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Amblyomma americanum Altered feeding pattern and longer feeding
period; decreased histamine-binding activity in
the salivary glands
[10, 58]
Salp14/ Salp9pac Ixodes scapularis Impaired feeding, decreased post-blood meal





A. americanum Decreased post-blood meal weight and
prolonged feeding time, decreased
anticoagulant secretion of salivary gland
[59]
Synaptobrevin A. americanum Inhibited secretion of anticoagulant stimulated
by PGE
[36]
Cystatin A. americanum Decreased post-blood meal weight, mortality




I. scapularis Decreased post-blood meal weight, decreased
Borrelia burgdorferi infection
[71]
Sialostatin L (cystatin) I. scapularis Failure to feed on the host, decreased post-
blood meal weight and failed oviposition
[77]
Aquaporin I. ricinus Decreased post-blood meal weight, decreased
volume of ingested blood
[78]
HlYkt6 (SNARE) Haemaphysalis longicornis Decreased post-blood meal weight, high
mortality, supressed salivary secretion and
anticoagulant activity
[65]







Prolonged attachment time, decreased post-
blood meal weight
[80]
Longistatin H. longicornis Mortality after attachment, failure to engorge,




A. americanum No effect on tick attachment, feeding and
oviposition
[82]





Decreased egg weight and egg conversion ratio [84]
N-ethylmaleimide sensitive
fusion protein (NSF)
A. maculatum Inhibition of engorgement, failure of
oviposition
[85]
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Target gene Tick species RNAi Effect Refs
Synaptosomal Associated
Protein of 25 kDa
(SNAP-25)
A. maculatum Decreased post-blood meal weight, decreased
egg weight, failure in hatching
[85]
Vti (SNARE) A. americanum, A. maculatum Decreased post-blood meal weight and
survival, failed oviposition
[86]
Glutaminyl cyclase (QC) A. maculatum, I. scapularis Decreased post-blood meal weight, egg weight
and hatch
[87]
AV422 A. americanum Decreased post-blood meal weight [88]
Acidic chitinase (Ach) A. americanum Leakage of blood from the mouthparts in late




Longepsin H. longicornis No effects reported [90]
Leucine aminopeptidase H. longicornis Extended pre-oviposition period, decreased egg
weight and egg conversion ratio, morphological




H. longicornis Longer blood feeding period, failure to
engorge, decreased inhibitory activity of




R. (B.) microplus Decreased oviposition [47]
Serine proteinase H. longicornis Suppressed erythrocyte degradation; decreased
post-blood meal weight
[94]
Longipain H. longicornis Impaired blood feeding, decreased post-blood
meal weight, increased B. gibsoni infection level
and transovarial transmission
[95]
Cathepsin L I. ricinus Decreased weight gain [96]
H. longicornis Decreased post-blood meal weight [97]




H. longicornis Decreased egg conversion ratio [98]
Vitellogenin receptor (VgR) Dermacentor variabilis Failure of Vg uptake by oocytes; failed
oviposition
[34]
H. longicornis Suppressed oocyte maturation and failed
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Target gene Tick species RNAi Effect Refs
A. hebraeum Suppressed oocyte maturation, long pre-
oviposition period,
[100]
Voraxin A. americanum Failure to engorge and lay eggs in females fed
with males injected with a combination of
subolesin and voraxin dsRNA
[101]
Vitellogenin (Vg) H. longicornis Decreased post-blood meal weight, abnormal
oocytes, decreased egg conversion ratio
[102]
GATA factor H. longicornis Disrupted egg development [103]
S6 kinase H. longicornis Disrupted egg development [103]
Target of rapamycin (TOR) H. longicornis Decreased post-blood meal weight, mortality
after engorgement, Failure of oocytes to mature
and failure to lay eggs
[104]




H. longicornis Decreased post-blood meal weight and survival[105]
β-Actin I. scapularis Decreased post-blood meal weight and
oviposition
[106]





H. longicornis Decreased post-blood meal weight [107]
Cyclophilins
(Immunophilin)
H. longicornis Lower post-blood meal weight, low survival
after blood feeding and failure to lay eggs after
silencing cyclophilin A
[108]
Ribosomal protein P0 H. longicornis Decreased post-blood meal weight, low




H. longicornis Mortality after engorgement, leakage of blood




A. americanum Decreased post-blood meal weight, oviposition
and egg conversion ratio
[37]
Ferritins (FER) I. ricinus Decreased post-blood meal weight, oviposition
and hatch
[111]





I. ricinus Decreased post-blood meal weight and
hatching of eggs
[111]
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Elongation factor 1-α R. annulatus, R. (B.)
microplus
High post-blood meal mortality, decreased






H. longicornis Longer blood feeding period, decreased post-
blood meal weight, longer pre-oviposition
period, decreased oviposition and hatch after
SDH silencing; higher volume of hemolymph
after LKR silencing
[114]
Ubiquitin R. (B.) microplus Shorter post-blood meal survival, decreased or
absence of egg output, impaired embryogenesis
[14, 29, 45,
72];
R. annulatus High mortality [45]
Glycogen synthase kinase-3
(GSK-3)
R. (B.) microplus Decreased oviposition and hatching [115]






A. americanum Decreased post-blood meal weight [117]
Putative 5.8S, ITS2 and 28S
rRNA
A. americanum High mortality and very low post-blood meal
weight
[118]
Putative 2B7 60S ribosomal
protein L13e




cytoplasm foci protein 45










A. americanum 100% mortality [118]
Putative mitochondrial 12S
rRNA





H. longicornis Mortality after attachment, retarded blood
feeding and longer feeding period, decreased
post-blood meal weight, decreased egg weight
and egg conversion ratio
[119]
Scavenger receptor H. longicornis Decreased post-blood meal weight, mortality
after engorgement, decreased oviposition and




Target gene Tick species RNAi Effect Refs
Elongation factor 1-α R. annulatus, R. (B.)
microplus
High post-blood meal mortality, decreased






H. longicornis Longer blood feeding period, decreased post-
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period, decreased oviposition and hatch after
SDH silencing; higher volume of hemolymph
after LKR silencing
[114]
Ubiquitin R. (B.) microplus Shorter post-blood meal survival, decreased or
absence of egg output, impaired embryogenesis
[14, 29, 45,
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R. annulatus High mortality [45]
Glycogen synthase kinase-3
(GSK-3)
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Putative 5.8S, ITS2 and 28S
rRNA
A. americanum High mortality and very low post-blood meal
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[118]
Putative 2B7 60S ribosomal
protein L13e




cytoplasm foci protein 45










A. americanum 100% mortality [118]
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rRNA





H. longicornis Mortality after attachment, retarded blood
feeding and longer feeding period, decreased
post-blood meal weight, decreased egg weight
and egg conversion ratio
[119]
Scavenger receptor H. longicornis Decreased post-blood meal weight, mortality
after engorgement, decreased oviposition and




Target gene Tick species RNAi Effect Refs
4E-BP (eIF4E-binding
protein)
H. longicornis Decreased lipid accumulation in the midgut
and fat bodies after long starvation period
[120]
Protein kinase B (AKT) H. longicornis Inhibition of engorgement and growth of
organs during blood feeding; decreased
expression of longepsin, HlMIF and HlVgs
[121]
R. (B.) microplus Decreased cell glycogen content and viability,
and altered cell membrane permeability
[57]
Spook (Spo) Ornithodoros moubata Arrested development and molting [53]
Shade (Shd) O. moubata Abnormal ecdysis and delayed molting [53]
Cystatin (RHCyst) R. haemaphysaloides Decreased attachment and hatching rate [122]
Tropomyosin H. longicornis Longer feeding time, decreased engorgement
rate and post-blood meal weight, high
mortality after blood feeding, failed oviposition
[123]
Protective antigens
Subolesin (4D8) I. scapularis Decreased post-blood meal weight, oviposition
and survival; failure of embryogenesis;
silencing in eggs and larvae when dsRNA
injected to engorged females
[43, 124]
A. americanum Decreased post-blood meal weight, oviposition
and survival
[43, 101, 124]
D. marginatus Decreased post-blood meal weight, oviposition
and survival
[124]
D. variabilis Decreased post-blood meal weight, oviposition
and survival; decreased fertility; silencing in
eggs and larvae when dsRNA injected to
engorged females
[43, 124]
R. sanguineus Decreased post-blood meal weight, oviposition
and survival; more dramatic effect when
simultaneously silenced with Rs86
[124, 125]
R. (B.) microplus High mortality, decreased post-blood meal
weight, oviposition and hatch in dsRNA-
injected adults and progeny of dsRNA-injected
adults
[42, 45, 46]
R. annulatus, Decreased post-blood meal weight [45, 126]
O. erraticus Decreased egg output [127]
O. moubata Decreased egg output [127]
RNA Interference – A Powerful Functional Analysis Tool for Studying Tick Biology and its Control
http://dx.doi.org/10.5772/61577
423
Target gene Tick species RNAi Effect Refs
Midgut protein Rs86 R. sanguineus Decreased post-blood meal weight and
oviposition
[125]
Midgut protein Hl86 H. longicornis Decreased post-blood meal weight [128]
Midgut protein Bm86 R. (B.) microplus Decreased number of engorging ticks, lower
post-blood meal body weight and survival after
feeding in B. bovis-infected host, decreased egg
weight
[129]
Midgut protein Ree86 R. evertsi evertsi No significant effect [130]
Midgut protein ReeATAQ R. evertsi evertsi No significant effect [130]
Longicin H. longicornis Decreased post-blood meal weight, increased B.
gibsoni infection in the midgut and ovary, and
transmission in the eggs
[131]
α2-macroglobulin proteins I. ricinus Decreased phagocytic action of hemocytes [132, 133]
Macrophage migration
inhibitory factor
A. americanum No effect on phenotypes [134]




I. scapularis Increased A. phagocytophilum infection level [135]
Dual oxidase (Duox) I. scapularis Decreased level of B. burgdorferi [136]
Peroxidase ISCW017368 I. scapularis Decreased level of B. burgdorferi [136]
Glutathione S-transferase R. (B.) microplus Decreased tick attachment and post-blood meal
weight
[45]
R.sanguineus Increased susceptibility to permethrin [137]
Selenoprotein W R. (B.) microplus Decreased tick attachment and post-blood meal
weight
[45]
Selenoprotein K A. maculatum Decreased oviposition [138]
Selenoprotein M A. maculatum Decreased oviposition [138, 139]





R. (B.) microplus Increased resistance to bacteria [140]
Pathogen acquisition/ transmission
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Target gene Tick species RNAi Effect Refs
R. (B.) microplus Decreased A. marginale infection level in
salivary glands and tick cells
[143]
Salp15 I. scapularis Decreased Borrelia burgdorferi transmission to
the host
[52]
Salp14 I. scapularis No effect on acquisition of A. phagocytophilum
and B. burgdorferi in nymphs
[49]
Salp16 I. scapularis Reduced A. phagocytophilum acquisition [48]
Salp25D I. scapularis Decreased acquisition of B. burgdorferi after
knockdown in salivary glands
[44]
Varisin D. variabilis Decreased A. marginale infection level [144]
Immunophilin R. (B.) microplus Decreased hatch, decreased larval survival,




R. (B.) microplus Inhibition of engorgement, decreased egg
weight
[41]




D. variabilis Inhibited A. marginale infection in the midgut
after acquisition feeding
[142]
Selenoprotein M D. variabilis Inhibited A. marginale infection and









R. (B.) microplus Decreased A. marginale infection level in




R. (B.) microplus Increased A. marginale infection level in tick
cells
[143]
Tick salivary lectin pathway
inhibitor (TSLPI)





D. variabilis Increased rickettsial infection in the midgut [146]
Kunitz-type protease
inhibitor 5 (KTPI)
R. annulatus, R. (B.)
microplus
Decreased post-blood meal weight [126]
Histamine release factor I. scapularis Decreased post-blood meal weight, decreased
B. burgdorferi transmission
[147]
TROSPA R. annulatus, R. (B.)
microplus
Decreased B. bigemina infection level; Decreased
post-blood meal weight in R. microplus
[126]
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Serum amyloid A R. annulatus, R. (B.)
microplus
Decreased B. bigemina infection level [126]
Ricinusin R. annulatus, R. (B.)
microplus
Decreased post-blood meal weight in R.
annulatus
[126]
Calreticulin R. annulatus, R. (B.)
microplus
Decreased B. bigemina infection level in R.





I. scapularis No significant effect on B. burgdorferi
acquisition or transmission
[50]
Antifreeze glycoprotein I. scapularis Decreased survival and mobility of ticks in





protein (E3 ubiquitin ligase,
XIAP)
I. scapularis Increased A. phagocytophilum infection [149]
Cytochrome c oxidase
subunit III
R. (B.) microplus Failure in transmission of A. marginale [150]
Table 1. Genes functionally characterized through RNAi in different tick species.
Silencing these genes through RNAi greatly reduced the reproductive capacity of female ticks,
which showed immature and light-colored oocytes. The uptake of vitellogenin in the oocytes
is facilitated by vitellogenin receptor, which has been characterized in D. variabilis [34],
H.longicornis [99], and A. hebraeum [100]. Aside from the negative impact in oviposition
consistently induced by RNAi in all these studies, silencing of H. longicornis vitellogenin
receptor also reportedly inhibited the transovarial transmission of Babesia gibsoni. Three factors
involved in the initiation of vitellogenesis, the GATA factor, S6 kinase [103], and target of
rapamycin (TOR) pathway [104], have been also characterized in H. longicornis ticks using
RNAi. The significance of other proteins to reproduction, such as a tick homologue of the
human follistatin-related protein [98] and the engorgement protein voraxin [101] from the male
gonad, has been also demonstrated using RNAi.
4.4. Genes related to structural and metabolic functions
Various gene encoding proteins important in cellular structure and metabolism have been
characterized using RNAi. Due to their wide distribution and systemic function, knockdown
of these proteins caused detrimental effects on different tick physiological functions and some
even proved to be lethal (Table 1). Among these proteins is the multifunctional ubiquitin,
which has been first targeted based on a homologous gene of D. melanogaster in a study
investigating the components of tick RNAi pathway [14]. Ubiquitin knockdown in R. (B.)
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microplus shortened the post-blood meal survival of ticks and impaired egg viability and hatch.
In separate studies, ubiquitin has also been the subject in examining off-target effects of RNAi
[29] and the feasibility of dsRNA feeding in R. (B.) microplus [72]. RNAi-mediated silencing of
ribosomal proteins in A. americanum [118], and ubiquitin, elongation factor-1 alpha and several
other proteins in R. (B.) microplus and R. annulatus [45] has been employed to screen potential
antigens for tick control.
In the hard tick H. longicornis, individual knockdown of glutamine:fructose-6-phosphate
aminotransferase [105], cyclophilin A [108], the ribosomal protein P0 [109], protein disulphide
isomerases [110], and tropomyosin [123] resulted to decreased survival of ticks after engorge‐
ment. Two proteins with apparent roles in withstanding long starvation period, lysine-
ketoglutarate reductase/saccharopine dehydrogenase (LKR/SDH) [114] and 4E-BP [120], have
also been characterized in H. longicornis. LKR/SDH mRNA expression is higher in starved ticks
than in unfed ticks and knockdown of LKR resulted to high volume of hemolymph after blood
feeding, suggesting its role in osmoregulation. Meanwhile, 4E-BP knockdown led to decreased
lipid storage in the midguts and fat bodies of ticks during longer starvation period. An
interesting report on the application of RNAi in studying tick neurobiology targetedβ-actin
and Na+-K+-ATPase of I. scapularis using fluorescently labeled dsRNAs to monitor the uptake
in tick synganglia [106].
The significance of proteins involved in iron metabolism to tick feeding and reproduction has
been also demonstrated using RNAi in two hard tick species, I. ricinus [111] and H. longicor‐
nis [112]. Silencing two types of the iron storage protein ferritin greatly reduced the ticks’
capacity to engorge and produce eggs, also affecting post-blood meal survival due to occur‐
rence of iron-mediated oxidative stress [113]. An iron regulatory protein responsible for
translation of iron binding proteins was characterized in I. scapularis, with its knockdown
greatly reducing egg hatchability [111]. Two enzymes, spook and shade, were characterized
in the soft tick O. moubata and were shown to be important in ecdysteroidogenesis through
RNAi [53]. Silencing spook protein in nymphs caused arrested development and molting,
whereas silencing shade delayed molting and led to abnormal ecdysis.
5. RNAi studies on tick protective antigens and immunity
The immune system of ticks has a vital role of protecting them from harmful substances in the
blood, including components of their host’s immune system, and from various pathogens that
they acquire in their blood feeding activity. Tick protective antigens, therefore, gain wide
interest due to their potential as target for tick control. The highly conserved tick protective
antigen subolesin, previously known as 4D8, was first identified from I. scapularis through
cDNA expression library immunization (ELI) [153], after which, it has been also identified in
other hard tick species, and using RNAi, was found to be important in the success of blood
feeding and reproduction [124]. An ortholog of subolesin has also been characterized in two
soft tick species and RNAi demonstrated that subolesin is also important in the reproduction
of soft ticks [127]. The function of subolesin is unclear, but a report showed that subolesin
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knockdown affected the expression of several genes involved in multiple cellular pathways,
suggesting a role in gene expression by interacting with regulatory proteins [154]. Aside from
being reported as a promising anti-tick vaccine antigen candidate in many studies, it has been
also proposed that subolesin may be targeted in ticks that subsequently will be released for
sterile acarine technique (SAT) [38].
The membrane-bound glycoprotein Bm86 expressed mainly in the midgut of R. (B.) micro‐
plus [155] is the first, and until recently, the only tick antigen that is commercially available as
an anti-tick vaccine in some countries. The exact function of Bm86, however, remains unclear
yet. RNAi has been employed to knockdown Bm86 and its homologues in other tick species,
including R. sanguineus, H. longicornis, and R. evertsi evertsi, which in most cases affected the
blood feeding and reproduction of adult ticks, except in R. evertsi evertsi wherein knockdown
of two homologues did not yield significant effects [130]. A study in R. (B.) microplus also
showed that knockdown of Bm86 decreased the blood feeding capacity and survival of ticks
after feeding on a B. bovis-infected host, suggesting that Bm86 may have a critical role in the
fitness of ticks after feeding from an acutely B. bovis-infected host [129].
The function of some components of immunity, such as α2-macroglobulin proteins [132, 133],
antimicrobial peptides [131], Janus kinase (JAK)-signaling transducer activator of transcription
(STAT) pathway [135], dityrosine network [136], and cysteine protease inhibitor in the
hemocytes [140] have been analyzed using RNAi. The α2-macroglobulin proteins of I.
ricinus, related to vertebrate complement system, were shown to be involved in the phagocytic
activity of hemocytes against Gram-negative bacteria [132, 133]. In contrast, a cysteine protease
Rmcystatin3 identified in R. (B.) microplus was implicated as a negative modulator of tick
immune response after its silencing greatly reduced the number of bacterial load in the ticks
[140]. The role of a defensin from H. longicornis, longicin, in ticks' immune defense against
Babesia parasites was demonstrated through RNAi, as exhibited by a higher load of B. gibsoni
in the midgut and ovary of longicin-silenced ticks after infestation in an infected host [131].
Meanwhile, JAK-STAT pathway was shown to be important in Anaplasma phagocytophilum
infection in ticks after its knockdown increased the infection in the salivary glands of nymphs
that fed on infected mice [135]. A dual oxidase and a peroxidase, ISCW017368, which together
forms a dityrosine network, were separately silenced in I. scapularis, both resulting to reduced
Borrelia burgdorferi persistence in ticks [136].
The obligatory blood feeding lifestyle of ticks exposes them to high levels of pro-oxidants that
may trigger oxidative stress. Antioxidant enzymes function to protect them from the harmful
effects of oxidative stress. Furthermore, these antioxidant enzymes provide detoxification
mechanisms to counteract toxins that they encounter in the environment, such as chemical
acaricides. RNAi has been very useful in evaluating the function of these antioxidants.
Silencing a selenoprotein in R. (B.) microplus reduced the engorged body weight and egg output
[45]. In contrast, a study on A. maculatum showed that silencing two selenoproteins did not
alter blood feeding, although the egg output was reduced. Interestingly, the total antioxidant
capacities of the saliva from knockdowned ticks were higher, indicating that other antioxidant
enzymes may have compensated for the absence of selenoproteins [138]. In another study,
silencing thioredoxin reductase, another selenoprotein, in A. maculatum did not have a negative
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that fed on infected mice [135]. A dual oxidase and a peroxidase, ISCW017368, which together
forms a dityrosine network, were separately silenced in I. scapularis, both resulting to reduced
Borrelia burgdorferi persistence in ticks [136].
The obligatory blood feeding lifestyle of ticks exposes them to high levels of pro-oxidants that
may trigger oxidative stress. Antioxidant enzymes function to protect them from the harmful
effects of oxidative stress. Furthermore, these antioxidant enzymes provide detoxification
mechanisms to counteract toxins that they encounter in the environment, such as chemical
acaricides. RNAi has been very useful in evaluating the function of these antioxidants.
Silencing a selenoprotein in R. (B.) microplus reduced the engorged body weight and egg output
[45]. In contrast, a study on A. maculatum showed that silencing two selenoproteins did not
alter blood feeding, although the egg output was reduced. Interestingly, the total antioxidant
capacities of the saliva from knockdowned ticks were higher, indicating that other antioxidant
enzymes may have compensated for the absence of selenoproteins [138]. In another study,
silencing thioredoxin reductase, another selenoprotein, in A. maculatum did not have a negative
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impact on blood feeding and reproduction. Likewise, variations in transcriptional expression
of some antioxidant enzymes were also observed, suggesting compensatory mechanism in the
absence of thioredoxin reductase [139]. However, the more interesting finding in that study
was the decreased microbiota population following thioredoxin reductase knockdown,
possibly because of disturbed redox homeostasis balance. Meanwhile, silencing a glutathione
S-transferase (GST) gene affected the attachment of ticks and reduced the post-blood meal
bodyweight of R. (B.) microplus [45]. It also made R. sanguineus ticks more susceptible to
permethrin, although no significant effects on tick attachment, feeding and reproductive
capacity were observed [137].
6. Understanding tick-pathogen interaction through RNAi
RNAi has undoubtedly paved a way to better understand the different aspects of ticks'
association with various pathogens. Numerous tick proteins with different functions have
been found to be involved in the acquisition, establishment, and transmission of pathogens.
Several proteins have been studied through RNAi to determine their importance in the
development cycle of different pathogens. The knockdown of subolesin [142, 156], GST,
vATPase, and selenoprotein M [142] in D. variabilis, and putative von Willebrand factor,
flagelliform silk protein and subolesin in R. (B.) microplus [143] decreased the infection level
of A. marginale in these hard ticks, implying that these proteins are significant in the establish‐
ment of infection of this rickettsia.
RNAi also demonstrated that the Lyme disease agent B. burgdorferi can utilize several proteins
of I. scapularis to facilitate its transmission to the host. These include salivary proteins such as
tick histamine release factor [147], Salp15 [52], and the lectin complement pathway inhibitor
(TSLPI) [145]; the latter two provide protection for B. burgdorferi against components of the
host immune system. Salivary proteins Salp14 [49], Salp16 [48], and Salp25D [44] have been
examined for their function in acquiring A. phagocytophilum or B. burgdorferi through RNAi.
Knockdown of Salp14 did not affect the acquisition of either rickettsiae, whereas the knock‐
down of Salp16 and Salp25D decreased the infection level of A. phagocytophilum and B.
burgdorferi in the tick, respectively.
An interesting study on I. scapularis showed that A. phagocytophilum promotes cold tolerance
through an antifreeze glycoprotein [148]. In the absence of this antifreeze glycoprotein, the
survival rate of ticks after exposure to extremely cold temperature and the infection level of
A. phagocytophilum following exposure was reduced. Tick defensins, varisin from D. variabi‐
lis [144], and ricinusin from Rhipicephalus ticks [126] have been silenced to examine their
functions in pathogen establishment; the former reduced A. marginale infection level, while the
latter did not have an effect on B. bigemina infection.
Several reports also demonstrated the interaction of Babesia parasites and tick proteins through
RNAi. Knockdown of the immunophilin gene in R. (B.) microplus had negative impact on the
reproductive performance of the tick and also increased the infection rate of B. bovis in larval
progeny [41], while knockdown of TROSPA, serum amyloid A, and calreticulin reduced the
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infection level of B. bigemina in Rhipicephalus ticks [126]. Silencing a Kunitz-type serine protease
inhibitor from D. variabilis increased the rickettsial infection in the midgut [146], whereas in R.
(B.) microplus, silencing a Kunitz-type serine protease inhibitor, Spi, tended to increase the
infection rate of B. bovis in larval progeny [41], but silencing of another Kunitz-type protease
inhibitor 5 (KTPI) did not have any effect on Babesia infection [126].
7. Future directions in tick research and application in tick control
Indeed, great progress in understanding tick biology has been already accomplished in the
past. However, many aspects of tick physiology and host-tick-pathogen interaction need to be
unraveled yet. Moreover, several optimizations can still be done to improve RNAi in tick
research. While being the most widely used method of introducing dsRNA, the injection
method (particularly microinjection) that requires elaborate equipment may not be accessible
to all laboratories. Moreover, injection is mostly applicable to adult and sometimes nymphal
stages, and may be injurious to the ticks, especially when performed by an inexperienced
researcher. The soaking method is simpler, less invasive, and less laborious. Electroporation
has been recently shown to be effective in introducing dsRNA in eggs [66] and may be useful
in studying the function of genes that are involved in embryogenesis and physiology of
immature tick stages.
RNAi may also prove to be a promising tick control method and not just a research tool. In
pest insect management, the possibility of using RNAi as a novel tool of pest control is already
being explored by feeding liposome-coated dsRNA or dsRNA expressed in transgenic plants
or bacteria [32]. RNAi targeting several genes have been accomplished by feeding plants
expressing dsRNA in several species of economically important crop pests [16]. Feeding
dsRNA to ticks is still an underdeveloped approach, which has been yet accomplished only
by artificial feeding. Coating dsRNAs with liposomes or nanocarriers may increase dsRNA
stability that may make it feasible for administration to the host. Genes that are highly
conserved across different tick species, and are of importance in tick survival are good
candidate targets. These include proteins with structural and metabolic functions, such as
ubiquitin, tropomyosin, and ferritin. However, the specificity of dsRNA to the tick gene should
be highly considered. Additional consideration would be the establishment of a minimum
effective dose, since the synthesis of dsRNA is costly.
Additionally, RNAi has been proposed as an alternative method for the sterile insect technique
in blood-sucking mosquitoes that will produce sterile males by feeding dsRNA in mosquito
larvae [64]. Quite similarly, the application of RNAi for tick control was also proposed in a
single report on D. variabilis, wherein the highly conserved subolesin was targeted leading to
reproductive incapacity [38]. In conclusion, the authors suggested that RNAi may be used to
massively produce sterile ticks (SAT) that may be released in the field. Releasing subolesin-
silenced ticks may also aid in the control of A. marginale, since it has been reported that
subolesin knockdown reduced the infection level of this pathogen [141–143]. Introducing
dsRNA to eggs through electroporation described above may be a more convenient way of
producing knockdowned ticks.
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pest insect management, the possibility of using RNAi as a novel tool of pest control is already
being explored by feeding liposome-coated dsRNA or dsRNA expressed in transgenic plants
or bacteria [32]. RNAi targeting several genes have been accomplished by feeding plants
expressing dsRNA in several species of economically important crop pests [16]. Feeding
dsRNA to ticks is still an underdeveloped approach, which has been yet accomplished only
by artificial feeding. Coating dsRNAs with liposomes or nanocarriers may increase dsRNA
stability that may make it feasible for administration to the host. Genes that are highly
conserved across different tick species, and are of importance in tick survival are good
candidate targets. These include proteins with structural and metabolic functions, such as
ubiquitin, tropomyosin, and ferritin. However, the specificity of dsRNA to the tick gene should
be highly considered. Additional consideration would be the establishment of a minimum
effective dose, since the synthesis of dsRNA is costly.
Additionally, RNAi has been proposed as an alternative method for the sterile insect technique
in blood-sucking mosquitoes that will produce sterile males by feeding dsRNA in mosquito
larvae [64]. Quite similarly, the application of RNAi for tick control was also proposed in a
single report on D. variabilis, wherein the highly conserved subolesin was targeted leading to
reproductive incapacity [38]. In conclusion, the authors suggested that RNAi may be used to
massively produce sterile ticks (SAT) that may be released in the field. Releasing subolesin-
silenced ticks may also aid in the control of A. marginale, since it has been reported that
subolesin knockdown reduced the infection level of this pathogen [141–143]. Introducing




In this chapter, we have reviewed the application of RNAi in tick research and described the
significant contribution of RNAi in advancing our knowledge on tick biology and tick-
pathogen interaction. RNAi has revolutionized the advancement of our understanding of
various aspects of tick blood feeding and digestion, reproduction, metabolism, and immunity.
As a functional analysis tool, RNAi has become very handy in elucidating the functions of
different proteins from more than 10 hard tick species and a few soft tick species. It has been
particularly helpful in screening potential target antigens for anti-tick and tick-borne pathogen
vaccine development [157]. Several methods of introducing dsRNA in ticks have been
employed but injection has remained to be the most widely used technique. The number of
published research on ticks that involves the application of RNAi has been continuously
increasing through the years, and it is expected to continue doing so. A great majority of the
published reports focused on hard ticks, but due to some physiological differences, more
research using RNAi on soft ticks should be conducted. Finally, with numerous potential target
genes already identified, the application of RNAi as a tick control method should be investi‐
gated in the future, starting with optimization of dsRNA delivery method for practical use.
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